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SUMMARY
Cicloxolone sodium (CCX) and the closely related 
compound Carbenoxolone sodium (CBX) have been shown to 
inhibit the growth of HSV 1 and HSV 2 in Flow 2002 and 
BHK-21 cells (Dargan and Subak-Sharpe, 1985). The anti-HSV
effect is characterised by the synthesis of poor quality
progeny virus particles (Dargan and Subak-Sharpe, 1986a and 
b). This results in an elevated particle/p.f.u. ratio in the 
virus yield accompanied by a small reduction in the total 
number of virus particles made. Based on their analysis of 
protein synthesis in infected cells, Dargan and Subak-Sharpe 
have concluded that CCX and CBX disrupt the normal 
functioning of host cell membrane, affecting aspects of 
protein synthesis, transport and post-translational 
processing, particularly glycosylation and sulphation. This 
proposed antiviral action involving cell membranes implies 
that the effect of CCX is of a more general nature, 
suggesting that the replication of several unrelated virus 
groups would be affected by the drug. In order to examine
the effect of CCX on the replication of a range of viruses,
cell lines permissive for virus growth and resistant to CCX 
treatment had to be identified, to allow uncoupling of
cytotoxic and antiviral effects. The aims of this thesis
were: 1) to determine the tolerance of a range of cell lines 
to CCX, 2) to determine the antiviral range of CCX and 3) to 
more clearly elucidate the mode of action of CCX.
Twenty cell lines were studied for their sensitivity 
to CCX treatment. The survey revealed that cell lines 
differed in their tolerance to the drug and could be 
designated as Resistant, Intermediate or Sensitive on the 
basis of cell viability counts. Nine cell lines (Flow 2002, 
RK-13, Chang Liver, Detroit 5 32, HeLa, Hep2, MDBK, MDCK and 
BS-C-1), fell into the Resistant class, six into the
Sensitive class (Ff-293, XTC-2, HOOD, Re oC , Re99 and PCEF),
while five displayed Intermediate sensitivity (BHK-21, Flow 
4000, MRC-5, Rabbit Epithelium and Rabbit Keratocytes). 
Although the viability of cells in the Resistant class 
remained high in the presence of CCX, the replication of 
cells was inhibited at high concentrations (200 and 300uM 
CCX). However, this should not contribute to any antiviral
effect as all virus dose-response experiments were performed 
in confluent monolayers. Most importantly, the effect on the 
cell lines used in the virus dose-response experiments wore 
shown to be fully reversible.
Using cell lines identified as resistant to CCX
treatment as hosts, a range of viruses was examined for 
their sensitivity to CCX and placed into three general 
groupings depending on their response. The first class is 
composed of Vesicular Stomatitis virus (VSV), Influenza A 
and the Herpes viruses Herpes Simplex virus 1 and 2 (HSV 
1/2), Equine Herpes virus (EHV-1) and Bovine Herpes virus 
(BHV-1), all of which exhibit a continuous drug
dose-dependant reduction in virus infectivity. The extent of 
the reduction varies for individual viruses from 100 fold 
(Influenza A) to greater than 10,000 fold (BHV-1). For 
Varicella Zoster virus (VZV) and Human Cytomegalovirus
(HCMV) only ED^q values could be ascertained. Since these 
values are lower than those obtained for HSV 1/2, it would 
seem likely that both these herpesviruses also belong
to this class.
The second class contains Bunyamwera and Germiston 
virus, Poliovirus-1, Reovirus-3 and Adenovirus-5. Members in 
general, exhibit a less extensive total CCX response, 
infectivity being reduced by only 20-100 fold, even with 
300uM CCX. All the dose-response curves reach their plateau 
level with concentrations between 100 and 200uM CCX. 
However, this second class falls into two sub-divisions: 
whereas both Adenovirus-5 and Reovirus-3 exhibit great 
sensitivity to low doses of drug and then reach their 
plateau values, Polio virus-1, Bunyamwera and Germiston are 
little affected by doses less than 50uM and only then 
respond to increased doses until a plateau is reached 
between 150-200uM CCX.
The third class, presently consists of only Semliki 
Forest virus (SFV), whose infectious virus yields are 
unaffected by CCX treatment when whole cell harvests are 
performed.
Representatives of each class were chosen for further 
investigation. However, VSV was the most extensively studied 
virus in this survey, as apart from the herpes viruses, this 
was most drastically affected by the drug. VSV infectious
yields from BS-C-1 cells are reduced -10,000 fold with 300uM 
CCX. The predominant anti-VSV effect is a reduction in 
particle production (typically -1000 fold), which is also 
accompanied by an elevation in particle/p.f.u. ratio
(typically 10 fold). This elevation can be explained by the 
direct inactivation of VSV particles.
CCX had a progressive effect operating throughout the 
virus life cycle. To determine how CCX reduces the
production of VSV particles, several stages in the virus 
life cycle were investigated. VSV secondary but not primary 
transcripts were progressively reduced with increasing CCX 
concentrations. Protein synthesis was affected in CCX 
treated VSV-infected cells: some bands decreased, as 
expected with increasing CCX (L, N and NS), while protein 
bands G, M and UK^ increased with increasing CCX despite 
reduced levels of transcripts. Dargan and Subak-Sharpe
(1986a and b) had shown that glycosylation was affected in 
HSV-infected BHK-21 cells. Comparative studies were 
performed with compounds known to disrupt glycosylation: 
tunicamycin, which blocks the addition of core sugar
normally occurring in the ER and monensin, which disrupts 
sugar processing occurring in the Golgi apparatus. These 
studies revealed that CCX did not completely block sugar 
addition. Similarities emerged between monensin and CCX; 
both resulted in elevated levels of G and M protein bands 
inside cells and both had no significant effect on 
glucosamine incorporation. Johnson and Schlesinger (1980), 
showed that monensin caused dilation of Golgi membrane and 
that transport of the VSV G protein from the Golgi apparatus 
to the cell surface was blocked. VSV assembly normally 
occurs following interaction of the nucleocapsid with G 
inserted into the PM, this interaction being mediated by the 
M protein. Retention of the G protein at the Golgi membrane 
therefore effectively inhibits VSV assembly. Given the 
similarities between CCX and monensin in VSV infected BS-C-1 
cells, it seems likely that this is also the explanation for 
the accumulation of these bands in CCX treated VSV infected 
cells, leading to inhibition of virus assembly. M and UK3 
may co-localize with G or accumulate elsewhere in the cell. 
CCX can also affect the PM of cells and this may also 
contribute to reduced particle numbers by disrupting the
interaction mediated by the M protein between nucleocapsid 
and G protein necessary for VSV assembly and budding.
Similarities between monensin and CCX also emerged in 
the investigation of the class three virus SFV. Total
infectious yields were not affected by CCX treatment.
However, when infectious yields were divided into cell 
associated (CA) and cell released (CR) fractions the CA 
fraction increased with increasing CCX and increasing 
monensin with a concomitant decrease in the CR fraction. In 
addition, both monensin and CCX induced similar changes in 
SFV polypeptide synthesis in treated BS-C-1 cells, resulting 
in the accumulation of viral glycoproteins. EM analysis of 
SFV infected BS-C-1 cells treated with CCX or monensin 
revealed nuclecapsids associated with and budding into 
vacuoles, thus accounting for the increase in the CA 
fraction.
Dose response experiments, performed with monensin and
CCX revealed that disruption of processing in the Golgi
could in theory account for the total anti-Bunyavirus effect 
of CCX. However, glycosylation is not required for 
Poliovirus, Adenovirus or Reovirus infectivity and so 
disruption of glycoprotein processing cannot contribute to 
the antiviral effect of CCX in these cases. More detailed 
studies were performed with Reovirus-3 and Adenovirus-5 as 
these viruses were very sensitive to low doses of CCX.
It was shown that the plateau obtained in the 
dose-reponse curves is not due to the selection of resistant 
virus. It seems likely therefore, that CCX affects a 
function either host or virus specified which enhances but 
is not essential for virus infectivity. The anti-Reovirus-3 
effect of CCX was of two types. At low CCX concentrations, 
the drug predominantly operated by lowering the quality of 
virus particles produced and at higher concentrations by 
inhibiting virus assembly (with quality unaffected). Protein 
synthesis in Reovirus-3 infected BS-C-1 cells was 
progressively reduced with increasing CCX, this almost 
certainly contributing to reduced particle numbers. 
Structural polypeptides of Reovirus-3 produced from drug 
treated cells have not been analysed and may explain the 
effect on virus quality at low CCX concentrations.
As evidenced by the reduction in particle number and
almost unchanged particle/p.f.u. ratio of Adenovirus-5 
yields from CCX treated infected HeLa cells, the 
anti-Adenovirus effect of CCX operates by inhibiting 
particle production. Polypeptides induced in CCX treated 
Adenovirus infected cells were progressively reduced (with 
the exception of low m.wt. bands 13 and 14K, which 
increased),in the presence of increasing CCX, at least 
contributing to the observed reduction in particle numbers. 
However, other factors may also play a role such as a direct 
effect on the nuclear membrane where virus assembly takes 
place.
ABBREVIATIONS
A adenine
ATP adenosine-5'-triphosphate
bp base pairs
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11. INTRODUCTION
2This thesis is concerned with the determination of the 
antiviral activity spectrum of the triterpenoid compound, 
Cicloxolone Sodium (CCX) (Fig 1), and shedding further light 
on its mode of action.
A successful antiviral compound must affect either 
one or more specific virus-encoded functions or a cellular 
function required for the growth of the virus but not 
essential for the cell. This principle is most clearly 
illustrated with reference to known antiviral agents, the 
viruses they affect and the specific targets within the life 
cycles of each of these viruses.
1.1. A REVIEW OF ANTIVIRAL CHEMOTHERAPY
This review will be split into four main sections : 
section one - compounds which affect early pre-synthetic 
steps in the virus life cycle; section two - compounds which 
affect transcription and/or processing of mRNA; section 
three - compounds which affect protein synthesis and/or 
post-translational modifications and section four - 
compounds which affect DNA and/or RNA replication. Some 
compounds have multiple targets and will therefore belong to 
more than one section. Such compounds will be discussed in 
turn in each section, with reference to the viruses affected 
by the action of the compound against that particular 
target.
CO
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0 -1
H0N
c o 2 h
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Figure 1
Structure and derivation of Cicloxolone Sodium.
31.1.1. COMPOUNDS WHICH AFFECT EARLY PRE-SYNTHETIC STEPS IN 
THE VIRUS LIFE CYCLE
Any virus infecting a cell, binds to the surface 
membrane, enters the cell and must shed at least part of 
its protein coat, before the synthetic steps e.g. DNA/RNA 
synthesis, protein synthesis, in the life cycle can occur. 
Agents which have been shown to effect these pre-synthetic 
steps are shown in Table 1.
OLIGOPEPTIDES
The penetration of both pivic-r^ xc and orthomyxoviruses 
into a cell, requires the cleavage of certain of their 
glycoproteins, which activates the fusion of the cellular 
and viral membranes. A deeper understanding of this process 
led to the design of oligopeptides as anti-paramyxo and 
orthomyxovirus agents.
PARAMYXOVIRUS
Two glycoproteins HN^  and F^are associated with the 
paramyxovirus envelope. The HN protein (m.wt. 65-70K), is 
present on the surface as a dimer, held together by 
disulphide bonds in the hydrophilic region and hydrophobic 
bonds at the base of the protein (Scheid et al., 1978). The 
isolated HN protein has receptor binding activity which is 
manifested by haemagglutination when the erythrocyte is used 
as the target cell, and neuraminidase activity which is 
capable of destroying the receptors for the virus (Scheid et 
al., 1972; Scheid and Choppin, 1973).Thus the HN protein is 
responsible for the first step in infection, the adsorption 
of the virus to the cell. Because neuraminic acid containing 
macromolecules that can act as receptors for paramyxo or 
orthomyxoviruses are ubiquitous on the surfaces of 
vertebrate cells, the adsorption of these viruses to 
receptors is not a step in replication that plays an 
important role in determining host range or tropism, in 
contrast to the situation with some other viruses, such as 
picornaviruses with which virus-receptor interactions play a 
decisive role in host cell specificity (Crowell, 1980). Thus 
the HN protein of paramyxoviruses, although it mediates the 
important step of virus adsorption, is not a significant 
factor in determining host range, tropism and virulence. In 
contrast, the other viral surface protein, F, plays a 
crucial role in these viral properties.
The evidence for the biological activity of the F 
protein came initially from studies showing that proteolytic 
cleavage of a precursor protein Fo, to yield two 
polypeptides F^ and F^ , activated virus-induced cell fusion 
and haemolysis, and the initiation of infection of the step 
of virus penetration , which is accomplished by fusion of 
the viral and cell membranes (Homma and Ohuchi, 1973; Scheid 
and Choppin, 1974, 1976, 1977). Each of these biological 
activities, virus penetration, cell fusion and haemolysis 
reflects the ability of the F protein to cause membrane
fusion. The proteolytic cleavage that activates the F 
protein is normally accomplished by a host protease and some 
cells lack an enzyme to cleave the F protein of certain 
viruses. For example, bovine kidney (MDBK) or mouse
fibroblast (L) cells lack an enzyme capable of cleaving the 
Sendai virus Fo. These cells produce non-infectious virions 
that are incapable of causing cell fusion and haemolysis. 
These biological properties can be activated in vitro by 
cleavage of the F protein with trypsin. Mutants have been
isolated that require different proteases from wild type
(wt) viruses for activation, and that exhibit a different 
host range at levels of both cultured cells and the chick 
embryo (Scheid and Choppin, 1976).
The proteolytic cleavage of Fo, m.wt. 65K, yields two 
disulfide linked polypeptides (F^ and F2 ), with m.wt. of 50K 
and 15K respectively (Scheid et al., 1972; Homma and
Ohuchi,1973; Scheid and Choppin, 1974, 1976, 1977). The C 
terminus of Fo, which is the C terminus of the F^ 
polypeptide, is embedded in the viral membrane, and the 
activating cleavage generates a new N terminus on F^ (Scheid 
and Choppin, 1977; Gething et al., 1978). The original N 
terminus of Fo is the N terminus of F^, and F^ is linked to 
F^ by disulphide bonds.
The new N terminal region of F^, is highly conserved 
among different viruses. The amino acid sequences of three 
different paramyxoviruses (Scheid et al., 1978; Gething, 
White and Waterfield, 1978; Richardson, Scheid and Choppin, 
1980) are shown in Table 2. In the first twenty amino acids 
there are only six positions at which differences occur 
among the three viruses shown in Table 2, and in each case 
one hydrophobic amino acid is substituted for another. This
region is also highly hydrophobic; there are no charged 
amino acids in the first twenty residues in each virus, and 
the first charged amino acid detected does not appear until 
residue 26.
The findings that the biological activities of the F 
protein (virus penetration, virus-induced cell fusion and 
haemolysis), appeared when the new N-terminus on the 
polypeptide was generated, and that the primary structure of 
this region is highly conserved and furthermore hydrophobic, 
suggested that this region of the molecule was involved in 
the membrane fusing activity of the protein (Scheid and 
Choppin, 1977; Scheid et al., 1978). The highly hydrophobic 
nature of this region raised the possibility that it could 
interact with the lipid bilayer of the target membrane 
(Scheid et al., 1978; Gething, White and Waterfield, 1978; 
Richardson, Scheid and Choppin, 1980;). Such a hydrophobic 
interaction could result in the F^ polypeptide facilitating 
fusion by bringing the bilayers of the cell and viral 
membrane together i.e. the N-terminus of F^ would be 
inserted into the cell membrane while its C -terminus was 
anchored in the viral membrane. This hypothesis was 
supported by the finding of a conformational change in the F 
protein upon cleavage .
The characteristics of the F protein discussed 
therefore suggested that the N-terminus of F^ was directly 
involved in membrane fusing activity. On the basis of these 
findings, Choppin, Richardson and Scheid (1984), synthesised 
oligopeptides that mimicked the N-terminal region of the F^ 
polypeptide, designed to competitively inhibit the action of 
the protein. A large number of oligopeptides 
synthesised, using the sequence of the N-terminus of Sendai 
virus as the primary model, but varying several parameters, 
including the sequence and steric configuration of the amino 
acids and various substitutions on both the N and C-terminal 
amino acids of the oligopeptides (Richardson, Scheid and 
Choppin, 1980, 1981; Richardson and Choppin, 1983; Choppin 
Richardson and Scheid, 1983). Some of these oligopeptides 
were tested against measles, canine distemper, SV5 and 
Sendai viruses, and oligopeptides with the appropriate 
structure were found to inhibit the membrane fusing activity 
of the F protein, as manifested by virus penetration and
virus-induced cell fusion and haemolysis. Although cell 
fusion and haemolysis were also inhibited, the most 
sensitive and efficient method of quantitating inhibitory 
activity, was to employ a plaque assay to determine 
inhibition of infectivity at the level of virus penetration. 
African green monkey kidney (CV-1) cells were used for most 
assays, and in each experiment the ability of . w \ \ - *v; 
concentrations of the oligopeptide to inhibit plaque 
formation was determined. Dose-response curves were obtained 
and 50% effective inhibitory concentrations were derived 
from these curves. It is very important to note that these 
experiments were performed under conditions in which the F 
protein is cleaved i.e. the oligopeptides do not act as 
protease inhibitors but as inhibitors of the membrane fusing 
activity of the F protein (Richardson, Scheid and Choppin, 
1980, 1981; Richardson and Choppin, 1983; Choppin,
Richardson and Scheid, 1983). Measles virus was found to be 
the most sensitive to inhibition by the oligopeptides, and 
therefore it was chosen for extensive structure-activity 
studies, which yielded the following information:
1.)Oligopeptides with the correct amino acid sequence are 
highly active specific inhibitors. The longer the
oligopeptide the more effective it is.
2.)The addition of certain hydrophobic groups to the 
N-terminal amino acid significantly increased activity e.g. 
carbobenzoxy group (Z), t-butylocarbonyl group.
3.)Esterfication of the C-terminal amino acid with a methyl 
group decreased activity.
4.)The steric configuration of the first and second 
amino acids was found to significantly affect activity e.g. 
Z-D-Phe-L-Phe-Gly was more active than Z-L-Phe-L-Phe-Gly- or 
Z-D-Phe-D-Phe-Gly. Table 3 shows the 50% effective 
concentrations derived from dose-response curves carried out 
with different oligopeptides which illustrate these points. 
The reason for the effects on the inhibitory activity of the 
additions at the termini of the oligopeptides is not yet 
clear, however the added groups may have an effect on the 
positioning of the oligopeptide at its site of action. The 
carbobenzoxy and dansyl groups add hydrophobicity to the 
N-terminus, and the esterification of the C-terminus 
decreases the polarity of the peptide. Such changes could
7affect the orientation of the peptide at its site of action 
at the membrane. The effect of the steric configuration of 
the amino acids is also not completely understood. The 
observed greater inhibitory activity of an oligopeptide with 
D-phenylalanine at the N-terminus, as compared to the 
naturally occurring L-amino acid may in part be explained by 
protection of the peptide from proteolytic activity. 
However, this is probably not the only factor involved, 
because the same structure-activity relationship was found 
when inhibition of haemolysis was used to assay activity, 
and proteolytic digestion of the peptide is less likely to 
occur in a short period of time in a haemolysis assay than 
in a plaque assay in cultured cells which requires several
days. It therefore appears that the steric configuration of
the terminal amino acids has an effect on inhibitory 
activity per se.
Three approaches were adopted to determine the precise 
site of action of the oligopeptides. Firstly, oligopeptides 
labelled with or were reacted at 4°C with purified
virus, mock-infected cells or infected cells, and after
washing, samples were assayed for radioactivity to 
quantitate binding. Such studies suggested that
oligopeptides bound to cells, whether infected or 
uninfected, but not to virus (Choppin, Richardson and
Scheid, 1983; Richardson, Scheid and Choppin, 1983). 
Secondly oligopeptides, such as Z-PPGCK, were synthesised 
that could bind irreversibly. Z-PPGCK was preincubated with 
monkey erythrocytes (rbc), or rbc plus adsorbed measles 
virus, or purified measles virus, and after extensive 
washing, haemolysis assays were performed (Richardson, 
Scheid and Choppin, 1983). It was found that Z-PPGCK
>>r'ewf-'sibly inhibited haemolysis when it was pre-incubated 
with rbc, or rbc plus virus, but not when it was 
pre-incubated with virus alone, indicating again that the 
oligopeptides act on the cell and not on the virus. The
third approach, involved the use of an oligopeptide
inhibitor containing an azido group as a photoaffinity probe 
i.e. Z-D-Phe-L-Phe-(azido)Phe(Z-APPP). This peptide retained 
activity when the azido group was added, rbc or measles 
virus were incubated with this peptide and exposed to 
ultraviolet light for various times to cross link the
8oligopeptide in situ. The samples were then washed 
extensively, and haemolysis assays carried out. 
Pre-treatment of virus with Z-APPP had no effect, but
pre-treatment of rbc with this oligopeptide inhibited 
haemolysis (Richardson, Scheid and Choppin, 1983). These
studies therefore show, that the site of action is on the 
target cell membrane, not on virus. The results further 
suggest, that the inhibitors compete with the N-terminus of 
the polypeptide for a site on the membrane. 
ORTHOMYXOVIRUSES
Influenza viruses (myxoviruses), also possess two
glycoproteins that form spike-like projections on their 
surface; however, unlike paramyxoviruses, the 
haemagglutinating and neuraminidase functions of influenza 
viruses reside on separate proteins designated HA and NA 
respectively. The influenza virus HA protein serves two 
functions; receptor binding and penetration. Like the F 
protein of paramyxoviruses, the HA protein of influenza 
virus is cleaved by a host cell protease to yield two 
disulfide bonded subunits (Lazarowitz, Compans and Choppin, 
19 71). This cleavage has no effect on h^eirvagglutinating 
activity (Lazarowitz, Goldberg and Choppin, 1973), but it 
activates the infectivity of the virus (Klenk et al., 1975; 
Lazarowitz and Choppin, 1975) at the level of viral 
penetration. Furthermore, not only is the membrane fusing 
activity of the HA protein activated by cleavage, as is the 
F protein but also the amino acid sequence of the new 
N-terminus generated on the HA 2  polypeptide by cleavage, 
resembles that of the paramyxovirus F^, except that glycine 
is the N-terminal amino acid. The structural and functional 
similarities between the HA and F polypeptides, led Choppin, 
Richardson and Scheid (1983), to synthesise oligopeptides 
that mimicked the N-terminus of the HA^ polypeptide, and to 
test their ability to inhibit influenza virus replication. 
With influenza virus also, inhibition was obtained that was 
amino acid sequence specific. As shown in Table 4, 
ct^opeptides that mimicked the N-terminal sequence of the 
HA^ polypeptide of influenza A and B viruses 
(Z-Gly-L-Leu-L-Phe-Gly and Z-Gly-D-Phe-L-Phe-Gly, 
respectively) were active against influenza virus, but 
inactive against measles virus, whereas the reverse was true
9with Z-D-Phe-L-Phe_Gly, which resembles the N-terminus of 
paramyxovi rus.
Although oligopeptides of this type have proved 
successful against paramyxo and orthomyxoviruses in vitro, 
good in vivo efficacy has not been reported.
LEUPEPT1N
The peptide leupeptin (acetyl-L-leucyl-L-argininal) is 
produced by actinomycetes, which is known to inhibit 
specifically trypsin, plasmin, papain, kallikrein and 
cathepsin B (Aoyagi and Umezawa, 1975). Recently leupeptin 
was shown to suppress the replication of influenza 
(A/swine/19 76/31 HlNl) and also the developn-^e^v of fatal 
pneumonia in mice co-infected with the virus and 
staphylococcus aureus (Tashiro, Klenk and Rott, 1987). As 
stated previously, the post-translational proteolytic 
cleavage of the viral haemagglutir- v w  glycoprotein by 
cellular proteases is essential for infectivity, spread of 
the virus in the host organism and pathogenicity (Rott and 
Klenk, 1986). In a host cell where an appropriate protease 
for cleavage is not present, and infectious virus cannot be 
produced, infectivity can be recovered by trypsin treatment 
of non-infectious virus in vitro (Klenk et al., 1975; 
Lazarowitz and Choppin, 1975). It has been shown that 
Staphylococcus aureus, which is most frequently isolated 
from patients with influenza pneumonia (Stuart-Harris, 
Schild and Oxford, 1985), secretes serine proteases that 
activate the infectivity of several influenza A viruses by 
proteolytic cleavage of the haemagglutinin (Tashiro et al., 
1987a and b). The presence of the bacterial enzyme enables 
the virus to undergo multiple replication cycles in host 
cells that do not contain an activating protease. 
Co-infection of mice with influenza A and S. Aureus, 
resulted in extensive lesions and an enormous increase of 
virus titre in the lung and death of the mice.
Leupeptin inhibits this activation by staphylococcal
protease both in cell culture and in mice (Tashiro, Klenk
and Rott, 1987). If chicken embryo cells (CE) were infected
_2
with influenza A (swine/19 76/, HlNl), at an m.o.i. of 10 
p.f.u./cell, progeny virus grew efficiently only in the 
presence of staphylococcal proteases (Tashiro et al., 1987a
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and b). Leupeptin could prevent multistep replication of 
virus when added in addition to staphylococcal proteases, 
the inhibitory aTffect dependent on the leupeptin dose: 
lOOug/ml leupeptin resulted in a 5 log reduction in virus 
titre, as determined by haemagglutination.
Mice co-infected with the virus and Staphylococcus 
aureus were treated with leupeptin several times a day over 
a 6 day period. Compared with control animals there was a 
significant reduction in infectious virus titre in the lung, 
reduction in the level of lung lesions and an improved 
survival rate.
Unlike the oligopeptides discussed earlier, leupeptin 
was proposed to act by directly inhibiting protease 
activity. Several lines of evidence supported this proposal. 
Levels of bacteria in mice treated or untreated with 
leupeptin were equal and although inhibition of bacterial 
protease production cannot be ruled out, it is pertinent 
that the infectivity of virus isolated from mice treated 
with leupeptin could be enhanced by trypsin treatment. This 
was not the case for virus isolated from untreated mice. 
Since the haemagglutinin of influenza virus has an arginine 
at its cleavage site, leupeptin would be expected to 
inhibit cleavage activation by the bacterial proteases, and 
polyacrylamide gel electrophoresis has shown this to be the 
case (Tashiro, Klenk and Rott, 1987). Whether this 
inhibition is selective for cleavage by staphylococcal 
enzymes, or affects cellular proteases also remains to be 
determined. Preliminary experiments confirmed that prolonged 
intranasal administration was not toxic and protected mice 
from developing severe pneumonia and death (Tashiro, Klenk 
and Rott, 1987). These observations suggest a possible way 
for theraputic treatment of influenza pneumonia by leupeptin 
or similar trypsin inhibitors, particularly in infections 
with bacteria which are resistant to antibiotics.
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AMANTHDINE AND RIMANTIDINE
Amantadine (1-aminoadamantane hydrochloride, Fig 2a), 
selectively inhibits influenza A viruses (Davies et al., 
1964). Many clinical trials have been conducted in man which 
show amantadine to be effective both prophylactically and 
z tically against influenza A but not B (Oxford and 
Galbraith, 1980; Galbraith, 1985). The drug was licensed in 
1976 for use against all influenza A subtypes, although its 
use has been limited, except in the Eastern block. 
Rimantidine (alpha-methyl-l-adamantane methylamine 
hydrochloride, Fig 2a), is as effective as amantidine, but 
with fewer side effects (Dolin et al., 1982), and this drug 
has been used extensively in the U.S.S.R.
While amantadine resistant variants can readily be 
obtained from tissue culture (Cochran et al., 1965; 
Appleyard, 1977), or from laboratory animals (Oxford, Logan 
and Potter, 1970), there is little information regarding the 
occurence of amantadine resistant viruses in the human 
population or their emergence as a result of clinical use of 
the drug. Therefore, information regarding the mode of 
action of amantadine has been obtained by investigation of 
resistant mutants isolated by passage in the presence of 
amantadine in tissue culture. Amantadine has been shown to 
exert two different actions depending on the concentration 
used (Hay and Zambon, 1984; Hay et al., 1986).
INHIBITION BY HIGH CONCENTRATIONS (0.5mM)
The inhibition of virus infection by high 
concentrations of amantadine, of the order 0.5mM, is not 
specific to influenza virus; it is seen with a number of 
enveloped RNA viruses which enter cells by endocytosis 
(Wallbank, Matter and Klinikowski, 1966; Skehel, Hay and 
Armstrong, 1978; Helenius et al., 1980). Nor is such
inhibition a property peculiar to amantadine, since a 
variety of amines, including for example, methylamine and 
ammonium chloride exhibit similar effects (Jensen and Liu, 
1963; Helenius, Marsh and White, 1982; Yoshimura et al., 
1982; Hay and Zambon, 1984). These high drug concentrations 
are cytotoxic and from the clinical standpoint do not 
reflect the highly restricted spectrum of antiviral activity 
in vivo.
At these concentrations, the drugs cause an elevation
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in the pH of endosomes. Many viruses, including influenza 
enter cells via receptor mediated endocytosis. The 
subsequent fusing of viral and endosomal membranes, 
initiating virus infection is pH dependent, lying between 5 
and 6 depending on the virus strain. Th.. fore raising the pH 
in these compartments, successfully blocks the interaction 
between viral and cellular membrane and so blocks initiation 
of infection.
Influenza virus resistance to high concentrations of 
amanttidine, maps to the haema^iu^tinin (HA) gene (Hay et al. , 
1986). As mentioned previously, influenza virus
(orthomyxovirus) penetration is dependant on the cleavage of 
HA by a protease, activating the fusion of viral and 
cellular membranes. Resistant mutants may be explained by a 
change in the structure of HA which allows fusion to proceed 
at a higher pH. The nature and location of such mutations 
suggests a lowering of the energy barrier to the
conformational change leading to the fusion active state 
(Daniels et al., 1985).
SELECTIVE ACTION OF LOW CONCENTRATIONS
The influenza A specific action of low concentrations 
of amantcidine correlates with selective activity in vivo, 
optimum inhibition varying from 0.3uM to 5uM (Hay et al., 
1986). The stage of virus replication inhibited varies
between virus strains. Human influenza A viruses for 
example, A/Singaporel/57, H2N2, appear to be inhibited at an 
early stage since drug must be present prior to infection 
and primary transcription is inhibited (Hay and Zambon,
1984). This is in contrast with data obtained from two avian 
strains, Rostock H7N1 and Weybridge, where early events are 
not affected, and virus inhibition occurs when the drug is 
added later suggesting that a late stage of virus 
replication, probably assembly is blocked (Hay and Zambon, 
1984; Hay et al., 1986). However, all amantfiLdine resistant 
variants following passage in 5uM amantiidine, contained a 
mutation in their M gene, leading to a single amino acid 
substitution in the M2 protein, whereas less than a quarter 
of such mutants had a change in the amino acid sequence of 
the HA (Hay et al., 1985). Resistance is consistently 
transferred with M2 and the optimum inhibitory concentration 
reflects the parental M gene. However, in addition the HA
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gene modifies the degree of susceptibi1ty and influences 
which stage (early or late) is inhibited. Amantadine 
treatment of Rostock-infected cells greatly reduced the 
membrane expression and antigenicity of HA; an effect which 
is relieved in resistant mutants (Hay et al., 1986). 
Therefore, both the HA and M2 proteins are implicated, 
suggesting that amantadine interferes with their functions 
or with interactions between the two proteins, in one case 
leading to a block in the initial stages of the virus life 
cycle and in the other inhibiting later stages in infection, 
most probably assembly.
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ARILDONE AND RELATED COMPOUNDS, WIN 51711 AND WIN 52084
Arildone (Fig 2b), is a lipophilic B-diketone, which 
displays some selectivity against a number of RNA and DNA 
viruses in cell culture (Diana et al., 1977). It has been 
shown to have particular effect against poliovirus both in 
cell culture (McSharry, Caliguiri and Eggers, 1979) and in 
mice (McKinlay et al., 1982). Arildone blocks cell mediated 
uncoating (Fig 3b) and also protects the virus capsid from 
activation by host and alkali (McSharry et al. , 1979 ). 
Unfortunately the rapid metabolism of this drug in man, 
makes it unlikely to be useful as a chemotheraputic agent 
(Eggers, 1985 ). A structure-activity based programme of 
research, starting from arildone, led to the develops -''i-r of 
compounds WIN 51711 and WIN 52084 (Fig 2b), which inhibit 
picornavirus replication in tissue culture and in animal 
models of human enterovirus disease (Smith et al., 1986). 
Disappointingly, no significant effect was observed when WIN 
51711 was evaluated clinically using a human rhinovirus 
challenge in man (Diana and Otto, 1985).
X-ray diffraction studies of WIN 51711 and WIN 52084 
bound to crystallised human rhinovirus 14 (HRV-14), revealed 
the site of attachment and information regarding the mode of 
action (Smith et al., 1986). The 3-dimensional structure of 
HRV 14 has been described in atomic detail (Rossman, 1985). 
The three larger structural viral proteins (VPl, VP2 and 
VP3), form the exterior of the viral capsid, while VP4 is at 
the interface between the capsid and the RNA. VPl, VP2 and 
VP3 are each folded into an 8 stranded B-barrel and are 
organised in the capsid with a pseudo T=3 surface lattice 
(Caspar and Klug, 1962).Four types of neutralizing antibody 
binding sites were found at insertions in the B-barrel 
structure, on the extreme surface of the virus, surrounding 
a 25 A deep canyon, on the viral surface. Each canyon 
encircles one of the 12 vertices of the virus and has been 
proposed to be the site of receptor binding (Rossmann,
1985). VPl is the major structural contributor to the walls 
and the floor of the canyon. The canyon floor is formed by 
relatively conserved sequences of known picornaviruses, 
while the neutralizing antibody sites are at hypervariable 
regions of the viral capsid proteins. The compounds WIN 
51711 and WIN 52084, consist of a 3-methylisoxazole group
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that inserts itself into the hydrophobic interior of the VPl 
B-barrel and a 4-oxazolinylphenoxyl (OP) group that covers 
the entrance to an ion channel in the floor of the canyon 
(Fig 3a). The functioning of the antiviral compounds might 
be compared to that of a nicotinamide adenine dinucleotide 
(NAD) cofactor in dehydrogenases (Adams, 1973; Holbrook et 
al. / 1975 ). The adenine end of NAD binds into a hydrophobic 
pocket and enhances protein stability just as it is 
envisaged that the methylisoxazole group of the WIN 
compounds might increase viral stability by filling the
empty hydrophobic pocket within the VPl B-barrel (Argos et 
al. , 1979 ). The nicotinamide of NAD is functionally
necessary for enzymic catalysis whereas the OP group of the 
WIN compounds perhaps blocks ions from entering the virion 
through the pore on the floor of the canyon, thus decreasing 
the permeability of the virion to caesium ions. 
Alternatively, the WIN compounds might lock the conformation 
of VPl such that the virus cannot disassemble by collapsing 
the hydrophobic pocket (Fig 3b).
That the binding of these compounds is responsible for
their antiviral activity is supported by two lines of
evidence. Firstly, the different effects of compounds
against individual human rhinovirus (e.g. HRV 2 and HRV 14),
can be explained in terms of the amino acid composition of
the structural viral proteins in their viral capsid. For
example, the minimum inhibitory concentration (MIC)
(concentration which reduces plaque numbers by 50% in cell
culture), of WIN 51711 for HRV 14 is 0.4uM compared with
3.8uM for HRV 2 (Smith et al., 1986). The most significant
difference in the WIN binding pocket between HRV 14 and HRV 
188 1912 is that Val and Val are replaced by leucine. This is 
likely to cause steric hindrance to the insertion of the
isoxazole group and aliphatic chain into the hydrophobic
pocket which would account for the increase in MIC. 
Secondly, the antiviral activity of the compounds can also 
be altered by modifications to the structure, including the 
length of the aliphatic chain and substitutions in the 
oxazoline and phenolic rings. The effects of these 
modifications are shown in Table 5. Any decrease in MIC 
(i.e. improvement in antiviral activity), in each case can 
be explained in terms of improved binding.
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LENGTH OF ALIPHATIC CHAIN
The optimal length of the aliphatic chain for
HRV 14 inhibition is when n is either 5 or 7 (Table 5). Less
than 5 would probably reduce the hydrophobic binding within
the pocket and cause steric hindrance to the isoxazole group
in the more restricted portions of the binding site; n
greater than 7 would cause severe steric hindrance as the
isoxazole group is pushed further into the hydrophobic
pocket and the aliphatic chain is severely buckled; n even
would require cis bonds in the aliphatic chain to keep the
isoxazole group (assuming the same binding of the OP group)
out of sterically hindered positions.
SUBSTITUTION ON THE OXAZOLINE GROUP
The asymmetric carbon atom in the oxazoline ring of
WIN 52084 is clearly important because the S isomer is ten
times more active than the R isomer (Table 5). The result
can be explained by improved hydrophobic interactions of the
S methyl group with a hydrophobic pocket formed by Leu^^ 
107and Ser , which would stabilise the conformation of the
oxazoline ring thereby allowing for a favourable orientation
219for hydrogen bonding to Asn . The R methyl group would be
expected to have no positive effect on hydrophobic
interactions consistent with similar MIC values obtained for
the R methyl compound and the desmethyl compound WIN 51711.
SUBSTITUTIONS ON THE PHENOLIC GROUP
The antiviral activity can be improved by introducing
suitable additional hydrophobic groups onto the phenyl group
(Table 5). Larger hydrophobic groups in position 2 increase
the efficacy against HRV 2 possibly because of a better
116interaction with a phenylalanine which replaces the Leu 
of HRV 14. Larger hydrophobic groups have little effect when 
the compounds are tested on HRV 14 where these aromatic 
groups are absent. (Comparative observations are available 
only when the aliphatic chain is of length n=5). The 
explanation of the MIC observations is at present entirely 
qualitative, but could be quantitated using energy 
calculations of various compounds bound to the 
conformationally changed virion and by checking the 
resultant predicted binding mode with X-ray diffraction 
observations, thereby comparing directly, binding and 
antiviral activity.
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This study amounted to the first description of the 
interaction of an antiviral drug with a virion at atomic 
resolution. The results offered plausible mechanisms for the 
biological activity of this class of compounds and raised 
the possibility of antiviral drug design for rhinoviruses as 
well as other picornaviruses.
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FLAVANOIDS AND CHALCONES
DICHLOROFLAVAN, CHALCQNE AND RMl-15,731
Dichloroflavan (41,6-Dichloroflavan), chalcone 
(41-Ethoxy-2'-hydroxy-4, 6'-dimethoxychalcone), and
RMI-15,731 (1-(5-Tetradeayloxy-2-furanyl)-ethanone) (Fig
2c), all exhibit antirhinovirus activity in cell culture 
(Ishitsuka, Ninomiya and Suhara, 1986). A comparative study 
was performed with these three compounds to elucidate their 
mode of action. Interaction with the viral capsid protein 
was suggested because different serotypes of human 
rhinovirus (HRV), varied widely in their susceptibility to 
the compounds and the major differences between serotypes 
are in the the capsid proteins. In addition, all three 
compounds can directly inactivate HRV, but infectivity can 
be restored to the original level by removal of the bound 
compounds with chloroform.
The specific interaction of with HRV was confirmed by 
using radiolabelled chalcone. After exposing the HRV type 2
3
to [ H] chalcone, the amount of the chalcone bound to the 
virus was assayed following centrifugation through a sucrose
3
gradient. A distinct peak of [ H] chalcone was observed at 
the position of the virus particles, indicating that the 
chalcone bound to the virus.This binding of radiolabelled
chalcone could be completely inhibited by unlabelled
chalcone and dichloroflavan, and to a lesser extent by RMI.
The infectivity of the peak fractions could be shown only 
after extraction of chalcone with chlorof orm.(l‘3n^_cu !'-
i: :*■ *. '
HRV type 2 subtypes, which are resistant to chalcone, 
dichloroflavan or RMI, were isolated by serial passage of 
the virus in tissue culture in the presence of sub-lethal 
concentrations of these compounds. HRV sublines resistant to 
both dichloroflavan and RMI showed cross-resistance to 
chalcone and vice versa. These results again suggest that
the modes of action of dichloroflavan and RMI are 
essentially the same as that of chalcone. However, since the 
sublines resistant to each of dichloroflavan and RMI were
not cross resistant, the interaction site for dichloroflavan
must be different from that for RMI. Chalcone binds to
intact HRV type 2 particles at a specific site not found on 
particles degraded by treatment at pH 5 or 56°C, or on 
viruses insensitive to the agents (Ninomiya et al., 1984).
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Dichloroflavan and RMI competed with chalcone for binding at 
this specific site, indicating that their binding sites were 
very similar to that for chalcone.
Evidence against the conclusion that chalcone, 
dichloroflavan and RMI have the same mode of action is that 
these three agents differ significantly in their antiviral 
spectrum in HRV serotypes (Ninomiya et al., 1985). It is 
thought that the conformation of the binding site on the 
capsid may slightly differ between HRV serotypes. Some 
difference at the binding site was suggested by the fact 
that chalcone could bind to the HRV subline resistant to 
dichloroflavan, and that there was no cross resistance 
between dichloroflavan and RMI. The capsid conformation on 
some serotypes may favour one compound while that on other 
serotypes favours the other compounds.
Instability at acidic pH's or 56°C is the most 
characteristic feature that distinguishes HRVs from other 
human picornaviruses (Stott and Killington, 1972; Newman, 
Rowlands and Brown, 1973). Exposure to acid pH or heating at 
56°C caused alteration in size, conformation and 
antigenicity of the virus (Korant et al., 1972, 1975; 
Lonberg-Holm and Yin, 1973). HRV bound to chalcone resists 
these alterations, through stabilisation of the virus 
conformation (Ninomiya et al., 1984). Infection of cells 
with rhinovirus is accompanied by the same type of 
alteration of the uncoating process as that observed by 
treatment at pH5 (Lonberg-Holm and Korant, 1972). Therefore, 
it seems likely that HRV, when bound to any of these 
compounds, is not able to undergo the normal process of 
uncoating in infected cells.
The mode of action is therefore the same as that 
proposed for arildone and related compounds. However, the 
activity of chalcone, DCF or RMI appears to be confined to 
rhinoviruses, while arildone, WIN 51711 and WIN 52084 
display activity against a range of DNA and RNA viruses, 
particularly picornaviruses. X-ray diffraction studies of 
HRV bound to chalcone, DCF or RMI would yield valuable 
information regarding the mode of action and perhaps reveal 
the basis for this selectivity.
So far the results of clinical trials have proved 
disappointing. Rhinovirus 9 is particularly sensitive to
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dichloroflavan, however, volunteers infected with this virus 
were not protected by oral administration of the compound 
(Phillpotts et al., 1983). Similarly, chalcone and the
pro-drug (which was inactive but absorbed and then converted 
to the active form by loss of a phosphate group), also had 
no effect when administered orally to volunteers. These 
disappointing results, may be due to the fact that 
concentrations of flavan and chalcone attained in the nasal 
mucosal cells were not sufficiently high to afford 
protection (Phillpotts and Tyrrell, 1985), emphasising the 
need to explore better ways for their delivery (e.g. by fine 
particle aerosols).
FLAVONE AND ENVIROXIME
Flavone and enviroxime (Fig 2d), also exhibit activity 
against a wide range of rhinoviruses (Ishitsuka, Ninomiya 
and Suhara, 1986). Their mode of action is however unclear. 
It has been reported that flavone and enviroxime inhibit 
processes before the initiation of viral RNA synthesis 
(Ishitsuka et al., 1982; Delong and Reed, 1980). Unlike 
chalcone, dichloroflavan and RMI, flavone and enviroxime do 
not directly inactivate HRV particles and continue to be 
active against virus sublines resistant to chalcone, 
dichloroflavan and RMI. HRV sublines resistant to flavone or 
enviroxime could not be isolated (Ishitsuka, Ninomiya and 
Suhara, 1986). The protein conformation with which these two 
agents associate may be important for virus replication to 
an extent that amino acid sequences at the interacting sites 
are genetically conserved and that mutation of these sites 
is lethal. An alternative explanation is that these two 
agents affect host cell functions or factors which are 
essential for viral relication.
In 1981, Phillpotts et al., reported that enviroxime 
was effective prophylactically in trials against rhinovirus 
9 in man, when delivered by mouth and nasal spray, with 
fewer colds and cold symptoms noted. However, adverse side 
effects, principally nausea and vomiting, attributed to the 
oral enviroxime, were unacceptably frequent. Intranasal 
therapy also proved ineffective, even prophylactically 
against rhinovirus type 4 (Levandowski et al., 1982) or type 
39 (Hayden and Gwaltney, 1982).
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FUSION OF VIRAL AND CELLULAR 
MEMBRANES THUS FACILITATING 
PENETRATION
LEUPEPTIN INFLUENZA A S.AUREUS PROTEASE 
(CELLULAR?)
INHIBITS PROTEASE ACTIVITY 
THEREBY PREVENTING CLEAVAGE 
OF VIRAL HA, NECESSARY TO 
ACTIVATE FUSION AND PENETRATION 
OF VIRUS
E-AMINO 
CAPKGIC ACID
INFLUENZA CELLULAR PROTEASE AS LEUPEPTIN
AMANTIDINE,
RIMANTIDINE
A RANGE OF 
ENVELOPED RNA 
VIRUSES 
(HIGH CONC. 
0.5 uM)
CELLULAR ENDOSOMAL 
COMPARTMENT
RAISES pH OF ENDOSOMAL 
COMPARTMENTS THEREBY BLOCKING 
pH DEPENDENT FUSION OF VIRAL 
AND CELLULAR MEMBRANES;
BLOCKS PENETRATION
HUMAN INFLUENZA A 
(LOW CONC. 0.3uM)
M AND HA PROTEINS NOT CLEAR; PROBABLY INTERFERES 
WITH FUNCTION/S OR INTERACTION 
BETWEEN THESE PROTEINS; BLOCKS 
EARLY EVENT (PENETRATION?)
BEFORE PRIMARY TRANSCRIPTION
ARILDONE, 
WIN 51711, 
WIN 52084
PICORNAVIRUSES VIRUS PARTICLE BINDS TO VIRUS, BLOCKING 
UNCOATING OF VIRUS
DICHLORO- 
FLAVAN, 
CHALCONE 
AND RMI
RHINOVIRUSES VIRUS PARTICLE
j
BINDS TO VIRUS, BLOCKING 
UNCOATING OF VIRUS
FLAVONE,
ENVIROXINE
RHINOVIRUSES 7 NOT CLEAR; ACTS BEFORE 
INITIATION OF RNA SYNTHESIS
Table 1
Compounds which affect early pre-synthetic steps in the 
virus life cycle: their antiviral spectrum and proposed mode 
of action.
^Antiviral spectrum: viruses affected by the action 
of the compound against the particular target shown.
References: Oligopeptides (Choppin, Richardson and Scheid, 
1983, 1984); Leupeptin and e-amino caproic acid (Tashiro, 
Klenk and Rott, 1987); Amantddine/Rimantidine (Hay and 
Zambon, 1984? Hay et al., 1986); Arildone/WIN 51711/WIN 
52084 (McSharry et al., 1979? Smith et al., 1986);
Dichloroflavan/Chalcone/RMI/Flavone/Enviroxime (Ishitsuka, 
Ninomiya and Suhara, 1986).
1 5  10
Sendai Phe-Phe-Gly-Ala-Val-Ile-Gly-Thr-Ile-Ala
SV5
NDV
Phe-Ala-Gly-Val-Val-Ile-Gly-Leu-Ala-AIa 
Phe-Ile-Gly-Ala-Ile-1le-Gly-Gly-Vai-Aia
11 15 20
Sendai Leu-Gly-Val-Ala-Thr-Ala-Ala-Gln-Ile-Thr
SV5 Leu-Gly-Val-Ala-Thr-Ala-Ala-Gln-Val-Thr
NDV Leu-Gly-Val-Ala-Thr-Ala-Ala-Gln-Ile-Thr
Peptide 50% Effective
Concentration uM
Z-D-Phe-L-Phe-Gly-D-Ala-D-Val-D-lle-Giy 0 02
Z-D-Phe-L-Phe-Gly 0 20
Z-D-Phe-L-Phe 28
Z-L-Phe-L-Ser 141
Z-Gly-L-Phe-L-Phe 530
Z-D-Phe-L-Phe-Gly 0 20
DNS-D-Phe-L-Phe-Gly 0 34
t-BOC-D-Phe-L-Phe-Gly 2 0
D-Phe-L-Phe-Gly 180
Z-D-Phe-L-Phe-Gly(methyl ester) 20
Z-D-Phe-L-Phe-Gly 0 20
Z-D-Phe-D-Phe-Gly 10
Z-L-Phe-L-Phe-Gly 23
Z-D-Phe-L-Phe-Gly(chloromethylketone) 0 20
Z-D-Phe-L-Phe-L(azido) Phe 0 28
Table 2
N-terminal amino acid sequences of the F polypeptides of 
three paramyxoviruses.
Underlining indicates residues that differ from the residue 
in that position in Sendai virus (from Chopin et al.y 1983).
Table 3
Inhibition by oligopeptides of plaque formation by Measles 
virus (from Chopin et al., 1983).
Z indicates a carbobenzoxy group; DNS, a dansyl group; 
t-BOC, a tertiary butoxylcarbonyl group.
PEPTIDE
50% EFFECTIVE CONCENTRATION uM
INFLUENZA A MEASLES
Z-GLY-L-LEU-L-PHE-GLY 20 1000
Z-GLY-L-PHE-L-PHE-GLY 53 870
Z-GLY-D-PHE-L-PHE-GLY 23 -
Z-D-PHE-L-PHE-GLY 290 0 . 2
COMPOUND | Z1 : Z2 j POSITION 2 i POSITION 3 ! n HRV14 HRV 2
OPTIMUM LENGTH OF ALIPHATIC CHAIN
WIN 53670 H H H H 4 Inactive 7 . 3
WIN 52035 H H H H 5 0.7 1.1
WIN 53337 H H H H 6 2.9 2.1
WIN 51711 H H H H 7 0 . 4 3.5
WIN 53455 H H H H 8 3.9 5.9
SUBSTITUTION OF THE OXAZOLINE GROUP
WIN 51711 H H H H 7 0.4 3.8
WIN 52084 S/R H CH3 H H 7 0.06 0.11
WIN 52084 S H CH3 H H 7 0.04 0.08
WIN 52084 R H CH3 H H 7 0.4 1.7
WIN 52193 CH3 CH3 H H 7 0.1 1.5
SUBSTITUTIONS ON THE PHENOLIC GROUP
WIN 52035 H H H H 5 1.2 1.0
WIN 54089 H H CH3 H 5 0.8 0.09
WIN 53338 H H CL H 5 2.5 0.06
WIN 54274 H H H CH3 5 1.6 1.2
WIN 54090 H H H CL 5 0.3 0.9
Table 4
Comparison of the inhibition of Influenza A and Measles 
viruses by different oligopeptides (Chopin et al., 1983).
Table 5
Effect of modifying the structure of WIN 51711 and WIN 52084 
on anti-HRV 14 and anti-HRV 2 activity: the numbers shown 
are "minimal inhibitory concentrations (MIC)", which is 
defined as the concentration which reduces plaque numbers by 
50% in cell culture (from Smith et al.f 1986).
1 ~ Mifntommim
fc y ifrw M u iU i (Am antadine)
Rnwitadm
WIN 51711
Arildone
WIN 52084
r o  09-0410
, 4 '-Ethoxy-2•-hydroxy-4,6'-dimethoxychaleone I
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Dichloroflavan KMI-15.731
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Figure 2
Structure of compounds which affect early pre-synthetic 
steps in the virus life cycle.
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Figure 3a
Diagrammatic representation of WIN compound binding site 
(from Smith et al., 1986).
Figure 3b
Model for attachment of picornaviruses, dismantling of the 
protective protein shell, and delivery of the RNA to a site 
where translation can begin.
1: Loose reversible attachment of antireceptor on 
the virion surface to one of the membrane-associated 
receptor units drifting in the liquid plasma membrane.
2: Attachment becomes tighter as mobile receptor 
units are recruited from the membrane surface: this process 
simultaneously draws the membrane around the virion to begin 
the invagination process.
3: Conformational alteration to the protein shell as 
indicated by susceptibility of the particle to digestion 
with proteases and loss of VP4 to form "A particles".
4a: Entry of particle, or delivery of the RNA 
genome, into the cytoplasm; this process is accompanied by 
many abortive events including elution or sloughing into the 
medium of A particles in the cases of polio, coxsackie, echo 
and human rhinoviruses (step 4b); or release of free RNA and 
12-14S protein subunits in the case of cardio and 
apthoviruses, whose shells are less stable (step 4c).
(from Boulanger and Lonberg-Holm, 1981).
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1.1.2. COMPOUNDS WHICH AFFECT TRANSCRIPTION AND/OR
PROCESSING OF mRNA 
RIBAVIRIN
Ribavirin (Fig 4a) was first synthesised in 1972, and 
was reported to have activity against a range of RNA and DNA 
viruses in vitro ( Sidwell et al., 1972). (Table 7). Its
mode of action is not entirely clear and cannot be
elucidated from resistant mutants, as these have not been
isolated to date. There are several possible reasons for the
inability to isolate mutants; the change required for relief 
from inhibition invariably leads to a lethal mutation in the 
virus (perhaps this locifthas multiple functions); there may 
be several targets for drug action such that simultaneous 
mutations in several loci are required; or this may reflect 
a lack of selective toxicity in the mode of action.
Upon entering the cell, ribavirin is rapidly 
phosphorylated by cellular adenosine kinase to its' 5' 
monophosphate and then further phosphorylated to its' 5' 
triphosphate presumably by cellular enzymes. Ribavirin and 
its' 5' phosphate derivatives are unique in that the amido 
group which should be preferably coplanar with the triazole 
ring, can be rotated so that ribavirin resembles adenosine 
for phosphorylation by adenosine kinase, or as in ribavirin 
5' triphosphate (RTP), the carbox-amido group can be rotated 
to resemble either GTP or ATP. The monophosphate form of 
ribavirin has been shown to inhibit IMP dehydrogenase, the 
enzyme responsible for the synthesis of GMP from IMP, 
resulting in reduced levels of GTP pools ( Streeter et al., 
19 73). The triphosphate form of ribavirin is thought to 
inhibit the action of RNA polymerase and in the case of 
influenza RNA polymerase, RTP was shown to compete with both 
GTP and ATP, for the substrate site. Ribavirin has also been 
shown to have activity against a range of retroviruses, 
including HIV (Sidwell et al., 1975; Shannon, 1977; Jenkins 
and Chen, 1981; McCormick et al., 1984). Furthermore, 
McCormick and co-workers (1984), reported considerable 
lowering of reverse transcriptase activity in the presence 
of the drug.
The structure of ribavirin, as noted by single crystal 
X-ray studies of Prusiner and Sundaralingam (1973), is 
strikingly similar to guanosine (Fig 4a), with the carbonyl
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oxygen and the amide nitrogen occupying stereochemically
similar positions to the carbonyl oxygen and the amide ring
in guanosine. The antiviral effect of ribavirin against
measles in Vero cells is partially reversed by guanosine
(Streeter et al., 1973). Guanosine also reverses the
inhibition of haemagglutinin produced by influenza A virus
in MDCK cells. Ribavirin 5' monophosphate is 1000 times more
potent than GMP acting as a feedback inhibitor of IMP
-7
dehydrogenase (Streeter et al. , 1973) (Ki=2.5 x 10
-4 . . .compared to Ki=2.2 x 10 for GMP). This potent inhibition
prevents the formation of XMP and therefore GMP in the cell. 
In this sense there is a remarkable self-potentiation effect 
of ribavirin, since the natural GTP pool is considerably 
lowered which diminishes the reversing effect of GTP, since 
GTP competes with ribavirin 5' triphosphate for the GTP 
sites on viral RNA polymerase.
The 5' triphosphate form of ribavirin has also been 
shown to affect capping of mRNA. Goswami and co-workers 
(1979) showed that ribavirin 5' triphosphate exhibits a 
potent inhibitory effect on the 5' terminal guanylation of 
in vitro synthesised uncapped viral mRNA of vaccinia virus. 
It has not been established whether ribavirin as the 5' 
triphosphate is actually incorporated into the cap in place 
of GTP. Further studies have shown that 5 1 triphosphate is 
an effective inhibitor of vaccinia viral mRNA
7
guanine-N -methyltransferase (Goswami et al., 1981).
Ribavirin 5' triphosphate at 25uM gives a 70% inhibition of 
this viral enzyme. Studies on the mechanism of action of 
ribavirin against VSV in CHO cells, indicated no effect on 
cellular protein synthesis, but while VSV mRNA was 
synthesised, it was not functional and could not be 
translated. Such studies support the concept of 
interferences with viral 5' cap formation (Toltzis and 
Huang, 1986).
Despite its' broad antiviral spectrum, ribavirin has 
been licensed in the U.S.A. and Canada, only for the 
treatment of respiratory syncytial virus (RSV) infections in 
infants. This is partly because of unpersuasive evidence of 
antiviral activity in man and partly because of indications 
of toxicity. More recently however, two areas have shown 
particular promise. Firstly in laboratory animal models ,
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ribavirin has been shown to have significant inhibitory 
effects against potentially dangerous pathogenic viruses 
such as Rift Valley fever virus, Punta Toro, Hantaan, 
Pichinde, Machupo and Lassa fever virus (Canonico et al., 
1984). Lassa fever virus-infected cynomologus monkeys die 
with a mean time of 15 days. All monkeys treated with 
ribavirin on days 0-4 survived. When treatment was delayed 
until day 7, 4 out of 8 monkeys still survived. This
remarkable protection with ribavirin, even late in 
infection, prompted a major clinical trial of ribavirin in 
Sierra Leone, West Africa against Lassa fever. McCormick et 
al. (1986), reported that ribavirin is effective in the 
treatment of Lassa fever either intravenously or orally and 
may be used at any point in the illness. In high risk 
patients, the fatality rate was reduced from 55% to 5% by 
ribavirin treatment.
Secondly, as stated previously, ribavirin displays 
activity against a range of retroviruses, and this prompted 
a study of the effects of this drug on HIV. McCormick and 
co-workers (1984), studied the effects of ribavirin against 
HIV in vitro, and reported viral suppression at 50ug/ml and 
considerable lowering of reverse transcriptase activity. A 
double-blind placebo controlled trial (Roberts et al., 1986) 
seemed to show that the drug delayed the progression of 
lymphadenopathy syndrome (LAS) to developing full blown 
AIDS. However, the Food and Drug Administration, citing 
irregularities of the protocol, rejected the manufacturers 
new drug application. Despite this, NIH has not totally 
given up on ribavirin.
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AZIDOTHYMIDINE (AZT, 3 1-AZIDQ-31-DEQXYTHYM1DINE, Fig 4b)
Azidothymidine (AZT), represents a 3'-modified 
derivative,first synthesised by Horwitz et al. , (1964). It 
can inhibit a range of retroviruses, including the 
aetological agent of acquired immune deficiency syndrome 
(AIDS), human immunodeficiency virus (HIV), and enjoys the 
distinction of being the first compound, licensed by the 
Food and Drug administration for the treatment of AIDS 
(1987). This discussion will be confined to the effects of 
AZT on HIV, in vitro and in vivo. It was first shown to--------    jCj<So
exhibit anti-HIV activity in vitro in 1985 (Mitsuya et al,) 
inhibiting HIV replication at concentrations in the range 
50-500nM. Furthermore, this inhibition was shown to be 
selective for HIV as the growth of uninfected human 
fibroblasts and lymophocytes was observed only at 
concentrations of AZT above luM.
AZT is converted to the 5' mono, di and triphosphate 
forms in both uninfected and HIV-infected cells, 
phosphorylation being performed by cellular kinases (Furman 
et al., 1986). Conversion to the monophosphate form is
performed by cellular thymidine kinase, while conversion to 
the di and triphosphate forms is performed by cellular 
thymidylate kinase. Kinetics of this process have been 
investigated and reveal that the phosphorylation process is 
highly dependent on the cell species i.e. in murine cells 
AZT is readily converted to the triphosphate form whereas in 
human and caprine cells, AZT accumulates as the 5' 
monophosphate form, with relatively low levels of the 
triphosphate form (De Clercq, 1988b).
At the triphosphate level, AZT is a very potent 
inhibitor of the HIV-encoded reverse transcriptase being a 
100 fold (Furman et al., 1986), or 1000 fold (Vrang et al., 
19 87) more potent than the inhibition of DNA polymerase 
Cheng et al., (1987), found AZT triphosphate to be 100 fold 
more inhibitory to HIV reverse transcriptase than to 
cellular DNA polymerase, the IC5Q (concentration of 
inhibitor that inhibits enzyme activity 50%), being 0.04uM 
and 39uM respectively. Therefore, although AZT is 
non-selectively phosphorylated, the triphosphate derivative 
efficiently and selectively binds to HIV reverse 
transcriptase. It is not clear whether AZT is incorporated
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into the synthesised DNA, but if it were then chain 
termination should ensue since AZT has no 3' hydroxyl 
(Furman et al., 1986; Ostertag et al., 1974). Furthermore 
AZT severely reduces intracellular dTTP due to inhibition of 
dTMP kinase by the monophosphate form of the drug (Furman et 
al., 1986), thereby facilitating interaction of the
triphosphate form of the drug with the reverse transcriptase 
by reducing levels of the competing substrate.
As stated previously, AZT was licensed for use against 
AIDS in 1987, only two years after it was first shown to be 
active against HIV in vitro. In July 1985, the first patUrnt 
was entered into a clinical study. A multicentre placebo 
controlled trial was initiated in early 1986, with 282 AIDS 
patients with pneumocystis carinii pneumonia or other 
AIDS-related complex (ARC). Sixteen weeks into the study an 
independent review committee noticed significant differences 
in the mortality rates. Sixteen of the 137 patients on the 
placebo had died, whereas none on AZT died. Patients taking 
AZT had fewer opportunistic infections, improved immune 
function with increased circulating T cells, weight gain and 
a general sense of well being. For these reasons the 
independent review board, prematurely terminated the study, 
and those on placebo were given AZT. This drug was therefore 
licensed in 1987, with many questions on long term benefits 
and effects left unanswered.
Until recently, AZT was recommended for the 
approximately 40,000 people with full blown AIDS or advanced 
"AIDS-related complex". However, clinicians and researchers 
hoped that if AZT could help these very sick individuals, it 
might be even more beneficial for infected people who were 
still healthy.
Recent clinical studies have confirmed these hopes 
(Marx, 1989). NIAID released the results of a study showing 
that AZT could slow the progression of AIDS in people with 
very early symptoms. These potential new users are infected 
with the AIDS virus but remain asymptomatic even though 
their counts of T4 immune cells have dropped below 5 00. (The 
normal count is in the range of 600 to 1200).
Another study included 3200 people, 1300 of whom had 
T4 counts less than 500. These individuals were divided into 
three equal groups; one of which received a placebo, the
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second a low dose of AZT (500mg/day), and the third a high 
AZT dose (1500mg/day). The end point for the study was 
progression to AIDS or severe AIDS related complex. It was 
shown that a person was twice as likely to progress on 
placebo as he was on AZT. The low dose worked as well as the 
high dose. In the placebo group, 38 people got worse, 
compared to only 17 in the low dose group and 19 in the high 
dose category. Many patients with advanced AIDS cannot take 
AZT because of the severe side effects it causes them. This 
may not be a problem for people who begin taking the drug 
before symptoms begin. The side effects were mild in 
asymptomatic patients, limited to nausea, in 3% of those 
who took the lower dose. On the basis of these results,
NIAID officials immediately stopped the portion of the trial 
that included people with T£ counts below 5 00, so that those 
in the placebo group could begin taking AZT. Meanwhile the 
study continues for those with T4 counts greater than 500, 
as there is not yet enough data to test whether the drug 
sUows AIDS progression in these people as well.
Larder et al. (1989), recently reported that isolates 
of HIV from patients receiving long term AZT therapy may 
have reduced sensitivity to the drug. Although no one knows 
just how long AZT will remain effective in asymptomatic 
patients, it may at the very least buy time for them until 
more effective and less toxic AIDS drugs can be developed.
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DIPEOXYCYTIDINE (ddCyd) (Fig 4b)
Dideoxycytidine (ddCyd) and other
21,3'-dideoxynucleosides including ddAdo, ddGuo, and ddThd, 
are all potent and selective inhibitors of HIV replication, 
with ddCyd being the most potent in the series (Mitsuya and 
Broder, 1986). At 0.5uM, it confers complete protection of 
ATH8 cells against the cytopathogenicity of HIV, while not 
being toxic for the host cells at concentrations up to 25uM. 
The mode of action of ddCyd is thought to be similar to that 
of AZT, with the triphosphate form interacting with HIV 
reverse transcriptase, <and- incorporat-ten into the DNA chain, 
leading to termination of elongation (Cooney et al., 1986). 
Unlike AZT, however ddCyd does not reduce the intracellular 
pyrimidine pools and therefore may not result in the bone 
marrow suppression that occurs with AZT. In addition, 
pre-clinical studies have found good oral bioavailablity, 
direct excretion by the kidney and relative lack of 
cytotoxicity in animals (Mitsuya and Broder, 1986). 
Comparative studies of AZT and ddCyd revealed that ddCyd was 
less potent than AZT, with an of O.OluM compared to
O.OOluM for AZT (De Clercq, 1988). (ED^: 50% effective dose 
required to achieve 50% protection of ATH8 or MT4 cells 
against the cytopathic effects of HIV). However, the 
selectivity of these compounds was the same, with a 
selectivity index of 500 (ratio of the 50% cytotoxic dose 
[required to reduce the viability of the uninfected host 
cells by 50%] to the ED^q ) (De Clercq, 1988b).
The potency and selectivity of this compound and its' 
relative lack of toxicity (at least in animals), has led to 
the setting up of clinical trials, which are currently being 
conducted.
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OTHER INHIBITORS OF REVERSE TRANSCRIPTASE
PYROPHOSPHATE ANALOGUES: PHOSPHONOPHORMIC ACID (PFA) AND 
CARBONYLBIPHOSPHONIC ACID (CPFA) (Fig 4c)
The pyrophosphate analogue PFA, is best known as an 
anti-herpetic compound. It has been shown to have selective 
activity against viral DNA polymerase, binding directly to 
the pyrophosphate binding site (Helgstrand et al., 1980). 
More recently PFA and another pyrophosphate analogue 
carbonylbiphosphonic acid, have been shown to inhibit 
reverse transcriptase (Vrang and Oberg, 1986; Sarin et al., 
1985; Sanstorm et al., 1985). PFA has recently undergone 
clinical evaluation in man for the treatment of AIDS, 
although preliminary results have been disappointing.
SURAMIN, EVANS BLUE AND AURINTICARBOXYLIC ACID (Fig 4d)
All of these compounds have activity against HIV. 
However, their mode of action is not entirely clear. It is 
thought that they owe their selectivity to
1.) greater affinity for HIV reverse transcriptase 
than for cellular DNA polymerase and/or
2.) easier accessibility to HIV reverse transcriptase 
(located in the cytosol) than to cellular DNA polymerase 
(located in the nucleus and mitochondria).
All three compounds probably exert their effect against HIV 
by reducing the affinity of the key reverse transcriptase 
enzyme for the template/primer molecule (De Clercq, 19 86).
Although suramin exhibited in vitro activity, and in 
vivo viral inhibition was observed, no significant clinical 
benefit or immunological improvement was found. This 
compound does not cross the blood/brain barrier, and has 
various toxic side effects, including lymphotoxicity and 
renal and adrenal toxicity. Not surprisingly therefore, 
suramin has not been selected for large scale clinical 
trials. The clinical efficacy of evans blue and 
aurinticarboxylic acid remains to be determined. 
OLIGONUCLEOTIDES
Modified oligonucleotides (triphosphates), have been 
made which are stable but are still internalised by the 
target cell (Gallo and Reitz, 19 88). These compounds seem to 
inhibit the reverse transcriptase of genomic RNA early in
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infection with HIV 1. They are thought to act by binding to 
the genomic RNA and blocking elongation of DNA. The in vivo 
efficacy and clinical application of these compounds remains 
to be determined.
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INHIBITORS OF CAPPING mRNA
NEPLANOCIN A AND RELATED COMPOUNDS: DHPA, AHPA, C-cADO, 
DHCA[13, AND DHCA[23 (Fig 4e)
All of these compounds are adenosine analogues which 
inhibit a range of RNA and DNA viruses in vitro (De Clercq, 
1988a) (Table 8). These compounds are all inhibitors of the 
enzyme s-adenosylhomocysteine hydrolase (AdoHcy), which 
plays a regulatory role in the transmethylation reaction 
required for capping of mRNA. Since capping and methylation 
of mRNAs were first identified (Reddy et al., 1974; Perry 
and Kelly, 1974), it has become apparent that cap structures 
are present on virtually all eukaryotic mRNAs. Similarly, 
mRNAs from most plant and animal viruses have been shown to 
contain caps (Banerjee, 1980). Only picornaviruses (e.g. 
polio), and the plant viruses, cowpea mosaic virus, 
satellite tobacco necrosis virus and its' helper virus have 
been found to lack cap structures. However, in place of a 
cap, the first two of this group (polio and cowpea mosaic 
virus), have a protein covalently linked to the 5' end of 
their RNA genome.
Much has been learned about the structure, mechanism 
of synthesis and the functional role of caps (Banerjee,
19 80). Capping has been shown to protect mRNA against 
nuclease digestion, from the 5' end of the molecule, thereby 
enhancing its' stability in the cytoplasm (Furuichi, 
Finandra and Shatkin, 1977). In addition, methylation of the 
blocking nucleosides increases the affinity for ribosome 
binding to the 5' end of the mRNA during formation of the 
translational initiation complex (Both et al., 1975). As a 
result, translational efficiency of capped mRNAs is 
significantly increased over that of uncapped mRNAs (Both, 
Banerjee and Shatkin, 1975). Because capping is observed to 
occur during the early steps of precursor heterogeneous 
nuclear RNA (hnRNA) synthesis, it has also been proposed 
that these structures are intimately involved in, and 
perhaps required for biosynthesis of complete precursor 
transcripts (Darwell, 1979). In several studies of viral 
transcriptional systems, there appears to be a direct 
relationship between the presence of 5' cap structures and 
completed viral mRNA transcripts and thus, viral replication
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(Banerjee, Abraham and Colonno, 1977).
The general structure of the 5' cap (Fig 5a), includes 
a blocking guanosine nucleoside bound to the penultimate 
residue of the mRNA through a unique 5'-5' inverted linkage. 
While the capping moiety is, with few exceptions, 
7-methylguanosine, the penultimate (Nl) and adjacent 
nucleoside (N2) can be either purine or pyrimidine bases. 
Moreover, the methylation of these latter two nucleosides 
can vary giving rise to three distinct cap structures: 
7mG(5')ppp(5')NlpN2p...(cap 0); 7mG(5')ppp(5')NlmpN2p...(cap 
1), and 7mG(5')ppp(5')NlmpN2mp...(cap 2). At least three 
specific enzymes are responsible for the biosynthesis of 
capped and fully methylated mRNAs (Fig 5b). mRNA 
guanyltransferase, in the presence of GTP, catalyzes the 
first step in these reactions in which the capping 
nucleoside is attached to a 5' nucleotide chain (primer), 
through the 5 1 — 5 * inverted linkage (Fig 5b). Subsequent 
methylation of this capped structure is accompanied by two 
specific AdoMet-dependent methyltranferases; guanine-7 
methyl transferase which methylates the 7 position of the 
guanosine residue and nucleoside-21 methyl transferase which 
methylates the 2' O-ribose moieties in nucleotides Nl and 
N2. All AdoMet-dependent methyltranferases follow a reaction 
scheme (Fig 5c), which results in the formation of the 
product S-adenosylhomocysteine (AdoHcy).As AdoHcy is a 
potent competitive inhibitor of these AdoMet-dependent 
methyltranferases, the rate of methylation is regulated by 
the existing intracellular ratio of AdoHcy/AdoMet (Cantoni 
and Chiang, 1980; Chiang and Cantoni, 1979). Consequently, 
AdoHcy must be continuously degraded or eliminated in order 
to maintain some potential for methylation to proceed.
In eukaryotic cells, the only route for metabolism of 
AdoHcy is via hydrolysis by AdoHcy hydrolase to adenosine 
and homocysteine (de la Haba and Cantoni, 1959) (Fig 5c). In 
vivo, the rapid metabolic elimination of both adenosine and 
homocysteine drive the reaction in the hydrolytic direction, 
maintaining relatively low intracellular levels of AdoHcy 
and permitting methylation to continue at the required rate.
In the light of the evidence that capped and 
methylated viral mRNAs, are required for the efficient 
translation into proteins which are essential for viral
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replication, these post-transcriptional modifications have 
become an attractive target for the design of antiviral 
agents. The most promising approach has been to design 
inhibitors of AdoHcy hydrolase, the key enzyme responsible 
for AdoHcy metabolism (Fig 5c); inhibition of the hydrolase 
will result in a direct increase in intracellular levels of 
the endogenuo^s product inhibitor of AdoMet-dependentmethyl 
transferase reactions.
On the basis of earlier reports that
5'-deoxy-5'-(isobutylthio)-adenosine apparently elicited 
antiviral effects (Raies et al., 1976)/ through the
inhibition of viral RNA methylation (Jacquemont and Huppert, 
1977), Cantoni and his colleagues established AdoHcy 
hydrolase as an antiviral target by showing that two 
inhibitors of this enzyme (3-deazaadenosine and 
5'-deoxy-5'-(isobutylthio)-3-deazaadenosine) could prevent 
the replication of Rous sarcoma and other viruses as well as 
the viral transformation of chick embryo cells (Bader et 
al., 1978; Chiang et al., 1978; Bodner, Cantoni and Chiang, 
1981). As a result of the increased understanding of the 
biochemical properties and mechanism of catalysis of AdoHcy 
hydrolase obtained since these initial studies, a wide range 
of adenosine analogues have been synthesised and evaluated 
as hydrolase inhibitors with antiviral activity: these 
include: Dihydroxypropyladenine (DHPA) (Vortuba and Holy,
1980; De Clercq et al., 1978b; De Clercq and Holy, 1979); 
Adeninylhydroxypropanoic acid (AHPA) (De Clercq and Holy,
19 85); Carboxylic deazaadenosine (C-cAdo) (Montgomery et 
al.,1982) and neplanocin A (Borchardt, Keller and 
Patel-Thombre, 1984; De Clercq, 1985) (Fig 4e).The antiviral 
spectrum of these compounds is similar, and their antiviral 
potency increases in the order DHPA < AHPA < C-cAda < 
neplanocin A, as does their inhibitory potency for AdoHcy 
hydrolase. In fact a close correlation has been established 
between the antiviral potency of these compounds (i.e. 
against vesicular stomatitis virus) and their Ki/Km values 
for bovine liver AdoHcy hydrolase activity (measured in the 
direction of AdoHcy synthesis. (De Clercq and Cools, 1985).
Current studies have focused' on the most potent of 
these compounds, neplanocin A. The catalytic mechanism of 
AdoHcy hydrolase, as described by Palmer and Abeles (19 76/
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19 79), involves an NAD+-dependent oxidation of the 3' 
hydroxyl group <>f AdoHcy, resulting in the generation of a 
series of 3'-keto intermediates prior to the release of 
adenosine and homocysteine. Inhibition,of AdoHcy hydrolase 
by neplanocin A is thought to be the consequence of the 
reduction of NAD+ to NADH. This is supported by the 
observation that in vitro enzymatic activity can be 
recovered by incubation with excess NAD+ (Matuszewska and 
Borchardt, 1987).
Neplanocin A, has been shown to inhibit AdoHcy
hydrolase in a variety of cultured cell lines (Borchardt,
Keller and Patel-Thombre, 1984; Aarbakke et al., 1985;
Keller and Borchardt, 1986; Whaun et al., 1986), resulting
in an accumulation of AdoHcy and a dramatic increase (10-12
fold), in the intracellular ratio of AdoHcy/AdoMet. These
changes however, are subsequently reflected in a decrease: in
AdoMet-dependent methylation in the treated cells.
Neplanocin A however, exhibits multifunctional activity (Fig
6a), since it is also a substrate for adenosine deaminase
(Tsujino et al., 1980), which rapidly converts it to the
i
biologically inactive neplanocin B, and for adenosine kinase 
leading to the formation of the triphosphate derivative
which AdoMet synthetase converts to the corresponding AdoMet 
derivative S-neplanocymethionine (NpcMet) (Glazer and Knode, 
1984; Keller et al. , 1985; Saunders, Tan and Robins, 1985; 
Inaba et al., 1986). Although deamination appears to be of 
little significance in studies with cultured cells (i.e. 
inhibitors of adenosine deaminase do not enhance the 
activity of neplanocin A), the latter metabolic route has 
been proposed to be responsible for the observed suppression 
of cellular RNA synthesis and the significant cytotoxic 
action of neplanocin A. After inoculation intranasally with 
VSV, young mice treated with neplanocin A showed partial
reduction in the mortality rate. However, toxicity of the 
compound was a problem e.g. 20ug of neplanocin A per mouse 
was found lethal to newborn mice if infected
intraperitoneally (De Clercq et al., 1985b). This
cytotoxicity of neplanocin A demonstrable both in vivo and 
in vitro is the major factor limiting its' use as an 
antiviral.
In an attempt to design more specific monofunctional
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antiviral agents (i.e.AdoHcy hydrolase inhibitors), with 
minimal other side effects (i.e. adenosine deaminase, 
adenosine kinase), two analogues
9-(trans-2'trans-3'-dihydroxycyclopent-41enyl)-adenine 
[DHCAl] and 3-deazaadenine [DHCDA 2], have been synthesised 
(Borcherding, 1987), which lack the 4' hydroxymethyl group 
of the corresponding parent molecule (Fig 4e). These 
analogues, like neplanocin A, produce time and concentration 
dependent inhibition of AdoHcy hydrolase (Borcherding, 
1987), while lacking substrate activity with either 
deaminase or the kinase, confirming their monofunctional 
design (Fig 6b). In mouse L 929 cells, the concentrations 
required to give 9 5% inhibition of AdoHcy hydrolase activity 
were 0.2uM, 0.5uM and 0.5uM for neplanocin A, DHCA 1 and
DHCA 2 respectively (Hasobe et al., 1988). Moreover, these 
analogues exhibited inhibition of cellular AdoHcy hydrolase, 
which persisted throughout 72h whereas that of neplanocin A 
began to recover after 48h. Similarly, the elevation of 
intracellular levels of AdoHcy by DHCA 1 and DHCA 2 was 
maintained throughout 72h in comparison to that of 
neplanocin A treated cells which had decreased to near 
control levels by this time. These compounds had no effect 
on either cellular RNA or DNA synthesis at concentrations up 
to lOuM.
Both compounds had potent antiviral activity against 
vaccinia virus-infected L 929 cells, exhibiting IC^q at 
0.28uM and 0.95uM, respectively as compared with 0.08uM for 
neplanocin A (Hasobe et al., 1988). More striking however, 
was the reduced cytotoxicity observed with these analogues: 
IDj.q for neplanocin A, DHCA 1 and DHCA 2 was 0.5uM, 17uM and 
56uM respectively. As a consequence of the reduced 
cytotoxicity of compounds DHCA 1 and DHCA 2, their antiviral 
effectiveness (ID5q/IC5q)' an(* ^9 respectively was found 
to be significantly higher than that of neplanocin A (i.e. 
6). These studies also indicated that the intracellular 
ratio of AdoHcy/AdoMet required for antiviral activity is 
significantly lower than that which elicits cytotoxic 
affects, suggesting that the virus specified 
methyltransferases may be inherently more sensitive to 
changes in this ratio than cellular counterparts, conferring 
some selectivity. It should be noted however, that the
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studies described have all been performed in vitro, and that 
the in vivo efficacy of these compounds needs further study.
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OTHER INHIBITORS OF CAPPING mRNA
ADOMET AND ADOHCY ANALOGUES (Fig 4f,q and h)
ADOMET ANALOGUES
Another approach to blocking the capping process, has 
been the design of inhibitors against the various 
AdoMet-dependent methyltransferases themselves. Numerous 
structural analogues of both AdoMet and AdoHcy have been 
prepared and examined with the aim of increasing their 
specificity and eliminatimng potential metabolic side 
effects (Zappia, Zydek-Cwick and Schlenk, 1969; Schlenk and 
Dainko, 1974; Borchardt et al., 1976; Schlenk, Hannum and 
Ferro, 1978). In general, these analogues have exhibited 
poor substrate and/or inhibitor properties, reflecting the 
high degree of structural specificity required by the 
methyltransferase enzymes. Two AdoMet analogues however, 
Sinefungin and A9145C (Fig 4f), which are artificial 
antibiotics were found to elicit potent inhibitory activity 
towards a variety of methyltransferases (Vedel et al., 1978; 
Fuller and Nagarajan, 1978; Borchardt et al., 1979), 
including the virion mRNA (guanine-7)-methyltransferase from 
both vaccinia and Newcastle disease viruses, and the mRNA 
(nucleoside-2')-methyltransferase from vaccinia virus (Pugh, 
Borchardt and Stone, 1978). These compounds were also 
observed to inhibit vaccinia virus plaque formation in 
monolayer cultures of mouse L 9 29 cells, but only in 
relatively high concentrations (Borchardt and Pugh, 1979), 
reflecting their low cellular permeability. This appears to 
be a major problem limiting the in vivo efficacy of AdoMet 
analogues which exhibit good in vitro activity.
ADOHCY ANALOGUES (Fig 4g and h)
Systematic analysis of base, amino acid or sugar 
modified analogues of AdoHcy was attempted to determine the 
structure-activity relationships for binding of specific 
inhibitors to particular methyltransferases. Using purified 
viral mRNA methyltransfersases, this approach has delineated 
significant differences in the structural requirements not 
only between Newcastle disease virus (NDV) and vaccinia 
virus mRNA (guanine-7)-methyltransferase, but also between 
this enzyme and the accompanying mRNA 
(nucleoside-2')-methyltransferase within the vaccinia virion
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itself (Borchardt and Pugh, 1979), suggesting that it is 
possible to design site specific agents. For example, the 
base modified analogues, S-tubercidinyl-L-homocysteine (Tub 
H) and 8-aza-AdoHcy were found to have potent inhibitory 
activity toward NDV mRNA (guanine-7-) methyltransferase but 
were essentially inactive toward the vaccinia virion enzyme, 
although Tub H did exhibit potent activity toward the 
vaccinia mRNA (nucleoside-21) methyltransferase.
3-deaza-AdoHcy however, was more selective for both the 
vaccinia enzymes as compared to that from NDV. In contrast 
to Tub H which like AdoHcy has been observed to be a more 
general inhibitor of AdoHcy-dependent methylation, other 
AdoHcy analogues such as AdoHcysulfone, AdoHcy sulfoxide and 
N^-methyl AdoHcy are reported to be more selective 
inhibitors for virion mRNA (guanine-7) methyltransferases 
(Pugh, Borchardt and Stone, 1977). Despite the promising 
activity that some of these analogues have exhibited in 
vitro, few have been found to elicit significant in vivo 
activity. Those with most notable activity are Tub H, whichc
has been shown to inhibit internal N -adenosine methylation 
in mRNA (as high as 80% at 500uM) in phytohaemagglutin 
stimulated rat lymphocytes, Novikoff heptoma cells and Hela 
cells (Chang and Coward, 1975; Kaehler, Coward and Rottman, 
19 79; Camper et al., 1984) and 5'-deoxy-5'-(isobutylthio) 
adenosine (SIBA) which has been observed to inhibit the 
replication of several viruses and virus-induced 
transformation of chick embryo cells at relatively high 
(500uM) concentrations (Raies et al., 1976; Jacquemont and 
Huppert., 1977). Thus, like AdoMet analogues, the low
cellular permeability of AdoHcy analogues appears to be a 
major factor limiting their in vivo effectiveness.
INTERFERON
Interferon (IFN), (Isaacs and Lindemann, 1957) is
produced by virus-infected cells and protects uninfected 
cells from viral infection, inducing in them an antiviral 
state against essentially all viruses. Investigation of 
IFNs' mode of action has revealed that it has multiple 
biological effects (Gresser et al., 1979). Several stages in 
the virus life cycle, including DNA, RNA and protein
synthesis are all affected (Stewart, 1979). Protein 
synthesis is inhibited by interferon in several ways
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including the inhibition of methylation of viral mRNA . Sen 
et al. (1977), first discovered that a labile inhibition of 
reovirus mRNA is induced in interferon treated cells. 
However, as only the 2-0-methylation of the ribose moieties 
is diminished the mRNA is translated satisfactorily. 
Subsequently, it was demonstrated that VSV mRNA is not 
translated in interferon treated cells because in this case 
the 5'-terminal guanosine cap is unmethylated, apparently as 
a result of interferon-induced changes in the levels of 
AdoMet and AdoHcy (de Ferra and Baglioni, 1981, 1983).
COMPOUND ANTIVIRAL
SPECTRUM
TARGET/S PROPOSED MODES OF 
ACTION
RIBAVIRIN RNA AND DNA
VIRUSES
(SEE TABLE 7)
RNA POLYMERASE 
(TRANSCRIPTION)
REVERSE TRANSCRIPTASE
■RNA GUANYL 
TRANSFERASE
(CAPPING)
IMP DEHYDROGENASE 
(POOLS OF GTP)
RIBAVIRIN-TRIPHOSPHATE 
COMPETES FOR THE 
SUBSTRATE SITE/S
RIBAVIRIN-MONOPHOSPHATE 
COMPETES FOR THE 
SUBSTRATE SITE
AZIDOTHYMIDINE
(AZT)
RETROVIRUSES 
INCLUDING HIV
REVERSE
TRANSCRIPTASE
dTMP
KINASE
(POOLS OF dTTP)
AZT-TRIPHOSPHATE 
COMPETES FOR SUBSTRATE 
SITE
INCORPORATION INTO DNA; 
TERMINATION OF 
ELONGATION
AZT-MONOPHOSPHATE 
COMPETES FOR SUBSTRATE
SITE
D1DEOXYCYT1DINt 
(ddCyd)
HIV REVERSE
TRANSCRIPTASE
SAME AS AZT
PHOSPHONOFORMIC 
ACID 
(PFA)
CARBONYL- 
BIPHOSPHONIC 
ACID (CBPFA)
HIV
REVERSE
TRANSCRIPTASE
BINDS TO 
PYROPHOSPHATE 
BINDING SITE
SUHARIN.
EVANS BLUE. 
AURINTR1CARBOXYLIC 
ACID
HIV REVERSE
TRANSCRIPTASE
NOT CLEAR; 
PROBABLY 
REDUCES THE 
AFFINITY OF RT 
FOR THE 
TEMPLATE
OLIOONUCLBOTIDBS 
(THIOPHOSPHATES)
HIV REVERSE
TRANSCRIPTASE
PROBABLY BY 
BINDING TO 
GENOMIC RNA AMD 
BLOCKING 
ELONGATION
NEPLANOCIN A 
AND BELATED 
COMPOUNDS
A RANGE OF 
CAPPED RNA AND 
DNA VIRUSES 
(SEE TABLE B)
SAH HYDROLASE 
(CAPPING OF aRNA)
REDUCES NAD 
(NAD— VNADH) 
REQUIRED FOR 
ACTIVITY OF SAH 
HYDROLASE
OLIGONUCLEOTIDES
(THIOPHOSPHATES)
HIV REVERSE
TRANSCRIPTASE
PROBABLY BY 
BINDING TO 
GENOMIC RNA AND 
BLOCKING 
ELONGATION
NEPLANOCIN A 
AND RELATED 
COMPOUNDS
A RANGE OF 
CAPPED RNA AND 
DNA VIRUSES 
(SEE TABLE 6)
SAH HYDROLASE 
(CAPPING OF aRNA)
REDUCES NAD
(NAD-- NADH)
REQUIRED FOR 
ACTIVITY OF SAH 
HYDROLASE; 
RESULTS IN 
ACCUMULATION OF 
SAH WHICH FEEDS 
BACK AND BLOCKS 
METHYL TRANSFER
SAM, SAM 
ANALOGUES
SOME CAPPED 
RNA AND DNA 
VIRUSES 
VACCINIA, NDV
SAM DEPENDENT 
METHYLTRANSFERASES 
(CAPPING OF aRNA)
COMPETES FOR 
SUBSTRATE SITE
®INTERFERON VSV 8AM AND SAH 
(CAPPING OF aRNA)
UPSETS THE 
RATIO OF 
SAM:SAH. 
THEREBY 
INHIBITING 
METHYLATION
Table 6
Compounds which affect transcription and/or processing of 
mRNA: their antiviral spectrum and proposed mode of action.
^Antiviral spectrum: viruses affected by the action 
of the compound against the particular target shown.
OVSV is given as a specific example where capping of 
mRNA has been shown to be affected, contributing to the 
antiviral effect of interferon.
References: Ribavirin (Streeter et al., 1973? Sidwell et 
al., 1975; Shannon, 1977; Jenkins and Chen, 1981? McCormick 
et al. , 1984); AZT (Furman et al., 1986; Vrarig et al., 1987 
Cheng et al., 1987; Ostertag et al., 1974); ddCyd (Mitsuya 
and Broder, 1986; Cooney et al., 1986? De Clercq, 1988); 
PFA/CBFA (Vrang and Oberg, 1986; Sarin et al., 1985?
Sanstrom et_al., 1985); Sumarin/Evans 
Blue/Aurintricarboxylic acid (De Clercq, 1986); 
Oligonucleotides (Gallo and Reitz, 1988); Neplanocin A etc. 
(Borchardt, Keller and Patel-Thombre, 1984? Matuszewska and 
Borchardt, 1987? Borcherding, 1987); SAM (AdoMet) and SAH 
(AdoHcy) analogues (Jacquemont and Huppert, 1977; Pugh, 
Borchardt and Stone, 1978; Camper et al., 1984); Interferon 
(de Ferra and Baglioni, 1981, 1983).
i DNA VIRUSES ! RNA VIRUSES i 
(EXCLUDING RETROVIRUSES) 1
RETROVIRUSES
Herpes simplex virus I Parainfluenza 1/3 i Freund Leukaemia
! Herpes simplex virus 2 ! Influenza A/B ! Gross murine leukaemia
! Pseudorabies j Rhinovirus 1 Kauscher murine leukaemia
! Murine Cytomegalovirus ! Coxsackie B Rous sarcoma virus
! Vaccinia | Vesicular Stomatitis virus | Human Immunodeficiency virus
! Myxoma ; Semliki Forest virus !
1 1 > 1 1 1
J Adenovirus-3 | !
■ > •
MODERATELY TO HIGHLY SUSCEPTIBLE
Rhabdovirusea (vesicular stomatitis virus)
Poxviruses (vaccinia virus)
Iridoviruses (African swine fever virus) 
Paramyxoviruses (parainfluenza virus, measles virus) 
Reovirus (reovirus, rotavirus)
NOT OR LESS SUSCEPTIBLE 
Adenovirus
Herpesviruses (HSV-I, HSV-2, VZV, ...... )
Picornaviruses (polio virus, coxsackie B virus, rhinovirus) 
Togaviruses (sindbis virus, semliki forest virus)
Table 7
Antiviral activity spectrum of Ribavirin (Witowski et al. , 
1972; Sidwell et al., 1972).
Table 8
Antiviral activity of neplanocin A and related compounds (De 
Clercq, 1988).
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Figure 4
Structure of compounds which affect transcription and/or 
processing of mRNA (a-d).
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Structure of compounds which affect transcription and/or 
processing of mRNA (e,f).
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Figure 4
Structure of compounds which affect transcription and/or 
processing of mRNA (g).(from Pugh,Borchardt and Stone,
1977).
1. RNA Polymerase:
ATP ♦ CTP ♦ GTP ♦ UTP —  PPpN- ♦ PP(
2. g u a n y ly l t ra n s fe ra s e :
y p a v C a a '* V 3
p p pG  ♦ P PpN .................................. GpppN- + Pi ♦ PPi
3. g u a n in e -7  m eth y l t ra n s fe ra s e :
Gp ppN - ♦ A doM et  m 7 G pppN - + A d o H cy
4. n u c le o s id e -2 '  m e th y l t ra n s fe ra s e :
m 7 GpppN- ♦ AdoMet - - - - - -  m 7 G p ppN m - ♦ Ado H cy
A cceptor-CHAcceptor
M e th y  I-
U a n s fe ra s e
product
inhibi t ion AdoHcy
ATP A d e n o s y l -
M e th io n in e  tr a n s fe r a s e
AdenosineA d o H c y .
H y d r o l a s e  H om ocyste ine
Figure 5a: Structure of mRNA 5'-terminal CAP.
Figure 5b: Enzymes involved in the biosynthesis of mRNA CAP 
structures.
Figure 5c; General reaction scheme for AdoMet dependent 
transmethylation.
Polyamines MTNpc
RXH methylase RXCH3YdcNpcMet
tyioMet 
decarboxylase NpcMet
RNA Synthesis 
Inhibition
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Methionine^] AdoMet
Synthetase
NpcTP
Adenosine 
kinase
AdoHcy (NpcHcy)
ADP
ATP
Inhbitionof
Methytation
AdoHcy
hydrolase
Other
Molecular
Sites
NpcA
Adenosine 
deaminase
Npcfr
Ado (Npc)
+
Homocysteine
RXH
AdoMet
RXCH,
methylase
AdoHcyv Inhibition
ATP
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Synthetase
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Ado
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Ino OHCA ( I  ]
D H C 0 A [2 ]
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No effects on 
Adenosine Kinase 
or Adenosine Deaminase
AdoHcy Hydrolase
Ado
In h ib itio n
Homocysteine
Figure 6a
Multifunctional activity of neplanocin A.
Npc, neplanocin A; Npc D, Neplanocin D; NpcTP, 
neplanocin A triphosphate; NpcMet, S-neplanocylmethionine; 
dcNpMet, decarboxylated neplanocylmethionine; MTNpc, 
methylthioneplanocin; NpcHcy, neplanocylhomocysteine; ADO, 
adenosine? RXH, methyl acceptor molecule; RXCH^, methylated 
acceptor molecule.
Figure 6b
Multifunctional activity of DHCA [1] and DHCA [2].
ADO, adenosine? INO, inosine; RXH, methyl acceptor 
molecule? RXCH3, methylated acceptor molecule.
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1.1.3. COMPOUNDS WHICH INHIBIT PROTEIN SYNTHESIS AND/OR 
POST-TRANSLATIONAL MODIFICATIONS: GLYCOSYLATION, 
PHOSPHORYLATION
1.1.3.1. COMPOUNDS WHICH AFFECT PROTEIN SYNTHESIS 
INTERFERON
The cause of tissue immunity was discovered in 19 57 by 
Issacs and Lindemann, when they were studying the 
interfering capacity of inactivated influenza virus. They 
incubated the inactivated virus with fragments of chick 
chorio-allantoic membranes and expected that, because the 
virus was absorbed by the chick cells, the interfering 
capacity of the preparation would decrease. To their 
surprise, the reverse happened, and they were able to show 
that interfering activity was caused by a non-viral agent. 
They named the agent interferon. Interferon appeared to be 
produced by quite a variety of species including fish and 
reptiles after induction by a variety of viruses, both alive 
and inactivated, and also an impressive number of viruses 
appeared to be sensitive to interferon (Stewart, 1979)
The antiviral activity of interferon has been a main 
theme of research for years. The paramount question is: how 
is viral replication inhibited in interferon treated cells 
and at what stage ? The initial lack of pure interferon 
preparations resulted in many different answers to this 
question. The mode of action of interferon is certainly 
complex and virtually all stages of virus replication have 
been reported to be affected by interferon (Stewart, 1979). 
Here, I will not attempt to provide an in-depth revU^w of 
interferon, but illustrate very simply how interferon is 
thought to affect protein synthesis.
Protein synthesis in cell-free extracts from 
interferon treated cells is extremely sensitive to 
inhibition by double stranded RNA (ds RNA)(Kerr, Brown and 
Ball, 19 74). This appears to be due to the activity of 2 
interferon induced, dsRNA-activated enzymes; a cAMP 
independent protein kinase and the 2-5 A synthetase 
(Baglioni, 1979? Revel, 1979; Lengyel, 1981, 1982) (Fig 7). 
PROTEIN KINASE
A dsRNA dependent protein kinase was found 
independently by Lebleu et al. (19 76) and Roberts et al. 
(1976) to phosphorylate at least one protein besides itself
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(autophosphorylation) in extracts of interferon treated 
cells, to which dsRNA had been added. This particular 
protein kinase, which is induced by interferon, was first 
purified by Sen et al. in 1977. The protein phosphorylated 
by the activated kinase was shown to be the alpha subunit of 
the eukaryotic peptide chain initiation factor, eIF-2 
(Farrell et al., 1978). The phosphorylated eIF-2 is
inactive, hence can no longer catalyze the formation of the 
ternary complex between itself, met-tRNA and GTP.
2-5 A SYNTHETASE
The enzyme (2,-5,)(A)n synthetase, induced in
interferon treated cells, catalyzes the synthesis of 2-5A 
from ATP (Baglioni, 1983; Lengyel, 1982). It is active only 
when bound to dsRNA, and its1 products are a family of 
oligoadenylates of a unique kind. The compounds designated 
(2'-5')oligo(A) or (2'-5')(A) , or more strictly,
(21-51)pppA(pA)n, were shown to be oligonucleotides
consisting of short chains of adenosines linked uniquely, by 
2'-5' phosphodiester bonds (rather than 3'-5' bonds found in 
all natural polynucleotides); the most abundant were di, tri 
and tetra-adenylates, but only trimers and longer oligomers 
were active (Kerr and Brown, 1978). Though 2-5A has a short 
half-life, it could be demonstrated in interferon treated, 
virus-infected cells. When introduced artificially into 
cells, 2-5A inhibited protein synthesis, cell division and 
viral multiplication (Cayley et al., 1981).
The mechanism of the antiviral action of 2-5A was
unravelled as a result of the work of several independent 
groups. In the presence of dsRNA and ATP, both reovirus mRNA 
and cellular mRNA were degraded more rapidly in extracts of 
interferon-treated cells (Lengyel, 1982). Clemens and 
Williams (1978), showed that addition of 2-5A to an in vitro 
protein synthesising system reduced the translation of mRNA. 
This was shown to be attributable to an endoribonuclease
that is activated by 2-5A, which destroys both viral and
cellular mRNA, as well as rRNA and perhaps other cellular 
RNAs, by specific cleavage on the 3'-side of U^N doublets 
(Baglioni, 1983; Lengyel, 1982).
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1.1.3.2. COMPOUNDS WHICH AFFECT GLYCOSYLATION
Oligosaccharides can be added to proteins via the 
group on the side chain of an asparagine residue (N-linked 
glycosylation), or less frequently, via the OH group on the 
side chain of serine, threonine or hydroxylysine residue 
(O-linked glycosylation). This discussion will be concerned 
only with N-linked glycosylation. The oligos&ocharide to be 
transferred to an asparagine residue must be present on the 
luminal side of the ER in an activated form. Activation is 
achieved by linking the oligosaccharide to a donor molecule 
via a high energy bond. A major advance came in the early 
19 70s with the discovery that the activated donor is a 
special lipid molecule, dolichol, to which the 
oligosaccharide is linked via a pyrophosphate bridge.
The oligosocoWvcwrk)e is built up sugar by sugar on this 
membrane-bound lipid molecule. Sugars are first activated in 
the cytosol by the formation of nucleotide-sugar 
intermediates, which then donate their sugar (directly or 
indirectly) to the lipid in an orderly sequence (Fig 8a). 
Dolichol is very hydrophobic and quite long; with its' 22 
five-carbon units, it can span the thickness of a lipid 
bilayer more than three times. Since it is firmly embedded 
in the membrane, the attached oligosaccharide is firmly 
anchored to the luminal surface of the ER, where 
glycosylation occurs.
Asparagine linked oligosaccharides are synthesised by 
the en-block transfer of the oligosaccharide (core sugar) 
Glc^MangGlcNac2/ from the lipid carrier dolichol phosphate 
to the nascent polypeptide (Kornfeld and Kornfeld, 1985) 
(Fig 8b). Glucose and several mannose residues are 
successively removed in the ER. The modified glycoprotein is 
then transported in vesicles to the Golgi apparatus where 
subsequent processing occurs. The Golgi apparatus consists 
of three distinct stacks; cis, medial and trans, with 
specific enzymes located in each stack (Fig 8b). The 
progress of a glycoprotein through cellular membranes can be 
traced by the extent to which the oligosaccharides are 
processed. Thus the enzyme, N-acetylglucosaminyltransferase 
1 is localized to the medial Golgi stack (Dunphy, Brands and 
Rothman, 1985), and a glycoprotein must reach that Golgi 
stack to obtain the peripheral GlcNAc residues. The
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galactosyl and sialyltransferases reside in the Golgi stack, 
and the addition of galactose or sialic acid reside in the 
trans Golgi stack, and the addition of galactose or sialic 
acid to an aspard^gine-linked oligosaccharide indicates that 
the particular glycoprotein has reached the trans Golgi 
membranes (Griffiths et al. , 198^ Griffiths, Quinn and
Warren,, 1983; Rothman, Miller and Urbani, 1984). The fully 
processed glycoprotein is then transported in vesicles to 
the plasma membrane and may be secreted from the cell.
Inhibitors of glycosylation were for a long time 
ignored as antiviral agents because cellular as well as 
viral glycoproteins are affected. This was despite the fact 
that these compounds could be safely appied topically to 
epithelial surfaces such as skin, eye or genital tract. 
However, more recently, a series of glucosidase inhibitors 
have been examined for their anti-HIV potential.The 
antiviral properties of a series of polyaroxyalkaloids 
against the growth of HIV in vitro have recently been 
described (Gruters et al., 1987; Tyms et al., 1987; Walker 
et al., 1987). These natural substances, which accumulate in 
plants and microorganisms, but can also be synthesised, bear 
a structural resemblance to monosaccharides. Three different 
structural types have been shown to be active, namely: 1.) 
polyhydroxy derivatives of octahydroindolizine 
(casternospermine; CAST); 2.) piperidine (deoxynorimycin; 
DNJ); 3.) pyrolidine (dihydroxymethyldihydroxypyrolidine;
DMDP) (Fellows, 1986) (Fig 9a). These compounds are 
characterised by their ability to inhibit glucosidase 
activities involved in the trimming of the oligosaccharide 
chains of glycoproteins (Fig 8b). CAST and DMDP both inhibit 
glucosidase 1 (Elbein et al., 1984) (Fellows, 1986), while 
DNJ inhibits both glucosidase 1 and 11 (Furmann, Bause and 
Proegh, 1985).
The external glycoprotein of HIV (gp 120), is the 
major surface component by which the virion attches to CD4 
(T4), cellular receptors on helper T cells (Dalgleish et 
al., 1984). The envelope gene of HIV-1 encodes a precursor
glycoprotein, gpl60 which is cleaved to yield gpl20 and 
gp41, a transmerabrane protein (Muesing et al., 19 85; Ratner 
et_al., 1985; Robey et al., 1985; Veronese et al., 1985).
The gpl20 is heavily glycosylated with up to 24 N-linked
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glycosylation sites (Muesing et al., 1985; Ratner et al., 
1985). The expression of this gp on the surface of the host 
cell after infection is responsible for cell fusion and 
synctium formation (Lifson et al., 1986), and this may 
contribute to the loss of CD4 + cells in AIDS (Barnes, 1986; 
Lifson et al., 1986).
Treatment of HIV-infected T cells in vitro with CAST, 
DNJ or DMDP at concentrations of luM or greater, had a 
profound effect on the production of synctia and virus 
production (Gruters et al., 1987; Tyms et al., 1987; Walker 
et al., 1987). The specificity of this effect was shown by
using CD4+ cells, constitutively expressing the HIV tat gene 
and transfected with a plasmid containing the art and env 
genes of HIV-1 (Sodroski et al., 1986). The spontaneous 
production of large synctia in these cells displayed a dose 
dependent inhibition when exposed to CAST (Walker et al., 
1987). In contrast, deoxymannojirimycin (DMJ) (Gruters et 
al., 1987), which blocks the cleavage of alpha 1,2 mannose 
residues by inhibiting mannosidase 1 (Fig 8b), or 
swainsonine (Montefion, Robinson and Mitchell, 1987), which 
prevents the removal of alpha 1,3 and alphal,6-linked
mannose residues by alpha-mannosidase 11, were both 
ineffective against HIV.
As indicated by the lectin binding studies (Lifson et 
al., 1986), these results support the hypothesis that
oligosaccharides of the high mannose type, present on gpl20 
are critical for correct interaction with the host cell.
When measured by reverse transcriptase or p24 antigen assays 
the extracellular levels of HIV from CAST treated cells were 
equal to those of untreated controls, but infectivity was 
reduced (Walker et al., 1987). It appeared therefore, that 
retention of glucose residues on the surface glycans of HIV 
interfered with infectivity (Gruters et al., 1987; Walker et 
al., 1987). However, incorrect trimming of glucose residues 
is also known to affect the cleavage of precursors and 
intracellular transport of gp and this can alter surface 
expression.
Recent studies with CMV have also shown large
increases in the particle/p.f.u. ratio in infected cells
treated with CAST (>lmM), which clearly correlated with an
s.
altered expression of viral gp on the virion surface (Taylor
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et al. , 1988). In this case, evidence points to the
non-cleavage of a precursor glycoprotein when the glucose 
residues are retained on the glycan moiety. Similarly a 
block in proteolytic treatment of pE2 (Sindbis virus) after 
treatment with methyl-DNJ accounted for the loss of 
extracellular virus (McDowell et al., 1987) and was
consistent with earlier observations made with VSV 
(Schlensinger, Malfer and Schlesinger, 1984) and mouse 
hepatitis virus (Repp et al., 1985)
CAST, DNJ and DMDP are well tolerated in cell culture 
at concentrations with antiviral activity, but only limited 
studies have been performed on in vivo toxicity. The 
injection of young rats with CAST (up to 2000mg/ip), daily 
for three days induced diarrhoea suggesting an inhibitory 
effect against gut glucosidases (Saul et al., 1985). This 
was eliminated when they were fed on a simple diet based on 
glucose rather than complex carbohydrate, although the 
inhibitory activity of 500mg/kg on alpha glucosidases found 
in the liver and other organs was not reversed. Evidence for 
the non-toxic nature of polyhydroxyalkaloids in man was 
provided when derivatives of DNJ were used to control Type 
11 diabetes (up to 200mg/day, orally for three days). The 
medication was well tolerated with no apparent side effects 
(Joubert, Bam and Manyane, 1986; Schnack et al., 1986). 
Further information on toxicity and antiviral activity of 
glucosidase inhibitors in vivo should come from the study of 
retroviral infections in animal models.
Enough is known about the antiviral, activity of 
glucosidase inhibitors to warrant serious clinical studies. 
Although essential supplies of these natural compounds are 
scarce, synthetic substitutes could alleviate the problem. 
Derivatives of these compounds are currently being 
investigated with the aim of identifying more potent agents 
with greater specificity for viral glycoprotein processing. 
Indeed, minor changes in the chemical structure of 
polyhydroxyalkaloids has already been shown to be important 
in influencing the antiviral activity (Tyms et al., 1987)
Finally, if altering the oligosaccharide structure of 
virus glycoproteins proves to be an effective antiviral 
strategy against AIDS, then it might be useful to use these 
in combination with compounds which affect other targets
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(e.g. AZT; r e v e r s e  t r a n s c r i p t a s e ) .
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1.1. 3. 3. COMPOUNDS WHICH AFFECT PHOSPHORYLATION: XANTHATES 
Xanthates display antiviral activity against a range 
of unrelated viruses. Vaccinia, herpes, coxsackie and 
vesicular stomatitis (VSV) viruses and simian virus (SV 40), 
can be inhibited at xanthate concentrations which still 
permit the mitotic activity of uninfected cells (Sauer et 
al. , 1984 ). The mode of action of ths xanthate compound,
tricyclo-decane-9-y1-xanthogenate (D609) (Fig 9b), against 
VSV was recently investigated (Muller-Decker, Amtmann and 
Sauer, 1987). Virus production in D609 treated cells was 
inhibited by around 2 logs by 30ug/ml of D609 at pH7. In 
order to discern the inhibitory affect of D609, the various 
events in the VSV growth cycle were studied. VSV particles 
are taken up into the cell by receptor mediated endocytosis, 
uncoating being facilitated by the fusion of viral and 
cellular membranes. The first synthetic event in the life 
cycle of VSV, is the transcription of its' negative stranded 
RNA genome, to yield 5 monocistronic mRNAs. Transcription 
occurs in two stages termed primary and secondary 
transcription. Primary transcription is performed by the 
virion-associated RNA polymerase complex, thought to 
comprise proteins L, NS and possibly N (Emerson and Yu, 
1975; Mellon and Emerson, 1978; Isaac and Keene, 1982). This 
step is therefore not dependent on new protein synthesis. 
Secondary transcription is performed by the viral polymerase 
consisting of proteins translated from the primary 
transcripts. This step therefore, is clearly dependent on 
protein synthesis following infection and can be blocked 
using inhibitors of protein synthesis, such as 
cycloheximide. The products of primary and secondary 
transcription are the same, consisting of 5 monocistronic 
RNAs. It was shown that while D609 did not affect primary 
transcription, secondary transcription and replication of 
viral RNA were markedly decreased in the presence of the 
compound (Muller-Decker, Amtmann and Sauer, 1987). 
Experiments in vitro have shown that NS protein is involved 
in regulation of the activity of the polymerase complex, as 
the highly phosphorylated form of NS protein stimulated 
VLral RNA transcription more efficiently than did its1 less 
phosphorylated form (Kingsford and Emerson, 1980; Hsu, 
Morgan and Kingsbury, 1982). The phosphorylated NS protein
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binds L protein to the RNA template (Mellon and Emerson,
1978). It was found that D609 inhibited the phosphorylation 
of NS protein in the infected cell, thereby inhibiting both 
secondary transcription and replication of RNA. The
unaltered primary transcription in the presence of D609 can 
be attributed to the phosphorylated NS protein contained in 
the infecting virus particles. Similarly, the degree of 
inhibition of late RNA synthesis (i.e. de novo mRNA and 
genomic RNA synthesis) was found to be multiplicity 
dependent. At a higher m.o.i. (e.g. 50 p.f.u./cell) D609 was 
less efficient. This can also be accounted for by larger 
amounts of previously phosphorylated NS protein L polymerase 
complexes from the infecting viruses. As they are unaffected 
by the inhibitory affect of D609, their biological activity 
is maintained. The phosphorylation of the bulk of cellular 
proteins was apparently not affected by D609, therefore 
inhibition of phosphorylation of the NS protein is a highly 
selective process. The basis for this selectivity is not 
clear. It was shown that a host-derived envelope associated 
kinase and purified L protein were both capable of 
phosphorylating NS protein in vitro (Imblum and Wagner, 
1974; Sanchez, De and Banerjee, 1985), leading to the 
activation of the RNA polymerase complex. In vitro, 
recombined NS protein was phosphorylated by a cellular 
kinase in the absence of any other VSV-coded protein (Hudson 
et al., 1986). It would be of interest to determine if D609 
has any differential effects on the phosphorylation of NS 
mediated by viral or cellular kinases.
As well as exhibiting antiviral activity, D609 also 
has the ability to cause the phenotype of transformed cells 
to revert to a normal morphology and growth pattern (Amtmann 
et al., 1985). In addition, the tumour promoter induced
phosphorylation of a cellular protein (m.wt. 80K) in 
fibroblasts mediated by protein kinase C is abolished in the 
presence of D609 (Muller-Decker, Amtmann and Sauer, 1987). 
This suggets some role for the inhibition of phosphorylation 
in the reversion from transformed to normal phenotype, 
mediated by D609.
The effect of D609, on the replication of other 
viruses, has been investigated. It was shown that this 
.ompound suppresses DNA and RNA synthesis in herpesviruses,
SV 40 and episomal bovine papillomavirus infected cells. 
However, it remains to be determined if like VSV, this is a 
consequence of inhibition of phosphorylation, or if other as 
yet unknown factors play a more significant role. (Saveveiciy^
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& II
INHIBITS THE PROCESSING 
OF gp's NORMALLY 
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RESULTING IN THE 
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OF VIRAL PROTEIN 
PHOSPHORYLATION NOT 
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Table 9
Compounds which affect protein synthesis and/or 
post-translational modifications: their antiviral spectrum 
and proposed mode of action.
❖  Antiviral spectrum: viruses affected by the action 
of the compound against the particular target shown.
OReovirus and encephalomylocarditis (EMC) virus 
represent specific examples where inhibition of protein 
synthesis has been shown to play an important role in the 
antiviral action of interferon.
References: Interferon (Farrell et al., 1978? Cayley et al. 
1987; Baglioni, 1983? Lengyel, 1982); Casternospermine 
(Gruters et al., 1987; Tyms et al., 1987; Walker et al., 
1987); Xanthate D609 (Sauer et al., 1984; Muller-Decker, 
Amtmann and Sauer, 1987).
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translation
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(activated)
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Figure 8a
The synthesis of the lipid (dolichol)-linked oligosaccharide 
in the ER membrane.
(from Alberts et al., 1984)
c a s t
d m d p
DN J
cis
Figure 8b
Schematic pathway of oligosaccharide processing and the site 
of action of glycosylation inhibitors: casternospermine 
(CAST),deoxynojirimycin (DNJ), 
dihydroxymethyldihydroxypyrolidine (DMDP), 
deoxymannojirimycin (DMJ), swainsonine (SWAIN). The 
reactions are catalyzed by the following enzymes: (1)
oligosaccharyltransferase; (2) alpha-glucosidase 1; (3)
alpha-glucosidase 11; (4) endoplasmic reticulum alpha 
1,2-mannosidase; (5) fatty acyl CoA-protein transferase 
(postulated); (5) Golgi alpha-mannosidase 1; (6)
N-acetylglucosaminyl transferase 1; (7) Golgi
alpha-mannosidase 11; (8) N-acetylglucosaminyltransferase 
11; (9) fucosyltransferase; (10) galactosyltransferase; (11) 
sialyltransferase. (RER) Rough endoplasmic reticulum. (■) 
N-acetylglucosamine; (O ) mannose; (A ) glucose; (A ) 
fucose; (• ) galactose; ( ♦) sialic acid.
(from Kornfeld and Kornfeld, 1985).
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Figure 9
Structure of compounds affecting post-translational 
modifications: a) glycosylation b) phosphorylation.
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1.1.4. COMPOUNDS WHICH AFFECT DNA AND/OR RNA REPLICATION
NUCLEOSIDE ANALOGUES
Several nucleoside analogues have been shown to be 
potent inhibitors of DNA synthesis. These compounds rapidly 
cross the membrane of the cell by a facilitated transport 
mechanism. Most nucleoside derivatives are phosphorylated 
within the cell by a viral or cellular kinase to the 5' 
phosphate nucleoside analogue, which is then further 
converted to the 5' di and then triphosphate, the active 
form of the drug. Once the nucleoside is phosphorylated it 
does not readily leave the cell (except via gap junctions to 
neighbouring cells in cell-cell contact) and should stay 
within the cell long enough to sucessfully inhibit viral 
replication. This discussion of nucleoside analogues which 
affect DNA replication will be divided into three parts:
1.) Nucleoside analogues which affect DNA polymerase 
(although this may not be the only target for the compound). 
This group can be further divided into first-generation 
nucleosides, where phosphorylation of the compound is 
performed by cellular kinases and second-generation 
nucleosides, where the phosphorylation to the monophosphate 
form is performed by a virally encoded kinase, thus largely 
confining activity to virus-infected cells.
2.) Nucleoside analogues which affect thymidylate 
synthase (and are not dependent on virus-encoded thymidine 
kinase).
3.) A novel class of nucleoside analogues, 
phosphonylmethoxyalkylpurines and pyrimidines, whose mode of 
action is not yet clear.
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NUCLEOSIDE ANALOGUES AFFECTING DNA POLYMERASE
FIRST GENERATION NUCLEOSIDES 
IDOXURIDINE (IDU) (Fig 10a)
This pyrimidine nucleoside was first synthesised by 
Prusoff in 1959, and was shown to be active against a range 
of DNA viruses in vitro by Herrmann in 1961. It was 
successfully employed for the treatment of herpes simplex 
keratitis in rabbits and man in 1962 (Kaufman, 1962), and 
enjoys the distinction of being the first antiviral 
chemotherapeutic agent to be licensed for human use. 
However, it is too toxic to be used systemically and was 
applied topically as 0.1% eyedrops to HSV infections
localized to the eye. It has now been overtaken by more
specific nucleosides e.g. ACV and BVDU.
IDU utilises the same anabolic and catabolic pathways 
as thymidine (Fig 11a). The catabolic enzyme responsible for 
the cleavage of IDU to IU (Iodouracil) is thymidine
phosphorylase and this activity did not vary much in cells
post-infection. In order for IDU to be active it must be 
first phosphorylated to its' monophosphate form (IDUMP). 
Herpes simplex virus type 1 (HSV 1)., herpes simplex virus 
type 2 (HSV 2), varicella zoster virus (VZV), and 
Epstein-Barr virus (EBV)-infected cells, each induce a new 
species of virus specified thymidine kinase which in 
addition to the cellular thymidine kinase, is capable of 
phosphorylating IDU and other nucleosides with differing 
efficiency (Littler et al., 1986; Turenne-Tessier et al.,
1986). The binding affinity of IDU to the virus-induced 
thymidine kinase is better than that of host thymidine 
kinase. Thus IDU phosphorylation takes place more 
efficiently in virus-infected than in host cells. Once it is 
converted to IDUMP, thymidylate synthetase could
dehalogenate this nucleoside analogue to form the normal
Vt . . .metabol^e dUMP. However, IDUMP is primarily phosphorylated by
TMP kinase to the diphosphate derivative, IDUDP, and then
further to the triphosphate derivative IDUTP, by nucleoside
diphosphate kinase.
IDU and its' various phosphorylated derivatives can 
competitively inhibit several enzymes concerned with the 
biosynthesis of DNA-thymine (thymidine kinase, thymidylate 
kinase and DNA polymerase), the triphosphate form can feed
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back and inhibit several regulatory enzymes (thymidine 
kinase, deoxycytidylate deaminase and ribonucleotide 
diphosphate reductase), and gene expression can be altered 
by incorporation of IDU into DNA (Prusoff and Lin, 1988). 
Incorporation into DNA is believed to be responsible for 
toxicity as well as the antiviral activity of IDU. Buether 
and Werchau (19 73) isolated infectious DNA from SV40 grown 
in the presence of IDU and showed a relationship between 
loss of infectivity and the extent of substitution of SV40 
DNA-thymidine by IDU. A direct correlation between uptake of 
IDU into the DNA of HSV 1 and loss of infectivity was found 
by Fischer et al., 1980.
The incorporation of IDUMP into the DNA chain does not 
prevent further elongation, but the substituted DNA does not 
serve as a good template for either DNA relication or RNA 
transcription. Incorporation of IDU into HSV 1 DNA produced 
no apparent effect on the physical integrity of the 
substituted DNA molecules since Fischer, Chen and Prusoff, 
(19 80), found no evidence of single strand or double strand 
breaks, when subjected to alkaline and sucrose density 
gradient centrifugation. Incorporation of IDU into the 
herpesvirus DNA produced pronounced effects on viral gene 
expression of those processes which rely on newly 
synthesised viral DNA, that is late RNA and protein 
synthesis. This treatment of HSV 1 infected Vero cells 
causes a 65% reduction in the amount of total viral RNA 
present at late times of infection. This decrease is 
apparent as early as 6h post infection, affecting the RNA 
viral cytoplasmic polyadenylated (poly A+)species to a 
greater extent than non-polyadenylated (poly A-) RNA. 
Cytoplasmic viral poly A+ RNA is present in treated cultures 
at a decreased amount relative to the control poly A+ 
levels, yet there is no evidence of a direct inhibition of 
RNA polyadenylation (Otto et al., 1984).
The RNA effects are reflected in the protein 
synthesised by HSV 1. Otto, Lee and Prusoff, (1982), found a 
reduction in the synthesis of late (Beta and Gamma), but 
not early (Alpha) proteins. There was a wide range of 
inhibition of Beta and Gamma proteins ranging from 46% to 
100% of control levels. However, two proteins (ICP 35 and 
39) were not affected and one (ICP 36) which migrated as
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thymidine kinase was actually increased. Also, the progeny 
virions had altered protein patterns (Prusoff and Otto, 
1983; Otto, Goz and Prusoff, 1984; Cheng and Prusoff,
1986). Therefore, although IDU acts at the level of DNA, DNA 
synthesis itself is not significantly inhibited, 
incorporation of IDU into DNA resulting in the inhibition of 
subsequent steps in the virus life cycle, such as RNA and 
protein synthesis.
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ADENINE ARABINOSIDE (ARA-A) (Fig 10b)
Although IDU was the first antiviral agent to be 
licensed for human use, due to its' toxicity it could only 
be applied topically. Adenine arabinoside (Ara-A), was the 
first agent to be licensed for the treatment of systemic 
herpesvirus infections in man (Whitley and Alford, 1978, 
1981; Muller, 1979; North and Cohen, 1979; Buchanan and 
Hess, 1980). It was first synthesised by Lee and co-workers 
at Stanford Research Institute in 1960. This compound can 
inhibit the replication of the human herpesviruses HSV 1 and 
HSV 2, varicella -zoster (VZV) and cytomegalovirus (CMV), in 
cultured cells with a considerably better therapeutic index 
than IDU.
The metabolic reactions to which Ara-A is subjected 
are shown in Fig lib. Ara-A is rapidly deaminated by 
adenosine deaminase in vivo to give 
9-B-D-arabinofuranosylhypoxanthine (Ara-HX), which is 
approximately 10 times less active than Ara-A in cell 
culture experiments. The in vivo efficacy and toxicity of 
Ara-A can therefore be augmented up to 2 0 fold by 
competitive inhibitors of adenosine deaminase such as 
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) (North and 
Cohen, 1979). Ara-A is relatively insoluble and so must be 
administered in a large volume of fluid by slow intravenous 
fusion. Ara-A monophosphate is much more soluble than Ara-A 
and can be administered intramuscularly or intravenously. It 
also has the added advantage that it is not subject to 
deamination by adenosine deaminase (North and Cohen, 1979). 
Ara-A is converted to its' monophosphate form by cellular 
adenosine and deoxycytidine kinase, the subsequent 
phosphorylation steps leading to the formation of the 
triphosphate form also being by cellular kinases; therefore, 
the formation of Ara ATP in HSV-infected cells is 
essentially the same as that in uninfected cells. There is
twVufe.-V>iovv o\
direct correlation between levels of Ara ATP and^HSV 
replication. The selective action of Ara ATP against HSV, 
appears to be a consequence of the preferential action of 
Ara ATP against HSV 1 and HSV 2 polymerases. Ara ATP has 
been shown to be a competitive inhibitor of dATP for 
mammalian as well as viral DNA polymerases; however, HSV DNA 
polymerase is about 15 fold more sensitive with a Ki of
0.3uM versus 5uM for DNA polymerase (Ostrander and Cheng, 
1980; Reink et al., 1978). Ara ATP is also a substrate for 
DNA polymerase and is incorporated in internucleotide 
linkage in both viral and cellular DNA. Pelling et al., 
1981, demonstrated that Ara-A is incorporated uniformly 
tHroughout the HSV 1 genome, resulting in defective viral 
DNA. Slowing of DNA elongation has been reported and this 
could be a consequence of 3 ' exonuclease associated with 
HSV DNA polymerase. Thus by continuous incorporation and 
removal of Ara AMP from the terminal position , Ara ATP 
could act as a pseudo chain terminator. It is interesting in 
this regard, that Ara ATP has also been reported to inhibit 
terminal deoxynucleotidyltransferase. Muller et al. (1977), 
have also shown that Ara-A treatment of HSV-infected cells 
resulted in the accumulation of short DNA fragments. It 
should be noted that as well as affecting DNA polymerase in 
both infected and uninfected cells, Ara-A can also affect 
the procesing of mRNA, inhibiting both polyadenylation and 
capping. However, this is believed to play a major role in 
producing cytotoxicity rather than antiviral activity (North 
and Cohen, 1979; Drach, 1983; Prusoff and Otto, 1983; 
Shannon, 1984; Cheng and Prusoff, 1986). It is clear 
therefore, that there are multiple sites of inhibition for 
this compound, although it is still not clear which is 
responsible for the antiviral activity.
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SECOND-GENERATION NUCLEOSIDES 
ACYCLOVIR (9-(2-HYDROXYETHOXYMETHYL) GUANINE) (Fig 10c)
Elion et al. first described the antiviral activity of 
the guanosine analogue, acyclovir in 19 77. Acyclovir is 
highly active in vitro against herpes simplex types 1 and 2 
(HSV 1 and HSV 2, respectively), moderately active against 
varicella zoster virus (VZV) and Epstein-Barr virus (EBV), 
and relatively inactive against cytomegalovirus (CMV) 
(Fiddian, 1988). The full extent of the clinical value of 
acyclovir is still being defined, but we already know much 
about its efficacy and tolerance in a wide range of herpes 
virus infections. Briefly, intravenous, oral, dermal and 
ophthalmic formulations of acyclovir have variously been 
shown to be effective in systemic, mucocutanous and ocular 
manifestations of HSV infection. For example, acyclovir is 
the most potent agent available in the treatment of herpes 
simplex encephalitis (Whitley et al., 1986), is the only 
drug of proven clinical value in the treatment of both 
immunocompromised and normal patients with HSV infections of 
the skin and mucous membranes (Meyers, 1985),and constitutes 
first line treatment in HSV eye infections (Nicholson, 
1984). In addition, there is extensive evidence to support 
the use of acyclovir for prophylaxis of HSV infections in 
normal patients (Fiddian, 1988).These data further attest to 
the excellent tolerance of acyclovir even over prolonged 
periods of time. Despite being less active against VZV, 
acyclovir has been shown to be effective on VZV infections, 
both in immunocompetent patients (Peterslund et al., 19 81) 
and in immunocompromised patients (Balfour et al., 19 83). 
Pagano, Sixbey and Lin (1983), reported that acyclovir 
reduced EBV-excretion in the throat but had minimal 
clinical benefit in patients with infectious mononucleosis. 
Andersson et al. (1986), confirmed these findings in a 
double-blind placebo controlled trial.
Studies of the mode of action of acyclovir (ACV) , 
revealed the basis for the differential affect of the 
compond on herpesviruses. Elion et al. (1977), showed that 
in herpes-infected cells, ACV is converted to the 
monophosphate by a viral specific thymidine kinase (Fig 
11c). In the uninfected host cell, phosphorylation occurs 
orly to a very limited extent. Subsequently, ACV was found
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to be phosphorylated 30-120 times faster with extracts from 
Vero cells infected with HSV 1 than with similar extracts of 
uninfected cells,and shown to be performed by viral
thymidine kinase (Fyfe et al., 1978). HSV 1 and HSV 2
infected cells convert ACV to the 5' monophosphate, which is 
further phosphorylated by host cell GMP kinase to acyclovir 
diphosphate, which is turn further phosphorylated to 
acyclovir triphosphate by unidentified cellular kinases (Fig 
11c). Obviously ACV can be expected to be active only 
against those viruses that encode a virus specific TK, as do 
HSV and VZV, and inactive against viruses which do not
encode their own TK, such as CMV. It is noteworthy that EBV
is quite sensitive to ACV, while it is still uncertain
whether or not EBV encodes its' own kinase.
ACV triphosphate, has been found to be a competitive
inhibitor of dGTP for HSV 1 and HSV 2 DNA polymerase
(Larsson, Sanquist and Parnuud, 19 86). In contrast, HeLa DNA 
polymerase is insensitive to inhibition by ACV triphosphate. 
Furthermore, ACV triphosphate was shown to be incorporated 
into thymus DNA primer template, this incorportion being 
much more rapid and extensive with HSV 1 DNA polymerase than 
with Vero cell DNA polymerase. This incorpoation of ACV 
ceased after 15 minutes since the template is chain 
terminated by acyclovir incorporation, due to the absence of 
a 3' hydroxyl group on which to continue elongation. The 
viral DNA polymerase was also inactivated by tight binding 
to the terminated template. McGuirt and co-workers (1984), 
have identified small DNA fragments synthesised in HSV 1 
infected cells in the presence of ACV. These fragments were 
shown to be viral in origin by hybridization to purified HSV 
1 DNA. ACV monophosphate terminated DNA thus was found to 
strongly inhibit HSV DNA polymerase catalyzed synthesis.
All this evidence indicates therefore, that ACV is 
selectively phosphorylated by herpesvirus TK to its' 
monophosphate form, then to its' triphosphate form by 
cellular kinases. The triphosphate form of ACV then acts as 
both a competitive inhibitor of dGTP for viral DNA 
polymerase and also as a substrate for viral DNA polymerase. 
Incorporation of ACV triphosphate into viral DNA follows, 
leading to chain termination, due to the absence of a 3' OH 
group.
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ANALOGUES DHPG AND DHBG (Fig 10c)
DHPG
Variations in the carbohydrate portion of acyclovir,
has resulted in a number of active analogues of acyclovir.
The 2' deoxyguanosine analogue, DHPG, differs from ACV only
by the addition of a 3' carbon and hydroxyl group attached
to the acyclic chain. Orally administered DHPG is 50 fold
more effacious than ACV in the treatment of systemic or
local HSV 1 or HSV 2 intravaginal infections in mice (Smee
et al., 1983). DHPG is reported to be a 30 fold more
efficient substrate for HSV 1 TK than ACV and cellular GMP
kinase phosphorylates DHPG monophosphate more readily than
ACV monophosphate. These differences result in 7 times more
DHPG triphosphate in HSV 1 infected rabbit kidney cells than
ACV triphosphate 6h after infection. This analogue also has
a greater spectrum of in vitro activity against herpes
viruses than ACV. DHPG was reported by Lin, Smith and
Pagano, (1984), to have a 6 fold greater activity aginst EBV
than ACV as measured by its1 ED..,. 0.05uM versus 0.3uM for
d u
ACV. In addition, DHPG also displayed activity against CMV, 
a herpesvirus which is almost completely insensitive to ACV 
(EDe-q values: 1.5uM (DHPG) versus 45uM (ACV)). Apparently 
DHPG is readily converted to its' active triphosphate form 
in the CMV-infected cells (Biron et al., 1986), providing 
some explanation for its' activity against this virus.
Like ACV triphosphate, DHPG triphosphate competitively 
inhibits incorporation of dGTP into DNA catalyzed by DNA 
polymerases, specified by both HSV 1 and HSV 2 (Robins and 
Revankar, 1988). DHPG also acts as an alternate substrate 
for dGTP for the viral specified DNA polymerase. However, 
unlike ACV, DHPG is incorporated into viral DNA in both 
terminal and internal linkages (Robins and Revankar, 1988), 
due to the presence of the additional hydroxyl group of 
DHPG. This incorporation results in the gradual slowing of 
viral DNA synthesis (like Ara-A in this regard).
Although the altered structure of this analogue, 
confers a greater spectrum of in vitro activity against 
herpes viruses, it also causes increased toxicity, 
particularly involving gonadal function, myelosuppression 
anc mutagenicity. Nevertheless, the risk-benefit ratio may 
be sufficiently favourable in serious EBV infections and in
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immunocompromised patients with severe and/or 
life-threatening CMV infections to warrant selected use in 
such target populations.
In particular, bone marrow transplant recipients and 
patients with AIDS are subject to high risk of morbidity 
and/or mortality from CMV diseases, including pneumonitis, 
retinitis and gastrointestinal disease. Several groups of 
such patients are being evaluated for acceptable tolerance 
and efficacy. Felsenstein et al. (1985) and Masur, Lane and 
Palestine, (1986), reported benifits in AIDS patients with 
CMV retinitis as evidenced by healing of retinal lesions and 
resolution of viraemia. However, relapse is common following 
cessation of treatment, so such patients may need to receive 
maintenance therapy for prolonged periods. Shepp et al., 
1985, also demonstrated an antiviral effect in bone marrow 
transplant patients with CMV pneumonia, but survival was not 
influenced. This finding suggests that even a potent agent 
such as DHPG, may have to be employed prior to the 
development of pneumonia if the outcome is to be favourably 
modified.
DHBG (Fig 10c)
Another ACV analogue, DHBG (Fig 10c), has been 
reported by Larsson et al. (1986). DHBG is similar to ACV in 
its' activity against HSV 1 keratitis in rabbits, and 
somewhat superior to ACV regarding HSV 2 infections in mice. 
However, it is less effective than ACV against HSV 1 induced 
encephalitis in mice and in mice infected intravaginally 
with HSV 2, DHBG systemically administered did not prevent 
the mortality and spread of the virus to the brain (Lundgren 
et al., 1986). Like ACV it is phosphorylated to its'
monophosphate form by viral TK. In Vero cells, DHBG proved 
to be a good substrate for HSV 1 and HSV 2 TK but not for 
cellular TK (Stenberg, Larsson and Datema, 1986). The 
monophosphate form of the compound is then further 
phosphorylated to its' triphosphate form by cellular 
guanylate kinase. The 5' triphosphate form is a selective 
and competitive inhibitor to dGTP as a substrate of the 
purified HSV 1 and HSV 2 DNA polymerases. However, unlike 
ACV, data suggests DHBG triphosphate inhibition of these 
polymerases occurs without incorporation into viral DNA 
(Stenberg, Larsson and Datema, 1986) (This may contribute to
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its1 reduced efficacy, compared with ACV against herpes 
encephalitis).
Given the variable in vivo results obtained with this 
compound, its' potential is unclear. A series of analogues 
of DHBG have been synthesised (Larsson et al., 19 86), 
although none of these has exhibited considerably better 
antiviral activity either in vitro or in vivo.
PRO-DRUGS OF ACV (Fig 10c)
The demonstration by McKendrick (1984, 1985), that 
higher doses of oral ACV (4 times), are required for herpes 
zoster than are recommended for HSV infections lends greater 
support for the development of prodrugs of ACV that might 
deliver higher plasma levels of active drug following oral 
administration. An additional benefit that might be achieved 
by such therapies is the convenience of less frequent 
dosing. The first pro-drug to be seriously considered was BW 
A134U (Fig 10c). Despite increased adsoroption compared with 
oral ACV, and subsequent conversion by the enzyme adenosine 
deaminase (Fig 11c), the consequent plasma levels of ACV in 
humans are disappointing. This finding as well as concerns 
about its' potential safety in humans (King and Fiddian,
1986), have diverted attention to another pro-drug 
candidate.
BW A515U (Fig 10c), is converted to ACV by xanthine 
oxidase (Krenitsy et al., 1984) (Fig 11c), an enzyme that is 
abundant in humans. Phase 1 studies have been reported 
(Selby et al., 1984). Absorption and subsequent conversion 
to ACV are almost complete, making this pro-drug an ideal 
candidate for further development. Phase 11 trials are 
currently in progress, but results will not be available for 
some time.
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bvdu a n d r e l a t e d c o m p o u n d s
BVPU (BROMOVINYLDEOXYURIDINE) (Fig lOd)
BVDU was synthesised by Jones, Verhelst and Walker in
1979 and was originally described by De Clercq et al.
(1979), as a potent and selective inhibitor of HSV 1. The in 
vivo and in vitro efficacy of BVDU has been demonstrated in 
various experimental model systems (De Clercq and Walker, 
1984), and its' antiviral spectrum encompasses quite a wide 
variety of herpes viruses including EBV and several herpes 
viruses of veterinary importance (Table 11). A number of 
clinical studies point to its' therapeutic value in the 
topical treatment of herpetic eye infections (Maudgal et 
al., 1984, 85) and systemic (peroral) treatment of HSV 1 and 
VZV infections in immunocompromised patients (Maudgal et 
al., 1985; De Clercq et al., 1985b; Tricot et al., 1986).
Since the spectrum of BVDU extends to EBV, SHV 1, BHV 1 and
bovine ulcerative mammilitis virus, BVDU should be further 
explored for its' potential in the treatment of EBV 
associated diseases (i.e. infectious mononucleosis, Burkitt 
lymphoma, nasopharyngeal carcinoma and certain 
lymphosarcommas in immunosuppressed patients), SHV 1 
infections (pseudorabies), in pigs, and infectious 
rhinotrachatis and ulcerative mammalitis in cows.
Like ACV, BVDU is phosphorylated to its' monophosphate 
form by viral TK (De Clercq, 1982c), thereby confering 
selectivity to virus infected cells (Fig lid). Unlike ACV, 
BVDU may be converted to its' 5' diphosphate form by the 
virus induced TK, or at least some virus induced TKs such as 
those specified by HSV 1, VZV, SHV 1 and BHV 1. These TKs 
therefore have dual enzyme activity. They successively act 
as both dThd kinase and dTMP kinase (Fig lid). The thymidine 
kinases derived from HSV 2 and EHV 1 are able to 
phosphorylate BVDU to its' 5' monophosphate (BVDUMP) but not 
further onto its' 5' diphosphate (BVDUDP) (Ayisi et al., 
1984; Kit, Ichimura and De Clercq, 1987) (Fig lid). This 
inefficient phosphorylation of BVUDP most probably explains 
why the replication of HSV 2 and EHV 1 is rather insensitive 
to BVDU. The diphosphate form of BVDU is then converted to 
the triphosphate by cellular kinases (Fig lid). The 
interaction of BVDU triphosphate with DNA polymerase differs 
from that of ACV triphosphate in that it is incorporated
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internally into the DNA strands, via an internucleotide
linkage . The consequences of this incorporaton have been
further studied with [125I] IVDU and C-[125] IVDU
(Bernaurts, Verbuggen and De Clercq, 1987). At
concentrations achieving an equivalent antiviral effect,
1 75[ I] IVDU is incorporated into HSV 1 DNA to much greater
extent than C-[125] IVDU. Furthermore, the [125I]
substituted DNA becomes much more heterogeneous than the 
125C-[ I] IVDU labelled DNA. From these data, one may infer
125 125that the incorporation of [ ] IVDU but not C-[ I] IVDU
into DNA leads to an increased susceptibility to strand
breakage. This together with the reduced functioning of the
substituted DNAs as templates for DNA and RNA polymerases
may account for the compounds ability to block virus
replication.
ANALOGUES OF BVDU:
CARBOXYLIC BVDU (C-BVDU) (Fig lOd)
BVDU is an efficient substrate for pyrimidine
nucleoside phosphorylases i.e. 2' deoythymidine (dThd) 
phosphorylase (Desgranges et al., 1983), which cleave the 
N-glycosidic linkage so as to release the free pyrimidine 
base BVU, which itself has no antiviral activity (De Clercq 
et al., 1986a). C-BVDU is completely resistant to
degradation (De Clercq et al., 1985a), thus increasing its' 
bioavailbility and is as good if not better a substrate of 
the HSV 1 TK than BVDU (De Clercq et al., 19 85a). Like BVDU, 
C-BVDU is incorporated into DNA strands (internally) via an 
internucleotide linkage. However, the extent of the
incorporation of C-BVDU is low (3.6% at the most) and the 
exact mode of action of C-BVDU is currently being 
investigated.
Since it is not degraded to BVU, C-BVDU should have 
greater bioavailablity and perhaps greater in vivo efficacy 
than BVDU. Experiments with C-BVDU in vivo however, did not 
seem to indicate that it was more effective than BVDU in the 
systemic or topical treatment of HSV 1 infections in mice 
(Herdewijn et al., 1985).
BROMOVINYLURACIL ARABINOSIDE (BVaraU) (Fig lOd)
BVaraU, a closely related analogue of BVDU is like
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BVDU, an effective anti-HSV and anti-VZV agent (Machida et 
al., 1982). Its' in vivo efficacy has been demonstrated in 
some animal models i.e. HSV 1 encephalitis and simian 
varicella (De Clercq, 1988a). The anti- HSV 1 activity of 
BVaraU is more stringently dependent on the choice of the 
cell system than that of BVDU (De Clercq, 1982). Like 
C-BVDU, it is also not a substrate for dThd phosphorylase 
(De Clercq et al., 1985c), again suggesting that it may have 
a longer bioavailability in vivo than BVDU. Whether this 
longer bioavailability would have any therapeutic 
implication and how BVaraU is eventually metabolized and 
eliminated by the organism are important issues that remain 
to be resolved.
63
OTHER 5 1 SUBSTITUTED 2' DEQXYURIDINES 
ETHYLDEOXYURIDINE (EDU) (Fig lOe)
EDU has been known since 1967 (De Clercq and Shugar, 
1975). Interest in the clinical potential of this drug has 
revived since Schinazi et al. (1985) and Spruance, Freeman 
and Smith, (19 85), demonstrated its' effectiveness in the 
topical treatment of HSV 1 and HSV 2 infections in mice and 
guinea pigs. De Clercq and Bernaerts (1987), have studied 
the metabolism of this compound in uninfected and 
HSV-infected cells. EDU is phosphorylated in both mock and 
HSV-infected cells, albeit to a larger extent in the 
virus-infected than the mock-infected cells, and is 
incorporated internally into viral and cellular DNA strands 
via an internucleotide linkage, although again to a larger 
extent into DNA of virus infected cells. Concomitantly, with 
the incorporation of EDU into viral and cellular DNA of 
HSV-infected cells, there is a marked reduction in DNA 
synthesis and this reduction is more pronounced for viral 
DNA than for cellular DNA.
CHLOROETHYLDEOXYURIDINE (CEDU) (Fig lOe)
CEDU was synthesised by Griengl et al. in 1985. CEDU 
is about 10 times less potent than BVDU against HSV 1 in 
vitro and about equally active as BVDU in the topical 
treatment of cutaneous HSV 1 lesions in hairless mice; when 
given systemically however, CEDU appears to be effective at 
a 5 to 15 fold lower dose than BVDU or ACV (De Clercq and 
Rosenwith, 1985). CEDU also holds great promise for the 
topical treatment of both epithelial and stromal HSV 1 
keratitis and HSV 1 uveritis readily penetrating the cornea 
(De Clercq, 1988). It is not clear why CEDU should be more 
effective than BVDU upon systemic (peroral or 
intraperitoneal) administration. This difference in efficacy 
does not seem to be related to differences in phosphorolytic 
cleavage by pyrimidine nucleoside phosphorylases (i.e. dThd 
phosphorylase), since CEDU is as good a substrate for this 
enzyme as other dThd analogues and it is as rapidly cleared 
from the bloodstream as is BVDU (Desgranges et al., 1986a).
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NUCLEOSIDE ANALOGUES WHICH AFFECT THYMIDYLATE SYNTHETASE 
(Fig lOf)
FLUORODEOXYURIDINE (FPU), TRIFLUOROTHYMIDINE (TFT),
NITRODEOXYURIDINE (NDU).
Some 5 substituted 2' deoxyuridines, that contain a 
small electronegative C-5 substituent such as fluorine (FDU, 
TFT) or nitro (NDU), exhibit antiviral activity against 
vaccinia virus, HSV 1, HSV 2 and VZV. These compounds are 
phosphorylated by cellular as well as viral TK. The initial 
phosphorylated product is the monophosphate, which interacts 
with and inhibits cellular thymidylate synthetase, the 
enzyme responsible for the de novo synthesis of thymidine 
monophosphate (dTMP), from dUMP (Fig 12).(the monophosphate 
form of IDU also interacts with thymidylate synthetase but 
unlike these compounds which inhibit this enzyme, IDUMP is 
dehalogenated to dUMP and then methylated to dTTP). That 
these compounds are inhibitors of thymidylate synthetase is 
based on a number of criteria such as:
1.) a much greater inhibitory effect on dUrd than dThd 
incorporation into DNA (Fig 12) (De Clercq et al., 1981)
2.) inability to sustain the growth of dTMP
synthase-deficient murine mammary carcinoma (FM3A/TS-) cells 
(Balzirini et al., 1984a and b)
3.) inhibition of tritium release from [5-3H]dCyd
(Balzarini and De Clercq, 1984)
4.) demonstration of inhibitory action of the
5-substituted 2'-dUMPs on the isolated dTMP synthase 
(Balzarini et al., 1982).
FDU, TFT and NDU (Fig lOf), rank among the most potent 
inhibitors of dTMP synthase, with Ki/Km values (for their 
monophosphate) in the range of 0.001 to 0.01 (Balzarini et 
al., 1982).
The activity spectrum of the dTMP synthetase 
inhibitors extends to TK- virus strains i.e. those TK- HSV 1 
mutants that may arise during therapy with ACV or any other 
viral TK dependent drug (De Clercq, Beres and Bentrude,
1987). Wild type TK+ HSV strains are less sensitive to the 
dTMP synthetase inhibitors than are their TK- counterparts. 
Apparently, TK- HSV mutants cannot rely on the dThd salvage 
pathway to ensure the necessary suply of dTMP and dTTP for 
their DNA synthesis (Fig 12), which makes them dependent on
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the de novo biosynthetic pathway of dTTP starting from 
N-carbamoyl aspartate and going through the dTMP synthetase 
step. The latter can be considered as the bottleneck in the 
de novo biosynthesis of dTTP. TK- HSV mutants should be 
particularly vulnerable to any disturbance in the conversion 
of dUMP to dTMP as they cannot compensate for the loss in 
dTMP through salvaging Thd because they lack the necessary 
kinase for it.
Further evidence for the role of dTMP synthetase in 
the inhibitory effect of FDU on TK- HSV 1 replication stems
from reversal experiments, which indicate when added
exogenously, dThd completely reverses the antiviral activity 
of FDU at concentrations as low as lug/ml, whereas dUrd 
fails to show any reversing effect even at concentrations as 
high as lOOug/ml. According to the scheme shown in Fig 12,
such a marked difference in the reversing effects of dUrd
and dThd can only be accounted for by an inhibitory action 
of FDU at the dTMP synthetase level.
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PHOSPHONYLMETHOXYALKYLPURINES AND PYRIMIDINES (Fig lOg)
(S)-HPMPA;
[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine], PMEA 
;[9-(2-phosphonylmethoxyethyladenine] and their cogeners 
(Fig lOg), have been recognised as a novel class of potent 
and selective antiviral agents (De Clercq et al., 1986b). 
These compounds display antiviral activity against a range 
of DNA viruses: adenoviruses (Baba et al., 19 87);
herpesviruses including HSV 1, HSV 2, VZV, CMV, EBV, SHV 1, 
BHV 1, EHV 1, TK- HSV 1, TK- VZV as well as seal (phocid) 
herpesviruses (De Clercq et al., 1986b); iridoviruses 
(African swine fever virus) (Gi1-Fernandez and De Clercq,
1987) and retroviruses including moloney murine sarcoma 
virus and HIV (De Clercq, 1988b) (Table 12).
(S)-HPMPA inhibits the replication of VZV in cell
culture at a mean 50% inhibitory concentration of 1.8ng/ml
(Baba et al., 1987), while not being toxic for the host
cells at a concentration up to 52ug/ml, thus achieving a
selectivity index of approximately 29,000. (S)-HPMPA is also
active against TK- HSV 1 strains (De Clercq et al., 1986b),
and this activity extends to the in vivo situation where
(S)-HPMPA has been found to be effective against TK- HSV 1
keratitis in rabbits (Maudgal, De Clercq and Huyghe, 1987).
. f
Among the di^erent phosphonylmethoxyalkylpurines and 
pyrimidines, there exist rather striking differences in 
antiviral activity depending on the nature of the virus 
infection (De Clercq, 1988b)The pattern of activity observed 
with respect to adenovirus, vaccinia virus and varicella 
zoster virus (in order of decreasing activity) is: (S)-HPMPA
> (S )-cHPMPA > (S )-HPMPDAP > (SJ^HPMPC > PMEDAP > PMEA >
PMEMAP. Towards HSV 1 and HSV 2 however, (S)-HPMPA, 
(S)-cHPMPA, (S)-HPMPC, PMEA and PMEDAP all appear about 
equally active, PMEMAP being definately less active. With a 
50% inhibitory concentration less than 0.lug/ml and a 
selectivity index > 1000, (S)-HPMPC is the most potent and 
selective inhibitor of CMV replication described so far, 
wheras in terms of anti-HIV activity, the order of 
(decreasing) activity is as follows: PMEDAP > PMEA > PMEMAP.
Using radiolabelled (S )-[U-14C-adenine] HPMA, it has 
been demonstrated that the compound is as such taken up by 
the cells and subsequently converted to its' mono and
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diphosphonyl derivatives. This phosphorylation must be 
achieved with cellular kinases as it occurs equally well in 
virus-infected and mock-infected cells (Vortuba et al. ,
1987). Thus, virus-specified phosphorylation, i.e. by the 
virus encoded dThd (dTMP) kinase, is not required for the 
antiviral action of (S)-HPMPA, a conclusion that could 
already be deduced from its' activity against TK- strains of 
HSV 1 and VZV.
Within the virus-infected cell, (S)-HPMPA selectively 
inhibits viral DNA synthesis without affecting cellular DNA 
synthesis. This has been clearly demonstrated in Vero cells 
infected with HSV 1. Only at a concentration of 500uM 
(150ug/ml), (S)-HPMPA effects a 50% reduction in cellular 
DNA synthesis (in both mock-infeted and virus-infected 
cells), while a 50% inhibition of viral DNA synthesis is 
achieved at a concentration of 5uM (1.5ug/ml). The 
differential effect of (S)-HPMPA on viral cellular DNA 
synthesis is even more pronounced in HEL cells infected with 
HSV 1, where (S)-HPMPA shuts off viral DNA synthesis at a 
concentration as low as 0.05uM (0.015ug/ml), while leaving 
cellular DNA synthesis unaffected at a concentration up to 
50uM (15ug/ml) (Vortuba et al., 1987). The exact mechanism 
by which (S)-HPMPA interferes with viral DNA synthesis needs 
further investigation and hence, the exact target for its' 
action remains to be identified. Whatever target (S)-HPMPA 
is directed at, it is clear that its' selectivity as an 
antiviral agent results in a specific effect on viral DNA 
synthesis.
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NON-NUCLEOSIDE INHIBITORS OF DNA AND/OR RNA REPLICATION
THI OS EMI CAR BAZ ON ES
The antiviral activity of thiosemicarbazones was first 
reported in 1950 by Hamre, Bernstein and Donovick, who found 
that derivatives of benzaldehyde thiosemicarbazone, were 
active against neurovaccinial infection in mice when given 
orally. Sidwell and co-workers (1969), evaluated a series of 
purine analogues as antiviral agents and demonstrated that 
purine-6 carboxaldehyde thiosemicarbazone was effective in 
suppressing both the cytopathic effect and titres of human 
cytomegalovirus (HCMV). It was subsequently demonstrated 
that 2-acetylpyrimidine thiosemicarbazone derivatives 
inhibited the replication of HSV 1 and HSV 2 (Shipman Jr. et 
al., 19 81). The mode of action of one of these compounds
designated A723U (Fig 13a), against HSV 1 was examined 
(Spector et al., 1985). Ribonucleotide reductase induced by 
HSV 1 was studied for its susceptibility to inhibition by 
this compound. Ribonucleotide reductase, is a key enzyme in 
DNA synthesis and catalyzes the reduction of the 4 
ribonucleosidediphosphates to the corresponding
deoxyribonucleosidediphosphates. In this study, its' 
activity was measured by the conversion of CDP to dCDP. The 
mode of inhibition was unconventional as instead of 
remaining constant, the degree of inhibition increased as 
the reaction proceeded. To test whether this decelerating 
reaction rate was caused by inactivation of the HSV 1 
ribonucleotide reductase, a small volume of fresh enzyme was 
added to the stagnant reaction mixture. This produced a 
second burst of CDP reduction that was similar to the first. 
Thus, it appeared that it was the enzyme that became 
defective during the reaction. The time dependence of this 
inactivation was investigated. No inactivation occurred when 
A723U was pre-incubated with HSV 1 ribonucleotide reductase 
prior to the initiation of the reaction with substrate. 
Inactivation only occurred when the enzyme was catalyzing 
the reduction of substrate. Thus the time dependence of the 
inactivation was not caused by the simple slow binding of 
the inhibitor to the resting enzyme. Studies with mammaijilian 
ribonucleotide reductase indicate that thiosemicarbazone 
inhibitors scavenge the free radical from the enzymes active 
site (Thelander and Graslund, 1983). It is possible that a
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similar mechanism is involved in the inactivation of HSV 1 
ribonucleotide reductase. However, because inactivation does 
not occur without catalysis, it is plausible that A723U 
inactivates by preventing the regeneration of the free 
radical.
A consequence of the inhibition of this enzyme is of 
course a reduction in the pool of dNTPs. In this same study 
(Spector et al., 1985), it was shown that A723U potentiated 
the action of ACV. As reported previously the triphosphate 
form of ACV competes with dGTP for DNA polymerase. A723U 
most likely potentiates the action of ACV by reducing dGTP 
pools and so reducing the amount of competitive inhibitor. 
If this is so, it would be of interest to determine if the 
action of compounds such as BVDU and AZT would also be 
enhanced by A723U.
PYROPHOSPHATE ANALOGUES 
PHOSPHONOACETATE (PAA) AND PHOSPHONOFORMIC ACID (PFA) (Fig 
13b)
Pyrophosphate analogues PAA and PFA exhibit in vitro 
activity against a range of herpesviruses (HSV 1 and HSV 2, 
CMV and EBV), and influenza virus. Helgstrand et al., 1978 
demonstrated that antiviral activity of these compounds 
correlates well with their inhibitory effect on the 
polymerases of these viruses (DNA polymerase for herpesvirus 
and RNA polymerase for influenza viruses), and that 
inhibition is selective. These analogues inhibit DNA/RNA 
polymerase by interacting with the pyrophosphate binding 
site thereby being a competitive inhibitor of the dNTP 
pyrophosphate exchange reaction.
PAA is extremely irritating to the skin when applied 
topically and is retained by bone whatever the route of 
administration, hence it is unlikely to be licensed for
|V
human use. PFA wheiji applied as a 3% cream is not an irritant 
and shortens the time mucocutaneous HSV 1 or HSV 2 lesions 
take to reach the stage of crusting and reduces the 
appearance of new vesicles (Helgstrand* 1980). PFA has also 
recently undergone clinical evaluation in man for the 
treatment of CMV infection of bone marrow and renal 
transplant patients* Results have been encouraging although 
toxicity was observed (some 30% of systemically available
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PFA is deposited in bone and cartilage). Given the toxicity 
problems associated with these compounds, the availablity 
and the effectiveness of ACV as well as attempts to broaden 
the antiviral range of ACV to include HCMV, by designing 
related analogues, the future of these compounds as 
anti-herpetic agents is not certain. These compounds and 
related analogues have been shown to have activity against 
HIV reverse transcriptase (Vrang and Oberg, 1986), and are 
inhibitory to HIV multiplication in cell cultures. However, 
preliminary clinical trials have not been encouraging.
GUANIDINE
Guanidine is an inhibitor of human enterovirus RNA 
replication (Crowther and Melnick, 1961). Many structural 
analogues of the guanidine derivative have been made; for 
example one phenyl ring can be replaced by a heterocyclic or 
certain acyclic ring systems. High in vitro activity was 
retained in a number of cases but none has shown significant 
activity in humans (Swallow and Kampfner, 1985).
Guanidine resistant variants of poliovirus were among 
the first drug resistant viruses to be isolated from tisue 
culture and experimentally infected monkeys (Melnic, 
Crowther and Barrero-Oro, 1961). Guanidine dependent viruses 
were also isolated (Loddo et al., 1962). Early studies 
revealed that resistant mutants retained neurovirulence in 
monkeys (Carp, 1964), although the guanidine dependent 
mutants were apathogenic (Loddo et al., 1962). These earlier 
workers were struck by the apparent ease with which 
resistance developed in their experimental systems and it 
was thought at that time to be a significant factor in the 
failure of chemotherapy in experimentally infected, 
guanidine treated monkeys (Barrera-Oro and Melnick, 1961)
Genetic recombination studies between guanidine 
resistant and sensitive strains identified the region 
encoding the coat protein as the important site for 
mutations leading to resistance (Cooper, 1968;
Cooper,Wentwoth and MacMahon, 19 70). Korant (19 77), showed 
that resistant variants differed from the original sensitive 
strains in the electrophoretic and chomatographic behaviour 
of their structural proteins only. However, subsequent 
findings were not compatible with these early reports.
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Recombination studies using a neutralizing monoclonal 
antibody resistant variant of the Mahoney strain indicated 
that guanidine resistance mapped to a region of the genome 
specifying the non-structural proteins (Emini et al., 1984). 
Anderson-Sillman et al.y 1984 carried out peptide mapping 
and isoelectric focuskruj studies which demonstrated that 
75% of guanidine resistant mutants had modifications in the 
37kD protein known as 2C (formerly pX), which is a 
non-structural protein of unknown function. Sequence 
analysis of interstrain guanidine resistant and antibody 
resistant variant recombinants (Pincus and Wimmer, 1986), 
showed that 6 independently isolated guanidine resistant 
mutants each contained a mutation in 2C at amino acid 179 
which resulted in a change of either ASP to ALA or ASP to 
GLY. Guanidine dependent mutants were also found to contain 
changes within 2C. Pincus and Wimmer (1986), produced 
resistant and dependent mutants from cloned cDNA 
demonstrating that mutations in polypeptide 2C are directly 
responsible for altered sensitivity to guanidine.
Similary, guanidine resistant mutations in foot and 
mouth disease virus have been mapped by isoelectric 
focusing , peptide mapping and recombination studies to p34, 
the counterpart of poliovirus 2C (Saunders and King, 1982; 
Saunders, Tan and Robins, 1985). A comparison of the amino 
acid sequence of the 2C equivalent protein in polio, foot 
and mouth, rhinovirus type 2 and 14 and
encephalomyelocarditis virus reveals strong homology over a 
region of 115 residues in length and all the mutations 
associated with guanidine resistance appear to lie within 
this conserved region (Pincus and Wimmer, 1986). It may be 
that this region is involved in interaction with other viral 
proteins required for RNA replication. Membrane bound 
replication complexes contain 2C and guanidine could inhibit 
viral RNA replication by interfering with this interaction 
between 2C and replication proteins.
COMPOUND - ANTIVIRAL 
^  SPECTRUM
target PROPOSED MODE OF ACTION
IDU HSV-I,HSV-2,VZV, 
EBV,CMV
DNA
POLYMERASE
O
via IDUTP; 1.COMPETITIVE 
INHIBITOR OF dTTP 
2. INCORPORATION INTO 
DNA : POOR TEMPLATE
ara A HSV-I,HSV-2,VZV, 
CMV,EBV,VACCINIA
DNA
POLYMERASE
o
via ara ATP; 1 .COMPETITIVE 
INHIBITOR OF dATP 
2. INCORPORATION INTO DNAI 
PSEUDO/CHAIN TERMINATION
ACYLOVIR
(ACV)
HSV-I,HSV-2,VZV, 
EBV, (NOT CMV)
DNA
POLYMERASE
via*ACVTP; 1.COMPETITIVE 
INHIBITOR OF dGTP.
2. INCORPORATION INTO DNA1 
TERMINATION.
DHPG
(ANALOGUE 
OF ACV)
AS ACV, PLUS CMV DNA
POLYMERASE
AS FOR ACV, EXCEPT 
INCORPORATED INTO BOTH 
TERMINAL AND INTERNAL
POSITIONS t GRADUAL 
SLOWING OF DNA SYNTHESIS
DHBG
(ANALOGUE 
OF ACV)
AS ACV DNA
POLYMERASE AS FOR ACV, EXCEPT NOT 
INCORPORATED INTO DNA
BVDU ANIMAL AND
HERPES
VIRUSES
(SEE TABLE 12)
DNA
POLYMERASE
•
via BVDUTP; 1. COMPETITIVE 
INHIBITOR OF dTTP 
2. INCORPORATION INTO DNA; 
POOR TEMPLATE
C-BVDU 
(ANALOGUE 
OF BVDU)
AS BVDU DNA
POLYMERASE AS FOR BVDU:GREATER 
BIOAVALIABILITY AS NOT A 
SUBSTRATE FOR dThd 
PHOSPHORYLASE
EDU, C-EDU HSV-I, HSV-2 DNA
POLYMERASE
PROBABLY SAME GENERAL 
MECHANISM AS BVDU. BASIS 
FOR DIFFERENTIAL EFFICACY 
NOT CLEAR
TFT,FDU,NDU HSV-I,HSV-2, 
VZV,VACCINIA
THYMIDYLATE
SYNTHASE
. o
via MONOPHOSPHATE; 
COMPETITIVE INHIBITOR 
dUMP
(S)- HPMA, 
PMEA AND 
CONGENERS
A RANGE OF DNA AND 
RETROVIRUSES 
(SEE TABLE 13)
MODE OF ACTION UNCLEAR; 
SPECIFICALLY INHIBITS 
VIRAL DNA SYNTHESIS
THIOSEMI-
CARBAZONES
HSV-I, HSV-2 RIBO­
NUCLEOTIDE
REDUCTASE
SCAVENGES THE FREE RADICAL 
FROM THE ENZYME'S ACTIVE 
SITE
PYROPHOSPHATE
ANALOGUES;
PFA AND PAA
HSV-I, HSV-2, CMV, 
EBV, VZV
INFLUENZA
DNA
POLYMERASE
RNA
POLYMERASE
BINDS TO PYROPHOSPHATE 
BINDING SITE
GUANIDINE ENTEROVIRUSES RNA
POLYMERASE
IN POLIOV1RUS, RELATED TO 
PROTEIN 2C
Table 10
Compounds which affect DNA and /or RNA replication: their 
antiviral spectrum and proposed mode of action.
Ophosphorylation performed by cellular and/or viral 
kinases.
# specific phosphorylation i.e. performed (at least to 
monophosphate) by viral kinase.
■^Antiviral spectrum: viruses affected by the action 
of the compound against the particular target shown.
References: IDU (Hermann, 1961? Prusoff and Lin, 1988; 
Fischer et al., 1980); ara A (Pelling et al., 1981?
Ostrander and Cheng, 1980; Reink et al., 1978); ACV (Elion 
et al., 1977? Larsson , Sanquist and Parnuud, 1986; McGuirt 
et al., 1984); DHPG (Smee et al., 1983? Robins and Revankar, 
1988); DHBG (Larsson et al., 1986? Stenberg, Larsson and 
Datema, 1986); BVDU (De Clercq and Walker, 1984? De Clercq, 
1982c; Bernaerts, Verbuggen and De Clercq, 1987); C-BVDU (De 
Clercq et al., 1985a); EDU/C-EDU (De Clercq and Bernaerts, 
1987; Desgranges et al., 1986a); TFT/FDU/NU (Balzarini et 
al., 1982); (S )-HPMA/PMEA etc. (De Clercq et al., 1986b); 
Thiosemicarbazones (Spector et al., 1985); PFA/PAA 
(Helgstrand et al., 1978); Guanidine (Crowther and Melnick, 
1961).
HIGHLY SUSCEPTIBLE
- Herpes simplex virus type 1 (HSV-I)
- Varicella zoster virus (VZV)
- Epstein Barr virus (EBV)
- Suid herpesvirus type 1 (SHV-I)
- Bovid herpesvirus type 1 (BHV-I)
- Simian varicella virus (SVV)
NOT (OR ONLY POORLY) SUSCEPTIBLE
- Herpes simplex virus type 2 (HSV-2)
- Cytomegalovirus (CMV)
- Equid herpesvirus type 1 (EHV-I)
- Adeno and poxviruses
- TK'variants of HSV-I and VZV
- RNA viruses
Moderately to highly susceptible 
-Adenoviruses
-Herpesviruses (HSV-1, HSV-2, VZV, CMV, EBV, SHV-1, BHV- 
EHV-1, TK HSV-1, TIC VZV....... )
-Poxviruses
-Iridoviruses (African swine fever virus)
-Retroviruses (human immunodeficiency virus (HIV))
Not susceptible
-RNA viruses (except for retroviruses)
Table 11
Antiviral activity spectrum of BVDU and related compunds (De 
Clercq, 1988).
Table 12
Antiviral activity spectrum of phosphonylmethoxyalkylpurine 
and purine derivatives (De Clercq, 1988).
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Structure of compounds which affect DNA and/or RNA 
replication (a-e).
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Structure of compounds which affect DNA and/or RNA 
replication (f,g).
IDU-
VIRAL OR CELLULAR 
THYMIDINE. KINASE
THYMIDINE
PHOSPHORYLASE
•IDUMP
CELLULAR 
TMP KINASE
CELLULAR 
NDP KINASE
-> IDUDP -> IDUTP
THYMIDYLATE
SYNTHETASE
IODOURACIL + 1- 1UMP + I-
CELLULAR 
ADENOSINE/DEOXYCYTIDINE 
KINASE
CELLULAR 
AMP KINASE
CELLULAR 
NDP KINASE
ara A 1 .ara AMP ara ADP- ara ATP
ADENOSINE
DEAMINASE
ara HX kara IMP
ACV
VIRAL
THYMIDINE KINASE 
1
IDENOSINE
DEAMINASE
T
BW A13AU
•ACVMP-
[NE 
OXIDASEr
BW 515U
CELLULAR 
GMP KINASE
->ACVDP
CELLULAR 
NDP KINASE
i  . ACVTP
HSV-1 TK 
VZV TK
SHV-1 TK 
BHV-1 TK
CELLULAR 
NDP KINASE
BVDU ■>BVDUMP ■> BVDUDP ■> BVDUTP
BVDU ♦BVDUMP ♦BVDUDP
HSV-2 TK CELLULAR
EHV-1 TK TMP KINASE
Figu r e  11
M e t a b o l i s m  of n u c l e o s i d e  a n a l o g u e s .
dCMP
t
dCDP
N-earbamoyl-
aspartate
dThd1
dTMPT
dTOPI
dTTPI
ONA
Thymidyiate synthase
COP1
CTP
dUrd
UMP i — dUMP
dUDP
t
UOP1
U T P
5-X-dUrdI
5-X -dU M P
I
Figure 12
Inhibitory action of 5-substituted 2 1-deoxyuridines 
(5-X-Urd), such as FDU,TFT and NDU, on thymidyiate syntha 
results in a marked reduction in the de novo biosynthesis 
dTTP starting from N-carbamoylaspartate.
c(s)nh2
2 acetylpyridine thiosemicarbazone
b <ho)2p(o)co h (ho)2p (o)ch2co2h
Phosphonoformic acid (PFA) Phosphonoacetic acid (PAA)
(CN3H6+)
guanidine
Figure 13
Non-nucleoside inhibitors of DNA and/or RNA replication.
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1.1.5. CONCLUSION OF ANTIVIRAL REVIEW
Only few antiviral substances have been licensed 
and/or are widely available for medical use. These include 
at present, amantidine and rimantidine for the prophylaxis 
and early treatment of influenza A virus infections, 
idoxuridine, trifluridine, adenine arabinoside (vidaribine) 
and acyclovir for the topical treatment of herpetic
keratitis, acyclovir for the systemic treatment (intravenous 
or peroral) treatment of HSV and VZV infections, adenine 
arabinoside for the systemic (intravenous) treatment of 
herpetic encephalitis (although ACV is superior in the 
treatment of herpetic encephalitis), ribavirin for the
topical (aerosol) treatment of respiratory synctial virus 
infections in infants and AZT for the systemic (intravenous 
or peroral), treatment of AIDS and AIDS-related complex
(ARC) .
There are a number of other compounds which have been 
introduced into clinical practice albeit on a compassionate 
basis: phosphonoformate and dihydroxypropoxymethylguanine
for the treatment of CMV infections, and BVDU for the
treatment of HSV 1 and VZV infections, in immunocompromised 
patients. In addition ribavirin, has proven efficacious in 
the treatment of some haemmorrtv^ rv ic fever virus infections 
(i.e. Lassa).
One of the major problems in the development of
antiviral compounds is the relevance and use of testing and 
screening assays. Antiviral chemotherapy is aimed at 
preventing or curing a viral disease in a human patient; yet 
with the exception of anti-HIV compounds, that is the last 
thing which one is allowed to do. The close association of a 
virus with its' host, not only brings problems in the design 
of safe antivirals but it also makes the design of relevant 
test systems difficult. Because of cost and the quantity of 
material available one is usually initially restricted to in 
vitro assays in cell culture. Some viruses cannot be so 
cultured, other systems are so artificial that their 
relevance to the clinical disease is tenuous at best, and 
yet this is the sort of system which has to be used to find 
leads. Sometimes it is relatively easy to stop viral growth 
in infected cells, but it proves to be much more difficult
when the compound is used in vivo. This can be because
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either transport or cell targetting or uptake is very 
different or that the drug is metabolised before it reaches 
the target site. In vitro cell lines do not usually contain 
a full complement of functional enzymes and thus a compound 
like BVDU works even better in vitro than it does in vivo/ 
where it is susceptible to nucleoside phosphorylase which is 
absent or present at only low levels in many cell lines. 
However,this does not have to be an all or none effect. 
Should a compound require activation by one or more enzymes 
before the active metabolite is produced, then small changes 
in concentrations of intermediates could mean that the Km 
for subsequent enzyme mediated transformations may not be 
achieved and so the active metabolite is not produced or 
some intermediate is side-tracked down another pathway.
Animal models often have their own problems. Usually 
one is trying to cure or prevent a human disease and the 
animal model, apart from being costly, may or may not be 
relevant. Uptake, distribution and metabolism of the drug 
may be very different, as is the nature of the viral 
infection and the immune system of the animal.
Toxicity assays also may not be relevant. For example, 
1- ( 2'-deoxy-21-fluoro-B-D-arabinofuranosyl)-5-iodocytosine 
(FIAC) (De Clercq et al., 1979 ), is poorly deaminated in
dogs used in toxicity studies, whereas in humans it is 
rapidly deaminated to the corresponding uracil derivative 
FIAU. It is therefore a very rvo^ve assumption to make, that 
all metabolism of compounds in test animals and humans is 
likely to be the same or even similar, particularly when 
huge doses of compound are used.
The chance of getting anything clinically useful from 
an in vitro screen which will then show promise in animal 
models, pass the toxicity tests and yet still work against 
the clinical disease is very small.
It is also noteworthy that although the existence of 
specific viral targets for attack has been recognised for 
some time, with the exception of amantidine, all the 
licensed antivirals are nucleosides and are targeted against 
virally encoded enzymes. I would suggest the reason for this 
is a financial one, with researchers with limited funds 
following an already proven successful approach. The advent 
of A I D S  mwever, has changed the situation with large
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amounts of money being made available and multiple 
approaches adopted including random screening of compounds 
and design of specific antiviral agents.
Random screening of compounds and elucidation of the 
mode of action of compounds that show activity, play a 
valuable part in antiviral chemotherapy, providing an 
already active antiviral compound as well as information 
regarding susceptible targets in the virus life cycle. This 
information can then be used to improve the existing 
compound as well as to develop novel agents against the 
identified target.
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1.2. CICLOXOLONE SODIUM
The subject of this thesis is the triterpenoid 
compound cicloxolone sodium (CCX), which is a synthetic 
analogue of glycchirizic acid (GA), which occurs naturally 
as a constituent of liquorice root (Fig 1). The parent 
compound GA, has been reported to have activity against a 
wide spectrum of unrelated RNA and DNA viruses in vitro: 
vaccinia, HSV 1, NDV, Influenza A and B and HIV (Pompei et 
al. , 1979 , 1983; Ito et al. ,1987 ). Cicloxolone sodium (CCX)
and the related compound carbenoxolone sodium (CBX), have 
been reported to have a beneficial effect in the treatment 
of HSV infections in man (Poswillo and Roberts, 1981; Csonka 
and Tyrrell, 1984; Partridge and Poswillo, 1984). More 
recently, Dargan and Subak-Sharpe have shown that both CCX 
and CBX inhibit the growth of HSV 1 and HSV 2 in Flow 2002 
and BHK-21 cells. Both these compounds displayed greater 
antiviral activity than the parent compound GA. HSV 2 was 
consistently more sensitive than HSV 1, while CCX 
consistently exhibited greater antiviral activity than CBX . 
The mode of action of CCX and CBX in vitro in infected Flow 
2002 (human ) and BHK (hamster) cells has been investigated 
(Dargan and Subak-Sharpe, 1985; 1986a and b; 1988). The 
anti-HSV effect is characterised by the synthesis of poor 
quality progeny virus particles. This results in an elevated 
particle/p.f.u. ratio in the virus yield accompanied by a 
small reduction in the total number of virus particles made.
These authors demonstrated that both CCX and CBX 
affected cellular membranes. At least three drug effects on 
the PM were identified. First, adsorption of virus to cells 
pre-treated with CCX was inhibited, although not completely 
blocked (Dargan and Subak-Sharpe, 1985). Second, at 
concentrations greater than 50uM, both uninfected and 
HSV-infected cellular membranes became increasingly leaky 
and third, concentrations less than lOuM appeared to 
stabilise membranes (Dargan and Subak-Sharpe, 1986 a and b). 
Symons and Parke (1980), also reported that CBX had a 
concentration dependent biphasic effect on the stability of 
both isolated lysosomal membranes and artificial 
phosphatidylcnoline/cholesterol liposomal membranes. Based 
on their analysis of protein synthesis in infected cells, 
Dargan anc ; jbak-Sharpe have concluded that CCX and CBX also
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disrupt the normal functioning of host cell membrane, 
affecting aspects of protein synthesis, transport and 
post-translational processing. It was shown that 
glycosylation and sulphation of both host and virus specific 
polypeptides are particularly sensitive to CCX inhibition, 
while phosphorylation is not greatly affected. This proposed 
antiviral action involving cell membranes, implies that the 
effect of CCX is of a more general nature and not just 
specifically directed against a particular virus protein, 
suggesting that the replication of several unrelated virus 
groups would be affected by the drug. In order to examine 
the effect of CCX on the replication of a range of viruses, 
cell lines permissive for virus growth and resistant to CCX 
treatment had to be identified to allow uncoupling of 
cytotoxic and antiviral effects. The aims of this thesis 
were three fold:
1.) to determine the tolerance of a range of cell 
lines to CCX
2.) to determine the antiviral activity spectrum of 
CCX (Table 13 shows the viruses examined and the families to 
which they belong).
3.) to more clearly elucidate the mode of action of
CCX.
VIRUS FAMILY NUCLEIC ACID ENVELOPED <E)/
RNA/DNA SS/DS S/NS NON-ENVELOPED (NE>
HSV-I, HSV-2 
(CONTROLS)
: HERPESVIRUS DNA DS NS : E
EHV-IfBHV-I, 
HCMV, VZV
HERPESVIRUS DNA DS NS E
VSV RHA800VIRUS RNA -SS NS E
SFV TOGAVIRUS RNA +SS NS E
BUNYAMMERA,
GERMISTON
BUNYAVIRUS RNA -SS S(3) E
PaiOVIRUS-I PICORNAVIRUS RNA +SS NS NE
REOVIRUS-3 REOVIRUS RNA DS S<10> NE
ADENOVIRUS-5 ADENOVIRUS DNA DS NS NE
INFLUENZA HYXOVIRUS RNA SS S(8) E
Table 13
Viruses screened for sensitivity to CCX.
+ positive strand viruses: genome is infectious i.
can be immediately translated upon coating.
- negative strand viruses: genome is not infectiou
i.e. viral transcriptase must synthesise a complememtary + 
copy from the - genome, which can then be translated.
numbers in parentheses indicate the number of
segments.
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2. MATERIALS AND METHODS
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9.1. MATERIALS
2 . 1 . 1 .  S T A N D A R D  R E A G E N T S
Chemicals were obtained from BDH Chemicals Limited, 
Poole, Dorset. Acrylamide and N, N " - bisacrylamide were 
"Electran" grade, sodium dodecyl sulphate (SDS) was 
••Biochemical" grade, specially purified for electrophoresis. 
All other reagents were Anala R or the highest available 
grade. Analafl - ethanol was supplied by James Burroughs, 
London and dimethyl sulphoxide (DMSO) by Koch-Light 
Laboratories, Colnbrook, Berks. Bovine serum albumin, Ficoll 
400 and Agarose (Type 1: Low EEO) were supplied by Sigma 
Chemical Company, Poole. Litex, Agarose Type HSA was 
purchased from Park Scientific Laboratories, Northhampton 
U.K. Ammonium persulphate and
N, N, N",N"-tetramethyl-ethylenediamine (TEMED) were supplied 
by Bio-Rad Laboratories, Richmond, California.
All tissue culture reagents were supplied by 
Gibco-Biocult, Paisley, Scotland.
2.1.2. FINE CHEMICALS
Cicloxolone sodium, CCX (m.wt.668.8), carbenoxolone 
sodium (m.wt. 614.7), and diastereoisomers of CCX, BX 688A 
and BX 690A, were the gift of Biorex Laboratories Limited 
(London, U.K.) and kindly supplied by Miss L. Baxendale and 
Dr. P. Thornton.
The following fine chemicals were obtained from the Sigma 
Chemical Company, Poole: monensin, tunicamycin, furosemide, 
and disulfirum. Lyovac Cosmegen (actinomycin D) was obtained 
from Merck, Sharpe and Dohme, New Jersey, U.S.A.
2.1.3. RADIOCHEMICALS 
32[ P]-inorganic orthophop^Tphate (carrier-free) was
supplied by the Western Infirmary, Glasgow. All other
radiochemicals were obtained from Amersham International
P.I.e., Amersham, Bucks :
[5-6 ^H]-uridine (specific activity, 900Ci/mmol)
3 5[ S]-methionine (specific activity, 900Ci/mmol)
3 5[ S]-sulphate (specific activity,9OOCi/mmol)
14
[ C '-glucosamine hydrochloride (specific activity, 
50-6 OmCi/ mmo .) 
r 14L C]-methylated protein mixture (catalogue no. CFA
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626)
(Unlabelled protein markers were obtained from Sigma 
Chemical Company, Poole: catalogue no. SDS-6H and SDS-7B)
2.1.4. TISSUE CULTURE VESSELS
Roller bottles, flasks, petri dishes and 24-well 
Linbro trays were manufactured by Nunc, Denmark and were 
supplied by Gibco, Biocult Limited, Paisley.
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2.2. METHODS
2.2.1. CELL CULTURE
2.2.1.1. MEDIA
Glasgow modification of Eagles medium supplemented 
with either 10% foetal calf serum (EFC10) or 10% newborn 
calf serum (EC10).
Eagles medium lacking methionine or phosphate was 
supplied by the Media Department, Institute of Virology, and 
was supplemented with either 2% foetal calf serum (EFC2) or 
2% newborn calf serum (EC2).
L-15 medium (Leibovitz, 1963), supplied as a powder, 
was made up in 101 batches and supplemented with 100 
units/ml penicillin, 100 units/ml streptomycin, 10% tryptose 
phosphate broth and 10% foetal calf serum. The medium was 
filter sterilised and stored at 4°C.
2.2.1.2. CELL LINES / CELLS
The cell lines used were as follows:
Human (Table 14 ); Rodent (Table 15); Miscellaneous 
(Table 16).
Primary Chick Embryo:
PCEF were prepared from 12 day old embryonated eggs of 
leukosis-free chickens. After washing the eggshell with 
ethanol, the area above the airspace was removed, allowing 
the chorioallantoic membrane to be removed. The embryo was 
gently lifted from the egg, decapitated and placed in a dish 
of sterile phosphate buffered saline (PBS) (Dulbecco and 
Vogt, 1954). Legs and wing buds were removed and discarded 
and then the embryos washed three times in PBS. The tissue 
was finely chopped, suspended in trypsin solution (0.25% 
Difco trypsin in 0.8% NaCl; 0.2% KC1; 0.01% Na2HP04; 0.1% 
dextrose; 0.3% Tris HCl,pH7.7; 0.015% phenol red), allowing 
5m 1 trypsin per embryo and stirred at 37°C for 30 minutes, 
when one tenth volume of serum was added. The supernatant 
was centrifuged at 8000g at 4°C for 10 minutes and the cell 
pellet washed twice with PBS. After resuspension in EC10 
(lml per embryo), the cells were filtered through a sterile 
gauze fil and seeded at 2 x 10^ cells per 50mm petri
dish. Cells were used the following day, after incubation 
overnight at 3 7°C, in an atmosphere of 5% CC^. Fresh cells
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Human cell lines.
a obtained from Institute cell bank and supplied by Mrs. 
MacNamara.
b obtained from Flow Laboratories, 
c supplied by Dr. V Mautner.
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Table 15
Rodent cell lines.
a obtained from Institute cell bank and supplied by Mrs. 
MacNamara.
b obtained from Flow Laboratories.
rv
c supplied by Dr. J. Macflfab. 
d supplied by Dr. S. Cooke.
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Miscellaneous cell lines.
a obtained from Flow laboratories
b supplied by Dr. H. Field,
c supplied by Dr. U. Desselberger
d supplied by Dr. R.M. Elliot.
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were prepared as described for each experiment.
2.2.1.3. CELL CULTURE, STORAGE AND RECOVERY 
CULTURE
Most cell lines were grown in EFC10, but BHK-21 cells 
and PCEF were grown in EC10, while XTC-2 cells were grown in 
L-15 medium (Section 2.2.I.I.). XTC-2 cells were passaged at 
3l°C in an ungassed incubator, while all other cells were 
passaged at 3 7°C in an atmosphere of 5% CC^. Confluent 
monolayers (of all cell lines except XTC-2) were subcultured 
by washing the cell sheet twice with a solution of versene 
(0.6mm ethylenediaminetetra acetic acid) containing 0.05% 
trypsin. Detached cells were resuspended in an equal volume 
of medium and pipetted vigorously until a uniform suspension 
was obtained. Cells were then split and re-seeded as 
appropriate. XTC-2 cells were not trypsinised, but were 
sub-cultured by pipetting medium over the surface of the 
cell monolayer until all of the cells detached making a 
uniform suspension. XTC-2 and Fg 293 cells could only be 
propagated in tissue culture flasks.
STORAGE AND RECOVERY
Cells were stored in liquid nitrogen (-173°C), at a
density of 2 x 10^ cells per vial, in storage medium (40%
normal growth medium, 40% foetal calf serum or newborn calf
serum and 20% DMSO or glycerol). Prior to long term storage,
the cells were frozen slowly by overnight incubation at 
o
-70 C in a polystyrene container. Cells were recovered by
thawing and agitating in a 3 7°C water bath. Cells were then
2seeded in a 2 5cm tissue culture flask containing prewarmed 
medium. The medium was replaced after 2 4 hours and the cells 
cultured as normal.
2.1.1.4. DETECTION OF BACTERIAL AND MYCOPLASMA CONTAMINATION 
Cells were routinely checked for both bacterial and
mycoplasma contamination. Bacterial contamination was 
detected by streaking cell suspensions onto blood agar and 
sabourand agar plates, which were then incubated at 3 7°C for 
several days.
The genus Mycoplasma is a large group of prokaryotes 
which lack a cell wall. These organisms frequently
contaminate established cell lines. The fluorescent staining 
method of Chen (1977) was employed to facilitate detection 
of these contaminants.
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2.2.2. VIRUS CULTURE.
2. 2.2.1. VIRUSES
Vesicular Stomatitis virus, Indiana strain and 
Germiston virus were supplied by Dr. Joseph Szilagyi; 
Bunyamwera virus by Dr. Richard Elliot; Influenza A virus by 
Dr. Ulrich Desselberger; Semliki Forest virus and Reovirus 
type 3 by Professor Craig Pringle; Equine Herpes virus type 
1 by Dr. Anne Cullinaine; Bovine Herpes virus type 1; strain 
6660 by Dr. Hugh Field ; Human Cytomegalovirus and Varicella 
Zoster virus by Dr. Derrick Dargan and Adenovirus type 5 by 
Dr. Vivian Mautner. Poliovirus type 1 (Sabin vaccine strain) 
was purchased from Burroughs Wellcome Company, Greenville.
2. 2.2.2. PREPARATION OF VIRUS STOCKS
Virus stocks were prepared by infecting confluent cell 
monolayers at low m.o.i. (0.001-0.01 p.f.u./cell), except 
Adenovirus-5 where the m.o.i. was 1-10 p.f.u./cell. Virus 
was added in medium containing 2% serum or in the case of 
Polio-1, in medium containing no serum. All virus stocks, 
except Adenovirus-5, were harvested by the same procedure, 
at the times indicated in Table 17. Growth media containing 
cell released viruses, was clarified by centrifugation at 
8000g for 10 minutes, and aliquots of the supernatant stored 
at -70°C. Cell associated virus was harvested btj 
resuspending the cell pellet in 2ml of growth medium and 
sonicating at least three times. Cell debris was pelleted 
after each sonication and the supernatants pooled and stored 
at -70°C.
The infectious yield of Adenoviruses is very cell 
associated, therefore the growth medium was discarded. The 
cell pellet was resuspended in 1ml of Tris Saline (0.8% 
NaCl; 0.038% KC1; 0.01% Na2HPC>4; 0.1% Dextrose; 0.3% 
Sigma-Tris {hydroxymethyl} amino methane), freeze thawed 
three times, the cell debris pelleted and the supernatants 
stored at -20°C.
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Table 17
Preparation of virus stocks
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2.2.3. VIRUS PURIFICATION (VSV)
2. 2.3.1- CONCENTRATION
Concentration of virus was by ultracentrifugation at 
12,000 r.p.m. at 4°C for 2 hours in a Sorvall GSA rotor.
2 . 2 . 3.2 GRADIENT PURIFICATION
Concentrated virus, resuspended in Eagles medium 
without phenol red (EPr-), was layered onto Ficoll 400
gradients, (5-15%, made up in EPr-), 500ul per gradient. 
Centrifugation was at 15,000 r.p.m. for two hours at 4°C in 
the AH 650 rotor. Visible viral bands were removed by 
aspiration, made to 5ml with EPr- and pelleted by 
centrifugation at 26K for 90 minutes at 4°C, in the AH650 
rotor. The pellet was resuspended in EPr- and stored at 
-70°C.
2.2.4. ASSAY OF VIRUS INFECTIVITY
One in ten serial dilutions of virus stocks were made
in PBS containing 2% foetal calf or newborn calf serum. 
lOOul i.xoculum of each virus dilution was added tog
confluent monolayers of cells (4 x 10 cells/50mm petri 
dish) and allowed to absorb at the appropriate temperature 
for 60 mins. (90 mins. for Adenovirus-5), prior to adding 
overlay (Table 18). For all viruses, except Adenovirus-5, 
the overlay was made by mixing 370ml EPr-, with 125ml of 
molten agarose solution (2.4% in EPr-). Foetal calf or 
newborn calf serum was added to 3% final concentration and 
the overlay equilibrated to 42°C in a water bath, before 4ml 
was added to each petri dish. In the case of Influenza A, 
trypsin was added to the overlay, to a concentration of 
4ug/ml.
The overlay for Adenovirus titrations was made by 
mixing 115ml of EPr- with 32ml of molten Noble agar (2.4% 
Noble agar in EPr-). Calf serum and 1.25M MgCl were added to 
a final concentration of 2% and 0.66% respectively and the 
overlay equilibrated to 42°C before adding 4ml to each petri 
dish.
Following incubation (as outlined in Table 18), the 
monolayers were fixed by flooding the plates with C1DEX/PBS 
Cultures were allowed to fix for at least 4 hours, 
the overlay removed, the monolayers stained with Giemsa and
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Table 18
Assay of v i r u s  i n f e c t i v i t y
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the numbers of virus plaques determined and the virus titres
calculated.
2.2.5. BIOLOGICAL ASSAYS
2.2.5.1. STOCK SOLUTIONS OF DRUGS
lOmM preparations of cicloxolone sodium (CCX), and the 
diastereoisomers of CCX, 690 and 688 were made with sterile 
distilled water and then diluted 1:1 with sterile bovine 
serum albumin, which stabilises the drug in solution. Fresh 
stocks were prepared for each experiment and used 
immediately.
Monensin was prepared as a lOmM solution in ethanol 
and tunicamycin prepared at a concentration of 5mg per ml in 
DMSO.
Disulfirum stock solutions were made at a 
concentration of 30mM in DMSO.
All dilutions were prepared in EFC2 or EC2.
2.2.5.2. SCREENING OF CELLS FOR TOLERANCE TO DRUGS 
DYE EXCLUSION
Cells were seeded at a low density (5 x 10^ cells per
535mm petri dish or 10 cells per Linbro well). Following 
overnight incubation, cells were overlaid with growth medium 
supplemented with 2% serum containing increasing 
concentrations of drug. After one or two days treatment with 
the drug, cell cultures were treated as follows : the growth 
medium was decanted from each dish/well into a sterile 
container. The monolayer was washed twice with
trypsin/versene (except for XTC-2 cells, where washes were 
in normal growth medium), and the washes added to the growth 
medium previously removed from the cells. Following 
centrifugation (at 8000g for 10 minutes), the supernatant 
was discarded, and the cell pellet resuspended in 1ml normal 
growth medium and returned to the trypsinised monolayer. A 
homogeneous suspension of the cells was obtained by vigorous 
pi pet* ing. lOOul of the cell suspension was then mixed with 
lOOul of Trypan Blue dye (0.5% in PBS). After staining for 
10 minutes, cells were counted in a Neubar Haemocytometer 
and two parameters measured : total cell number and the 
number of viaole cells i.e. those excluding the dye.
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2. 2 - 5 . 3 .  D O S E - R E S P O N S E  E X P E R I M E N T S
Cells w e r e  s e e d e d  on 3 5mm p l a s t i c  t i s s u e  c u l t u r e  
dishes (NUNC), at a d e n s i t y  of 10^ c e l l s  p e r  d i s h  or on 24
5
well Linbro trays at 5 x 10 cells per well, and incubated 
overnight at 37°C. Confluent monolayers of cells were 
infected with virus at a m.o.i. of 5 p.f.u./cell (10 
p.f.u./cell for Adenovirus-5), and allowed to absorb for lh 
(90 minutes for Adenovirus-5) at the appropriate temperature 
(Table 18). The monolayers were washed three times with PBS 
supplemented with 5% calf serum (4ml/plate or lml/well), 
then overlaid with EFC2 containing varying concentrations of 
drug.
Virus infected cells were incubated for 24h (or 48h in 
the case of Adenovirus-5) at the appropriate temperature 
(Table 18), after which the cells were harvested by scraping 
into the growth medium. Cell associated virus was released 
by ultrasonic disruption of the cells, and the yield of 
infectious virus determined by titration (Section 2.2.3.). 
To control for cytotoxicity, mock-infected cells (from the 
same batch as those used in the virus dose-response), were 
treated in parallel with drug. Cell viability was determined 
by Trypan Blue dye exclusion, after 24h (48h for Hela cells) 
drug treatment.
2. 2.5.4. PLAQUE REDUCTION ASSAYS 
VARICELLA ZOSTER VIRUS (VZV)
Monodispersed VZV infected Flow 2002 cells were mixed 
with uninfected Flow 2002 cells, then seeded into 50ml 
tissue culture flasks and incubated at 3 7°C overnight. Next 
day the medium was replaced with EFC2 containing either no 
drug or 12.5, 25, 50, 75 or lOOuM CCX and the incubation 
resumed until 5 days post-infection, at which time the 
monolayers were fixed, stained and the number of virus 
plaques determined.
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human CYTOMEGALOVIRUS (HCMV)
Monolayers of Flow 2002 cells were infected with 600 
p.f.u. HCMV. Following absorption for lh at 37°C, the
monolayers were overlaid with EFC2 containing either no drug 
or 10, 20, 30, 40, 50, 60uM CCX, and incubated at 37°C for 
eight days (with a liquid medium change on the fourth day). 
The monolayers were then fixed, stained and the virus 
plaques counted.
These experiments were performed in duplicate and
uninfected control monolayers checked microscopically for 
cytotoxicity : Flow 2002 cell monolayers are known to be
resistant to CCX (Dargan and Subak-Sharpe, 1985).
2. 2.5.5. ONE-STEP GROWTH CURVES
Cell monolayers (4 x 10^ cells/50mm petri dish) were 
infected with virus at a m.o.i. of 5 p.f.u./cell. Following 
absorption (Table 18), the cells were washed three times 
with PBS and overlaid with EFC2 either drug-free or
containing 300uM CCX. At the indicated times after 
absorption, the infectious virus yield from selected 
cultures were harvested, sonicated and titrated.
2. 2.5.6. ABSORPTION CURVES
7
8 x 10 cells (Table 18), were suspended in 1ml PBS 
containing either no drug or 300, 600 or 900uM CCX. The cell 
suspension was incubated for 1 h at 37°C in a shaking water 
bath, to allow the drug to interact with the cells. The 
cells were then pelleted, the supernatant drawn off and the 
cell pellet washed with 10ml PBS to remove cell-free drug. 
The drug pre-treated cells were then resuspended in 1ml PBS 
containing 10^ p.f.u. of virus and incubated in a shaking 
water bath at 37°C. At the indicated times post- infection, 
lOOul samples of the infected cell suspension, were 
withdrawn and mixed with 9.9ml of ice cold PBS. The cells 
were pelleted and the residual unbound virus titrated.
2.2.5.7. DIRECT INACTIVATION OF VIRUS PARTICLES
Virus suspensions were incubated at either 4°C or 37°C 
for 24h, with either 300uM CCX or an equal volume of BSA 
(mock drug). The virus suspensions were titrated before
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addition of either 300uM CCX or BSA, immediately after 
addition and then 24h after treatment (48h in the case of 
Adenovirus-5 ) .
2.2.5.8. THERMOSTABILITY OF VIRUS PARTICLES PRODUCED IN THE 
PRESENCE AND ABSENCE OF CCX
Infectious virus yields from CCX virus dose-response 
experiments were employed to investigate the thermolability 
of virus grown in the presence of CCX. The BSA content of
each sample was standardised. Following standardisation, 1ml
of virus grown in the absence or presence of 50, 150, 300uM 
CCX, was incubated at 42°C in a shaking water bath. At 0,
15, 30, 45, 60, 75, 90, 105 and 120 minutes after
incubation, lOOul aliquots were withdrawn from each sample 
and immediately titrated. The percentage of surviving 
infectious virus at each time was then calculated relative 
to that present at 0 time.
2.2.6. ELECTRON MICROSCOPY STUDIES
2. 2.6.1.NEGATIVE STAIN
5ul of virus suspension was mixed with an equal volume
of stain (uranyl acetate), containing a known number of
latex beads (1.43 x 10 ^/ml). After staining for two minutes 
the mixture was transferred to a plastic coated grid, and 
allowed to stand for a few minutes. Excess sample was 
removed by touching the meniscus of the sample with the edge 
of a filter paper. The virus remaining on the grid was 
examined under a Siemens 101 electron microscope. Particle 
counts were estimated by comparing the number of latex beads 
(Wildy et al, 1960) .
2.2.6.2. EMBEDDING IN EPON / THIN SECTIONING
BS-C-1 cell monolayers (4 x 10^ cells/50 mm petri 
dish) were infected with SFV at m.o.i. of 5 p.f.u./cell, 
allowed to absorb for lh at 37°C, washed twice with PBS 5% 
FCS to remove unbound virus and overlaid with EFC2 without 
drug or containing 300 uM CCX or lOuM monensin. After 18 h 
incubation at 37°C, selected cultures were harvested and 
either processed for electron microscopy or assayed for 
infectivity. Tne growth medium was removed and the 
monolayers fixed by adding 4ml of 2.5% gluteraldehyde (EM
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grade) and incubating overnight at 4°C. The monolayers were 
then washed three times with PBS, and stained with 1% osmium 
^tetraoxide in PBS for at least 2h. After further washing in 
PBS, the cells were scraped into PBS and pelleted by 
centrifugation at 8000g at 4°C for 10 minutes. The cell 
pellet was dehydrated by 15 minute washes in a series of 
increasing alcohol concentrations (30, 50, 70, 90 and 100%, 
made up in anala R H^O).Cells were permeated with Epon : 
Ethanol (1:1) and allowed to stand overnight. The pellets 
were then embedded in fresh undiluted Epon which was 
polymerised by baking at 60°C, for 48h. Thin sections were 
cut with a diamond knife, stained with uranyl acetate, 
counter stained with lead citrate and examined in a Siemens 
101 electron microscope operating at 60kv.
2.2.7. BIOCHEMICAL TECHNIQUES
2.2.7.1. RADIOLABELL1NG OF CELLULAR AND VIRUS-SPECIFIED 
POLYPEPTIDES
TREATMENT OF CELLS PRIOR TO VIRUS INFECTION
5
Cells were seeded in Linbro trays at 5 x 10 
cells/well in normal growth medium or medium deficient in 
methionine (EFC2met- or EC2met-), or phosphate (EFC2phos- or 
EC2 phos-) as appropriate, and incubated at 37°C overnight. 
However in the case of Adenovirus-5, cells were seeded in 
normal growth medium, which was only replaced by the 
appropriate deficient medium 3h prior to the addition of 
label. Before infection with SFV, cells were treated with 
5ug/ml actinomycin D for 3h and actinomycin D was maintained 
in the medium throughout infection.
VIRUS INFECTION AND ADDITION OF RADIOACTIVE LABELS
Virus infection and treatment with varying drug 
concentrations was as described in 2.2.5.3., except m.o.i. 
was 100 p.f.u./cell for Adenovirus-5 and 10 p.f.u./cell for 
all other viruses. Radioactive labels were added in the
O c ( rt>Cn*'V.i -C • • • •  ~>2
appropriate medium ( S met : EFC2 / EC2 met- ; P : EFC2
/EC2 ^phos- ; ^Cglucosamine : EFC2 /EC2).The time of label
addition varied and is indicated for each experiment.
At the time of harvest, the growth medium was removed 
and the monolayers washed twice with 1ml cold PBS. The 
washes and the growth medium for each sample were pooled and
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centrifuged at 8000g at 4°C for 10 minutes to pellet any 
detached cells. Pelleted cells and cells remaining on the 
dish were lysed in lOOul proton dissociation mix, (0.125M 
Tris, HCl,pH6.8; 4% SDS; 10% 2-mercaptoethanol; 20% 
glycerol; 0.1% bromophenol blue) and pooled. Adenovirus-5 
was lysed in a different dissociation mix (8mM Tris,
HC1,pH6.8; 2% SDS; 10% glycerol; 2mM PMSF; 0.1M DTT; 0.2%
bromophenol blue).
2.2.7.2. RADIOLABELLING OF PURIFIED VSV STRUCTURAL 
POLYPEPTIDES PRODUCED IN THE PRESENCE AND ABSENCE OF CCX AND 
MONENSIN
Sub-confluent roller bottles of BS-C-1 cells were
incubated overnight at 37°C in EFC2 met-. The cells were
then infected with VSV at m.o.i. 10 p.f.u./cell and the
virus allowed to absorb for lh at 3 7°C. Unabsorbed virus was
then removed by washing the monolayers twice with EFC2 met-.
Incubation was continued (for 24h) in EFC2 met- containing
3 525uCi /ml of S met and either no drug or varying 
concentrations of CCX or monensin. After 24h, radiolabelled 
virions were purified as described in Section 2.2.3. Virus 
associated bands in Ficoll 400 gradients were resuspended in 
protein dissociation mix and analyzed by SDS-PAGE.
2.2.7.3. RADIOLABELLING OF CELLULAR AND VIRUS-SPECIFIED RNA 
SPECIES
VSV-INFECTED CELLS : LABELLING OF PRIMARY TRANSCRIPTS
For 2h prior to infection, monolayers of BS-C-1 cells
7(in 9 0mm petri dishes; 1 x 10 cells) were treated with 5ug 
per ml actinomycin D (Act. D) and 200ug per ml cycloheximide 
(CHX). Act D and CHX concentrations were maintained 
throughout the experiment. Cells were then infected in the 
usual way. Infected monolayers were overlaid with EFC2 
containing 25uCi/ml 3H uridine and either no drug or various 
concentrations of CCX. RNA was extracted at 8h p.i. as shown 
in Figure 14.
VSV-INFECTED CELLS : LABELLING OF SECONDARY TRANSCRIPTS
BS-C-1 cells were seeded onto 9 0mm petri dishes in 
efC2 phos- at a density of 1 x 10^ cells per dish, and 
incubated overnight at 37^C. Two hours prior to infection
EXTRACTION OF CYTOPLASMIC RNA
CELLS SCRAPED INTO COLD 
PBS AND PELLETED
S/N REMOVED AND PELLET 
RESUSPENDED BY VORTEXING 
IN 375ul ICE COLD LYSIS (TABLE1®) 
BUFFER. INCUBATED 3-5 MIN. ON ICE.
SPUN IN BENCH TOP MICROFUCE 
( BTM) 2 MIN. V C
S/N REMOVED TO CLEAN TUBE 
CONTAINING Aul OF 20X SDS 
VORTEXED IMMEDIATELY
2.5u1 OF 20mg/ml PROTEINASE 
ADDED. INCUBATED 15 MIN. 37‘
AOOul OF P/C/A ADDED, VORTEXED, 
1 MIN. SPUN 5 MIN. (BTM)
AQUEOUS PHASE (UPPER) REMOVED 
TO CLEAN TUBE. AVOIDING PRECIPITATED 
MATERIAL FROM THE INTERFACE.
AOOu 1 OF P/C/A ADDED; EXTRACTION 
REPEATED
AQUEOUS PHASE REMOVED TO CLEAN 
TUBE. AOOul OF C/IA ADDED. 
VORTEXED 15-30 SEC; SPUN 1 MIN 
( BTM)
AQUEOUS (UPPER) PHASE REMOVED 
TO CLEAN TUBE. AOul OF 3M SODIUM 
ACETATE. pH 5.2 AND 1ml ETHANOL 
ADDED. INCUBATED 0/N AT -20°C
RNA RECOVERED BY CENTRIFUGATION 
FOR 15 MIN., A°C
PELLET RINSED 1ml 75X ETHANOL/ 
25X 0.1M SODIUM ACETATE, pH 5.2
PELLET DRIED AND RESUSPENDED 
IN lOOul DEPC-TREATED H O  
STORED AT -70°C
Figure 14
Extraction of cytoplasmic RNA 
Footnotes:
1. All solutions were made up in Diethylpyrocarbonate (DEPC) 
treated water.
7
2. All volumes given are for 4x10 cells.
3. Spins performed in bench top microfuge (BTM), at 
13,OOOr.p.m.
4. P/C/A/ : 25:24:1 Phenol/Chloroform/Isoamylalcohol 
C/IA : 24:1 Chloroform/Isoamylalcohol
5.Lysis Buffer (see Table 19).
Sample Buffer
5ul 10 x MOPS running buffer 
8.75ul 37% formaldehyde 
25ul formamide
Formaldehyde Loading Buffer
ImM EDTA, pH8 
0.25% Bromophenol Blue 
0.25% Xylene Cyanol 
50% glycerol
10 x MOPS [3-(N-morphilino)-propanesulphonic acid] running 
buffer
41 . 8g MOPS wa s  added to 800ml DEPC-treated H20; pH adjusted 
to 7. To this was added 16.6ml of 3M DEPC-treated sodium 
acetate and 20ml 0.5M DEPC-treated EDTA, pH8, the final 
volume brought to 11 with DEPC-treated H 20.
Th e  buffer was filtered before use.
Cell Lysis Buffer
Chemicals Volume (ml)
500mM Tris HC1, pH8 10
ImM NaCl 10
50mM M g C l 2 10
Nonidet P-40 0.5
H2 0 69.5
Table 19
Solutions and buffers used in agarose gel electrophoresis of 
RNA.
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Table 20
Single concentration (a) and gradient (b) polyacrylamide 
gels
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and throughout the experiment cells were treated with 5ug 
per ml Act D. The cells were then infected with VSV at an 
m.o.i. of 50 p.f.u./cell, in the usual way, using EFC2 phos- 
for washes and overlays. Infected cells were then grown in 
the presence or absence of various concentrations of CCX. 
Secondary transcripts were labelled by adding 
32p_0rthophosphate (25uC/ml) between 4 and 8 h p.i.RNA was 
extracted as shown in Figure 14.
LABELLING OF TOTAL RNA IN MOCK-INFECTED CELLS
7
Mock-infected BS-C-1 cells (90mm petri dishes; 1 x 10
3 2cells/dish were labelled with P-orthophosphate (25uCi/ml 
between 1 and 8h and 1 and 24h and RNA extracted as shown in 
Figure 14.
2.2.8. BIOPHYSICAL TECHNIQUES
2.2.8.1. POLYACRYLAMIDE GEL ELECTROPHORESIS OF POLYPEPTIDES 
(SDS PAGE)
Proteins were separated on polyacrylamide gels in the 
presence of 0.1% SDS using the discontinuous buffer system 
of Laemmli modified by Marsden. (Laemmli, 1970; Marsden, 
Crombie and Subak-Sharpe, 1976).The ratio of acrylamide to 
bisacrylamide was generally 39:1 for single concentration 
gels and 19:1 for gradient gels. Separating gels contained 
either 10 or 12.5% acrylamide and stacking gels contained 3% 
acrylamide (Table 20).The molecular weights of 
virus-specified proteins were estimated by reference to 
molecular weight protein standards (Section
2.1.).Electrophoresis of polypeptides was optimal when a 
constant current of 60mA was run through the gel.
2.2.8.2. PREPARATION OF POLYACRYLAMIDE GELS FOR 
ELECTROPHORESIS
Polyacrylamide gels con t a i-n-i-ng e 1 q ct-r-opb-er i s-ed 
polypeptides were routinely soaked in fix / stain [0.2% 
Comassie Blue and methanol, H20/ Glac;i-al acetic acid 
(50:43:7)] for lh. Bands were visualised by continuous 
shaking in destain [methanol, H^O, glacial acetic acid 
(5:88:7)] overnight. When it was necessary to increase the 
sensitivity of detection of poorly labelled proteins, gels 
were first fixed (45% methanol, 5% acetic acid) for at least
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3
4 5  minutes, then soaked m  En Hance (New England Nuclear)
for lh and finally washed in water for lh. Gels used to 
3 2analyze P-labelled proteins were treated according to the 
method of Petri et al (Petri, Patterson and Dimmock,1982). 
After electrophoresis gels were fixed in methanol and acetic 
acid as above, soaked for lh at 9 0°C in 5% TCA and washed 
twice in 5% TCA at room temperature for lh. This treatment 
with hot and cold TCA removes the phosphate which is not 
covalently linked to protein (Bhorjee and Pederson, 1976) 
and so reduced background radiation in the resulting 
autoradiographs.
All gels were dried onto Whatman number 1 filter paper 
under vacuum (30 units) at 80°C for 1.5h. Dried gels were 
placed against X-Omat film. Exposure of gels was at room
3
temperature, unless they had been treated with En Hance when 
exposure was at -70°C. Exposed autoradiograph films were 
developed and fixed automatically in an X-Omat film 
developer.
2.2.8.3. AGAROSE GEL ELECTROPHORESIS OF RNA 
PREPARATION OF SAMPLES
The yield of RNA was first quantitated by measuring
the O.D. (optical density) at 260nm with a Cecil CE 595
double beam digital spectrophotometer, assuming an O.D. of 
one at 260nm in a 1cm pathlength to be equivalent to 50ug 
RNA. Samples were prepared for electrophoresis by adding 
38.75ul of sample buffer (Table 19) to 11.25ul of RNA, and 
then adding lOul of formaldehyde loading buffer (Table 19).
ELECTROPHORESIS OF SAMPLES ON 1.2% AGAROSE / FORMALDEHYDE 
GELS
Samples were analyzed on a 1.2% agarose/formaldehyde 
gel containing 1% MOPS running buffer and 0.5% formamide.
The gel was run at a constant voltage of 5V/cm until the
bromophenol blue band had migrated halfway down the gel 
(—3h). The gel was then allowed to sit in excess water 
overnight. The next day the water was decanted and ethidium 
bromide added (25ul of lOmg/ml in 500ml H20)* The gel was 
then allowed to stain for 45 minutes and then photographed 
under short wave U.V. illumination (260nm),thus allowing 
visualisation of total RNA. The gel was then dried and
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placed against X-Omat S film. Exposed autoradiographs were 
developed and fixed automatically in X-Omat film developer, 
revealing radiolabelled RNA.
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3. RESULTS
•3.1. CELL SURVEY
3 .1.1. CLASSIFICATION OF CELL LINES AS RESISTANT,
INTERMEDIATE OR SENSITIVE TO CCX TREATMENT
Dargan and Subak-Sharpe (1985), reported that three 
cell lines differed in their sensitivity to treatment with 
up to 300uM CCX : Flow 2002 cells (human) were resistant, 
Vero cells (monkey) were sensitive, while BHK-21 cells
(rodent) displayed intermediate sensitivity. The present 
study which has expanded the range of cell lines was 
performed with two objectives in mind. Firstly, to identify 
cell lines resistant to CCX treatment and permissive for
virus growth to allow uncoupling of antiviral and cytotoxic 
effects. Secondly, to establish how a range of cell lines 
compare in their tolerance to CCX treatment and attempt to 
determine the basis for differential CCX sensitivity.
Cell monolayers overlaid with various concentrations 
of CCX were treated with trypan blue 24h and 48n after drug 
addition, and total cell number and the number of viable 
cells then determined (Materials and Methods, Section
2.2.5.2.). On the basis of cell viability in the presence of 
CCX, the cell lines fell into three groups (Resistant, 
Intermediate or Sensitive), the designation of individual 
cell lines to a particular group depending upon a consistent 
performance in three independent experiments. Curves showing 
cell viabilities and total cell numbers with increasing CCX 
concentrations are plotted in Figures 15-17.
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r e s i s t a n t
Nine cell lines fell into the Resistant class : Flow
2002, RK-13, Chang Liver, Detroit 532, HeLa, Hep2, MDBK,
MDCK, BS-C-1 (Fig.l5a-i). In general, for cell lines
classified as Resis*\-.‘ the decrease in viability obtained 
with 300uM CCX was not greater than 20% at 24n, and 30% at 
4 8 n .
The decrease m  cell viability was less tnan or equal 
to 10% after 24n treatment with CCX to 300uM, in all cases 
(Fig. 15a,d ,c,d ,e ,g,n,i , ), witn the exception of Hep2 
(Fig.l5f), wnere the reduction was 19%. 48h treatment to 
300uM CCX, resulted in the viability of Flow 2002, Chang 
Liver, Detroit 532 , HeLa and BS-C-1 cells (Fig.15a,c,d,i ) 
being reduced by less than or equal to 10%, with tine
reduction in Hep 2 cell viability (Fig.l5f), being just
slightly greater at 11%. RK-13, MDBK and MDCK (Fig.15b,g,n ,) 
cell viability decreased by 28%, 15% and 24% respectively 
after 48n treatment with CCX to 300uM. Tne effect on ceil 
viaoility increased witn increasing CCX in tne case of MDBK 
and MDCK (Fig.l5g,h). In contrast, RK-13 cell viability 
(Fig. 15b) was unaffected by CCX to 200uM, with a sudden 
decrease achieved with 300uM CCX. This result was shown to 
be consistent in repeat experiments.
The total cell number typically rose 2 fold in a 24h 
period in the absence of CCX. 24h treatment at the highest 
concentration had some effect on the replication of cell 
lines in this class: cell numbers rose to between 68% (Hep2, 
Fig 15f ) and 84% (Chang Liver, Fig 15c) of the drug free 
control. The effect on cell replication progressed with both 
increasing drug and time, cell numbers rising to between 52% 
(Flow 2002, Fig 15a) and 68% (Chang Liver and Detroit 532, 
Fig 15c and d) of the drug free control after 48h treatment 
with 300uM CCX. Therefore, while the viabilities of 
resistant cell lines was not significantly affected, their 
growth was impaired by CCX treatment. These cell lines were 
classified as suitable for use as hosts in virus 
dose-response experiments using concentrations to 300uM. As 
virus dose-response experiments were performed in confluent 
monolayers, the effect on cell number could not contribute 
to any effect on virus replication.
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Figure 15
CCX Resistant cell lines: a) Flow 2002, b) RK-13.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ).
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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Figure 15
CCX Resistant cell lines: c) Chang Liver, d) Detroit 532.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A ), after 24h and 
48h drug treament. The total cell number at Oh is denoted by 
(< ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viabilty percentages are 
relative to the total number of cells on each plate.
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CCX Resistant cell lines: e) HeLa, f) HEp2 .
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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Figure 15
CCX Resistant cell lines: g) MDBK, h) MDCK.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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CCX Resistant cell lines: i) BS-C-1.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
97
i n t e r m e d i a t e
Five cell lines fell into the Intermediate class : 
BHK-21, Flow 4000, MRC-5, Rabbit Epithelium, Rabbit 
Keratocytes (Fig 16a-e). Viabilities of all cell lines 
belonging to this class were progressively reduced with both 
increasing drug and time.
After 24h, a significant reduction in cell viability 
was achieved with only lOOuM CCX in all cases (BHK-21,15%; 
Flow 4004,21%; MRC-5,15%; Rabbit Epithelium,14%; Rabbit 
Keratocytes,15%) (Fig.l6a-e). This reduction progressively 
continued as concentration of drug increased,so that BHK 
cell viability was reduced by 90%, MRC-5 by 8b%, Rabbit 
Epithelium by 8t% and Rabbit Keratocytes by 90%
(Fig.16a,c,d,e). No viable MRC-5 cells could be detected at 
300uM CCX (Fig.16c), with only 5%, 8% and 2% of the cells 
being viable in the case of BHK-21, Rabbit Epithelium and 
Rabbit Keratocytes (Fig.16a,d,e). Flow 4000 cell viability 
was not as dramatically affected by the drug, viability 
reduced by 66% with 300uM CCX, with 25% of the cells still 
viable (Fig.16 b ).
Treatment for 48h, with the lowest C C X  concentration 
(50uM), had a significant effect on cell viability with 
BHK-21, Flow 4000, MRC-5, Rabbit Epithelium and Rabbit 
Keratocyte cell viability reduced by 24%, 23%, 11%, 13% and 
14% respectively (Fig.l6a-e). The effect was progressive 
with reductions in viability of between 45%-58% being 
achieved with 150uM C C X , and no viable cells detected with 
300uM CC X in all cases, except Flow 4000, where only 3% of 
the cells were viable.
After only 24h, total cell number was decreased with 
increasing C C X  concentration, resulting in almost complete 
inhibition of cell replication at 300uM in all cases 
(Fig.l6a-e). After 48h, total cell number again decreased 
with increasing C C X  concentration. However, some cell growth 
occurred at concentrations of C C X  less than 300uM, with the 
exception of Rabbit Keratocytes where cell replication was 
completely inhibited with 200 and 300uM C C X  (Fig.l6e).
Replication of cell lines belonging to the 
Intermediate class was progressively reduced with increasing 
drug. However, no progression in the inhibition of cell 
replication was observed in the second 24h period.
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CCX Intermediate cell lines: a) BHK-21, b) Flow 4004.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( < ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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CCX Intermediate cell lines: c) MRC-5, d) Rabbit Epithelium.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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Figure 16
CCX Intermediate cell lines: e) Rabbit Keratocytes.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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SENSITIVE
The Sensitive class consists of six cell lines : Fg
293 , XTC-2, HOOD, Re;<-, Re9 9 and PCEF (Fig 17a-f ) . The most
sensitive cell line was Fg 293, the viabilty of these cells 
decreasing by 70% after 24h treatment with only 50uM CCX 
(Fig 17a). The same percentage decrease in cell viability
after 24h, was achieved with Re cells at lOOuM CCX and for
all the rest of the cell lines in this group, except Re 99
at 150uM (Fig 17b,c,f). 48h treatment with only 50uM CCX
almost completely abolished Fg 293 cell viability (Fig 17a). 
While XTC-2 and HOOD cell viabilities decreased by 71% and 
73% respectively (Fig 17b,c), with ReR and Re99 reduced by 
50% and 30% respectively (Fig.l7d,e), PCEF cells showed 
somewhat greater tolerance to treatment with CCX 
concentrations less than 150uM, over a 48h period (Fig.l7f).
At 50uM CCX, viability remained high and was similar to that 
observed with Resistant cell lines (Fig. 15a-i ) . However 
cell viability was progressively reduced culminating in 
total death of the cell culture with 200uM CCX, in common 
with other members of the group.
Little or no cell replication occurred even at low 
drug concentrations for all cell lines in this group, except
\i‘^j -rtnev ,Aev>iv>cv' )
PCEF, whose cell growth was ftet rrva-rHtetlly affected* by 2 4h twvs
treatment with drug concentrations lower than 200uM CCX 
(Fig. 17f). Cell growth was affected by 48h treatment with 
all drug concentrations: there was a progressive reduction 
in total cell number, leading to almost total inhibition 
with 150uM CCX. Thus, for all cell lines in this Sensitive 
group the effect on total cell number parallels the effect 
on cell viability.
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CCX Sensitive cell lines: a) Fg 293, b) XTC-2.
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treament.The total cell number at Oh is denoted by 
(< ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
c d
100 100
eo eo
60 60
24h 24h
A -40
A- -
20 20
100 100 Ar
00 eo
60 60
48h 48h
40 40
20 20
30025050 250100 150 200 300 200150100
UM CCX uM CCX
Figure 17
CCX Sensitive cell lines: c) HOOD, d) Re-*- .
The effect of increasing CCX concentrations on cell 
viabilities (□) and total cell numbers (A), after 2 4h and 
48h drug treatment. The total cell number at Oh is denoted 
by (< ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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CCX Sensitive cell lines: e) Re 99, f) PCEF.
The effect of increasing concentrations of CCX on cell 
viabilities (□) and total cell numbers (A), after 24h and 
48h drug treatment. The total cell number at Oh is denoted 
by ( <  ) .
All total cell number percentages are relative to the drug 
free control after 48h, while cell viability percentages are 
relative to the total number of cells on each plate.
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A summary of the cell lines examined and the classes 
into which they fall are shown in Table 21. Of the twenty 
cell lines in the survey, nine were found to be Resistant, 
five Intermediate, and six Sensitive to CCX treatment. The 
species may be important : of nine human cell lines, six 
proved Resistant, two Intermediate and only one Sensitive, 
while of eight rodent cell lines, only one was Resistant, 
three were Intermediate and three Sensitive. It should be 
noted that the only human cell line which is sensitive to 
CCX is the Adenovirus DNA transformed cell line Fg 293, 
which expresses the Adenovirus Ela and Elb genes. Several 
other transformed lines (HOOD, Re and Re99) also fall into 
this Sensitive group. Cell type per se may play some role in 
conferring tolerance to CCX: of the nine fibroblastic lines
tested only 2 fell into the Resistant class, with 3 
Intermediate and 4 falling into the Sensitive class.
Five of the nine cell lines identified as resistant to 
CCX were chosen because of their biological properties, as 
suitable hosts in which to perform virus dose-response 
experiments : Flow 2002, BS-C-1, HeLa, MDCK and RK-13. The 
most useful cell line identified was the BS-C-1 line as this 
is permissive for the growth of five viruses in the study.
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Table 21
Classification of cell lines based upon their sensitivity to 
CCX.
[H] human 
[R] rodent 
[S] simian 
[C] canine 
[B] bovine 
[A] amphibian 
[Av] avian
Transformed Lines
Fg 293: transformed with Ela and Elb region of Adenovirus-5 
DNA.
Re : transformed with HSV 1 (strain HFEM)
Re 99: transformed with ts 1 HSV 2 (strain HG 52)
HOOD: immortalised by serial passage
e: epithelial; f: fibroblastic
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3.1.2. r e c o v e r y  o f  d r u g  t r e a t e d  c e l l s
For better evaluation of the cytotoxic effect of CCX
on the cell lines employed in virus dose-response
experiments, and to determine whether cell death is a
factor in the antiviral effect, reversibility of the
cytotoxic effect was examined. BS-C-1, HeLa, MDCK and RK-13
c e l l s  were treated with mock drug (the solution containing
BSA in w h i c h  CCX is m a d e  up), or v a r i o u s  uM c o n c e n t r a t i o n s
of CCX. A f t e r  24h or 48h as a p p r o p r i a t e  the CCX w a s  r e m o v e d
from the cell cultures by three washes with PBSccFCS andb %
then overlaid with drug-free medium and incubated at 37 C 
for a furtner five days. The total number of cells and the 
percentage of viable cells was then determined for each cell 
line in the usual way (Table 22). As previously noted with 
Flow 2002 cells, presence of increasing concentrations of 
CCX in all cases slows down cell replication; RK-13 < HeLa < 
BS-C-1 < MDCK. Cell viability is least affected in BS-C-1 
cells suggesting they represent very favourable hosts for 
investigating the antiviral effects of CCX treatment. In 
every case, the effect on cell replication was reversible as 
evidenced by increasing total cell numbers and constantly 
high cell viabilities. The reversible effect of CCX on Flow 
2002 (and BHK-21) cells was previously demonstrated by 
Dargan and Subak-Sharpe, 1985.
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Table 22
Recovery of drug-treated cells.
Cells were treated with increasing concentrations of CCX and 
after 24h or 48h drug addition cells were either harvested 
(column a), or washed and overlaid with drug-free medium, 
and incubation continued for a further 5 days before 
harvesting (column b).
Harvested cells were then subjected to dye exclusion (trypan 
blue) and both total cell number and the number of viable 
cells determined.
In both column a and b, numbers in brackets indicate 
percentages of viable cells.
Column a: numbers are percentages of the total cell count 
relative to the 48h drug-free control.
Column b: the given numbers are multipliers indicating the 
increase during the 5 day recovery period in total cell 
number, relative to the numbers observed in the individual 
cultures after 24h or 48h CCX treatment (column a).
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3.1.3. S T R E S S  P R O T E I N S  I N D U C E D  IN CCX T R E A T E D  C E L L S
Dargan and Subak-Sharpe (1986a), previously reported 
the appearance of novel protein bands in CCX treated Flow 
2002 and BHK-21 cell extracts, subjected to SDS PAGE. Tney 
proposed these bands represented proteins which might play a 
role in determining whetner cells are resistant or sensitive 
to CCX treatment. A detailed study was undertaken. Firstly, 
to establish whether the CCX induced polypeptides were 
stress proteins and secondly to determine whether different 
classes of cells (i.e. Resistant, Intermediate and 
Sensitive), would induce different novel bands when treated 
with CCX.
Mammalian cells induce different sets of stress
w
p r o teins m  r e s p o n s e  to d i f f e r e n t  e n v i r o m e n t a l  i n s u l t s .  For 
example, t h e y  r e s p o n d  to h e a t  s h o c k  a n d  o t h e r  e n v i r o m e n t a l  
insults by i n d u c i n g  t h e  s y n t h e s i s  of a s m a l l  set of h e a t  
shock p r o t e i n s  (hsp) a n d  to g l u c o s e  s t a r v a t i o n  a n d  
g l y c o s y l a t i o n  i n h i b i t o r s  by i n d u c i n g  the s y n t h e s i s  of 
another s e t  of p r o t e i n s  d e s i g n a t e d  g l u c o s e - r e l a t e d  p r o t e i n s  
(grp) (Shiu e t  a l ., 1977). A l t h o u g h  t h e  g r p s  a r e  r e l a t e d  to 
the hsps, t h e y  a r e  n o t  i n d u c e d  by h e a t  s h o c k  ( S o r g e r  a n d  
Pelham, 1987; M u n r o  a n d  P e l h a m ,  1986). T h e  t w o  m a j o r  hsps, 
have m . w t s .  of 90K a n d  70K, w h i l e  the two m a j o r  g r p s  a r e  94K 
and 78K.
To help identification of the novel bands induced by 
CCX in different cell lines, compounds known to induce 
different sets of stress proteins were employed in a 
comparative study with CCX : disulfirum (hsp control; 
Notarianni and Preston, 1982) or tunicamycin (grp control; 
Welch et al., 1983; Pouysseyur and Yamada, 1978). Figure 18 
shows the SDS PAGE profile of extracts from CCX, tunicamycin 
and disulfirum treated cells. Tne cells used represent the 
three classes : Resistant - HeLa (1-4), Flow 2002 (9-12), 
BS-C-1 (13-16); Intermediate - BHK-21 (17-20) and Sensitive 
- Fg 293 ( 5-8 ) .
In all CCX treated extracts, novel bands were induced. 
However, the number, molecular weight and intensity of these 
bands differs between cell lines. Although the bands 
corresponding to grp 78 and hsp 90 appear in all CCX treated 
extracts, Fg 293 cell extracts differ from other cells in 
the relative abundance of these bands; with the grp 78 oand
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present in moderate amounts, while the hsp 9 0 band is very 
marked. In all other cell lines, grp 78 is induced more 
strongly (particularly in HeLa and Flow 2002), than hsp 90. 
The amounts of grp 94 in all CCX treated cell extracts was 
very small (undetectable in BHK-21 cells). In contrast, hsp 
70 was induced very strongly in all cells (particularly in 
Flow 2002 cells), treated with CCX, the exception being 
BS-C-1 cells where this band was virtually absent.
A d d i t i o n a l  n o v e l  b a n d s  not i d e n t i f i e d  as s t r e s s
proteins were also induced in CCX treated human cell lines,
Fg 293, F l o w  2002 a n d  H e L a  c e l l s  (Fig. 18, l a n e s  7,11 a n d
3 5
3).CCX t r e a t m e n t  r e s u l t e d  in a r e d u c t i o n  of S m e t h i o n i n e  
i n c o r p o r a t i o n  i n t o  the a c t i n  b a n d  w i t h  m o s t  cell lines, a n d  
was p a r t i c u l a r l y  n o t a b l e  in the c a s e  of F l o w  2002 a n d  BHK-21 
cells .
The SDS PAGE gel (Fig 18), shows that CCX treatment of 
three CCX Resistant, one Intermediate and one Sensitive cell 
line (from three different species) resulted in the 
synthesis of a set of polypeptides some of which co-migrate 
with recognised major stress proteins, both of the grp and 
hsp types. The fact that similar polypeptides are made in 
cells of diverse origin, make it most likely that these are 
indeed cellular stress proteins. It is not yet clear how CCX 
triggers the stress response, or whether the same CCX 
induced effect/s regulate the synthesis of grps and hsps in 
different cell lines. It is interesting however, that the 
only sensitive cell line examined, Fg 293/ was exceptional 
in the low level of grp 78 made in drug treated cells.
III s 
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F igure 18
The synthesis of cellular stress proteins after 18h 
treatment with CCX.
SDS PAGE autoradiograph of HeLa (lanes 1-4); Fg 293 (lanes 
5-8); Flow 2002 (lanes 9-12); BS-C-1 (lanes 13-16) and 
BHK-21 cells (lanes 17-20).
Cells were either drug free (lanes 1,5,9,13 and 17), or 
treated for 18h with 0.3uM disulfirum (lanes 2,6,10,14 and 
18), CCX (lanes 3,7,11,15) or 5ug/ml tunicamycin (lanes 
4,8,12,16 and 20). The CCX concentrations which produced the 
strongest stress response varied between different cell 
lines: HeLa and BS-C-1 (300uM); Flow 2002 and BHK-21 (200uM) 
and Fg 293 (lOOuM).
Novel protein bands produced in the presence of disulfirum 
( ■ ); tunicamycin (O ); CCX ( ♦ ) .
grp 94 and 78K, and hsp 90 and 70K are identified.
(Disulfirum has also stimulated the expression of some 
grps) .
103
3.2. VIRUS SURVEY
3.2.1. CCX INFECTIOUS YIELD DOSE-RESPONSE CURVES AND PLAQUE
REDUCTION ASSAYS
Cicloxolone sodium (CCX), is a synthetic analogue of 
glycyhrrhizic acid (GA), which itself displays broad 
antiviral activity in vitro : Vaccinia, HSV-1, NDV, VSV, 
Influenza A and B and HIV (Pompei et al., 1979, 1983; Ito et 
al. , 1987 ). Dargan and Subak-Sharpe (1985 , 1986a and b) ,
demonstrated that CCX exhibited anti-HSV activity (more 
potent activity than GA), and postulated that CCX operates 
by disturbing the normal function of host cell membranes. 
This proposed general mechanism, suggested that the 
replication of several unrelated viruses could be affected 
by the drug.
To test this proposition, the wider antiviral range of 
CCX was studied using HSV-1 and HSV-2 as positive controls. 
Dose-response experiments scoring infectious virus yield 
(2.2.5.3.) were performed with the viruses shown in Table 
13. For technical reasons, in the cases of human 
cytomegalovirus (HCMV) and varicella zoster virus (VZV), 
plaque reduction assays and not infectious yield assays were 
performed.
The dose-response curve obtained for VSV (Fig 19a), 
demonstrates that CCX has a strong antiviral effect: drug 
treatment reduced the infectious yield about 10,000 fold at 
300uM CCX. The magnitude of this reduction is similar to
that previously reported for HSV-1 and HSV-2 i.e. from 1,000 
to 100,000 fold (Dargan and Subak-Sharpe, 1985). In all the
experiments the mock-infected controls show that cell
viabilty was not significantly affected.
When two non-human herpesviruses were tested the
infectious virus yields of both EHV-1 and BHV-1 were
progressively reduced (Fig 19b). In the case of EHV-1, this 
resulted in a 1,000 fold reduction in infectious virus yield 
with 300uM CCX. BHV-1 proved very sensitive exhibiting a
5000 fold reduction in infectious yield with lOOuM CCX, with 
infectivity completely abolished when cultures were treated 
with 300uM CCX. Similar reduction has been obtained in
analogous experiments performed in MDBK cells infected with 
BHV-1 (Field, H.J. and S.K. Bandyopadhyay; personal 
communication). The antiviral activity against EHV-1 and
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BHV-1 parallels the previously reported observations made 
with the human herpesviruses HSV-1 and HSV-2 and and 
suggests that sensitivity to CCX may be a property common to 
the herpesvirus family.
Figure 19c shows the curve obtained for Influenza A. 
While 50uM CCX had no detectable effect, higher doses result 
in a progressive reduction in infectious virus yield, 
reaching 100 fold with 300uM CCX. Typical dose-response 
curves ror two Bunyaviruses, Bunyamwera and Germiston, are 
shown in Figure 20a; while treatment with 50uM CCX had no 
significant effect, there was a progressive reduction in 
infectious virus yield for both viruses, with lOOuM and 
200uM CCX dropping tne titre to about a r-Xu.-tieth with little 
further effect on increasing the CCX dose to 300uM. The 
dose-response curve for Polio-1 is shown in Figure 20d. CCX 
treatment of Polio-1 virus-infected cells results in a 
moderate 35 fold decrease in infectious virus yield with the 
antiviral activity consistently reaching a plateau at 150uM 
CCX. Also shown in this figure is the dose-response curve 
for SFV, the straight line obtained indicating total 
resistance to the drug.
The dose-response curve for Reovirus-3 is given in 
Figure 20c. Tnere is great sensitivity to the presence of 
even small amounts of the drug resulting in a sharp drop in 
yield to a thirtieth with 50uM CCX; subsequent reduction in 
infectious virus yield continued to 100 fold with 150uM CCX 
at which concentration the dose-response curve reaches its 
plateau level. Additional experiments in which 
concentrations lower than 50uM CCX have been used, show that 
treatment with only 20uM already produces a significant 
effect (Fig 20c). Adenovirus-5 behaves similarly, giving the 
dose-response curve shown in Figure 20d; infectivity was 
reduced about 80 fold and the plateau level reached with 
lOOuM CCX.
Plaque reduction assays were performed in the case of 
HCMV and VZV, as it is difficult to obtain cell-free 
infectious virus in these cases. values of 28uM and
52uM were obtained for HCMV and VZV respectively (Figure 
21). Analogous experiments with HSV-1 and HSV-2 produced 
ED50 values °f 186uM and 118uM respectively. Therefore, both 
VZV and HCMV have significantly lower values than
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either HSV-1 or HSV-2, indicating greater sensitivity to CCX 
treatment.
These investigations of the antiviral range of CCX
allowed placement of the viruses into three broad classes
depending upon their dose-related response to the drug
(Table 23). The first class is composed of VSV, Influenza A
and the Herpesviruses HSV-1, HSV-2, EHV-1 and BHV-1, all of
which exhibit a continuous drug dose-dependent reduction in
virus infectivity. The extent of the drop varies for
individual viruses, from 100 fold (Influenza A) to greater
than 100,000 fold (BHV-1). VZV and HCMV probably fall into
the same class, but here only the EDC0 values which were5 U
50uM and 28uM respectively could be ascertained. Since these 
values are lower than the ED,_q values for HSV-1 or HSV-2, it 
would seem highly likely that both these important
herpesviruses also belong to this class.
The second class contains Bunyamwera and Germiston 
virus, Polio-1, Reovirus-3 and Adenovirus-5. Members in 
general exhibit a less extensive total CCX response, 
infectivity being reduced by only 20-100 fold even with
300uM CCX. All the dose-response curves reach their plateau 
level with concentrations between 100 and 200 uM CCX.
However, this second class falls into two sub-divisions : 
whereas both Adenovirus-5 and Reovirus-3 exhibit great 
sensitivity to low doses of drug and then reach their
plateau values, Polio, Bunyamwera and Germiston are little 
affected by doses less than 50uM and only then respond to 
increased doses until a plateau is reached between 150-200uM 
CCX.
The third class, does not manifest any effect of CCX 
treatment irrespective of drug concentration. Presently only 
SFV falls into this non-responsive class.
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Figure 19a
The effect of increasing concentrations of CCX on the 
infectious virus yield from BS-C-1 cells infected with VSV 
(Indiana).
Virus dose-response curve ( ■  ) .
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with increasing concentrations of CCX 
( •). Cell viability is plotted on a linear scale while 
virus yield is plotted on a log^Q scale.
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Figure 19b
The effect of increasing concentrations of CCX on the 
infectious virus yield from RK-13 cells infected with EHV-1 
and BHV-1.
Virus dose-response curves: EHV-1 (B);BHV-1 (♦).
Viability of uninfected RK-13 cells from control cultures 
treated in parallel with increasing concentrations of CCX 
(•).
Cell viability is plotted on a linear scale while virus
yield is plotted on a log^Q scale.
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Figure 19c
The effect of increasing concentrations of CCX on the 
infectious virus yield from MDCK cells infected with 
Influenza A.
Virus dose-response curve ( ■  ).
Viability of uninfected MDCK cells from control cultures 
treated in parallel with increasing concentrations of CCX 
( • ) .
Cell viability is plotted on a linear scale while virus
yield is plotted on a log-^ scale.
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Figure 20a
The effect of increasing concentrations of CCX on the 
infectious virus yield from BS-C-1 cells infected with 
Bunyamwera and Germiston virus.
Virus dose-response curves: Bunyamwera ( ■); Germiston (♦). 
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with increasing concentrations of CCX 
( •).
Cell viability is plotted on a linear scale while virus
yield is plotted on a l°g^o sca^e *
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Figure 20b
The effect of increasing concentrations of CCX on the 
infectious virus yield from BS-C-1 cells infected with 
Polio-1 and SFV.
Virus dose-response curves: Polio-1 ( ■  ); SFV ( ♦  ) . 
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with increasing concentrations of CCX 
(•).
Cell viability is plotted on a linear scale while virus
yield is plotted on a log^Q scale.
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Figure 20c
The effect of increasing concentrations of CCX on the 
infectious virus yield from BS-C-1 cells infected with 
Reovirus-3.
Virus dose-response curves (■). The second curve, where 
additional low concentrations of drug were used, has been 
transposed down by half a log unit to allow clearer 
presentation.
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with increasing concentrations of CCX 
(•). Cell viability is plotted on a linear scale while 
virus yield is plotted on a scale.
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Figure 20d
The effect of increasing concentrations of CCX on the 
infectious virus yield from HeLa cells infected with 
Adenovirus-5.
Virus dose-response curve ( ■  ).
Viability of uninfected HeLa cells from control cultures 
treated in parallel with increasing concentrations of CCX 
( • ).
Cell viability is plotted on a linear scale while virus
yield is plotted on a scale.
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Figure 21
The effect of increasing concentrations of CCX on the number
of plaques formed by HCMV and VZV on Flow 2 002 cells.
Plaque reduction obtained with HCMV ( ■  ).
Plaque reduction obtained with VZV ( •  ).
The number of plaques counted on drug free plates were 6 58
and 500, for HCMV and VZV respectively.
ED^q values obtained from these curves are shown.
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Table 23
Classification of response of viruses to CCX treatment.
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3.2.2. D1ASTEREQISOMER STUDY
Comparative dose-response experiments were performed 
with CCX and diastereoisomers of CCX, "690" and "688". It 
was hoped this might reveal information concerning the 
active form of the drug and allow inferences concerning its' 
mode of antiviral action versus toxicity. Three viruses each 
a member of a different group (as classified in section
3.2.1.) were chosen for the study : VSV (group 1), Germiston
(Group 2) and SFV (Group 3). All virus infections were 
performed simultaneously in BS-C-1 cells and controlled for 
cytotoxicity. The results of dye exclusion performed on 
mock-infected BS-C-1, set up in parallel to the virus 
infected cells are shown in Table 24.
In agreement with previous observations, treatment
with up to 300uM CCX, had little significant effect on cell
viablity (resulting in a drop of only 6%), but did inhibit
cell replication to some degree, with total cell number 
rising to 77% of the control level. Cell viability was not 
affected by treatment with up to 300uM "690" and only a very 
slight effect on cell replication was observed, with the 
total cell number in cultures treated with 300uM, reaching 
88% of the control level. "690" is therefore less toxic to 
cells than CCX, allowing uncoupling of any antiviral and 
cytotoxic effects. In contrast, treatment with
diastereoisomer "688" had a very marked effect on cell 
viability, which was reduced 20% with only 50uM. At lOOuM 
"688", just over half the cells were viable, dropping to 
only 24% viability with 300uM "688". Cell replication was 
also markedly reduced with increasing concentrations of 
"688", resulting in complete inhibition with 300uM. 
Therefore, "688" is much more toxic to cells than CCX, 
making separation of antiviral and cytotoxic effects 
difficult at concentrations over lOOuM.
Corresponding virus dose-response curves are shown in 
Figures 22, 23 and 24. In these experiments, virus yields 
were divided into cell-associated (CA) and cell-released 
(CR) fractions. Figure 22 shows the curves obtained for VSV. 
The CCX dose-response curve (Fig 22a), reveals that the CA 
fraction was reduced by 2 logs, compared with a 4 log 
reduction in the CR fraction. Diastereoisomer "690" (Fig 
22b), hardly affected VSV CA yields even at concentrations
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as high as 300uM. Although the reduction in CR infectious 
virus yields was less dramatic than that achieved with 
similar concentrations of CCX, the reduction of almost 3 
logs achieved with 300uM "690" is still significant.
Treatment with "688" (Fig 22c), resembles CCX in that there 
is a more dramatic reduction in the CR fraction compared to 
the CA fraction. However, the increase in knockdown of 
infectious virus yields is probably due to the cytotoxic 
effect of "688" on the cells (Table 24).
Figure 23 shows the curves obtained for Germiston 
virus. Treatment with up to 300uM CCX progressively reduces 
the CA fraction by almost 2 logs (Fig 23a). The CR fraction 
was reduced by just over a log with lOOuM CCX, addition of 
higher concentrations having little further affect. "690" 
treatment had very little significant effect on infectious 
virus yields of either the CA or CR fractions, achieving an 
overall reduction of only 0.5 log (Fig 23b).However, the 
reduction was complete at low concentrations of "690"; 50uM 
in the case of the CA fraction and lOOuM in the case of the 
CR fraction. As expected, due to its1 cytotoxic effect, 
diastereoisomer "688" reduced infectious virus yields more 
markedly than CCX (Fig 23c) : the CA fraction was reduced by
almost 3 logs and the CR fraction by just under 2 logs.
The dose-response curves for SFV are shown in Figure 
24. Increasing concentrations of CCX, resulted in a 
progressive increase in the CA fraction of about 1 log, with 
a concomitant decrease in the CR fraction (Fig 24a). This 
agrees with the apparent resistance of SFV to CCX treatment 
when both fractions were pooled before titration. Increasing 
concentrations of "690", also resulted in a slight increase 
in the CA fraction (0.5 log), with a larger reduction in the 
CR fraction (1 log) (Fig 24b). The results for "688" again 
are distorted by the cytotoxic affect on the cells, yielding 
a reduction of over 3 logs in the CR fraction and 2 logs in
the CA fraction (Fig 24c). It is interesting that a small
rise in the CA fraction did occur, at the less cytotoxic 
concentrations of 50 and lOOuM.
In conclusion, the extent of reduction in infectious 
virus yields, appears to be linked to the cytotoxic affect 
on cells with "690" < CCX < "688". The cytotoxicity of "688" 
at relatively low concentrations, renders it unsuitable for
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use as an antiviral. Although "690" had no significant 
effect on infectious yields of Germiston virus or SFV, it 
did reduce infectious VSV yields by 3 logs in the CR 
fraction and 1 log in the CA fraction . It therefore 
displays significant anti-VSV activity although this is less 
potent than that exhibited by CCX.
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Table 24
The effect of CCX and diastereoisomers of CCX ("690" and 
"688") on BS-C-1 cell viability and replication over 2 4h 
(performed in parallel to virus dose-response experiments 
with CCX and diastereoisomers).
Total cell number: numbers are the total cell counts 
relative to the 0 drug control given as a percentage.
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Figure 22
The effect of increasing concentrations of CCX (a),
"690" (b) or "688" (c) on the cell-associated (CA) ( ■) and 
cell-released (CR) (□) infectious yields of VSV (Indiana), 
from BS-C-1 cells.
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Figure 23
The effect of increasing concentrations of CCX (a), 
"690" (b) or "688" (c) on the cell-associated (CA) (■) 
cell-released (CR) ( □  ) infectious yields of Germiston 
virus, from BS-C-1 cells.
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Figure 24
The effect of increasing concentrations of CCX (a), 
"690" (b) or "688" (c) on the cell-associated (CA) (■) 
cell-released (CR) ( □  ) infectious yields of SFV, from 
BS-C-1 cells.
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3.3. THE EFFECT OF CCX ON THE REPLICATION OF VSV (INDIANA) : 
REPRESENTING THE CLASS 1 RESPONSE
3.3.1. VSV REPLICATION IN THE PRESENCE OF CCX
A one-step growth curve was performed at 3 7°C in 
monolayers of BS-C-1 cells in the presence and absence of 
CCX (Fig 25). VSV failed to replicate in the presence of 
300uM CCX with no evidence that any new progeny virus was 
produced during the 36h period studied. The virus yield 
observed is probably just cell adsorbed virus that failed to 
penetrate from the initial infecting innoculum.
3.3.2. THE EFFECT OF INCREASING CONCENTRATIONS OF CCX ON VSV 
PARTICLE NUMBER AND PARTICLE / P.F.U. RATIOS
Virus particle counts were performed by electron 
microscopy ( 2.2.6.1.) on total virus yields from
dose-response experiments. Table 25 shows the results 
obtained from three independent experiments. The data show 
that increasing CCX concentrations resulted in a significant 
reduction in particle number, accompanied by a somewhat 
greater decrease in infectious yields, resulting in 
elevated particle/p.f.u. ratios (typically 10 fold).
These results therefore indicate, that the anti-VSV 
effect of CCX operates by inhibiting virus particle 
production and in addition by lowering the quality of those 
virus particles which are produced.
3.3.3. POLYPEPTIDE ANALYSIS OF VSV PARTICLES PRODUCED IN
BS-C-1 CELLS TREATED WITH CCX
35S methionine radiolabelled VSV yields from CCX 
treated and untreated BS-C-1 cells were purified by passing 
through Ficoll gradients, and the structural proteins 
analyzed by SDS PAGE (Fig 26). The mobility of the G band is 
marginally increased in CCX treated tracks, suggesting some ,
effect on tire glycosylation of this protein.A Apart from 
this, the polypeptide composition of VS virions produced in 
the presence and absence of 150uM CCX are similar. This is 
in contrast to HSV virions produced in the presence of CCX, 
which have abnormal polypeptide composition, with some 
protein bands under-represented and others over-represented 
(Dargan and Subak-Sharpe, 1986a and b). There is no evidence
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Figure 25
VSV replication in BS-C-1 cells in the presence of CCX.
One-step growth curve obtained without drug ( □  ) or in the 
presence of 3 0 0uM CCX ( ■  ).
The m.o.i. was 5 p.f.u./cell and incubation was at 37°C.
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Table 25
The effect of increasing concentrations of CCX on VSV 
particle numbers, infectious virus yields (p.f.u.) and 
particle/p.f .u. ratios, after 24h.
1,2 and 3 represent data from 3 independent experiments.
N.D. not determined
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Figure 26
SDS PAGE profile on a 10% gel of the structural proteins of 
VSV produced in BS-C-1 cells treated with 0 (a), 150uM CCX 
(b) or 3 00uM CCX (c).
The m.o.i. was 5 p.f.u./cell and yields were harvested at 
24h p.i. and purified by centrifugation through 5-15% Ficoll 
gradients. 2 bands were collected; upper band containing 
D.I. particles (which contain short, defective RNA) (1) and 
a lower band containing purified VSV particles (which 
contain normal length RNA) (2).
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of production of any VSV proteins in the 300uM samples.
3.3.4. DIRECT EFFECT ON 1NFECTIV1TY OF VSV PARTICLES IN 
SUSPENSION
To determine whether CCX directly inactivated virus 
particles, suspensions of virus were incubated with either 
mock drug or 300uM CCX (2.2.5.7.), at 4°C or 37°C for 24h 
and infectious yields titrated before and after drug 
addition. This experiment was performed several times, 
yielding varying results, from almost no effect to almost a 
log reduction in infectivity. The results from two separate 
experiments, representing the two extremes are shown in 
Table 26.
3.3.5. ADSORPTION OF VSV TO BS-C-1 CELLS PRE-TREATED WITH 
VARYING CONCENTRATIONS OF CCX
Adsorption experiments (2.2.5.6.), were performed with 
VSV and BS-C-1 cells pre-treated with varying concentrations 
of CCX (Fig 27). Although there was some slight effect on 
VSV adsorption to pre-treated cells, at concentrations as 
high as 900uM CCX, virus was clearly still able to bind to 
receptors. In addition, adsorption had not gone to 
completion (plateau) during the 40 minute observation 
period. It is therefore unlikely that inhibition of 
adsorption of virus to pre-treated cells could play a 
significant part in limiting the spread of infection at 
least in vitro.
TIKE (hr) TEMP (C) DRUG TITRE % AGE REDUCTION
0 -
ORIGINAL
STOCK
7
3.2*10
24 4
MOCK
DRUG
7
1.75*10 100
14.7
24 4
300 uM 
CCX
7
1.5*10 85.7
24 37
MOCK
DRUG
6
2.0*10 100
37.5
24 37 300 uM 
CCX
6
1.25*10 62.5
TIME (hr) TEMP (C) DRUG TITRE ft ^GE REDUCTION
0 -
ORIGINAL
STOCK
7
3.6*10
24 4
MOCK
DRUG
7
2.85*10 100
90.0
24 4
300 uM 
CCX
6
2.85*10 10
24 37
MOCK
DRUG
6
6.0*10 100
85.9
24 37 300 uM 
CCX
5
8.5*10 14.1
Table 26
Direct effect on VSV particle infectivity by CCX. 
a) and b) represent data from 2 separate experiments.
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Figure 27
Adsorption of VSV particles to BS-C-1 cells pre-treated for 
lh at 37°C with 0 ( ■  ) , 300uM CCX ( □  ), 600uM CCX (A  ) or 
900uM CCX ( A ) .
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3.3.6. THE EFFECT ON INFECTIOUS VSV YIELDS FROM BS-C-1 CELLS 
BY ADDITION OF CCX AT VARIOUS TIMES POST-ADSORPTION
CCX to 300uM was added to the growth medium of 
VSV-infected BS-C-1 cells at the times indicated in Figure 
28. The curve obtained indicates that the effect of CCX was 
progressive throughout the life cycle, with larger yield 
reductions achieved the earlier the drug was added. As 
expected there was no significant effect on infectious 
yields if CCX was added 12h or later after adsorption, as 
the virus life cycle should be complete at this time. The 
small decrease in titre observed may be due to direct 
inactivation of virus particles.
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Figure 28
Effect on infectious VSV yields from BS-C-1 cells (m.o.i. 
p.f.u./cell), by addition of CCX at various times 
post-adsorption.
CCX (to 300uM) was added at 2,4,6,8,10,12,14,16 and 24 hou 
post-adsorption and infectious virus yields estimated at 
24h.
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3.3.7. THE EFFECT OF CCX ON RNA AND PROTEIN SYNTHESIS
VSV TRANSCRIPTION
VSV transcription occurs in two distinct stages, 
termed primary and secondary transcription :
Primary transcripts are synthesised from infecting VSV 
genomes, by the viral transcriptase, which is a structural 
component of the virus particle (thought to comprise L, NS 
and N) (Marcus et al., 1971)
Secondary transcripts are synthesised from either 
infecting parental VSV genomes or progeny genomes and is 
carried out by the newly made viral transcriptase i.e. 
consisting of L, NS and N proteins synthesised from primary 
transcripts. Secondary transcription is dependent on protein 
synthesis (Flamand and Bishop, 1974).
The products of primary and secondary transcription 
are identical and consist of a leader RNA and 5 
monocistronic mRNAs (Fig.29) (Moyer et al., 1975; Moyer and 
Banerjee, 1975; Freeman et al., 1977; Rhodes et al., 1977).
VSV TRANSLATION
VSV mRNAs are efficiently translated on host cell 
ribosomes. Transcriptional rather than translational control 
is normally used to regulate the quantity of each VSV 
protein synthesized; thus the amount of each protein 
synthesized is proportional to the amount of each mRNA. 
Since VSV transcription is both sequential and polar, the N 
mRNA and hence the N protein are most abundant, while the L 
mRNA and L protein least abundant (Villarreal et al., 1976).
An experiment was designed to yield three pieces of 
information :
1.) Does CCX affect VSV transcription; primary and/or 
secondary? What is the effect on transcription in 
mock-infected BS-C-1 cells?
2.) Does CCX affect protein synthesis in VSV-infected 
and/or mock-infected BS-C-1 cells?
3.) Does CCX affect transcription and/or translation?
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Figure 2 9
Diagram of the genome of VSV
The gene order is shown above the genome, while the numbers 
in brackets represent the number of nucleotides not found in 
the transcription products. Transcribed regions are shown as 
heavy black lines with the length of the transcript in 
nucleotides given below.
This diagram is not drawn to scale.
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EXPERIMENTAL DESIGN (Table 27)
RADIOLABELLING :
TIME
VSV primary transcripts, cellular transcripts and 
polypeptides synthesized in VSV-infected and mock-infected 
BS-C-1 cells were all labelled in parallel from l-8h p.i.
VSV secondary transcripts , cellular transcripts and 
polypeptides synthesised in VSV-infected and mock-infected 
BS-C-1 cells were all labelled in parallel from 4-24h p.i. 
(Also see one-step growth curve, Fig. 25).
RADIOLABELS
3
VSV primary transcripts were labelled with H uridine,
3 2VSV secondary transcripts and cellular transcripts with P
35orthophosphate and all polypeptides with S methione. 
Radiolabelling was performed as described in 2.2.7.3.
USE OF INHIBITORS
Labelling of VSV primary transcripts was performed in 
the presence of cycloheximide (CHX), which inhibits protein 
synthesis and therefore blocks the production of secondary 
transcripts.
Actinomycin D (Act.D) was used when labelling both 
primary and secondary transcripts to selectively suppress 
host RNA synthesis (blocks DNA directed RNA synthesis, but 
not RNA directed RNA synthesis)
Polypeptides synthesized in CCX treated infected cells 
were therefore labelled in the presence and absence of 
Act.D. to determine 1.) how CCX affected polypeptide 
synthesis 2.) whether addition of Act.D. in any way modifies 
the action of CCX and 3.) to allow comparison of mRNA and 
protein levels.

Table 27
Determining the affect of CCX on RNA and protein synthes 
experimental design.
ACT.D. Actinomycin D 
CHX Cycloheximide
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3.3.7.1, THE EFFECT OF INCREASING CONCENTRATIONS OF CCX ON 
RNA AND PROTEIN SYNTHESIS IN MOCK-INFECTED AND VSV-INFECTED 
BS-C-1 CELLS FROM l-8h p.i.
THE EFFECT OF CCX ON RNA SYNTHESIS IN MOCK-INFECTED BS-C-1 
CELLS
Fig 30a shows a redaction in radiolabelled cellular 
transcripts with only lOOuM CCX, becoming more marked with 
200 and 300uM CCX. The reduction in radioactive label with 
200uM CCX, was in part due to the underloading of this lane 
(Fig 30b, lane 3). However this is not the case with 300uM 
CCX, as this lane had in fact been overloaded (Fig 3 0 d , lane 
4). Therefore the results show that the production of 
cellular cytoplasmic RNA was progressively inhibited with 
increasing concentrations of CCX.
THE EFFECT OF CCX ON VSV PRIMARY TRANSCRIPTION IN INFECTED 
BS-C-1 CELLS
The extraction of VSV primary transcripts was not 
successful: samples were subjected to electrophoresis on a
1.2% agarose / formaldehyde gel, but RNA was not detected 
after soaking the gel in EtBr and iluminating with U.V. 
(260nm). Radiolabelled RNA was not detected after exposing 
the gel to X-Omat film. This experiment was only attempted 
once and must therefore be repeated.
THE EFFECT OF CCX ON POLYPEPTIDE SYNTHESIS IN MOCK-INFECTED 
AND VSV-INFECTED BS-C-1 CELLS IN THE PRESENCE AND ABSENCE 
OF ACT D.
MOCK-INFECTED CELL EXTRACTS 
- ACT.D.
Host cell protein synthesis was progressively 
inhibited with increasing concentrations of CCX, in the 
absence of Act.D., shown by the progressive reduction in 
T.c.A. precipitable counts with increasing CCX to 61.8% of 
the drug free control with 300uM (Table 28, Fig 32). 
Analysis by SDS PAGE, revealed no apparent qualitative 
change in the polypeptides induced in CCX treated,
mock-infected BS-C-1 cells over this time (Fig 31b, lanes
6-9)
28S
18S
b
F i g u r e  30a and b
The effect of 8h treatment with increasing concentrations of 
CCX on cellular cytoplasmic levels
32-P orthophosphate labelled cytoplasmic RNA was isolated 
from mock-infected cells treated with either no drug (lane 
1) or 100,200,300uM CCX (lanes 2-4), from l-8h p.i. RNA was 
analyzed by electrophoresis on a 1 .2% agarose/formaldehyde 
gel, equal quantities of RNA loaded onto each track (yields 
were estimated by measuring O.D. at 260nm).
The radiolabelled RNA in each track was visualized by 
exposing the gel to X-Omat S film (a).
The total RNA added to each track was visualized by soaking 
the gel in EtBr and illuminating under short wave U.V.
(260nm) (b) . (This allowed estimation of loading errors).
The position of the 28S and 18S rRNA are indicated.
IIP1!"!
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F i g u r e  31a
SDS PAGE profile on a 10% gel of the infected cell 
polypeptides induced in BS-C-1 cells treated with either no 
CCX (lanes 1,2 and 6 ) or 100,200 or 300uM CCX (lanes 3-5 and 
7-9 ), from l-8h p.i.
Cells were also pre-treated for 2h before infection, during 
?infection and for 8 h p.i. with 5ug/ml ACT.D.
Cells were either mock-infected (lanes 1 and 6-9) or
infected with VSV at m.o.i. of 50 p.f.u./cell (lanes 2-5)
35and Smet added from l-8h p.i.
Equal numbers of counts were loaded onto each track.
Letters on the left indicate the positions of known 
virus-encoded proteins (L,G,NS,N and M ) , a low m.wt. band of 
unknown origin present in virus-infected but not 
mock-infected cell extracts (UKl) and a novel cellular band 
induced in mock-infected cells in the presence of ACT. D.
Figure 31b
SDS PAGE profile on a 10% gel of the infected cell 
polypeptides induced in BS-C-1 cells treated with either no 
CCX (lanes 1,2 and 6 ) or 100,200 or 300uM CCX (lanes 3-5 and 
7-9) , from l-8h p.i.
Cells were either mock-infected (lanes 1 and 6-9) or
infected with VSV at a m.o.i. of 50 p.f.u./cell (lanes 2-5) 
35and Smet added from l-8h p.i.
Equal numbers of counts were loaded onto each track.
Letters on the left indicate the positions of known 
virus-coded proteins (L,G,NS,N and M) and 2 low m.wt. bands 
of unknown origin present in virus-infected but not 
mock-infected cell extracts (UKl and UK2).
CCX (urt) ♦ ACT.D. -ACT.D.
0 105,008 130,270
VSV-INF. 100 55,852 124,566
BSC-I 200 37,279 85,987
CELLS 300 45,400 80,545
0 89,365 304,016
MOCK-INF 100 80,787 233,043
BSC-I 200 79,932 186,967
CELLS 300 42,919 136,164
CCX <uH> L 6 N NS M UKl
ACT. 0. 0 328 <100) 552.3 (100) 367.4 (100) 316.1 (100) 226.7 (100) 94.8 (100)
100 176.4 < 54) 136 ( 35) 125.3 ( 34) 158.2 ( 50) 72.1 ( 32) 33.6 ( 35)
200 M l . 3 < 34) 86.7 ( 16) 69.4 ( 19) 97.6 ( 31) 39.2 ( 17) NO
300 53.0 ( 18) 102.6 ( 18) 61.4 ( 17) 94.4 ( 30) 35.2 ( 16) 14.18( 15)
-ACT. 0. 0 
100
453.4 <100) 604.2 (100) 404.9 (100) 
361.6 < 89)
321.3 (100) 198.3 (100) 73.8 (100)
333.2 ( 87) 557.4 ( 32) 308.5 ( 96) 238.0 (120) 92.9 (126)
200 348.0 ( 76) 510.0 ( 84) 310.0 ( 76) 256.33 ( 80) 225.7 (114) 75.7 (103)
300 324.0 < 71) 442.77< 73) 250.4 ( 62) 217.32 ( 68) 174.6 ( 88) 60.2 < 62)
Table 28
35Incorporation of S-methionine into VSV infected or mock 
infected cells (i.e. T.C.A. precipitable counts), treated 
with increasing concentrations of CCX, in the presence and 
absence of ACT.D., from l-8h p.i.
Table 29
Densitometer scan of .polypeptide bands in VSV infected 
tracks: tracks were scanned and the surface areas of each 
band divided by the volume added to each track, in order to 
standardise in terms of protein and not radioactive counts.
Numbers in parentheses are percentages: in each case the 0 
value is 1 0 0 %.
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Figure 32
The effect of increasing concentrations of CCX on the
35incorporation of Smet into polypeptides induced m  
VSV-infected ( O,  #) and mock-infected ( □  , ■) BS-C-1 
in the presence (0,111) and absence ( • , ■ )  of ACT.D. 
(5ug/ml) .
cells
35Smet counts shown in Table 28, plotted as a percentage of 
the drug free controls.
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+ ACT.D.
As expected T.C.A. precipitable counts in ACT. D. 
treated cell extracts were lower than in untreated cell 
extracts, falling to 29.3% of - Act.D. drug free control 
(Table 28, Fig 32) In the presence of Act.D., counts 
remained constant with 100 and 200uM CCX. However, treatment 
with 300uM CCX in the presence of Act.D. resulted in a fall 
of approximately 50%, similar to the decrease seen at this 
concentration in the absence of Act.D. (Fig 32). Analysis 
of polypeptides by SDS PAGE, revealed that treatment with 
Act.D. alone induced a novel band (NB), just below the actin 
band, which disappeared on the addition of CCX (Fig 31a, 
lanes 6-9 ) .
VSV-INFECTED CELL EXTRACTS
Labelled infected cell extracts were analyzed by SDS 
PAGE (Fig 31a and b) and the virus-infected tracks 
densitometrically scanned and standardised for equal amounts 
of protein in each track (Table 29).
EFFECT OF ACT.D.
Analysis by SDS PAGE, revealed no qualitative 
difference in viral polypeptide bands induced in 
VSV-infected BS-C-1 cells in the presence of Act.D. (Fig 
31a, lane 2), or in the absence of either drug (Fig 31b, 
lane 2). Densitometric scanning of the tracks also revealed 
no significant difference in the relative abundance of viral 
protein bands within each track (Table 29). Thus, Act.D. by 
itself had no significant effect on viral protein synthesis 
during the period l-8h p.i.
EFFECT OF CCX
Treatment with increasing concentrations of CCX, did 
not significantly inhibit the synthesis of any viral protein 
with levels remaining above 60% of the drug free control in 
all cases (Table 29). However CCX treatment did result in 
slight changes in the relative abundance of bands; L, G, N 
and NS all progressively decreased with increasing CCX to 
70*5%, 73.2%, 61.8% and 67.8% of drug free levels
respectively in the presence of 300uM CCX (Table 29). In 
contrast, levels of M were increased with both 100 and 200uM
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CCX to 120% and 113.8% respectively, falling to just below 
drug-free levels (8 8%) with 300uM CCX. UK^ (an unknown band 
present in VSV-infected but not mock-infected cell 
extracts), increased very slightly with lOOuM CCX to 125.8% 
of drug free levels, fell to drug free levels with 200uM CCX 
(102.8%) and to below drug free levels (81.5%) with 300uM 
CCX (Table 29). Another band designated UK^, which also 
appeared in virus-infected but not mock-infected cell 
extracts, was too faint to scan, but appeared to increase 
and decrease with UK^, with increasing CCX concentrations 
(Fig 31b) .
There was also a slight shift downwards in polypeptide 
band G, with all CCX concentrations, indicating some effect 
on glycosylation (Fig 31b).
EFFECT OF ACT.D. AND CCX
It is clear that the synthesis of all viral 
polypeptides was markedly inhibited at all concentrations of 
CCX, in the presence of Act.D. (Table 29). The downward 
shift in the G band is greater than that seen with CCX in 
the absence of Act.D., suggesting a greater effect on 
glycosylation (Fig 31b). However, as the gel was 
standardised to contain equal counts in each track; more BSA 
was added to tracks 3-5 in Fig 31a than the same tracks in 
Fig 31b. BSA can cause distortion of the gel in this area 
and may explain at least in part, the apparent marked shift 
in this band.
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CONCLUSIONS
CELLULAR TRANSCRIPTION AND POLYPEPTIDE SYNTHESIS
8h treatment with increasing concentrations of CCX, 
resulted in a progressive decrease in levels of cellular 
cytoplasmic RNA and protein. Whether the decrease in 
polypeptide levels was entirely due to decreased levels of 
transcript, or was also a consequence of a separate effect 
of CCX on the translation process is not clear and will be 
discussed more fully later.
VSV PRIMARY TRANSCRIPTION AND POLYPEPTIDE SYNTHESIS
When Act.D or CCX were added together viral protein 
synthesis was inhibited much more dramatically than in the 
presence of either compound alone. Therefore, the presence 
of Act. D. affected the action of CCX over this time (l-8h 
p.i.). Since primary transcripts were labelled from l-8h 
p.i. in the presence of both these compounds,no conclusions 
could be drawn from the result of this experiment, regarding 
the effect of CCX on primary transcription.
A significant reduction in primary transcription seems 
unlikely as all viral proteins were synthesised in 
substantial amounts in infected cells treated with CCX from 
l-8h p.i. However, there was some change in the relative 
intensity of viral polypeptide bands with some slightly 
decreased (L, G, N and NS) and others increased (M, UK^ and 
UK^). These changes could in theory be due to differential 
effects on transcription (primary and/or secondary).
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3. 3 . 7 . 2 . THE EFFECT OF INCREASING CONCENTRATIONS OF CCX ON 
RNA AND PROTEIN SYNTHESIS IN MOCK-INFECTED AND VSV-INFECTED 
BS-C-1 CELLS FROM 4-24h p.i.
THE EFFECT OF CCX ON RNA SYNTHESIS IN MOCK-INFECTED BS-C-1 
CELLS
Treatment with 100 and 200uM CCX (Fig 33a, lanes 2 and
3), resulted in increased incorporation of radiolabel into 
the 28S band, and decreased incorporation of radiolabel into 
the 18S band. However, both these tracks had been overloaded 
with RNA (Fig 33b, lanes 2 and 3), indicating that the 
overall reduction in radiolabelled transcripts was greater 
than that suggested by Fig 33a.
All radiolabelled transcripts were markedly reduced 
with 300uM CCX (Fig 33a, lane 4). EtBr staining revealed 
that this track had also been overloaded with RNA (Fig 33b, 
lane 4), therefore the actual reduction in radiolabelled 
transcripts was again greater than that suggested by Fig 
33a.
This experiment therefore revealed, that the 
production of cellular cytoplasmic RNA was progressively 
inhibited with increasing concentrations of CCX.
THE EFFECT OF CCX ON SECONDARY TRANSCRIPTION IN 
VSV-INFECTED BS-C-1 CELLS
There was a marked reduction in radiolabelled VSV 
secondary transcripts with 100 and 200uM CCX; L mRNA was 
virtually undetectable in extracts labelled with only lOOuM 
or 200uM CCX (Fig 34a, lanes 2 and 3). Radiolabelled 
transcripts disappeared completely with 300uM CCX (Fig 34a, 
lane 4). However, EtBr staining of this gel (Fig 34b, lane
4) showed that considerably less RNA had been loaded onto 
this track. Thus, the great reduction in radiolabel could 
have been largely due to a loading error. Lanes 2 and 3 of 
Fig 34 also contained less RNA than lane 1, however, in this 
case the difference was not great enough to account for the 
very pronounced decrease in radiolabelling observed. It is 
concluded therefore, that VSV secondary transcription 
becomes progressively inhibited by increasing concentrations 
of CCX.
THE EFFECT OP rrv ON POLYPEPTIDE SYNTHESIS IN MOCK-INFECTED
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AND VSV-INFECTED BS-C-1 CELLS IN THE PRESENCE AND ABSENCE 
OF ACT.D.
MOCK-INFECTED CELL EXTRACTS
Host cell protein synthesis was progressively reduced 
with increasing concentrations of CCX, irrespective of Act.
D., as shown by the progressive decrease in T.C.A. 
precipitable counts; the counts fell to 1 1 % of the drug-free 
level in the presence and absence of Act.D., with 300uM CCX 
(Table 30, Fig 36). Analysis of polypeptides by SDS PAGE, 
revealed that in the absence of Act. D . , 100, 200 and 300uM 
CCX induced polypeptide bands previously identified as host 
cell stress proteins (Fig 35b, lanes 8 and 9). Furthermore, 
the novel band observed after 8 h Act.D. treatment (Fig 31a, 
lane 6 ), was not detectable at 24h (Fig 35a, lane 6 ).
VSV-INFECTED CELL EXTRACTS
Labelled infected cell extracts were analyzed by SDS 
PAGE (Fig 35a and b), the virus-infected tracks 
densitometrically scanned and standardized for equal amounts 
of protein in each track (Table 31).
EFFECT OF ACT.D.
24h treatment had no significant qualitative or 
quantitotwvt effect on viral polypeptides induced in 
VSV-infected BS-C-1 cells (Fig 35, compare a and b, lane 2; 
Table 31) .
EFFECT OF CCX
Only polypeptide bands L and N progressively decreased 
with increasing concentrations of CCX. L fell to 83.7% of 
drug free controls at lOOuM CCX, becoming too faint to scan 
at 200 and 300uM CCX, while N fell to 41.6% of drug free 
levels with 300uM CCX. (Fig 35b, Table 31).Band UK1 was 
greater than drug-free levels at lOOuM CCX (154% of drug 
free control), falling to below drug-free levels with 200 
and 300uM CCX (to 53.3% and 41.2% respectively). Bands G and 
were increased over drug-free levels at both 100 and 
200uM CCX (to 135.5% and 188% respectively) only falling 
below drug-free levels (to 5 3 % and 40% respectively) at 
300uM CCX. Bands NS, M and UK^ were greater than drug-free
b
Figure 33a and b
The effect of 24h treatment with increasing concentrations 
of CCX on cellular cytoplasmic RNA levels.
Mock-infected cells were treated with either no CCX (lane 1)
or 100,200 or 300uM CCX (lanes 2-4) from l-24h p.i.
32P-orthophosphate was added from 4-24h p.i., then 
cytoplasmic RNA extracted and analyzed on a 1.2% 
agarose/formaldehyde gel.
Approx i ,
Equal quantities of RNA were added to each track. (Yields 
were estimated by measuring O.D. at 260nm).
The radiolabelled RNA in each track was visualised by 
exposing the gel to X-Omat S film (a).
The total RNA added to each track was visualised by soaking 
the gel in EtBr and illuminating under short wave U.V.
(260nm) (This allowed estimation of loading errors).
The positions of the 2 8S and 18SrRNA are indicated.

Figure 3 4a and b
VSV specific secondary transcription in CCX treated and 
untreated BS-C-1 cells.
Cells were pre-treated for 2h with 5ug/ml ACT.D. and in the
continued presence of ACT.D., VSV infected (m.o.i. 50
p.f.u./cell) cells were treated with either no CCX (lane 1)
32or 100,200 or 300uM CCX (lanes 2-4). -P orthophosphate was 
added from 4-24h p.i., then cytoplasmic RNA extracted and 
analyzed by electrophoresis on a 1 .2 % agarose/formaldehyde 
gel.
AfjVo * t wvcvte
Equal quantities of RNA were added to each track. (Yields 
were estimated by measuring O.D. at 260nm).
The radiolabelled RNA in each track was visualized by 
exposing the gel to X-Omat S film (a). The position of the 
virus coded transcripts L,G,NS,N and M are indicated and the 
sizes of the transcripts (in kb) are shown in brackets.
The total RNA added to each track was visualised by soaking 
the gel in EtBr and illuminating under short wave U.V. 
(260nm). (This allowed estimation of loading errors).
The positions of the 28S and 18srRNA are indicated.
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Figure 35a
SDS PAGE profile on a 10% gel of the infected or 
mock-infected cell polypeptides induced in BS-C-1 cells 
treated and pre-treated for 2 h before infection, during 
infection and for 24h p.i. with 5ug/ml ACT.D. and either no 
CCX (lanes 1,2 and 6 ) or 100,200 or 300uM CCX (lanes 3-5 and
7-9 ), from l-24h p.i.
Cells were either mock-infected (lanes 1 and 6-9) or
infected with VSV at m.o.i. of 50 p.f.u./cell (lanes 2-5)
35and Smet was added from 4-24h p.i.
Equal amounts of counts were loaded onto each track.
Letters on the left indicate the positions of known virus 
coded proteins (L,G,NS,N and M) and 4 low m.wt. bands of 
unknown origin present in the virus-infected but not 
mock-infected cell extracts (UKl, U K 2 , UK3 and UK4).
Figure 35b
SDS PAGE profile on a 10% gel of the infected or 
mock-infected cell polypeptides induced in BS-C-1 cells 
treated with either no CCX (lanes 1,2 and 6 ) or 100,200 or 
300uM CCX (lanes 3-5 and 7-9), from l-24h p.i.
Cells were either mock-infected (lanes 1 and 6-9) or
infected with VSV at m.o.i. of 50 p.f.u./cell (lanes 2-5)
35and Smet was added from 4-24h p.i.
Equal numbers of counts were loaded onto each track.
Letters on the left indicate the positions of known
virus-coded proteins (L,G,NS,N and M) , If low m.wt. bands of
unknown origin present in virus-infected but not
o KU
mock-infected cell extracts (UKl, UK2 a*d- UK3) and cellularA
stress proteins (94grp, 90hsp and 78grp).
OCX (uM) ♦ ACT.D. -ACT.O.
0 145,385 172,060
V S V -Ilf. 100 94,481 159,065
BSC-1 200 65,027 159,433
CELLS 300 28,637 96,904
0 289,183 603,696
Nooc-iir. 100 106,767 473,653
BSC-1 200 68,717 300,971
CELLS 300 31,506 70,736
OCX («H> L 6 N N3 H UKl UK2 UK3 UK4
♦ACT.D. 0 73.4 <100) 201.7 (100) 321.3 (100) 36.9 (100) 93.4 (100) 237.1 (100) 44.9 - -
100 75.8 (103) 132.1 ( 65) 274.0 ( 85) 63.0 (170) 222.3 ( 76) I79 .6 ( 76) 54.0 51.9 48.4
200 37.8 < 51) 71.7 ( 36) 124.7 ( 40) 39.4 (107) 150.8 (161) S7.6( 24) 27.7 34.27 24.7
300 10.2 ( 14) 15.3 ( 8) 30.2 ( 9) 6 ( 16) 30.3 ( 32) - - - -
-ACT.O. 0 86 (100) 160.5 (100) 409 (100) 46.4 (100) 83.5 (100) 146.1(100) 77.7 (100) - -
100 72 ( 84) 217.2 (135) 405.8 ( 99) 64.6 (139) 248.S (297) 225.5(154) 146.2(188) 57.4 -
200 - 165.9 (103) 329.2 ( 80) 122.9(265) 220.1 (263) 77.9 ( 53) 137.7(177) 84.3 -
300 - 85.1 ( 53) 170.5 ( 42) 89.4 (193) 119.3 (143) 60 .3 ( 41) 31.5 (40) 113.3 -
Table 30
“ . 35
Incorporation of S-methionine into polypeptides induced in
VSV-infected or mock-infected cells treated with increasing
concentrations of CCX, in the presence or absence of ACT.D.
35from 1-24h p.i. ( S-met was added from 4-24h p.i.)
Table 31
Densitometer scan of polypeptide bands in VSV-infect%. tracks 
(4—24h p.i.): tracks were scanned and the surface areas of 
each band divided by the volume added to each track in order 
to standardise in terms of protein and not radioactive 
counts.
Numbers in parentheses are percentages: in each case the 0 
value is 100%.
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Figure 36
The effect of increasing concentrations of CCX on the
35incorporation of Smet into polypeptides induced in VSV 
infected ( 0 , 1 )  and mock-infected ( □ , § )  BS-C-1 cells in 
the presence (0,111) and absence ( # , ■ )  of ACT.D. (5ug/ml).
35S met counts shown in Table 30, plotted as a percentage of 
the drug free controls.
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levels at all concentrations of CCX, NS peaking at 200uM 
(264.8% of drug free levels), M at lOOuM (297% of drug free 
levels) and UK^ at 300uM CCX (0 band too faint to scan) 
(Table 31) .
In addition, the mobility of the G band was increased 
at all CCX concentrations, resulting in a downward shift of 
this band. This is most likely due to an effect on the 
glycosylation of this protein (Fig 35).
EFFECT OF ACT.D. AND CCX
In the presence of Act.D., polypeptide bands L, G, N, 
UK^ and (JK^  all progressively decreased with increasing CCX 
concentrations, to 13.8%, 7.5%, 9.3% (UK^ and UK^ were too 
faint to^ scan) of drug free levels respectively with 300uM 
CCX.Polypeptide bands M, UK^ and UK^ (a band only present 
in infected cell extracts treated with both CCX and Act. D . ) 
all increased to lOOuM CCX (M to 238% of drug free levels 
while LJK^  and UK^ were too faint to scan),then fall dropping 
to below drug-free levels (M to 32.4%)at 300uM CCX, although 
in all cases levels are greater than drug-free (M to 161.4%) 
at 200uM CCX. Levels of band NS are greater than drug free 
at lOOuM CCX (170% of drug free control), and 200uM CCX 
(106.7%), falling to below drug free levels with 300uM CCX 
(to 16.2%).(Table 31, Fig 35).
The increase in the mobility of the G band with 
increasing CCX concentrations, appeared greater in the 
presence of Act.D. As previously stated, this may be due to 
a greater effect on glycosylation or greater amounts of BSA 
in these tracks.
CONCLUSIONS
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CELLULAR TRANSCRIPTION AND POLYPEPTIDE SYNTHESIS
24h treatment with CCX resulted in decreased levels of 
cellular cytoplasmic RNA and proteins. Cytoplasmic RNA 
levels may be reduced by blocking transport of RNA from the 
nucleus to the cytoplasm , by directly affecting the 
transcription process itself or by more rapid degradation in 
the cytoplasm. Levels of cytoplasmic and total RNA in CCX 
treated cells should be compared to differentiate between 
these possibilities.
Whether the reduction in cellular polypeptides was 
entirely due to reduced levels of mRNA is not clear and a 
separate effect on translation by CCX cannot be dismissed. 
Transcriptional and translational effects could be more 
clearly separated by in vitro assays; utilising 
nucleocapsids isolated from CCX treated VSV-infected cells 
in in vitro transcription systems and then . the resultant 
transcripts in in vitro translation systems.
VSV SECONDARY TRANSCRIPTION AND POLYPEPTIDE SYNTHESIS
Levels of NS, M and UK^ polypeptide bands were greater 
than drug-free levels with 100 and 200uM CCX, in the 
presence of Act.D. and at all CCX concentrations in the 
absence of Act.D. Therefore, the general trend was the same 
although the increase was greater in the absence of Act.D. 
In contrast, transcript levels were less than drug-free 
levels at all CCX concentrations; therefore the accumulation 
of these polypeptides must be a consequence of some 
post-transcriptional effect of CCX. There are several 
possible explanations which include 1.) differential mRNA 
stability 2 .) preferential translation of these transcripts 
3.) differential secretion of polypeptides and /or 4.) 
differential polypeptide stability in the presence of CCX.
Although bands G, UK1 and UK2 increase to varying 
degrees with CCX in the absence of Act.D., all of these 
bands progressively decrease with increasing CCX in the 
presence of Act.D. The contrasting results obtained in the 
presence and absence of Act.D. do not allow direct
comparison between mRNA and protein levels in these cases 
and therefore does not allow separation of transcriptional
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and post-transcriptional effects of CCX.
L and N mRNA and polypeptide levels progressively 
decreased with increasing CCX in the presence and absence of 
A c t .  D. This therefore allows comparison of mRNA and 
polypeptide levels and meaningful conclusions drawn 
regarding- regarding the action of CCX. It seems likely that 
the reduced polypeptide levels were a consequence of reduced 
levels of mRNA, although additional post-transcriptional 
effects cannot be ruled out.
The mobility of polypeptide band G was increased in 
the presence and absence of Act.D., indicative of an effect 
on glycosylation. The increase in mobility was greater in 
the presence of Act.D.; this may be due to greater effect on 
glycosylation or because these tracks contained more BSA, 
than Act.D. free tracks (due to standardisation of 
radioactive counts).
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3.3.8. THE EFFECT OF CCX ON POST-TRANSLATIONAL
modifications
3.3.8.1. THE EFFECT OF CCX ON PHOSPHORYLATION
There was no detectable effect on the phosphorylation
of proteins in CCX treated mock-infected (Fig 37a) or
VSV-infected (Fig 37b) BS-C-1 cells. It should be noted
however, that the NS protein was not markedly
phosphorylated, the predominant phosphorylated band in
infected cells being a low m.wt. band. This band occurs only
in VSV-infected tracks and may be one of the low m.wt. bands
35previously observed in S methionine labelled VSV-infected 
BS-C-1 cells.
3.3.8.2. THE EFFECT OF CCX ON GLYCOSYLATION
SDS PAGE analysis of CCX treated and untreated 
VSV-infected BS-C-1 cells revealed that the G protein band 
in CCX treated tracks was increased in mobility, suggesting 
some effect on the glycosylation of this protein. In 
addition, Dargan and Subak-Sharpe have previously shown that 
glycosylation was affected in HSV-1 and HSV-2 infected and 
mock-infected Flow 2002 and BHK-21 cells. To determine if 
and to what extent glycosylation was affected in 
VSV-infected and mock-infected BS-C-1 cells, comparative 
studies were performed using monensin, which disrupts Golgi 
functions where processing of sugars occurs and tunicamycin, 
which completely blocks addition of core sugars normally 
occurring in the ER.

Figure 37
SDS PAGE profile obtained on a 10% gel of ^P-labelled
polypeptides induced in mock-infected (a) and VSV-infected
(m.o.i. 5 p.f.u./cell) (b) BS-C-1 cells treated with
1,100,200 or 30OuM CCX (lanes2-5), from l-24h p.i.
35Lane 1 shows Smet-labelled polypeptides induced in 
drug-free mock-infected (a) and VSV-infected (m.o.i. 5 
p.f.u./cell) (b) BS-C-1 cells.
32 35P-orthophosphate and S-methionine were added 2-24h p.i.
Equal volumes of sample were added to each track.
The positions of the known VSV-encoded proteins L,G,N,NS and
M and the unknown low m.wt. phosphorylated band, present in
VSV-infected but not mock-infected BS-C-1 cells, designated
UKp, are indicated.
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SDS PAGE ANALYSIS OF 35S-METHIONINE VSV-INFECTED AND
MOCK-INFECTED BS-C-1 CELLS TREATED WITH CCX,MONENSIN OR 
TUNICAMYCIN
MOCK-INFECTED CELL EXTRACTS 
PROTEIN SYNTHESIS (Table 32)
3 5T.C.A. precipitable S-met counts progressively 
decreased with increasing concentrations of CCX, falling to 
62.8% of drug free levels with 300uM CCX (Table 32). 
Treatment with lOuM monensin resulted in a slight increase 
in T.C.A. precipitable counts (121.1% of drug free control), 
while the counts obtained with tunicamycin were almost 
identical to those obtained in the absence of any drug (100% 
of drug free control). Therefore, while CCX inhibited 
protein synthesis, monensin caused a slight increase and 
tunicamycin had no effect.
STRESS RESPONSE (Fig 39)
Analysis by SDS PAGE revealed that in this experiment, 
neither CCX (Fig 39; lanes 10,11,12) or monensin (Fig 39, 
lane 13) induced any stress response. However, tunicamycin 
induced the synthesis of glucose-related stress proteins; 
grp 94 and 78 (Fig 39, lane 14).
VSV-INFECTED CELL EXTRACTS 
35S-met labelled infected cell extracts were analyzed 
by SDS PAGE (Fig 39), the virus-infected tracks 
densitometrically scanned and standardised for equal amounts 
of protein in each track (Table 33).
RELATIVE ABUNDANCE OF VIRAL PROTEIN BANDS (Table 33)
L, N, and NS all progressively decreased with 
increasing concentrations of CCX, falling to 31.6%, 31.4% 
and 31.7% of drug free levels respectively, with 300uM CCX 
(Table 33). Levels of M and G were greater than drug free at 
all CCX concentrations, peaking at 200uM CCX (231% of drug 
free levels)in the case of the M protein band and lOOuM CCX 
(239% of drug free levels)in the case of the G protein band. 
Low m.wt. bands (JK^ , LJK2 and UK^ were too faint to scan. 
However, Fig 39 shows that (JK^  increased with increasing
CPH
VSV INFECTED BS-C-I MOCK IIFECTED BS-C-1
0 74,706 166,238
c
uH C
100 58,167 157,263
X
200 60,263 103,281
300 38,078 104,443
uM HON 10 71,173 201,172
ug/al TUN 2 78,316 166,333
I 6 N NS M
: c 
:«h c
X
0 663.5 (100) 131.8 (100) 2348.5(100)353.1(100) 210 (100)
100 507 < 76) 316 (233) 2110 ( 72)203 ( 56) 385 (183)
200 334 ( S3) 307 (232) 1766 ( 60)183 (51) 486 (231)
300 210 ( 32) 278 (210) 928 (31) 114 ( 32) 326 (1S5)
uH HON 10 734 (113) 855 (648) 2307 ( 78)238 ( 66) 686 (326)
Iug/m1 TUN 2 1023 (155) 325 (701) 2413 ( 82)353 ( 38) 203 ( 37)
Table 32
T.C.A. precipitable 35S-methionine counts from VSV-infected 
and mock-infected cell extracts treated with 0, 100, 200, 
300uM CCX, lOuM Monensin or 2ug/ml Tunicamycin.
Table 33
Densitometer scan of polypeptide bands in VSV-infected 
tracks on Figure 39: tracks were scanned and the surface 
areas of each band divided by the volume added to each 
track, in order to standardise in terms of protein and not 
radioactive counts.
Numbers in parentheses are percentages: in each case the 0 
value is 100%.
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Figure 38
The effect of 100, 200 and 300uM CCX, lOuM monensin and
3 52ug/ml tunicamycin on the incorporation of Smet into 
polypeptides induced in VSV infected ( •  ) and mock-infected 
(■) BS-C-1 cells.
35S met counts shown in Table 32, plotted as a percentage of 
the mock-infected drug free control.
1 2 3 4 5 6 7 8 9 1 0 1 1  1 2 1 3 1 4
UK 3 - 
UK 1 •
UK 2 .
Figure 39
SDS PAGE profile on a 10% gel of polypeptides induced in 
infected BS-C-1 cells treated with 0 (lanes 1,2,8 and 9), 
lOOuM CCX (lanes 3 and 10), 200uM CCX (lanes 4 and 11), 
300uM CCX (lanes 5 and 12), lOuM monensin (lanes 6 and 13) 
or 2ug/ml tunicamycin (lanes 7 and 14).
Cells were either mock-infected (lanesl,9-14), or infected
with VSV at m.o.i. 5 p.f.u./cell (lanes 2-8).
35Smet was added from l-24h p.i.
Letters on the left indicate the positions of known 
virus-coded proteins (L,G,N,NS and M) and 3 low m.wt. bands 
of unknown origin present in virus-infected but not 
mock-infected cell extracts (UK1,UK2 and UK3). Go denotes 
the position of the unglycosylated form of G.
Also marked are glucose-related stress proteins present in 
tunicamycin treated BS-C-1 cells; 94grp and 78grp.
Equal numbers of counts were loaded onto each track.
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concentrations of CCX, while UK^ and UK^ decreased.
Levels of bands L, N and NS in monensin tracks were 
119%, 78.2% and 66.2% of those in drug free tracks
respectively (Table 33). Monensin treatment resulted in a 6 
fold increase in the level of protein band G (to 648% of 
drug free levels) and a 3 fold increase (326% of drug free 
levels) in the level of protein band M. While low m.wt. band 
UK^ / may have increased slightly, both UK^ and (JK^  levels 
were comparable to those in drug-free tracks. (Fig 39).
In tunicamycin tracks, levels of bands N, NS and M 
were comparable to levels in drug free tracks (81.8%, 9 8.3% 
and 96.6% of drug free levels respectively) while the level
of band L rose to 155% of the drug free control. The
unglycosylated form of the G protein, designated Gq , 
produced in the presence of tunicamycin appeared to
accumulate in infected cells; levels of band Gq were seven 
times greater than levels of band G in the drug free track 
(rising to 70% of drug free levels).
MOBILITY OF G BAND (Fig 39)
In agreement with previous observations, treatment 
with CCX caused a slight increase in the mobility of G (Fig 
39, lanes 3-5). Treatment with monensin also resulted in 
only a slight shift downward of this band (Fig 39, lane 6). 
In contrast, the unglycosylated form of G, produced in the 
presence of tunicamycin runs considerably lower than the 
fully glycosylated form of the protein (Fig 39, lane 7). 
Therefore, although CCX may have affected processing of 
sugars occurring in the Golgi, it did not completely inhibit 
sugar addition.
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CONCLUSIONS
1. In this experiment, levels of the NS band decreased with 
increasing concentrations of CCX. This does not agree with 
the previous experiment (Fig 35; Table 31), where NS 
actually increased with increasing CCX. This difference may 
be related to a variable inducement of the stress response
as in this experiment, again in, contrast to Fig 35, no
C K- WvMf- vwv F ‘g 33
stress response was induced. This will be discussed more
\X> W'-pO-z^dr V*> S  f ) - | (JUi f*? ** tA
fully later.
2.In agreement with previous observations, CCX 
treatment resulted in increased levels of G, M and UK^ in 
infected cells. It is interesting that monensin treatment 
also resulted in increased levels of these bands, suggesting 
some similarity in the mode of action. The fact that levels 
of L, N and NS were constant in monensin treated cells, yet 
reduced in CCX treated cells, may be due to differential 
effects on protein synthesis (Note that monensin caused a 
slight increase in T.C.A. precipitable counts in 
mock-infected cells, while counts were progressively 
decreased with increasing concentrations of CCX).
3. It is clear that CCX did not completely block 
addition of sugar onto the VSV G protein, as treatment with 
CCX resulted in only a slight slight downward shift in this 
band. In contrast, the unglycosylated form of this protein, 
produced in tunicamycin treated infected cells runs 
considerably lower than the fully glycosylated form.
Monensin treatment also results in only a slight shift 
downward.
Therefore, CCX did not completely block sugar 
addition, but may have disrupted processing steps occurring 
in the Golgi apparatus.
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SDS PAGE ANALYSIS OF 14C-GLU AND 35S-MET LABELLED
V S V - INFECTED AND MOCK-INFECTED BS-C-1 CELLS TREATED WITH
CCXfMONENSIN AND TUNICAMYCIN
To establish more clearly how CCX affects sugar
addition, VSV-infected and mock-infected BS-C-1 cells
treated in parallel with CCX, mond&sin or tunicamycin were 
14labelled with C-glucosamine and S-methionine. Labelling 
14with C-galactose was also attempted but was not 
successful.
35S-MET LABELLED CELL EXTRACTS
35S-MET LABELLED MOCK-INFECTED CELL EXTRACTS
PROTEIN SYNTHESIS
3 5T.C.A. precipitable S-met counts progressively 
decreased with increasing concentrations of CCX, falling to 
41.9% of drug free levels with 300uM CCX. In this 
experiment, counts were also decreased in monensin treated 
extracts, falling to 77.7% and 64.3% of drug free levels 
with 5 and lOuM respectively. Tunicamycin again had no 
significant effect on T.C.A. precipitable counts, falling to 
95.4% Of drug free levels. (Table 34)
Therefore, CCX progressively inhibited host cell 
protein synthesis. Although monensin also inhibited protein 
synthesis at both 5 and lOuM, the reduction was less than 
that achieved with CCX. In agreement with previous 
observations, tunicamycin had little if any effect on 
protein synthesis.
STRESS RESPONSE
Analysis by SDS PAGE revealed that in this experiment, 
stress proteins 70h, 94g and 78g were all induced with 150, 
200 and 300uM CCX, the response becoming more marked with 
increasing CCX (Fig 40a, lanes 6,7 and 8). In contrast, 
there was no notable inducement of stress proteins in 
monensin treated cell extracts (Fig 40a, lanes 9and 10). 
Glucose related stress proteins, 94g and 78g and a - high
ojy/b <V kOK fvoFtuvv
m.wt. bandA were strongly induced in tunicamycin treated 
cells (Fig 40a, lane 11). Therefore, CCX induced both hsps 
and grps, tunicamycin only grps and monensin no stress 
proteins.
35S-MET LABELLED VSV-INFECTED INFECTED CELL EXTRACTS
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35S-met labelled infected cell extracts were analyzed 
by SDS PAGE (Fig 41a), adding equal volumes of sample onto 
each track, and the virus-infected tracks densitometrically 
scanned (Table 35).
RELATIVE ABUNDANCE OF VIRAL BANDS (Table 35)
Levels of polypeptide band L, progressively decreased 
with increasing concentrations of CCX to 31.9% of drug free 
levels with 300uM CCX. Levels of band NS also fell 
progressively with increasing CCX concentrations to 200uM 
CCX (to 33.8% of drug free levels). At 300uM CCX, levels of 
band NS increased but were still below drug free levels (to 
74.6%)
In this experiment, levels of bands G, M and 
progressively increased with increasing CCX. Levels of G and 
M at 300uM CCX were 385% and 575% of drug free levels 
respectively, while drug free levels of UK3 were too faint 
to scan. There was little significant change in the levels 
of band UK^ at most CCX concentrations, falling to 63.9% of 
drug free levels.
Levels of bands L, N and NS in the 5uM monensin track 
were only slightly greater than levels in drug free tracks 
(110.3%, 105% and 125.5% of drug free levels respectively). 
Levels of L and NS rose slightly in the lOuM monensin track 
(to 124.1% and 114.4% respectively), while levels of N were 
almost identical to those in drug free tracks (99.8%). 
Levels of band UK^ were increased slightly with 5uM monensin 
(to 133.3% of drug free levels) and decreased slightly with 
lOuM monensin (to 88.8% of drug free levels). Although 
levels of these bands were changed, the differences were 
small and their significance, if any, unclear. Levels of 
bands G and M were increased with both 5uM (to 543% and 322% 
of drug free levels respectively) and lOuM (to 516% and 244% 
respectively) monensin, with the increase being slightly 
greater with 5uM monensin. The increase in these bands was 
much greater than the increase in any other viral bands. 
Levels of G and M were approximately five and three times 
greater than drug free levels respectively. Band UK^ was 
also increased over drug free levels, but was too faint to 
scan (Fig 41).
In tunicamycin tracks, levels of band L were almost
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Table 34
35 14T.C.A. precipitable S-methionine and C-glucosamine
counts from VSV-infected and mock-infected cell extracts
treated with 0, 25, 50, 75, 100, 150, 200, 300uM CCX, 5,
lOuM Monensin or 2ug/ml Tunicamycin.
The numbers in parentheses are percentages: in each case the 
0 value is 100%.
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Table 35
Densitometer scan of polypeptide bands in VSV-infected 
tracks in Figure 4 0a.
The numbers in parentheses are percentages: in each case the 
0 value is 100%.

Figure 40
35SDS PAGE profile on a 10% gel of Smet-labelled (a) or 
14Cglu-labelled (b) polypeptides induced in mock-infected 
BS-C-1 cells. Radiolabel was added from 8-24h p.i.
35(a) Smet-labelled cell extracts
M o c k - i n f e c t e d  c e l l s  w e r e  t r e a t e d  w i t h  0,25,50,75,100,150,200 
o r  300uM CCX ( l a n e s  1-8), 5 o r  lOuM m o n e n s i n  ( l a n e s  9 a n d
10) or 2ug/ml tunicamycin (lane 11).
Letters on the right indicate the positions of stress 
proteins; 94grp, 78grp and 70h.
(b) 14Cglu-labelled cell extracts
M o c k - i n f e c t e d  c e l l s  w e r e  t r e a t e d  w i t h  0,25,50,75,100,150,200 
o r  300uM CCX ( l a n e s  2-9), 5 o r  lOuM m o n e n s i n  ( l a n e s  10 a n d
11) or 2ug/ml tunicamycin (lane 12).
Bl, B2 and B3 denote 3 highly glycosylated cellular 
proteins.
^5Lane 1 shows Smet-labelled mock-infected cell extract.
Equal volumes of sample were loaded onto each track.
1 2 3 4  5 6 7 8  9 1 0 1 1 1
10 11 12
Figure 41
SDS PAGE profile on a 10% gel of 35Smet-labelled (a) or 
•^Cglu-labelled (b) polypeptides induced in VSV-infected 
(m.o.i. 5 p .f .u ./cell), BS-C-1 cells. Radiolabel was added 
from 8-24h p.i.
35(a) Smet-labelled cell extracts
V S V - i n f e c t e d  c e l l s  w e r e  t r e a t e d  w i t h  0,25,50,75,100,150,200 
o r  300uM CCX ( l a n e s  1-8), 5 o r  lOuM m o n e n s i n  ( l a n e s  9 a n d
10) or 2ug/ml tunicamycin (lane 11).
L e t t e r s  o n  t h e  l e f t  i n d i c a t e  t h e  p o s i t i o n  o f  k n o w n  
v i r u s - c o d e d  p r o t e i n s  (L,G,N,NS a n d  M) a n d  3 l o w  m . w t .  b a n d s  
o f  u n k n o w n  o r i g i n  p r e s e n t  i n  v i r u s - i n f e c t e d ,  b u t  n o t  
m o c k - i n f e c t e d  c e l l  e x t r a c t s  (UK1,UK2 a n d  UK3).
Gp denotes the position of the partially glycosylated G 
protein .
Go d e n o t e s  t h e  p o s i t i o n  o f  u n g l y c o s y l a t e d  G p r o t e i n .
A drug free mock-infected track is shown on the left hand 
side.
14(b) Cglu-labelled cell extracts
VSV-infected cells were treated with 0,25,50,75,100,150,200 
or 300uM CCX (lanes 2-9), 5 or lOuM monensin (lanes 10 and
11) or 2ug/ml tunicamycin (lane 12).
14Lane 1 shows Cglu-labelled mock-infected cell extracts. 
The position of VSV glycoprotein G is marked.
Equal volumes of sample were loaded onto each track.
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the same as drug free levels (107.8% of drug free 
control),while levels of band N were slightly increased (to 
131.2% of drug free levels) and NS slightly decreased (77.3% 
of drug free levels). Again, the changes in these cases was 
small and their significance, if any, unclear. The levels of 
the unglycosylated form of G designated Go, rose to 4 26% of 
drug free levels i.e. four times greater than levels of the 
fully glycosylated form of G produced in the absence of 
drug. In this experiment, levels of bands M and UK^ in 
tunicamycin tracks were almost double those in drug free 
tracks (rising to 174.4% and 174.6% of drug free levels 
respectively).
MOBILITY OF G BAND (Fig 41a)
The mobility of the G band was progressively increased 
with increasing concentrations of CCX, resulting in a slight 
shift downward with 300uM CCX (Fig 41a, lanes 1-8). A 
similar shift in the position of the band was seen with both 
5 and lOuM monensin (Fig 41a, lanes 9 and 10). As expected, 
Gq - the unglycosylated form of G produced in tunicamycin 
treated cells runs considerably lower than the fully 
glycosylated form of the protein (Fig 41a, lane 11). This 
agrees with previous observations and indicates that 
although CCX may have affected sugar processing,it did not 
completely inhibit sugar addition.
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14C-GLU LABELLED CELL EXTRACTS
14C-GLCJ LABELLED MOCK-INFECTED CELL EXTRACTS
14C-glu labelled cell extracts were subjected to SDS 
P A G E ,  adding equal volumes of sample onto each track (Fig 
40b). Tunicamycin, as expected, almost completely abolished 
glucosamine incorporation. Only two bands were evident in 
the tunicamycin track (Fig40b, lane 12) and are most 
probably glycoprotein precursors (Bio and B3o), the shift in 
m.wt. explained by the almost complete block in sugar 
addition.
Monensin treatment had no detectable effect on 
glucosamine incorporation into bands B1 and B3, while band 
B2 could not be detected (Fig 40b, lanes 10 and 11). 
However, there was a slight downward shift in the mobility 
of bands B1 and B3 (Fig 40b, lanes 10 and 11) in monensin 
tracks.
Although there was no significant change in T.C.A. 
precipitable counts (Table 34), from CCX treated samples, 
analysis by SDS PAGE revealed a progressive reduction in 
glucosamine labelled proteins (Fig 40b, lanes 2-9). This is 
most probably predominantly due to the decrease in protein 
synthesis (Fig 40a, Table 34). However, bands Bl, B2 and B3 
increased in mobility with increasing concentrations of CCX 
(Fig 40a, lanes 2-9), the shift in mobility (achieved with 
concentrations to 200uM) being similar to that seen in the 
monensin tracks. The shift in mobility obtained with 
monensin and CCX may be due to a block in the addition of 
sugars other than glucosamine e.g. galactose or possibly
sialic acid, which are normally added after glucosamine.
14Attempts to label with C-galactose however were 
unsuccessful and so this must remain speculation.
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14-C GLU LABELLED VSV-INFECTED CELL EXTRACTS 
14C-glu labelled infected cell extracts were subjected
to SDS PAGE, adding equal volumes of sample to each track 
14(Fig 41b). C-labelled G protein increased progressively
with increasing CCX, to 200uM CCX, in agreement with the
35 . . .increase seen in S-met labelled extracts, indicating that
at these CCX concentrations there was no significant
inhibition in incorporation of glucosamine (Fig 41a, lanes
1-7 and Fig 41b, lanes 2-8). However, while levels of band G
3 5increased with 300uM CCX in S-met labelled extracts,
14levels of C-glu labelled G actually decreased at this 
concentration, indicating some inhibition of glucosamine 
incorporation.
14 3 5Levels of C-glu and S-met labelled G protein were
both increased with 5 and lOuM monensin. Therefore, monensin
had no effect on glucosamine incorporation. In contrast,
14 . . .C-glu labelled G protein was not detectable in tunicamycin
3 5tracks, despite increased levels of S-met labelled GQ . 
Therefore, tunicamycin, as expected completely abolished 
incorporation of glucosamine.
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CONCLUSIONS
1. The aim of this experiment was to determine the affect of 
CCX on the VSV G protein. In agreement with the previous 
experiment, both CCX and monensin treatment resulted in 
increased levels of bands G, M and UK^ (although the 
increase in band UK^ was greater in CCX tracks). In addition 
there was a similar slight increase in the mobility of the G 
band witn botn CCX and monensin indicating some slight 
effect on glycosylation by both these compounds. In 
contrast, due to the absence of sugar on the G protein, 
resulting in a significant difference in m.wt., the mobility
of the G band was greatly increased in tunicamycin tracks.
142. As expected, incorporation of C-glucosaaine was 
completely inhibited in tunicamycin treated infected cells.
It has previously been shown that the unglycosylated form of 
the G protein accumulates in the ER. The accumulation of G
0
is therefore a consequence of non-glycosylation. M (and 
possibly UK^) may associate with GQ (unglycosylated form of 
G) in tunicamycin treated cells resulting in the 
accumulation of all these proteins.
In contrast, monensin and CCX to 200uM had no effect 
on glucosamine incorporation. However, these compounds may 
block the addition of sugars (e.g. galactose) occuring in 
the trans face of the Golgi. Labelling with ^C-galactose 
however was not successful.
3. Levels of band N remained constant with increasing 
CCX concentrations, while band NS decreased progressively to 
200uM CCX, then increased slightly at 300uM CCX. The changes 
in levels of N and NS, in the presence of CCX, varied 
between experiments; in two experiments levels of N 
progressively decreased and in one remained constant. Levels 
of NS were decreased in the presence of CCX in two 
experiments, but progressively increased to 200uM CCX in one 
other experiment. It is interesting that protein synthesis 
in host cells was most markedly affected and a very strong 
stress response induced where NS decreased, perhaps 
suggesting the involvement of the stress response in 
variable levels of NS.
In this and all other experiments, levels of the L
133
band consistently decreased with increasing CCX 
concentrations.
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THE EFFECT OF CCX, MONENSIN AND TUNICAMYCIN ON PARTICLE 
NUMBERS, INFECTIOUS VIRUS YIELDS (P.F.UJ AND 
PARTICLE/P.F.U. RATIOS
This experiment was performed to directly compare the 
effects of these three compounds on infectivity, particle 
production and particle/p.f.u. ratios. Treatment of infected 
cells with CCX, reduced VSV particle production, however, 
the reduction was greater in the presence of CCX 0 2  logs; 
no particles detected at 300uM CCX; Table 36), than in the 
presence of either monensin or tunicamycin (reduced particle 
numbers by 2 logs; Table 36). This greater reduction by CCX 
is most likely due to the additional effects of CCX on 
protein synthesis.
Virus particles which were produced from monensin or 
tunicamycin treated cells were as infectious as those 
produced under drug free conditions i.e. particle/p.f.u. 
ratios were essentially unchanged (Table 36). In contrast, 
virus yields produced from cells treated with higher 
concentrations of CCX (150, 200 and 300uM CCX) had elevated 
particle/p.f.u. ratios (10 fold or greater; Table 36). This 
elevation is most likely due to direct inactivation of VSV 
particles by CCX. (See Tabte 2t)
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Table 36
The effect of CCX, Monensin and Tunicamycin on VSV particle 
numbers, infectious virus yields (p.f.u.) and 
particle/p.f.u. ratios.
N.D. not determined.
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3.4. THE EFFECT OF CCX ON THE REPLICATION OF SEMLIKI FOREST 
VIRUS (SFV) ; REPRESENTING THE CLASS 3 RESPONSE
3.4.1. DIRECT INACTIVATION OF SFV PARTICLES 
Suspensions of SF virus particles were incubated with
either mock drug or 300uM CCX (2.2.5.7.) at 4°C or 37°C for 
24h. Infectious virus yields were titrated before and 24h 
after drug addition. The experiment was performed twice, and 
the results are shown in Table 37. CCX reduced the 
infectivity of SF virus yields by an average of 26% (There 
was only a 10% difference between the effect of CCX at 3 7°C 
and 4°C).
3.4.2. ADSORPTION OF SFV TO PRE-TREATED BS-C-1 CELLS
Fig 43 shows the adsorption curves obtained for SFV 
and BS-C-1 cells pretreated with 0, 300, 600 or 900uM CCX 
(as described in 2.2.5.6.). Although there was some slight 
effect on virus adsorption, the majority of virus was still 
able to adsorb even to cells pre-treated with 900uM CCX. 
Therefore, CCX had only a slight effect on subsequent SFV 
adsorption to BS-C-1 cells.
3.4.3. THE EFFECT OF CCX, MONENSIN AND TUNICAMYCIN ON 
INFECTIOUS SFV YIELDS FROM TREATED BS-C-1 CELLS
When SFV-infected BS-C-1 cells were treated with 
increasing concentrations of CCX, a progressive increase in 
cell-associated (CA) infectious virus yields (-1 log) 
resulted which was accompanied by a concomitant decrease in 
the cell-released (CR) fraction (-1 log) (Fig 44a). A 
similar result was obtained with increasing concentrations 
of monensin (Fig 44b). In contrast, tunicamycin treatment 
reduced the infectivity of both CA and CR fractions by -3 
logs, indicating that the addition of core sugar is 
important for virus infectivity.
The increase in the cell-associated fraction observed 
in both CCX and monensin treated SFV-infected BS-C-1 cells 
could be due to retention of virus particles at the PM 
and/or budding of virus particles at intracellular membrane. 
The latter possibility seems most likely as budding of SFV 
particles into Golgi vacuoles has been observed in 
SFV-infected BHK cells treated with monensin (Griffiths,
Quinn and Warren, 1983).
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Direct inactivation of SFV particles by CCX.
a) and b) represent data from 2 separate experiments
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Figure 43
Adsorption of Semliki Forest virus particles to BS-C-1 cells 
pre-treated with 0 ( ■  ), 300uM CCX ( □) , 600uM CCX ( A ) or 
900uM CCX ( A ) .
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Figure 44
The effect of CCX (a), monensin or tunicamycin (b)on 
infectious yields from SFV-infected BS-C-1 cells.
The m.o.i. was 5 p.f.u./cell and virus yields were harvested 
at 24h p.i. and divided into cell-associated (■) and 
cell-released (□) fractions.
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with CCX, monensin or tunicamycin ( ▲ ).
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3.4.4. THE EFFECT OF CCX, MONENSIN AND TUNICAMYCIN ON 
POLYPEPTIDES INDUCED IN MOCK-INFECTED AND SFV-INFECTED 
BS-C-1 CELLS
MOCK-INFECTED CELL EXTRACTS (Fig 46a)
There was no significant effect on host cell protein
synthesis, with CCX, monensin or tunicamycin.
Glucose-related stress proteins, grp 74 and 78 aftd a high
a u©*
m.wt. band (120)^ were induced in tunicamycin treated BS-C-1 
cells (Fig 46a, lane 6). No stress response was induced in 
either CCX treated (Fig 46a, lanes 2-4), or monensin treated 
(Fig 46a, lane 5) BS-C-1 cells.
SFV-INFECTED CELL EXTRACTS (Fig 46b)
Only structural SFV proteins were detected. This may 
be due to the short half life of the non-structural proteins 
(Keranen and Ruohonen, 1983). Levels of glycoproteins p62, 
El (possibly E2; difficult to separate El and E2 as they are 
so close in m.wt.), increased with increasing CCX 
concentrations and also in the presence of monensin (Fig 
25b, lanes 1-5). In both CCX and monensin treated tracks, 
the intensity of the capsid (C) was decreased. A high m.wt. 
band also accumulates in CCX, monensin and tunicamycin 
tracks. This band may be the glucose-related stress protein 
grp 9 4 (induced in mock-infected tunicamycin tracks). 
However, if this is so, it is difficult to explain the 
absence of this band in the mock-infected CCX and monensin 
treated tracks.
Levels of all viral bands were increased in 
tunicamycin tracks. As expected, due to the inhibition of 
sugar addition, there was a marked downward shift in 
glycoprotein bands p62, and El (and possibly E2).
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Figure 45
Semliki Forest Virus: Proteins
The genome of SFV ( and all other alphaviruses) is organized 
into 2 distinct regions. The 5' two thirds of the genome 
encodes the non-structural proteins, which are translated as 
a polyprotein from a messenger that is indistinguishable 
from the virion RNA.These precursors are then cleaved 
post-translationally to produce ultimately 4 products, 
non-structural proteins, nspl (70K), nsp2 (86K), nsp3 (60K) 
and nsp4 (72K) (Lachmi and Kaariarnen, 1976; Keranen and 
Ruohonen, 1983). These proteins function as the 
replicase/transcriptase for the virus (Clewley and Kennedy, 
1976; Ranki and Kaariainen, 1979; Keranen and Kaarianinen, 
1979; Gomatos et al., 1980).
The 3 1 third of the genome that encodes the 
structural proteins i.e. the polypeptide components of the 
mature virion (Garoff et al., 1980a,b; Rice and Strauss, 
1981a). Semliki Forest virus (SFV), consists of a 
nucleocapsid containing the single-stranded virus RNA 
complexed with a basic protein, surrounded by a lipid 
bilayer, containing 2 integral glycosylated membrane 
proteins (E2 and El) and a small peripheral protein (Simons 
and Garoff, 1980). The translation of the structural 
proteins is initiated at a single site on a subgenomic 26S 
mRNA. Three co-translational cleavage events release the 
capsid (33K), p62 (a precursor of E3 [10K]) and E2 [51K] 
proteins), a non-structural 6K protein and finally the El 
protein (50K) from a polyprotein (130) .
■ ;  A f l K H
Figure 46
SDS PAGE profile on a 10% gel of the infected cell 
polypeptides induced in BS-C-1 cells treated with 0,100,200 
or 300uM CCX (lanes 1-4), lOuM monensin (lane 5) or 2ug/ml 
tunicamycin (lane 6) from l-24h p.i.
Cells were either mock-infected (a) or infected with SFV at
a m.o.i. of 50 p.f.u./cell (b).
35Smet was added from l-24h p.i. in the presence of ACT. D. 
(5ug/ml).
Equal volumes of sample were loaded onto each track.
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3.4.5. EM ANALYSIS OF MONENSIN AND CCX TREATED SFV-INFECTED 
BS-C-1 CELLS
In the absence of any drug, SFV was observed to bud 
exclusively from the PM of BS-C-1 cells (Fig 47a). In CCX 
treated cells, SFV nucleocapsids were found associated with 
intracellular vacuoles (Fig 47b). Closer examination of 
these vacuoles (Fig 47c), revealed that nucleocapsids had in 
fact budded into the vacuoles. Intravacuole budding was also 
observed in monensin treated SFV infected BS-C-1 cells, 
although aggregates of nucleocapsids were also found at the 
PM (Fig 47d). Budding of SFV into intracellular vacuoles, 
has previously been reported in a variety of monensin 
treated SFV-infected cells, including BHK and CEF 
(Griffiths, Quinn and Warren, 1983; Pesonen and Kaariainen, 
1982). In these cases, staining with specific cytochemical 
markers and lectins, revealed that these vacuoles were Golgi 
derived. Given the similarities observed between monensin 
and CCX, it seems likely that the vacuoles observed in CCX 
treated cells are also derived from Golgi membrane.

Figure 47 (a and b)
c
Monolayers of BS-C-1 cells (4 x 10 cells/50mm plate), were 
infected with SFV at m.o.i. of 50 p.f.u./cell. Following 
virus adsorption for lh at 37°C, infected monolayers were 
washed 3 times with PBS and overlaid with drug-free medium 
(a) and EFC2 containing 300uM CCX (b).
At 2 4h p.i. infected cell monolayers were embedded in epon 
and thin sections examined by transmission EM. (as described 
in 2.2.6.2 . )

Figure 47 (c and d) ^
Monolayers of BS-C-1 cells (4 x 10 cells/50mm plate), were 
infected with SFV at m.o.i. of 50 p.f.u./cell. Following 
virus adsorption for lh at 37°C, infected monolayers were 
washed 3 times with PBS and overlaid with EFC2 containing 
300uM CCX (c) and lOuM monensin (d).
At 2 4h p.i. infected cell monolayers were embedded in epon 
and thin sections examined by transmission EM. (as described 
in 2 .2 .6 . 2 . )
139
3.5. THE EFFECT OF CCX, MQNENSIN AND TUNICAMYCIN ON CLASS 2 
VIRUSES
3.5.1. THE EFFECT OF CCX, MQNENSIN AND TUNICAMYCIN ON 
INFECTIOUS YIELDS FROM GERMISTQN AND BUNYAMWERA VIRUS 
INFECTED BS-C-1 CELLS
The effect of CCX, monensin and tunicamycin on 
infectious virus yields from both Germiston and 
Bunyamwera-infected BS-C-1 cells was determined (Fig 48). 
Mock-infected BS-C-1 cells were treated in parallel with 
drug and cell viabilty determined by trypan blue dye
exclusion at the time of harvest (24h). There was no 
significant effect on cell viability with CCX, monensin or 
tunicamycin (viabilities remaining above 80%), allowing 
uncoupling of antiviral and cytotoxic effects. Virus yields 
were separated into cell-associated (CA) and cell-released
(CR) fractions, revealing no inhibition of virus release
from the cell in the presence of any drug. In fact,
decreased CA/CR ratios indicate a slight increase in virus 
release.
Infectious yields of both fractions were progressively 
reduced with increasing monensin concentrations achieving a 
100 fold reduction with lOuM monensin (Fig 48b). Treatment 
with tunicamycin (to 2ug/ml) (Fig 48b) also reduced both
fractions by 100 fold. This reveals that processing of 
glycoprotein in the Golgi is important for virus 
infectivity, disruption of this step reducing infectivity by 
the same magnitude as that achieved by completely blocking 
sugar addition.
Treatment with 50uM CCX had little significant effect 
on virus infectivity in either fraction (Fig 48a).This was 
followed by a progressive reduction in both fractions with 
increasing concentrations of CCX to 200uM, with little 
further effect at 300uM, achieving a 100 fold reduction in 
infectivity (Fig 48a). This reduction is the same as that 
obtained with monensin, therefore, disruption of sugar 
processing in the Golgi could totally account for the 
anti-Bunyamwera and anti-Germiston effect of CCX.
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Figure 48
The effect of CCX (a), monensin or tunicamycin (b) on
infectious yields from Germiston ( A A ) and
Bunyamwera (■ □ )  infected BS-C-1 cells.
The m.o.i. was 5 p.f.u./cell and virus yields were harvested
at 24h p.i. and divided into cell-associated (CA) (A ■  ) 
and cell-released (CR) ( A D )  fractions.
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with CCX, monensin or 
tunicamycin t—A — ) .
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3.5.2. THE EFFECT OF CCX, MONENSIN AND TUNICAMYCIN ON 
INFECTIOUS VIRUS YIELDS FROM POLIOVIRUS-1 INFECTED BS-C-1 
CELLS
The effect of CCX, monensin and tunicamycin on 
infectious yields from Poliovirus infected BS-C-1 cells was 
determined (Fig 49). Mock-infected controls show that cell 
viability remained high at all drug concentrations. Yields 
were divided into cell-associated (CA) and cell-released 
(CR) fractions: CA/CR ratios were not significantly altered 
by CCX, monensin or tunicamycin indicating no effect on 
virus release from the cell.
There was a 30 fold reduction in virus infectivity, 
with CCX in both the cell-associated and cell-released 
fractions (Fig 49a). The reduction was progressive with 
increasing concentrations of CCX to 150uM CCX, with little 
further effect at 200 and 300uM CCX. In contrast, neither 
monensin or tunicamycin had any effect on virus infectivity 
(Fig 49b). This is the expected result as poliovirus 
contains no glycoprotein. Therefore, disruption of
glycoprotein processing can play no role in the
anti-Poliovirus effect of CCX. Poliovirus infectivity may be 
reduced by inhibition of protein synthesis and/or binding of
CCX directly to virus particles^ ams t-V vvvQ.cJtAYo'tvon
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Figure 49
The effect of CCX (a), monensin or tunicamycin (b) on 
infectious yields from Poliovirus-1 infected BS-C-1 cells.
The m.o.i. was 5 p.f.u./cell and virus yields were harvested 
and divided into cell-associated (CA) (■) and cell-released 
(CR) (Q) fractions.
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with CCX, monensin or tunicamycin (▲ ).
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3.5.3. THE EFFECT OF CCX, MQNENSIN AND TUNICAMYCIN ON 
INFECTIOUS YIELDS FROM ADENOVIRUS-5 INFECTED HELA CELLS
The effect of CCX, monensin and tunicamycin on 
infectious yields from Adenovirus infected cells was
determined (Fig 50a). Mock-infected controls show that
viability was not significantly affected at any drug 
concentration. Virus yields were divided into cell 
associated (CA) and cell-released (CR) fractions revealing 
no effect on virus release from the cell.
The CCX dose-response curve obtained for Adeno-5, was 
as previously observed (Fig 50a). Cell-associated and 
cell-released virus yields were reduced 150 fold with only 
50uM CCX, with little further effect at higher CCX
concentrations.
In contrast, neither monensin or tunicamycin had any 
effect on Adenovirus infectivity (Fig 50b). Unlike
Poliovirus-1, Adenovirus-5 does contain gtyt&profcfcvjors.. 
However, these results suggest that neither the addition of 
core sugar or subsequent processing in the Golgi are 
important for Adenovirus infectivity. Therefore, disruption 
of glycosylation can play no role in the anti-Adenovirus 
effect of CCX. The effect of CCX on Adenovirus replication 
was investigated further and will be discussed more fully 
later.
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Figure 50
The effect of CCX (a), monensin or tunicamycin (b) on 
infectious virus yields from Adenovirus-5 infected HeLa 
cells.
The m.o.i. was 5 p.f.u./cell and virus yields were harvested 
at 48h p.i. and divided into cell-associated (CA) (■) and 
cell-released (CR) (□) fractions.
Viability of uninfected HeLa cells from control cultures 
treated in parallel with CCX, monensin or tunicamycin ( ▲  ).
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3.5.4. THE EFFECT OF CCX, MQNENSIN AND TUNICAMYCIN ON 
INFECTIOUS YIELDS FROM REOVIRUS-3 INFECTED BS-C-1 CELLS
The effect of CCX, monensin and tunicamycin on 
infectious yields from Reovirus-3 infected BS-C-1 cells was 
determined (Fig 51). Mock-infected controls show that cell 
viability remained high at all drug concentrations. Virus 
yields were separated into cell associated (CA) and cell 
released (CR). CA/CR ratios were slightly increased in the 
presence of CCX, monensin and tunicamycin indicating some 
block in virus release.
CCX reduced cell-associated and cell-released 
Reovirus-3 infectious yields 100 fold (Fig 51a). Reovirus-3 
was very sensitive to low concentrations of CCX, the curve 
reaching a plateau between 100 and 200uM CCX. In contrast, 
infectious yields were not significantly affected by either 
monensin or tunicamycin treatment (Fig 51b). Therefore, 
although Reovirus-3 contains glycoproteins, disruption of 
glycosylation does not affect virus infectivity and the 
reduction in infectious virus yields obtained with CCX 
cannot therefore be due to inhibition of sugar addition or 
transport. The effect of CCX on Reovirus-3 replication was 
investigated further and will be discussed more fully in the 
next section.
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Figure 51
The effect of CCX (a), monensin or tunicamycin (b) on 
infectious yields from Reovirus-3 infected BS-C-1 cells.
The m.o.i. was 5 p.f.u./cell and virus yields were harvested 
at 24h p.i. and divided into cell-associated (CA) (■) and 
cell-released (CR) (□) fractions.
Viability of uninfected BS-C-1 cells from control cultures 
treated in parallel with CCX, monensin or tunicamycin ( ▲ ).
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3.6. THE EFFECT OF CCX ON THE REPLICATION OF REOVIRUS-3; 
REPRESENTING THE CLASS 2 RESPONSE
3.6.1. ANALYSIS OF REOVIRUS-3 PRODUCED IN CCX TREATED BS-C-1 
CELLS
THERMOSTABILITY OF REOVIRUS-3 PROGENY VIRUS PRODUCED IN 
BS-C-1 CELLS TREATED WITH CCX
Although the CCX dose-response curve obtained for 
Reovirus-3, plateaued at higher CCX concentrations, 
indicating no further effect on virus infectivity, it was 
important to determine the quality of progeny virus produced 
in the presence of CCX. The thermostability of infectious 
virus produced from BS-C-1 cells treated with 0, 50, 150 or 
300uM CCX was determined by incubating the virus at 42°C for 
various times and then immediately titrated. The curves 
obtained (Fig 52), suggests no evidence of difference in the 
thermostability of virus produced in the presence and 
absence of CCX.
ANALYSIS OF REOVIRUS-3 SYNTHESISED IN BS-C-1 CELLS : 
SUSCEPTIBILITY TO REPEATED TREATMENT WITH CCX (DOSE-RESPONSE 
CURVES)
Reovirus-3 was very sensitive to low concentrations of 
CCX, with the dose-response curve reaching a plateau between 
100 and 200uM CCX. To determine if the plateau resulted from 
the selection of a sub-population of resistant virus, virus 
produced in CCX treated and drug-free cells, was used in 
repeat dose-response experiments. The resulting curves (Fig 
53), indicate that this was not the case, with virus 
produced in CCX treated cells responding to further CCX 
treatment in the same way as virus produced in drug free 
cells.
3.6.2. ADSORPTION OF REOVIRUS-3 TO BS-C-1 CELLS TREATED WITH 
VARYING CONCENTRATIONS OF CCX
Adsorption experiments (as described in 2.2.5.6.) were 
performed with Reovirus-3 and BS-C-1 cells pre-treated with 
varying concentrations of CCX (Fig 54).There was only a 
slight effect on virus adsorption (reduction of about 10% 
for all three tested concentrations of CCX), with Reovirus-3 
still able to bind to cell receptors at concentrations as
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Figure 52
Thermostability of Reovirus-3 progeny virus made in BS-C-1 
cells treated with CCX : 0 (■), 50uM CCX (□),
150uM CCX ( ▲ ), 300uM CCX (A).
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Figure 53
The effect of increasing concentrations of CCX on infectious 
virus yields from BS-C-1 cells infected with
(■) virus produced from drug-free cells
(□) virus produced in cells maintained in 50uM CCX
(A) virus produced in cells maintained in 150uM CCX
(A ) virus produced in cells maintained in 300uM CCX.
Dose-response curves have been transposed down by 0.5 log 
( □), 1 log ( A ) or 1.5 log (A ), to allow clear 
presentation.
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Figure 54
Adsorption of Reovirus-3 particles to BS-C-1 cells 
pre-treated for lh at 37°C with 0 (■), 300uM CCX (□), 
600uM CCX ( ▲ ) or 9 00uM CCX (A ).
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high as 900uM. It is therefore unlikely that inhibition of 
adsorption of virus to pre-treated cells would play a 
significant role in limiting the spread of infection at 
least in vitro.
3.6.3. THE EFFECT OF INCREASING CONCENTRATIONS OF CCX ON 
PARTICLE NUMBERS, INFECTIOUS VIRUS YIELDS (P.F.CJ.) AND 
PARTICLE/P.F.U. RATIOS
Virus particle counts were performed by electron 
microscopy (2.2.6.1.) on total virus yields from 
dose-response experiments. Table 3 8 shows the results 
obtained from two independant experiments. The data show 
that both particle numbers and infectious virus yields were 
progressively reduced with increasing concentrations of CCX. 
However, at 10 and 50uM CCX, the reduction in infectivity 
was consistently greater than the reduction in particle 
numbers, resulting in elevated particle/p.f.u. ratios. 
Surprisingly, at 150 and 300uM CCX, the particle/p.f.u. 
ratios were similar to those produced under drug free 
conditions. This suggests that at low CCX concentrations 
there was some block in virus assembly accompanied by a 
lowering in the quality of at least some of the virus which 
was produced. At higher CCX concentrations, the reduction in 
infectivity and particle numbers were similar, with progeny 
virus produced in the presence of CCX being as infectious as 
virus produced from drug free infected cells. This suggests 
that the lower quality particles could no longer be 
assembled. Therefore, the anti-Reovirus-3 effect of CCX was 
essentially of two types: a) reduction in the number of 
particles produced b) production of low quality particles 
only at low (up to 50uM CCX) concentrations of CCX.
3.6.4. DIRECT INACTIVATION OF REOVIRUS-3 PARTICLES
To determine whether CCX directly inactivated Reovirus 
particles, suspensions of virus were incubated with either 
mock drug or 300uM CCX (2.2.5.7) at 4°C or 37°C for 24h and 
infectious yields titrated before and after drug addition. 
The experiment was performed twice and the results are shown 
in Table 39. There was no significant reduction in virus 
titre in either experiment suggesting that direct 
inactivation of particles does not play a major part in the
CCX
(uM)
PARTICLE
NUMBER
P.F.U. PARTICLE/P.F.U. 
RATIO
0
10
7.15*10
8
3 .4*10 210
10
10
6.44*10
8
1.4*10 495
(1) 50
10
2.57*10
7
1.8*10 1,427
9 6
150 1.43*10 8.0*10 178
9 6
300 1.43*10 6.0*10 238
0
10
5.6*10
8
2.23*10 251
10
10
2.9*10
7
8.0*10 362.5
(2) 50
10
1.4*10
7
1.3*10 1,076
150
9
2.8*10
6
9.0*10 311
300
9
1.4*10
6
7.0*10 200
Table 38
The effect of increasing concentrations of CCX on Reovirus 
particle numbers, infectious virus yields (p.f.u.) and 
particle/p.f.u. ratios.
1 and 2 represent data from 2 independent experiments.
TIME(hr) TEMP ( C) DRUG TITRE «AGE REDUCTION
0 - ORIGINAL
STOCK
6
4.1*10
24 4 MOCK
DRUG
6
3.7*10 100
21.7
24 4 300 UM
CCX
6
2.9*10 78.3
24 37 MOCK
DRUG
6
5.8*10 100
0
24 37 300 uM 
CCX
6
5.8*10 100
TIME(hr) TEMP ( C) DRUG TITRE «AGE REDUCTION
0 - ORIGINAL
STOCK
6
6.0*10
24 4 MOCK
DRUG
6
5.2*10 100
15.4
24 4 300 uM 
CCX
6
4.4*10 84.6
24 37 MOCK
DRUG
6
5.7*10 100
7.9
24 37 300 uM
CCX
6
5.25*10 92.1
Table 39
Direct inactivation of Reovirus particles by CCX. 
a) and b) represent data from 2 independent experiments
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anti-Reovirus-3 action of CCX.
3.6.5. THE EFFECT OF CCX ON POLYPEPTIDE SYNTHESIS IN 
MOCK-INFECTED AND REOVIRUS-3 INFECTED BS-C-1 CELLS
MOCK-INFECTED CELL EXTRACTS (Fig 55a)
Host cell protein synthesis was not affected by CCX 
treatment in this experiment. In addition, no stress 
response was induced in CCX treated mock-infected BS-C-1 
cells.
REOVIRUS-3 INFECTED CELL EXTRACTS (Fig 55b)
Treatment with increasing concentrations of CCX
resulted in a progressive decrease in all identified viral
bands. Several low m.wt. bands appeared in virus-infected
but not mock-infected tracks; these were designated UK^,
UK0, UK , UK. and UKC. Protein bands UK,, UK„ and UK„2 3 4 5 1 2 3
increased with increasing CCX, levels of band UK, remained
4
constant and levels of band UK^ decreased.
3.6.6. THE EFFECT OF CCX ON THE PHOSPHORYLATION OF 
POLYPEPTIDES INDUCED IN REOVIRUS-3 INFECTED BS-C-1 CELLS
Dargan and Subak-Sharpe (19 86a and b), reported that 
phosphorylation was not significantly affected in either 
mock-infected or HSV-1 and HSV-2 infected Flow 2002 and 
BHK-21 cells. In CCX treated, Reovirus-3 infected BS-C-1 
cells, there was no demonstrable reduction in the 
phosphorylation of protein bands. If anything, 
phosphorylation of some bands actually appeared to be 
slightly increased.
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Figure 55
SDS PAGE profile on a 10% gel of the infected cell 
polypeptides induced in BS-C-1 cells treated with 0 ,50,
100, 200 or 3 00uM CCX (lanes 1-5), from l-24h p.i.
Cells were either mock-infected (a) or infected with 
Reovirus-3 (b) at m.o.i. 10 p.f.u./cell.
35Smet was added from l-24h p.i. and equal volumes of sample
were loaded onto each track.
The positions and m.wt. of known Reovirus-3 coded proteins 
are indicated on the left :
1 (155K), 2 (140K), 3 (135K);
1 (80K), NS (75K), lc (72K), 2 (70K);
1 (42K), 2 (38K), NS (36K), 3 (34K);
The positions of 5 low m.wt. bands of unknown origin present 
in Reovirus-3 infected but not mock-infected cell extracts 
are also indicated (UK1, UK2, UK3, UK4 and UK5).
M
l
Figure 56
SDS PAGE phosphorylated polypeptide profile on a 10% gel 
from BS-C-1 cells treated with 0, 50, 100, 200 or 300uM CCX 
(lanes 2-6) .
Cells were either mock-infected (a) or infected with
Reovirus-3 at m.o.i of 10 p.f.u./cell.
32P-orthphosphate was added from 1-24h p.i. in parallel with
35Smet (shown in Figure 55).
35Lane 1 shows Smet-labelled polypeptides induced in 
mock-infected (a) and Reovirus-3 infected (b) drug-free 
BS-C-1 cells.
Equal volumes of sample were loaded onto each track.
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3.7. THE EFFECT OF CCX ON THE REPLICATION OF ADENOVIRUS-5; 
REPRESENTING THE CLASS 2 RESPONSE
3.7.1. ANALYSIS OF ADENOVIRUS-5 PRODUCED IN CCX TREATED 
BS-C-1 CELLS
THERMOSTABILITY OF ADENOVIRUS-5 PROGENY VIRUS MADE IN HELA 
CELLS TREATED WITH CCX
The thermostability of infectious virus made in cells 
treated with 0, 50, 150 or 300uM CCX was studied to assess 
the quality of Adenovirus-5 progeny synthesised during drug 
treatment. Virus was incubated for various times at 42°C and 
then immediately titrated. The curves show that there was no 
significant difference in the thermostability of Adenovirus 
produced in CCX treated and untreated HeLa cells (Fig 57). 
In all cases, progeny virus was sensitive to high 
temperature, reducing infectivity by greater than a log. 
Therefore, the quality of virus produced in the presence and 
absence of CCX, was approximately the same.
SUSCEPT1BIITY OF ADENOVIRUS-5 PRODUCED IN HELA CELLS TO 
REPEATED TREATMENT WITH CCX (DOSE-RESPONSE CURVES)
Like Reovirus-3, Adenovirus-5 was very sensitive to 
low concentrations of CCX, the dose-response curve reaching 
a plateau between 100 and 200uM CCX. To determine if the 
plateau resulted from the selection of a sub-population of 
resistant virus, virus produced in CCX treated and drug free 
cells was used in repeat dose-response experiments. The 
resulting curves (Fig 58), indicate that this was not the 
case with virus produced in CCX treated cells responding to 
further CCX treatment in the same way as virus produced in 
drug free cells.
3.7.2. ADSORPTION OF ADENOVIRUS TO PRE-TREATED HELA CELLS 
Adsorption experiments were performed with
Adenovirus-5 and HeLa cells (as described in 2.2.5.6.) The 
adsorption curves obtained (Fig 59) are very similar and 
clearly show that even at 9 00uM CCX, Adenovirus was still 
able to bind to cell receptors. It is therefore unlikely 
that inhibition of adsorption of virus to pre-treated cells 
would play any part in limiting the spread of Adenovirus-5 
infection at least in vitro.
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Figure 57
Thermostability of Adenovirus-5 progeny virus made in HeLa 
cells treated with CCX : 0 (■), 50uM CCX (□), 150uM CCX 
( A ) , 30 0uM CCX ( A ) .
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Figure 58
The effect of increasing concentrations of CCX on infectious
Adenovirus yields from HeLa cells infected with
( ■  ) virus produced in drug-free cells
(□) virus produced in cells maintained in 50uM CCX
( ▲ ) virus produced in cells maintained in 150uM CCX
(A ) virus produced in cells maintained in 300uM CCX
Dose-response curves have been transposed down by 0.5 log 
( □  ), 1 log ( ▲ ), or 1.5 log ( A ) to allow clear 
presentation.
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Figure 59
Adsorption of Adenovirus-5 to HeLa cells pre-treated with 
(■ ), 300uM CCX ( □  ), 6OOuM CCX ( ▲ ) or 900uM CCX ( A ).
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3.7.3. THE EFFECT OF INCREASING CONCENTRATIONS OF CCX ON 
PARTICLE NUMBERS, INFECTIOUS VIRUS YIELDS (P.F.U.) AND 
PARTICLE/P.F.U. RATIOS.
Virus particle counts were performed by electron 
microscopy (2.2.6.1.) on total virus yields from 
dose-response experiments (Table 40). The data show that 
treatment with CCX had no effect on particle/p.f.u. ratios, 
with particle numbers and Adenovirus-5 infectivity affected 
to the same extent at each CCX concentration. Therefore, CCX 
acts by blocking the assembly of Adenovirus-5 at relatively 
low concentrations, with no further effect at higher 
concentrations of CCX.
3.7.4. DIRECT INACTIVATION OF ADENOVIRUS-5 PARTICLES
Suspensions of Adenovirus-5 particles were incubated
with either mock drug or 300uM CCX (2.2.5.7.) at 4°C or 
37°Cfor 48h, and infectious yields titrated before and after 
drug addition.
This experiment was performed twice and the results 
are shown in Table 41. The data show that CCX was able to 
directly inactivate virus particles, with the extent of the 
effect varying between 10% and 50% . This reduction in 
infectivity however was not great enough to account for the 
total anti-Adenovirus-5 effect of CCX.
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Table 40
The effect of increasing concentrations of CCX on 
Adenovirus-5 particle numbers, infectious virus yields 
(p.f.u.) and particle/p.f.u. ratios.
T1ME(hr) TEMP ( C) DRUG TITRE %AGE REDUCTION
0 - ORIGINAL
STOCK
7
1.6*10
48 4 MOCK
DRUG
7
1.38*10 100
51.5
48 4 300 uM 
CCX
6
6.7*10 48.5
48 37 MOCK
DRUG
6
5.8*10 100
10.4
48 37 300 UM 
CCX
6
5.2*10 89.6
TIME(hr) TEMP ( C) DRUG TITRE «AGE REDUCTION
0 - ORIGINAL
STOCK
7
1.9*10
48 4 MOCK
DRUG
7
1.4*10 100
35.8
48 4 300 uM 
CCX
6
9.0*10 64.2
48 37 MOCK
DRUG
6
4.7*10 100
53.2
48 37 300 uM 
CCX
6
2.2*10 46.8
Table 41
Direct inactivation of Adenovirus-5 particles by CCX. 
a) and b) represent data from 2 independent experiments.
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3.7.5. THE EFFECT OF CCX ON POLYPEPTIDES INDUCED IN 
MOCK-INFECTED AND ADENOVIRUS-5 INFECTED HELA CELLS FROM 
8-48h P.I.
MOCK-INFECTED CELL EXTRACTS
There was no significant effect on host cell protein 
synthesis with 10, 20, 30, 40 or 50uM CCX (Fig 60a, lanes 
2-6). Treatment with 100, 200 or 300uM CCX resulted in a 
reduction in most cellular bands, accompanied by the 
induction of proteins previously identified as stress 
proteins; grp 94 and 78 and also a lower m.wt. band (Fig 
60a, lanes 7-9).
ADENOVIRUS-INFECTED CELL EXTRACTS
Treatment with increasing concentrations of CCX, 
resulted in a progressive reduction in most viral bands, 
with the exception of the low m.wt. bands 14K and 13K, which 
were actually increased in the presence of CCX (the increase 
in band 13K, becoming marked with 100, 200 and 300uM CCX). 
Levels of the fibre band (62K) and the non-structural DNA 
binding protein band (72K), were markedly reduced at 30 and 
20 uM CCX respectively. In addition, at concentrations of 
20uM CCX and above the 72K band becomes less diffuse and 
separates into 2 distinct bands, becoming barely detectable 
with 100, 200 or 300uM CCX (Fig 60b, lanes 3-9). This
protein is normally phosphorylated, a variety of 
phosphorylated forms existing in infected cells. The 
appearance of distinct bands with CCX, may indicate some 
effect on phosphorylation. It is interesting that the 
structural protein band, m.wt. 66K, which is also 
phosphorylated, also becomes less diffuse with increasing 
concentrations, separating into 2 distinct bands with 100, 
200 or 300uM CCX (Fig 60b, lanes 3-9).

Figure 60
SDS PAGE profile obtained on a 12.5% gel of the infected 
cell polypeptides induced in HeLa cells treated with 0, 10, 
20, 30, 40, 50, 100, 200 or 300uM CCX (lanes 1-9)
Cells were either mock-infected (a) or infected with
Adenovirus-5 at 100 p.f.u./cell (b).
35Smet was added from 8-48h p.i.
Equal volumes of sample were loaded onto each track.
The positions and m.wt. of known Adenovirus-coded proteins 
are indicated.
1 4 9
4. DISCUSSION
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4.1. t h e  EFFECT OF CICLOXOLONE SODIUM (CCX) ON A RANGE OF
CELL LINES
Prior to the investigation of the antiviral action of 
CCX, it was necessary to identify cell lines resistant to 
the drug and permissive for virus growth, to allow 
separation of antiviral and cytotoxic effects. Dargan and 
Subak-Sharpe (19 85) had previously reported that the three 
cell lines they examined (each from a different species), 
differed in their sensitivity to CCX : Flow 2002 (human) 
cells were resistant, Vero (monkey) cells were sensitive, 
while BHK-21 (rodent) cells displayed intermediate
sensitivity. Therefore twenty cell lines were screened for
sensitivity to CCX treatment, not only to identify cell 
lines resistant to the drug and thus suitable hosts for 
virus CCX dose-response experiments, but also to establish 
how different cell lines tolerated CCX and to check whether 
any consistent pattern emerged i.e. would all human cells be
more resistant than all monkey and rodent cells ?
The survey revealed that the cell lines differed in 
their tolerance to the drug and could be designated as 
Resistant, Intermediate or Sensitive on the basis of cell 
viability counts. It should be noted that the viability of 
cells in the Resistant class was not significantly affected, 
but the replication of these cells was inhibited at high CCX 
concentrations (200uM and 300uM CCX). However, this should 
not contribute to any antiviral effect as all virus CCX 
dose-response experiments were performed in confluent 
monolayers. Most importantly, the effect of CCX on the cell 
lines used in the virus dose-response experiments was shown 
to be fully reversible.
Cell lines did not clearly separate into classes 
depending upon their species of origin. For example the 
Resistant class contains human, rodent, monkey and canine 
cells (TableZl). However all human cell lines except one, 
fell into the Resistant or Intermediate class, while all of 
the rodent cells fell into the Intermediate or Sensitive 
class, with the exception of RK-13 cells which proved 
resistant. It is interesting that the sensitive human cell 
line, Fg 293, is an artificially transformed cell line 
(transformed with Adenovirus Ela and Elb), and that other 
artificially transformed cell lines also fall into this
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group i.e. Re*, Re99 and HOOD cells. However, Hela cells 
which are naturally transformed with human papillomavirus 
and have also been grown extensively in culture belongs to 
the Resistant class. It may be that differences between 
artificially transformed and naturally transformed cell 
lines contribute to their sensitivity / tolerance to CCX. 
This inference could be tested indirectly by screening a 
wider range of naturally and artificially transformed cell 
lines. If the hypothesis is correct, then it should be 
possible to change the phenotype of a Resistant cell line to 
a Sensitive cell line by transforming the cell line in 
vitro.
Why cell lines should differ in their tolerance to CCX 
is not yet clear. There are however several possible 
explanations. Dargan and Subak-Sharpe (19 86a and b), 
reported that CCX affected glycosylation in both 
HSV-infected and mock-infected Flow 2002 and BHK-21 cells. 
It may be that some cells are able to tolerate inhibition of 
glycosylation better than others. This could be tested by 
performing comparative cytotoxicity studies with CCX and 
specific inhibitors of glycosylation e.g. tunicamycin which 
blocks addition of N-linked core sugar in the ER; 
deoxymannojirimycin (DMJ), which specifically inhibits the 
cleavage of 1,2 mannose residues by inhibiting mannosidase 
1 located in the cis stack of the Golgi apparatus and 
swainsonine which inhibits - mannosidase 11, located in the 
medial stack of the Golgi (Montefron, Robinson and Mitchell,
1987).
The triterpenoid compounds are all known to have 
mineralcorticoid activity (Epstein et a l ., 1977; Baron and 
Green, 1986; Stewart et a l ., 1987). In humans this presents 
as hypokalemia (loss of serum potassium) and serum sodium 
retention (pseudoaldostereoism). At the cellular level, the 
related compound carbenoxolone seems to stimulate the 
activity of the Na+ K+ ATP"ase (i.e.the sodium pump), thus 
pumping K+ into and Na+ out of the cell. Cells may differ in 
their tolerance to changes in ion levels, or indeed resist 
gross changes in ion levels by having fewer sodium pumps, 
less active sodium pumps or altered sodium pumps with less 
affinity for triterpenoid compounds. To determine if there 
is any correlation with the mineralcorticoid activity and
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CCX tolerance, intracellular ion levels in drug-free and
8 6drug-treated cells could be measured using rubidium (a
2 2model for potassium) and sodium (Baron and Green, 1986) 
and directly compared with cell viability. Cicloxolone 
treatment has been observed to cause cells to shrink. This 
may be a consequence of the effect of CCX on the sodium pump 
thought to regulate cell volume.
CCX treatment was shown to induce a stress response in 
cell lines belonging to the Resistant class (Hela, Flow 2002 
and BS-C-1), the Intermediate class (BHK-21) and the 
Sensitive class (Fg 293),although the number, m.wt. and 
intensity of stress protein bands differed between cell 
lines. The significance of this is not clear and may simply 
be a consequence of differential cell cycle inducement (all 
samples were harvested after 18h treatment with CCX). The 
CCX-induced cellular stress response is unusual in that both 
recognised classes of stress protein are induced i.e. heat 
shock proteins (hsp) and glucose related proteins (grp). The 
latter are probably induced by the effect of CCX on 
glycosylation as other glycosylation inhibitors also induce 
this set of proteins. However, Kozutumi et a l . (1988) have 
shown that malfolding of proteins, rather than inhibition of 
glycosylation per se, induces the synthesis of grps. CCX is 
known to have a high affinity for proteins and may cause 
malfolding and so trigger the synthesis of grps. The 
mineralcorticoid activity of CCX, may also contribute to the 
inducement of the stress response as other compounds which 
disrupt ion fluxes such as ouabain which inhibits the sodium 
pump, also induces a stress response.
Induction of stress proteins involves a vigorous 
activation of transcription, as well as selective 
translation of the stress protein mRNA.This is accompanied 
by a reduction in the transcription and translation of other 
cellular mRNAs.(Ashburner and Bonner,1979? Schlesinger et 
al., 1982). It seems likely therefore that the stress
response contributes to the observed inhibition of cell 
growth mediated by CCX. The functions of stress proteins 
have long been a matter for speculation; it is widely 
assumed that these proteins protect cells from the effects 
of stress, although the mechanisms are not entirely clear. 
Sorger and Pelham (19 87), have suggested that all of the
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major stress proteins, grp 94, grp 78, hsp 90, and hsp 70 
have essentially the same function, which is to solubilise 
aggregates of malfolded or denatured proteins, but do so at 
different locations within the cell. All of the major stress 
proteins are present in the lumen of the ER and it is 
possible that all may function within that particular 
enviroment. However, in addition hsp 70 is found within the 
nucleus (Sorger and Pelham, 1987), while grp 9 4 has been 
localised within the Golgi apparatus (Welch et a l ., 1983) 
and hsp 9 0 is also abundant within the cytoplasm (Sorger and 
Pelham, 1987). Disruptive vacuolation of CCX-treated cells 
has been observed, and several lines of evidence suggest 
that the vacuoles are derived from the Golgi apparatus. It 
is tempting to speculate that the low levels of grp 9 4 
observed is related to this vacuolation.
The fact that different classes of cell line induce 
the stress response at different concentrations e.g. Fg 293 
(Sensitive) at lOOuM CCX, BHK-21 (Intermediate) at 200uM CCX 
and BS-C-1 (Resistant) at 300uM CCX may simply reflect 
differences in the efficiency of the uptake of the drug. 
Sensitive cell lines may take up the drug more efficiently 
and so become susceptible at lower concentrations. Another 
possible explanation is that sensitive cell lines do not 
have the the capacity to metabolize or store high 
concentrations of CCX.
In summary, cell lines clearly exhibit differential 
sensitivity to CCX. The drug affects glycosylation, exhibits 
mineralcorticoid activity and can induce a stress response 
in all classes of cell line. Whether these contribute to the 
cytotoxic effect of CCX is not yet clear, although it seems 
likely that they play some role. Dargan and Subak-Sharpe 
(1985, 1986a and b), from their investigations of
CCX-treated HSV-infected and mock-infected Flow 2002 and 
BHK-21 cells have postulated that the drug acts by 
disturbing the normal functioning of host cell membranes. 
Elucidation of the anti-cellular effect of CCX would then 
also provide valuable information regarding the antiviral 
effect of the drug.
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4.2. THE EFFECT OF CICLOXOLONE SODIUM (CCX) ON A RANGE OF
VIRUSES
4.2.1. THE ANTIVIRAL ACTIVITY SPECTRUM OF CCX
A range of viruses was examined for their sensitivity 
to CCX, and placed into three general groupings depending 
upon their response (Table 23).This spectrum of CCX 
sensitivities cannot be correlated with greater sensitivty 
of DNA viruses compared to RNA viruses; nor double-stranded 
compared to single-stranded genomes; nor positive compared 
to negative-stranded RNA genomes; or segmented compared to 
non-segmented genomes.
Dargan and Subak-Sharpe (19 88), have shown that CCX 
reduced the overall percentage of enveloped HSV particles in 
the yield from drug-treated cells. Of the viruses now 
studied, only Polio-1, Reovirus-3 and Adenovirus-5 are 
non-enveloped. There was no evidence to suggest that the 
growth of enveloped viruses per se was more affected by CCX 
than that of non-enveloped viruses. Moreover the 
dose-response curves obtained both with the enveloped 
(Bunyaviruses) and non-enveloped (Reovirus, Adenovirus and 
Polivirus) viruses reach well defined plateaus. This could 
be because virus stocks are composed of genetically 
sensitive and resistant virus, with the plateau reflecting 
the surviving fraction. However, this was shown not to be 
the case for both Reovirus-3 and Adenovirus-5. 
Alternatively, CCX may affect a host or virus-specified 
function which enhances but is not essential for virus 
infectivity. Until CCX resistant mutants are isolated the 
latter explanation is favoured.
CorrobarCUtive evidence that the antiviral activity of 
CCX is linked to its effects on host cells is supplied by 
the diastereoisomer study, where the antiviral activity of 
the compounds paralleled their cytotoxic activity (690 < CCX 
<688). This is in agreement with the proposed mode of action 
of CCX i.e. by disturbance of the normal functions of host 
cell membranes (Dargan and Subak-Sharpe 1985, 1986a and b) . 
Investigation of the anti-HSV effect of CCX has indicated 
that the mechanism of action is complex and that with HSV at 
least, the virus replication cycle provides multiple targets 
for CCX inhibition (Dargan and Subak-Sharpe,1986a and b, 
1988). Clearly irrespective of whether viruses are enveloped
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or not, to varying extents,they must utilise during their 
replication cycle, either pre- existing or virally modified 
membrane systems of the cell. The effect of CCX on the 
replication of viruses from each group was investigated, 
with the purpose of more precisely pinpointing the 
particular antiviral targets that block production of 
infectious virus yield and identifying the mechanism of 
action in these very diverse cases.
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4.2.2. THE EFFECT OF CCX ON THE REPLICATION OF VSV (INDIANA)
: REPRESENTING THE CLASS 1 RESPONSE
CCX exhibited potent activity against the rhabdovirus, 
vesicular stomatitis virus (VSV) (Indiana strain), 
progressively reducing infectious virus yields with 
increasing concentrations of CCX, 3 0 0 u M  achieving a 10,000 
fold reduction. VSV was the most extensively studied virus 
in this survey, as apart from the herpesviruses (CCX-treated 
HSV-1 and HSV-2 infected Flow 2002 and BHK-21 cells, were 
investigated by Dargan and Subak-Sharpe, 1985, 1986a and b, 
1988), this was most drastically affected by the drug. 
Growth curves performed in the absence and presence of CCX, 
revealed that CCX inhibited VSV replication. That the 
reduction in infectious yields was not due to delay in virus 
growth was established, as inhibition was sustained 
throughout a 3 6h period.
The effect of increasing concentrations of CCX on 
infectious virus yields (p.f.u.), particle numbers and 
particle/p.f.u. ratios was determined.The results indicated 
that the anti-VSV effect of CCX, operates both by lowering 
the quality of progeny virions and through strong inhibition 
of virus particle production. This is in contrast to the 
anti- HSV effect of CCX, where there is only a slight 
reduction in particle numbers, the predominant effect being 
the lowering of potential infectivity of progeny virus 
particles (Dargan and Subak-Sharpe, 1985). The dramatic 
alteration in the particle/p.f.u. ratio in HSV yields from 
CCX treated cells, was deduced to be a consequence of 
abnormal virus assembly as evidenced by the polypeptide 
composition of virus produced in the presence of CCX: some 
proteins are under-represented and others are 
over-represented. (Dargan and Subak-Sharpe, 1986a and b) . 
This was not the case for VSV, where the virion polypeptide 
composition appeared to be unaffected by CCX. However, there 
was an increase in the mobility of the G band, indicative of 
an effect on glycosylation processing, possibly including 
sialic acid addition. Schloemer and Wagner (19 75), 
demonstrated that removal of sialic acid by neuraminidase 
inhibits adsorption of VSV particles to L cells (Schloemer 
and Wagner, 1975). CCX however is able to inactivate VSV 
particles directly causing up to a 10 fold reduction in
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infectivity, which also furnishes an explanation for the 
observed rise in particle/p.f.u. ratio. CCX treatment 
directly reduces HSV particle infectivity, but this only 
makes a minor contribution to the much greater rise in
particle/p.f.u. ratio.
How direct inactivation is achieved is not clear. CCX 
is a highly lipophilic compound and has strong affinity for 
proteins (Symons and Parke, 1980). The drug may bind to 
virus particles by hydrophobic interaction with the virus 
envelope membrane and/or by interaction with the
glycoprotein protruding from the virus envelope. Binding in 
turn may inhibit adsorption to cellular receptors. This 
however has not been investigated and must remain 
speculation.
To determine how CCX reduces the production of VSV
particles, several stages within the life cycle of the virus 
were investigated for susceptibility to CCX. Drug addition 
experiments, where CCX was added at various times
post-adsorption, revealed that CCX did not block any 
specific stage in the VSV life cycle. CCX had a progressive 
effect operating throughout the life cycle, with greater 
yield reductions achieved, the earlier the drug was added. 
This is in agreement with the progressive effect of CCX on 
HSV-1/2 replication (Dargan and Subak-Sharpe, 1985). VSV 
enters cells mainly by receptor-mediated endocytosis 
(Schlegel et a l ., 1982), viral nucleocapsid being released 
into the cell cytoplasm following fusion of viral and 
endosomal membranes. In all CCX dose-response experiments, 
CCX was added after virus absorption had been allowed to 
occur (i.e. lh p.i.). Therefore, although CCX may be capable 
of affecting virus absorption, inhibition of this step can 
play no role in the reduction of infectious virus yields 
achieved in these one step growth curve experiments.
The first synthetic event in the infectious cycle of 
any negative strand RNA virus, including VSV, is mRNA 
synthesis. RNA synthesis was shown to be affected in 
CCX-treated mock-infected and VSV-infected BS-C-1 cells. 
However, there was a differential effect on VSV 
transcription: primary transcription was not thought to be
affected (as protein synthesis from l-8h p.i. was not 
significantly affected by CCX treatment). In contrast, there
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was a progressive reduction with increasing concentrations 
of CCX, in levels of all secondary VSV transcripts. It is 
not known how CCX affects transcription. However, there are 
several possible explanations for the reduction in levels of 
both cellular cytoplasmic RNA VSV secondary transcripts, 
based on other known actions of CCX (Table 42). Each of 
these will be considered in turn and should not be regarded 
as mutually exclusive.
Dargan and Subak-Sharpe (19 86a and b),have previously 
reported that in CCX treated HSV-1/2 -infected or 
mock-infected Flow 2002 and BHK-21 cells, the 
nuclear/cytoplasmic distribution of certain proteins is 
disturbed. This disturbance may be due to the alteration of 
the nuclear membrane by CCX, thereby affecting the transport 
of proteins between the nucleus and the cytoplasm. Reduced 
levels of cellular cytoplasmic RNA, may therefore be a 
consequence of impaired transport of RNA, from the nucleus 
to the cytoplasm. This however cannot affect levels of VSV 
transcripts, as VSV replication is completely cytoplasmic.
CCX induces a stress response in both mock-infected 
and VSV-infected BS-C-1 cells. Induction of stress proteins 
involves a vigorous activation of stress protein mRNA 
transcription as well as their selective translation, 
accompanied by the inhibition of the transcription and 
translation of other mRNAs (Ashburner and Bonner, 19 79; 
Schlesinger et a l ., 1982). It is likely that this at least 
contributes to the reduction in cellular cytoplasmic RNA. 
However, it can play no role in reducing the levels of VSV 
secondary transcripts, as labelling of these transcripts was 
performed in the presence of actinomycin D (Act. D) which 
abolishes the cellular stress response.
The phosphorylation of VSV NS protein has been shown 
to regulate transcription in vitro (Kingsford and Emerson, 
1980; Hsu, Morgan and Kinsbury, 1982). The xanthate 
compound, D609, inhibits VSV secondary but not primary 
transcription, by inhibiting the phosphorylation of VSV NS 
protein (Muller-Decker, Amtmann and Sauer, 1977). However 
CCX has no effect on phosphorylation in VSV-infected or 
mock-infected BS-C-1 cells. Since phosphorylation is not 
inhibited by CCX, this cannot contribute to reduced cellular 
cytoplasmic or VSV secondary transcripts (this also confirms
2
O
CO
.-3 X
h  x 00
>  < E-t
h  a 2
•J 2 t-t
O 2
Q O o
W U m
CJ 00 z
n <
Q > 2
U COE-t
2  >
M 1 u
O 1 l-t
2 1 X
SO 1 00
3 1 2  <a 1 0  3 b
u 1 04 O
00 I 2 0  00
2 • OfrtEnE-to 1 ih X  2  2o 1 H O O h  
• «h ^.04 2
u 1 CQ OS 00 u>3 I *H4<2 CO
CQ 1 X M < 2
tH 1 2 * 3  <2 2
00 1 IH CJ E-t <2
CO 1 Z3 E-to 1 2
04 1
2
o
z  
2  O O n 
tH E-t 
H  2 
t-t ih 
CQ 2  
►H U  
X  CO
cc
H
CO
OU.CO 
2  O <  
tn f
H x a  
O E-t h  
W H K 
2 > CJ 
2  ih CO 
<  E-t 2  O < 
< 2 
E-
2
O X  «<
Q t—4 M 2
1 U Eh -h- 3 2 2
\  > Z 2 2  2  2
+  J o t—1 O  X  2  2
o t-l 2 2 IH O  O
'— 2  > e-t o b« 0-> Eh 2  O PQ
2  0  2 04 O CO IH O  CO tJ
O t-t t-t z < z CQ U  »3 CQ
IH Z 2 o 2  2 < H 2 m w <
E-t O COO t—l 2  O 2 X  O  < >  EH< H « CO E-t t-t Eh 2  ih  Eh W CO
>  E-t O z < CO EH ih £h 2  t3 2
t—t t-t E-t < > © bl t< CO CO 4< tH O
E-t CQ O 2 t-t a a > co w x Eh U 2  aU H < E-t U H U U K
<  X  2 O 2  EH w  <  tJ U  bl CQ O O
2 2 < -  o  O Eh 2  2 O iH Z D - v
t-t l t—i 2 M < O O X H Q c Q Q
2 a 2  bl  O Q O 2 W Zt O t Q U X  Eh 2 3
W 
CO 
CO Z  
CO O 
W  04 
2  CO 
E-t H 
CO DC
U
2
IH
a
2
►Ho
2 Eh
CO
E- X W
U CJX
W CJX
2 N
IH2 2
a o CO
Table 42
Inhibition of transcription by CCX: proposed mode of action.
P \ Possible 
N P ' Net PoscWie
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that the observed reduction in transcripts is real, and not 
a consequence of reduced uptake of radioactive phosphate).
Carbenoxolone can bind to various enzymes causing 
either activation or inhibition (Roberts and Taylor, 1980). 
Given that cicloxolone and carbenoxolone are closely 
related, it seems likely that CCX can similarly inhibit or 
activate enzymes. One of the enzymes inhibited by 
carbenoxolone, is gastric 15-OH dehydrogenase. Pre-treatment 
of cells with indomethacin, which also alters the 
biosynthesis of prostaglandins, renders cells reversibly 
non-permissive for productive infections of VSV, at the 
level of viral RNA and protein synthesis (Mukherjee and 
Simpson, 1987). These authors suggested that indomethacin 
may act by modifying a cellular factor required for the 
transcriptase activity of the VSV nucleocapsids. As both CCX 
and indomethacin alter the biosynthesis of prostaglandins, 
CCX may also inhibit transcription in this way. The effect 
of CCX and indomethacin on prostaglandin biosynthesis may be 
directly responsible for the modification of this cellular 
membrane-associated factor, as prostaglandins are 
continuously synthesised from membrane phospholipids. 
However, while indomethacin inhibited primary VSV 
transcription, CCX inhibited only secondary transcription. 
This may be explained by the fact that cells were 
pre-treated and maintained in indomethacin, while CCX was 
added only after virus absorption had occurred. Therefore 
CCX uptake at the time of primary transcription may not be 
sufficient to saturate target molecules. If the mode of 
action of these compounds is indeed similar, then 
pre-treatment of cells with CCX should result in the 
inhibition of primary transcription.
Of course, other possibilities exist, which include 
the activation of RN"ases, resulting in degradation of RNA, 
activation of proteases resulting in the degradation of the 
transcriptase complex or direct binding to the transcriptase 
complex itself, thereby modifying or inhibiting its function 
to produce reduced amounts of RNA or unstable RNA. These 
general mechanisms involving binding to enymes are equally 
applicable to viral or cellular transcription.
In conclusion, although there are several possible 
explanations for the reduction in cellular cytoplasmic RNA,
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and VSV secondary transcription, until further 
investigations of the effect of CCX on transcription are 
performed, the various possibilities outlined here must 
remain speculation.
Dargan and Subak-Sharpe (1986a and b), reported that 
polypeptide synthesis and post-translational modifications, 
particularly glycosylation and sulphation were all affected 
in CCX-treated mock-infected and HSV-1/2 -infected Flow 2002 
and BHK-21 cells. In my experiments protein synthesis in 
CCX-treated mock-infected BS-C-1 cells was also inhibited 
although the extent of the inhibition varied between 
experiments. It is notable that inducement of a stress 
response correlated with the degree of inhibition of protein 
synthesis; the stress response being induced strongly in 
cells where protein synthesis inhibition was marked, and not 
detectably induced when protein synthesis was only slightly 
affected. This would seem to indicate the involvement of the 
stress response in the inhibition of protein synthesis 
mediated by CCX. Howver, this cannot furnish the entire 
explanation, as protein synthesis is inhibited with 
increasing concentrations of CCX in the presence of 
Actinomycin D, which inhibits the stress response. As CCX is 
a highly lipophilic compound with great affinity for 
membranes (Symons and Parke, 1980), protein synthesis may 
also be inhibited by a direct effect on the ER.
CCX also affected protein synthesis in VSV infected 
cells. However the result was unexpected, with some bands 
decreasing with increasing CCX (L, N and NS), while protein 
bands G, M and (JK^  increased with increasing CCX, despite 
reduced levels of transcript. There are several possible 
explanations for this result including differential 
secretion of proteins (as CCX affects the PM, causing it to 
become progressively leaky with increasing CCX 
concentrations; Symons and Parke, 1980), differential 
stability of mRNAs and/or differential translatibility of 
mRNAs. However investigations of the effect of CCX on 
glycosylation in CCX-treated VSV-infected BS-C-1 cells 
provided the most likely explanation.
Dargan and Subak-Sharpe (19 86a and b), showed that 
glycosylation in both mock— infected and HSV-1 and HSV—2 
infected BHK-21 cells, was inhibited by CCX, as evidenced by
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the reduction in mannose incorporation with increasing
concentrations of CCX. It seemed likely that glycosylation
would also be affected in CCX-treated VSV-infected and
mock-infected BS-C-1 cells. Comparative studies were
performed using compounds known to disrupt this process :
tunicamycin (Tzack and Lampen, 1975), which blocks addition
of the core sugar occurring in the ER, and monensin (Ledger
and Tanzer, 1984; Boss et al ., 1984), which disrupts the
Golgi apparatus where sugar processing occurs.
3 5
Smet-labelled polypeptide profiles obtained from 
VSV-infected BS-C-1 cells treated with CCX, monensin and
tunicamycin revealed that 1) CCX did not affect
glycosylation as dramatically as tunicamycin as evidenced by 
the relative mobility shifts; there was a marked downward 
shift in the G band with tunicamycin, concomitant with the 
significant change in m.wt., due to the absence of the sugar 
moiety. 2) monensin and CCX were similar in that both these 
tracks contained elevated levels of G and M. In addition 
both caused only a slight shift in the mobility of the G 
band. As expected, tunicamycin completely blocked 
glucosamine incorporation. In contrast, monensin had no 
effect, while CCX only had a slight effect at 300uM CCX. 
Glucosamine is added to protein both as part of the core 
sugar in the ER, and then during processing in the medial 
stack of the Golgi apparatus. These results therefore 
indicate that monensin and CCX (at concentrations < 300uM) 
had no effect on the medial stack of the Golgi. However 
further modifications occurring in the trans stack of the 
Golgi e.g. galactose or sialic acid addition, may be 
inhibited by CCX and monensin. This however must remain 
speculation as galactose labelling of the VSV G protein in 
BS-C-1 cells was not successful. Thus, unlike CCX-treated 
HSV-1 and HSV-2 BHK-21 cells (Dargan and Subak-Sharpe, 1986a 
and b), glycosylation was not strongly inhibited in 
CCX-treated VSV-infected BS-C-1 cells. Moreover, these 
studies revealed similarities between CCX and monensin 
treated VSV-infected BS-C-1 cells.
Monensin-treated VSV-infected cells have been 
extensively studied elsewhere. Johnson and Schlesinger 
(1980), showed that monensin caused dilation of Golgi 
membrane, and that the transport of the VSV G protein from
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the Golgi apparatus to the cell surface was blocked in 
monensin-treated VSV-infected BHK and CEF cells. VSV 
assembly normally occurs at the PM, at the site of insertion 
of the G protein (Simons and Garoff, 1980). Retention of the 
G protein at the Golgi membrane therefore effectively 
inhibits VSV assembly. The VSV matrix protein (M) is thought 
to play a pivotal role in assembly mediating the interaction 
between virus nucleocapsid and glycoprotein (Simons and 
Garoff, 1980). Monensin also blocks the assembly of the 
paramyxovirus Newcastle Disease virus, in BHK cells (Yoshida 
et a l ., 1986). The M protein of paramyxovirus also performs 
a similar function i.e. also interacts with nucleocapsid and 
glycoprotein, thereby facilitating assembly (Simons and 
Garoff, 1980). These studies revealed that the transport of 
NDV glycoprotein from the Golgi apparatus to the cell 
surface is inhibited and furthermore that the M protein 
cannot associate with the glycoprotein retained at the Golgi 
membrane or with the cell surface membrane. This may also be 
the case in monensin treated VSV-infected BS-C-1 cells with 
M protein accumulating at another site within the cell. 
However it is possible that the M protein can associate with 
the G protein at the Golgi membrane, but not in the correct 
manner to facilitate budding (whereas the other proteins may 
be less stable if assembly is prevented).
It is not entirely clear how monensin blocks 
glycoprotein transport to the cell surface. It does not seem 
likely to be due to the effect on glycosylation, as monensin 
is not a specific drug blocking at different stages in 
different virus/cell systems. For example, monensin blocks 
glycoprotein transport between the medial and trans stacks 
of the Golgi in SFV-infected BHK cells, but blocks 
post-trans Golgi in SFV-infected CEF cells (Griffiths, Quinn 
and Warren, 1983; Pesonen and Kaariainen, 1982). Therefore 
in SFV-infected BHK cells, the processing steps normally 
occurring in the trans stack are blocked, while the 
glycoprotein is presumably fully processed in the 
SFV-infected cells. However, the transport of both to the 
cell surface PM is inhibited. This block therefore cannot be 
due to disruption of glycosylation.
This block in glycoprotein transport seems more likely 
to be linked to the disturbance of ion fluxes in the cell,
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mediated by monensin. Monensin is a linear polyether which
has affinity for Na+ (Pressman, 1976). A comparative study
was performed with monensin and A23187, which is also an
2+lonophore, depleting Ca inside cells. Both these compounds 
were shown to inhibit the transport of VSV and Sindbis 
glycoprotein to the cell surface in BHK and CEF infected 
cells (Johnson and Schlesinger, 1980). CCX also disrupts ion 
transport by enhancing the activity of the sodium pump 
(Epstein et al . , 1977; Baron and Green, 1986; Stewart et
al., 1987). In addition CCX has also been shown to induce
vacuolation in treated cells (Dargan and Subak-Sharpe,
1988). Monensin and CCX most probably block VSV G transport 
from the Golgi membrane to the cell surface, by disrupting 
ion fluxes, the consequence in each case being inhibition of 
VSV assembly.
It has recently been proposed that monensin Elicits 
its effects on sorting, processing and movement of proteins 
through the Golgi region by neutralising the trans portion 
of the organelle (Anderson and Orci, 1988). This mode of 
action would also explain the differential effects on 
glycosylation observed in CCX-treated HSV-1 and HSV-2 BHK 
cells (fibroblasts) and CCX-treated VSV-infected BS-C-1 
cells (epithelial). While all cells have acidic trans Golgi 
vesicles, only fibroblasts have acidic trans stacks 
(Anderson and Orci, 1988). This therefore means that 
monensin and presumably CCX would neutralize the trans stack 
in fibroblastic cells, resulting in disruption of 
glycosylation, whereas only trans-Golgi vesicles would be 
affected in epithelial cells. This proposition could be 
further tested then by comparing the effects of CCX and 
monensin on glycosylation in VSV infected BS-C-1 cells and 
BHK-21 cells and HSV infected BS-C-1 cells and BHK-21 cells.
In conclusion, CCX perturbs protein synthesis in 
VSV-infected BS-C-1 cells, resulting in decreased levels of 
L, N and NS and increased levels of G and M (and The
decrease in levels of L, N and NS could be due to 
differential effects on transcription (reduced levels of 
transcript were obtained with CCX), translation, mRNA 
stability and/or polypeptide secretion. Like CCX, monensin 
causes an increase in G and M. It seems most likely that the 
ionophoric activity of these compounds, results in the
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vacuolation of the Golgi and inhibition of transport of 
glycoprotein to the cell surface PM. As VSV assembly 
normally occurs at the PM at the site of insertion of 
glycoprotein, the production of VSV particles is reduced in 
both CCX and monensin-treated infected cells. The greater 
reduction in particle number, achieved by CCX is probably 
due to its additional effect on protein synthesis. A summary 
of the anti-VSV effect of CCX is shown in Figure 61.
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T h e  a n t i - V S V  e f f e c t  of CCX.
1 6 5
4.2.3. T H E  E F F E C T  OF CCX ON T H E  R E P L I C A T I O N  O F  S F V
R E P R E S E N T I N G  T H E  C L A S S  3 R E S P O N S E
T o t a l  i n f e c t i o u s  y i e l d s  w e r e  not a f f e c t e d  by CCX 
t r e a t m e n t ,  the v i r u s  thus b e i n g  c l a s s i f i e d  as r e s i s t a n t  to 
d r u g  t r e a t m e n t .  H o w e v e r ,  w h e n  i n f e c t i o u s  y i e l d s  w e r e  d i v i d e d  
into c e l l - a s s o c i a t e d  (C A ) a n d  c e l l - r e l e a s e d  (C R ) f r a c t i o n s ,  
the CA f r a c t i o n  was seen to i n c r e a s e  w i t h  i n c r e a s i n g  CCX 
c o n c e n t r a t i o n s  w i t h  a c o n c o m i t a n t  d e c r e a s e  in the CR 
f r a c t i o n .  T h e r e f o r e ,  a l t h o u g h  t o tal v i r u s  y i e l d s  are not 
red u c e d ,  v i r u s  m a t u r a t i o n  is a f f e c t e d  by CCX t r e a t m e n t .  
M o n e n s i n  d o s e - r e s p o n s e  e x p e r i m e n t s  p e r f o r m e d  in p a r a l l e l ,  
p r o d u c e d  s i m i l a r  results, w i t h  the CA f r a c t i o n  i n c r e a s i n g  
a n d  the CR f r a c t i o n  d e c r e a s i n g .  In a d d i t i o n ,  b o t h  m o n e n s i n  
a n d  CCX i n d u c e d  s i m i l a r  c h a n g e s  in S F V  p o l y p e p t i d e  s y n t h e s i s  
in t r e a t e d  B S - C - 1  cells, r e s u l t i n g  in the a c c u m u l a t i o n  of 
v i r a l  g l y c o p r o t e i n s .  M o n e n s i n  t r e a t e d  S F V - i n f e c t e d  B H K  c e l l s  
w e r e  i n v e s t i g a t e d  by G r i f f i t h s ,  Q u i n n  a n d  W a r r e n  (1983), w h o  
s h o w e d  t h a t  m o n e n s i n  c a u s e d  v a c u o l a t i o n  of G o l g i  c i s t e r n a e ,  
a n d  f u r t h e r m o r e  t h a t  S F V  n u c l e o c a p s i d s  a s s o c i a t e d  w i t h  a n d  
b u d  into t h e s e  vacuoles. T h e  E M  a n a l y s i s  d e s c r i b e d  h e r e  
r e v e a l e d  t h a t  t his a l s o  o c c u r r e d  in b oth m o n e n s i n  a n d  
C C X - t r e a t e d  S F V - i n f e c t e d  B S - C - 1  cells.
M o r e  r e c e n t l y ,  M c D o w e l l  et a l . (1987), h a v e
i n v e s t i g a t e d  the e f f e c t  of 1 - d e o x y m a n n o j i r i m y c i n  (dMM), a 
m a n n o s i d a s e  1 i n h i b i t o r  (cis s t a c k  of G o l g i ) ,  on
S F V - i n f e c t e d  BHK cells. W h i l e  a p p e a r a n c e  of v i r u s  in the 
m e d i u m  was i n h i b i t e d ,  w h e n  the y i e l d  of v i r u s  f r o m  the cells 
a n d  m e d i u m  w a s  c o m b ined, t h e r e  was no d i f f e r e n c e  b e t w e e n  
u n t r e a t e d  a n d  d M M  t r e a t e d  c u l t u r e s .  W h e n  e x a m i n e d  by EM, in 
d M M  t r e a t e d  c u l t u r e s ,  n u c l e o c a p s i d s  w e r e  f o u n d  l i n i n g  
i n t r a c e l l u l a r  m e m b r a n e s ,  a n d  b u d d i n g  of v i r u s  was s e e n  to 
o c c u r  at t h e s e  m e m b r a n e s .  T h e s e  r e s u l t s  t h e r e f o r e  i n d i c a t e ,  
t h a t  a l t h o u g h  i n i t i a l  s t a g e s  of m a n n o s e  r e m o v a l  are
i m p o r t a n t  for the t r a n s p o r t  of S F V  g l y c o p r o t e i n ,  it is not
r e q u i r e d  for the i n f e c t i v i t y  of the virus.
In c o n c l u s i o n ,  t o t a l  S F V  i n f e c t i o u s  y i e l d s  are not 
a f f e c t e d  by CCX t r e a t m e n t ,  d u e  to the a b i l i t y  of t his v i r u s  
to b u d  i n t o  i n t r a c e l l u l a r  v a c u o l e s ,  t h e  v i r u s  p r o d u c e d  in 
t h e s e  v a c u o l e s  b e i n g  as i n f e c t i o u s  as t h o s e  n o r m a l l y  
p r o d u c e d  at the PM. It is p o s t u l a t e d  t h e r e f o r e ,  t h a t  the 
d i f f e r e n t i a l  s e n s i t i v i t y  of V S V  a n d  S F V  to C C X  t r e a t m e n t  is
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a c o n s e q u e n c e  of the d i f f e r e n t  m o d e  of a s s e m b l y  of t h e s e  
v i r u s e s .  W h i l e  S F V  a s s e m b l y  r e q u i r e s  o n l y  a s i m p l e  
i n t e r a c t i o n  b e t w e e n  n u c l e o c a p s i d  a n d  g l y c o p r o t e i n ,  V S V  
a s s e m b l y  is m o r e  c o mplex, r e q u i r i n g  the m a t r i x  p r o t e i n  M to 
m e d i a t e  the i n t e r a c t i o n  b e t w e e n  n u c l e o c a p s i d  a n d  
g l y c o p r o t e i n ,  t hus f a c i l i t a t i n g  v i r u s  a s s e m b l y  a n d  budding.
1 6 7
4.2.4. T H E  E F F E C T  OF CCX ON C L A S S  2 V I R U S E S  : P A R T I C U L A R L Y
R E O V I R U S - 3 A N D  A D E N O V I R U S - 5
S i m i l a r i t i e s  b e t w e e n  the e f f e c t s  of m o n e n s i n  a n d  CC X  
e m e r g e d  in both V S V - i n f e c t e d  a n d  S F V - i n f e c t e d  B S - C - 1  cells. 
T h e s e  s t u d i e s  s u g g e s t e d  t h a t  CCX, l i k e  m o n e n s i n ,  a l s o  
d i s r u p t e d  G o l g i  m e m b r a n e s ,  a f f e c t i n g  p r o c e s s i n g  a n d  
t r a n s p o r t  of g l y c o p r o t e i n  to the s u r f a c e ;  in CCX t r e a t e d  
V S V - i n f e c t e d  B S - C - 1  c e l l s  this c o n t r i b u t e d  to the a n t i - V S V  
e f f e c t  of CCX w h i l e  in CCX t r e a t e d  S F V - i n f e c t e d  B S - C - 1  c e l l s  
this w a s  r e s p o n s i b l e  for the a p p a r e n t  r e s i s t a n c e  of S F V  to 
CCX t r e a t m e n t  w h e n  w h o l e  c ell y i e l d s  w e r e  m e a s u r e d .  It was 
i m p o r t a n t  to e s t a b l i s h  h o w  m o n e n s i n  a f f e c t e d  o t h e r  v i r u s e s  
a n d  of i n t e r e s t  w h e t h e r  a n d  to w h a t  e x t e n t  this e f f e c t  on 
t he G o l g i  c o n t r i b u t e d  to the a n t i v i r a l  a c t i o n  of CCX in e a c h  
c a s e .
A l l  e a r l i e r  t e s t e d  c l a s s  2 v i r u s e s  w e r e  i n c l u d e d  in 
this c o m p a r a t i v e  study. M o n e n s i n  a n d  C C X  b o t h  r e d u c e d  
c e l l - a s s o c i a t e d  a n d  c e l l - r e l e a s e d  y i e l d s  f r o m  G e r m i s t o n  a n d  
B u n y a m w e r a  i n f e c t e d  cel l s  by 100 fold. In t his c a s e  
t h e r e f o r e ,  the e f f e c t  on the G o l g i  m e m b r a n e ,  c o u l d  a t  l e a s t  
in theory, a c c o u n t  for the t o t a l  a n t i -  B u n y a v i r u s  e f f e c t  of 
C C X .  H o w e v e r ,  m o n e n s i n  had no e f f e c t  on the i n f e c t i v i t y  of 
the o t h e r  t h r e e  v i r u s e s  in this class: P o l i o v i r u s - 1 , 
A d e n o v i r u s - 5  a n d  R e o v i r u s - 3 .  In t h e s e  c a s e s  t h e r e f o r e ,  
d i s r u p t i o n  of the G o l g i  a p p a r a t u s  c a n n o t  c o n t r i b u t e  to the 
a n t i v i r a l  e f f e c t  of C C X .  R e o v i r u s - 3  a n d  A d e n o v i r u s - 5  w e r e  of 
p a r t i c u l a r  i n t e r e s t  as t h e s e  two v i r u s e s  e x h i b i t e d  g r e a t  
s e n s i t i v i t y  to l o w  c o n c e n t r a t i o n s  of C C X .  Indeed, the 
r e d u c t i o n  in i n f e c t i v i t y  w i t h  low c o n c e n t r a t i o n s  w a s  e v e n  
g r e a t e r  than t hat a c h i e v e d  for c l a s s  1 v i r u s e s  w i t h  s i m i l a r  
c o n c e n t r a t i o n s ,  w i t h  the e x c e p t i o n  of BHV-1. M o r e  d e t a i l e d  
s t u d i e s  w e r e  t h e r e f o r e  p e r f o r m e d  w i t h  t h e s e  t w o  viruses.
W i t h  b o t h  R e o v i r u s - 3  a n d  A d e n o v i r u s - 5 ,  t h e r m o s t a b i l i t y  
e x p e  r i m e n t s  r e v e a l e d  that the v i r u s  p r o d u c e d  in C C X - t r e a t e d  
cells, w a s  s i m i l a r  in q u a l i t y  to t h a t  o b t a i n e d  f r o m  
d r u g - f r e e  cells. T h i s  is in c o n t r a s t  to the o b s e r v e d  
i n c r e a s e d  t h e r m o l a b i l i t y  of H S V  p a r t i c l e s  p r o d u c e d  f r o m  C C X  
t r e a t e d  F l o w  2002 a n d  B H K  21 cells. The v i r u s  p r o d u c e d  f r o m  
C CX t r e a t e d  cel l s  w a s  f u r t h e r  i n v e s t i g a t e d  to d e t e r m i n e  
w h e t h e r  the p l a t e a u  o b t a i n e d  in the CCX d o s e - r e s p o n s e  c u r v e s  
w a s  a c o n s e q u e n c e  of the s e l e c t i o n  of a s u b - p o p u l a t i o n  of
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resistant virus. Progeny virus from CCX dose-response 
experiments, was grown up to high titre and then employed in 
second generation CCX dose-response experiments. Similar 
dose-response curves were obtained for virus produced from 
drug-free and CCX treated cells, indicating that the plateau 
was not a consequence of survival of genetically resistant 
virus. It seems likely therefore, that CCX affects a 
function (either host or virus-specified) which enhances but 
is not essential for virus replication.
The effect of increasing concentrations of CCX on 
Reovirus-3 and Adenovirus-5 particle numbers, infectivity 
and particle/p.f.u. ratios was determined. The 
anti-Reovirus-3 effect of CCX appeared to be of two types. 
At low CCX concentrations, the drug operated predominantly 
by lowering the quality of virus particles produced, at 
higher CCX concentrations by inhibiting virus particle 
assembly (with the quality of virus unaffected). In 
contrast, there was no significant effect on particle/p.f.u. 
ratios of Adenovirus yields from Hela cells at any CCX 
concentration. The anti-Adenovirus effect of CCX therefore 
operates totally by inhibiting particle production, with 
those particles that are produced from CCX treated 
Adenovirus-infected Hela cells, being equally as infectious 
as virus produced from drug-free cells.
Reovirus-3 particle infectivity was not significantly 
affected by direct exposure to CCX. Therefore unlike HSV-1 
and HSV-2 (Dargan and Subak-Sharpe, 1985, 1986a and b) ,
where direct inactivation of particles contributed to the 
elevation in particle/p.f.u. ratio and VSV, where it totally 
accounts for the rise in particle/p.f.u. ratio, direct 
inactivation can play no role in the observed lowering in 
the infectivity of Reovirus-3 particles at low CCX 
concentrations. One possible explanation, is that CCX has a 
progressive effect on virus particle assembly; at low 
concentrations CCX may not be able to effectively block 
virus particle production, but is able to modify virus 
assembly resulting in the production of high numbers of 
non-infectious particles. With regard to this, HSV particles 
assembled in the presence of CCX, have abnormal polypeptide 
composition which predominantly contributes to the elevated 
particle/p.f.u . ratios of these yields. Whether this is also
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true for Reovirus-3 produced from cells treated with low 
concentrations of CCX has not been determined.
Cells infected with reovirus develop characteristic 
cytoplasmic inclusions referred to as viral "factories" 
(Gomatos, Tamm, Dales and Franklin, 1962). These begin as 
phase-dense granular material scattered in the cell 
cytoplasm and subsequently coalesce and move towards the 
nucleus. Inclusions have been shown to contain dsRNA 
(Gomatos, Tamm, Dales and Franklin, 1962; Silverstein and 
Schur, 1970), virus specific polypeptides (Fields, Raine and 
Baum, 1971; Spenlove, Lennette, Knight and Chin, 1963)and 
both complete and incomplete viral particles (Dales, Gomatos 
and Hsu, 1965; Fields, Raine and Baum, 1971). Viral 
particles are often found in crystalline arrays. Ribosomes 
are not part of viral factories; viral mRNA must travel 
outside the factory and newly synthesised structural 
proteins must travel back for assembly into virus particles. 
This process may be perturbed at low drug concentrations, 
resulting in abnormal virus assembly, and transport of 
proteins inhibited at higher CCX concentrations resulting in 
inhibition of particle assembly.
Immunocytochemical studies of intermediate filaments 
in infected cells show progressive disruption of vimentin 
filament organization (Sharpe, Chen and Fields, 1982). 
Inside viral factories masses of vimentin filaments appear 
to pass between microtubules. Virus particles are intimately 
associated with these filaments (Sharpe, Chen and Fields, 
1982; Dales, 1963). It has been suggested that vimentin 
plays an important role in the organization of viral 
factories and therefore, the entire process of replication 
(Sharpe and Fields, 1983; Sharpe, Chen and Fields, 1982). 
From their EM studies of CCX treated HSV-infected Flow 2002 
and BHK cells, Dargan and Subak-Sharpe have postulated an 
effect on the cell cytoskeleton (D. Dargan, personal 
communication). This therefore might furnish an explanation 
for at least part of the anti-Reovirus activity of CCX.
Investigations of the polypeptides induced in CCX 
treated Reovirus-3 and mock-infected BS-C-1 cells, revealed 
a selective progressive reduction in Reovirus-3 proteins 
with increasing CCX. The basis for this has not been 
investigated and may be a consequence of reduced
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transcription and/or interference with the translation 
process itself. Regardless of the mechanism this reduction 
in viral protiens almost certainly contributes to reduced 
particle numbers in the presence of CCX.
As evidenced by the reductions in particle number and 
almost unchanged particle/p.f.u. ratio of Adenovirus yields 
from CCX treated infected Hela cells, the anti-Adenovirus 
effect of CCX operates totally by inhibiting particle 
production. Investigations of polypeptides induced in CCX 
treated Adenovirus infected cells revealed a general 
reduction with increasing CCX in most Adenovirus bands, with 
the exception of low m.wt. bands 14 and 13K, which actually 
increased in the presence of CCX (the increase in 13K 
becoming marked with high CCX concentrations). It is 
interesting that both these proteins are hexon-associated 
(Everitt and Philipson, 1974; Persson et al., 1978). Levels 
of the fibre protein band (62K and the non-structural DNA 
binding protein band 72K), were markedly reduced at 30 and 
20uM respectively. In addition the diffuse 72K band 
separated into 2 distinct bands at this low CCX 
concentration. This protein is normally phosphorylated, a 
variety of phosphorylated forms existing in infected cells 
(Russell and Blair, 1977; Linne and Philipson, 1980). The 
appearance of distinct bands may therefore be indicative of 
an effect on phosphorylation by CCX. With regard to this it 
is interesting that the structural protein band (66K), which 
is also phosphorylated, also becomes less diffuse with 
increasing CCX concentrations, separating into 2 distinct 
bands with 100, 200 and 300uM CCX. How any effect on
phosphorylation may contribute to the anti-Adenovirus effect 
of CCX is not clear. However removal of phosphate from 72K 
protein by alkaline phosphatase, does not affect the DNA 
binding function of this protein, although other unknown 
functions of the protein may be affected. Even at low 
concentrations, CCX clearly perturbs protein synthesis in 
Adenovirus-infected cells. However, whether this contributes 
to or is a consequence of disruption in virus assembly is 
not clear.
Dargan and Subak-Sharpe (1986a and b), have previously 
reported that the nuclear/cytoplasmic distribution of 
proteins in CCX treated HSV-1 and HSV-2 infected Flow 2002
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and BHK-21 cells is disrupted. The nuclear/cytoplasmic 
distribution of proteins in CCX treated Adenovirus-infected 
cells has not been examined. However, if affected this would 
almost certainly contribute to the reduction in virus 
particle production from CCX treated cells, as Adenovirus 
assembly occurs in the nucleus and is dependent on the 
transport of proteins from the cytoplasm to this site of 
assembly.
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4.3. FUTURE WORK
This study confirmed that CCX displays broad antiviral
activity. In some cases only one repesentative of a family
has been tested, although where more than one virus from a 
family has been studied e.g. Herpesviruses and Bunyaviruses, 
no notable difference in the class of dose-response to CCX
has emerged. Whether this will be a general finding remains
to be determined. This survey therefore, could be extended
by screening additional viruses belonging to families
already investigated, and viruses belonging to other 
families e.g. Poxvirus, Papovavirus, Retrovirus, Arenavirus, 
Hepadnavirus, Rotavirus etc.
In all CCX dose-response experiments, the drug was 
added after virus absorption had been allowed to occur 
(virus absorption = adsorption {binding to receptor on the 
cell surface} + penetration) Therefore, although CCX may be 
able to affect the pre-synthetic stages of the virus life 
cycle, this cannot contribute to the observed reduction in 
infectivity. Virus adsorption to cells pretreated with CCX 
has been investigated, revealing some slight effect in all 
cases. The effect of CCX on virus penetration however has 
not been examined. Two observations suggest that CCX may
have some effect on this step. Firstly, this study revealed
similarities between monensin and CCX. It is known that 
monensin inhibits virus receptor-mediated endocytosis, by 
raising the pH of endosomes, thereby blocking fusion of 
viral and endosomal membranes (Marsh et al., 19 82). 
Secondly, CCX enhances the activity of the sodium pump, 
which pumps sodium out of and potassium into the cell. 
Presumably, the net result is decreased levels of 
intracellular sodium and increased levels of potassium. It 
has been shown that alteration of sodium and potassium 
levels in the growth medium can affect entry of SFV into 
cells. Growth medium normally contains high sodium and low 
potassium levels. If this is reversed i.e. low sodium and 
high potassium (lOmM NaCl and lOOmM KC1), SFV entry into 
cells is inhibited, by blocking release of SFV particles 
from endosomes (Helenius et al., 1985). Additional
dose-response experiments should therefore be performed with 
all viruses, adding CCX before or at the time of infection.
This antiviral study allowed placement of viruses into
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three broad classes, depending upon their dose-related 
response to the drug. The first class exhibit a continuous 
drug dose- dependent reduction in virus infectivity, the 
extent of the drop varying from 100-100,000 fold. The second 
class exhibit a less extensive total CCX response, 
infectivity being reduced by only 10-100 fold even with 
300uM CCX, and all the dose-response curves reach their 
plateau level with concentrations between 100 and 200 uM 
CCX. The third class contains only SFV, whose total 
infectious progeny yields were not affected by CCX
treatment. VSV was the virus most extensively studied as
with the exception of the Herpesviruses, this was most 
dramatically affected by CCX treatment. Various stages in 
the VSV life cycle were examined for sensitivity to CCX. CCX 
was shown to reduce levels of both VSV secondary transcripts 
and cellular cytoplasmic RNA. However this experiment only 
allows tentative conclusions to be drawn as it was only 
performed once and therefore must be repeated and the 
results confirmed. In addition, in vitro transcriptase 
assays could be employed to determine how CCX may affect 
transcription. Products of in vitro transcriptase assays 
could then be used as templates in in vitro translation 
systems to uncouple effects of CCX on the processes of 
transcription and translation.
Both CCX and monensin were shown to induce vacuolation 
in treated cells. In monensin trated cells these vacuoles
have been shown to be derived from Golgi membrane, using
cytochemical markers e.g. thiamine pyrophosphatase, and 
phosphatase (specific for trans Golgi cisternae) and lectin, 
Riccinus communis agglutinin 1 (RCA) (specific for the 
middle and trans stack of the Golgi cisternae). Similar 
experiments should be performed to determine if vacuoles in 
CCX treated cells are also Golgi derived, as postulated.
Polypeptide analysis revealed that both CCX and 
monensin treatment of infected cells, resulted in elevated 
intracellular levels of VSV G and M proteins. Investigations 
of VSV-infected cells revealed that glycoprotein transport 
from the Golgi to the cell surface was inhibited (Griffiths, 
Quinn and Warren, 1983). Immunofluorescent experiments were 
performed using monoclonal antibody to VSV G protein, to 
determine if glycoprotein transport was also inhibited in
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CCX treated cells. However, these experiments were not 
successful due to poor quality antibody. These experiments 
should therefore be repeated and the location of G and M in 
CCX treated cells more precisely determined by EM studies 
(immunogold labelling). Another approach would be to use 
radiolabelled CCX and monensin to follow the entry of these 
drugs into the cell and reveal any specific target 
organelles. It has also been shown that CCX can directly 
inactivate virus infectivity; radiolabelled drug could be 
useful in determining if this is due to binding of CCX to 
virus particles.
Class 2 viruses, Adenovirus-5 and Reovirus-3, were 
shown to be extremely sensitive to relatively low 
concentrations of CCX. Comparative infectious yield 
experiments, performed with CCX and monensin, revealed that 
disruption of glycoprotein transport and processing could 
play no role in the anti-Adenovirus or anti-Reovirus 
activity of CCX. Effects of CCX on the cell cytoskeleton and 
nuclear membrane may play a role in the anti-Reovirus and 
anti-Adenovirus activity of CCX, respectively.However, more 
detailed investigations of the effect of CCX on these
viruses is required to determine why their replication is so
£•
sensitive to low CCX concentrations with no further effect 
at higher CCX concentrations.
The mode of action of CCX therefore is clearly 
complex. Although this study has revealed that CCX affects 
different stages in the VSV life cycle (transcription, 
protein synthesis and distribution), how CCX affects these 
steps is not clear. Dargan and Subak-Sharpe ( 1986a and b) , 
from their investigations of CCX treated HSV-1 and HSV-2 
infected Flow 2002 and BHK cells postulated that CCX 
operated by disturbing the normal functions of host cell 
membrane. This study revealed that CCX had a differential 
effect on both cells and viruses, and that the cytotoxic and 
antiviral activities of CCX were linked (demonstrated by the 
diastereoisomer study where the cytotoxic and antiviral 
activities of the compound correlated : 690 < CCX < 680). 
CCX has multiple effects on cells, including enhancement of 
the sodium pump, induction of the stress reponse, binding to 
proteins and vacuolation of membranes, all of which have 
been implicated in the anti-cellular and antiviral activity
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of the compound. To more clearly elucidate the mechanism of 
action, it is clearly necessary to investigate more fully 
the effect of CCX on cells and the consequence of particular 
effects on the cell on the replication of various virus 
groups.
This study has investigated the action of CCX in vitro 
against a large number of cells and viruses. While CCX and 
CBX have been shown to have beneficial effects in the 
treatment of HSV infections in man (Poswillo and Roberts, 
1981; Csonka and Tyrrell, 1984; Partridge and Poswillo, 
1984), clinical trials have not been performed with any of 
the other viruses in the survey. If shown to be effective in 
vivo, CCX could be employed in combination with drugs which 
affect other targets, or to treat cases where resistance to 
other drugs has developed. Carbenoxolone, which is closely 
related to CCX, was used for many years in the treatment of 
duodenal ulcers. This was administered with diuretics as CBX 
altered sodium and potassium levels, resulting in 
hypokalemia (loss of serum potassium) and sodium retention 
(pseudoaldostereoism) . Therefore, CCX could conc^e-vably be 
administered orally, although topical application, where 
possible would be favoured.
Finally, it is of particular interest, that the parent 
compound Glycchirizic acid (GA), has been shown to have in 
vitro activity against HIV (Ito et al., 1987). This study 
has shown that CCX has a similar antiviral range as GA, and 
furthermore that its1 activity is more potent, suggesting 
that the effect of CCX on HIV should be investigated. A 
compound affecting multiple targets would be useful in the 
treatment of AIDS patients, particularly in the light of 
reports of AZT resistance (Larder et al., 1989), currently 
the only licensed anti-HIV drug available.
REFERENCES
AARBAKKE,J ., GORDON,R.K., CROSS,A.S., MIUKA,G .A . and 
CHIANG,P.K. 1985. Correlation between DNA hypomethylation 
and differentiation of HL-60 promyelocyte cells induced by 
neplanocin A and 3-deaza nucleosides. FED. PROC. 44 : 464 
Abstract 313.
ADAMS,M.J. 1973. Structure function relationships in 
lactate dehydrogenase. P.N.A.S. 70 : 1968-1972.
ALIZON,M ., WAIN-HOBSON,S ., MONTAGNIER,L. and SONIGO,P. 
1986. Genetic variability of the AIDS virus : nucleotide 
sequence analysis of two isolates from African patients.
CELL 46 : 63-74.
AMTMANN,E., MULLER,K., KNAPP,A. and SAUER,G. 1985. 
Reversion of bovine papillomavirus induced transformation 
and immortalization by a xanthate compound. EXP. CELL RES. 
161 : 541-550.
ANDERSSON,J., BRITTON,S., ERNBERG,I., ANDERSSON,U., 
HENLE,N ., SKOLDENBERG,B and TISELL,A. 1986. Effect of 
acyclovir on infectious mononucleosis : A double-blind, 
placebo controlled study. J. INFECT. DIS. 153 : 283-290.
ANDERSON,R.G .W . and ORCI,L. 1988. A view of acidic 
intracellular compartments. J. CELL BIOL. 106 : 539-543.
ANDERSON-SILLMAN,K., BARTAL,S. and TERSHAK,D .R . 1984. 
Guanidine resistant poliovirus mutants produce modified 37kD 
proteins. J. VIROL. 50 : 922-928.
AOYAGI,T.A. and UMEZAWA,H. 1975. Structures and 
activities of protease inhibitors of microbial origin. In : 
"PROTEASES AND BIOLOGICAL CONTROL", pp 4 29-4 54. Edited by
D.B. Rifkin and E. Shaw. New York : Cold Spring Harbor 
Laboratory.
APPLEYARD,G. 1977. Amantidine resistance as a genetic 
marker for influenza viruses. J. GEN. VIROL. 36 : 249-255.
ARGOS,P., ROSSMAN,M.G., GRAU,U.M., ZUBER,H., FRANK,G. 
and TRATSCHIN,J.D. 1979. Thermal stability and protein 
structure. BIOCHEM. 18 : 5698-5703.
ASHBURNER,M . and BONNER,J.J. 1979. The induction of 
gene activity by heat shock. CELL 17 : 241-254.
ASSELINE,U., DELARUE,M., LANCELOT,G., TOULME,F.,
THUONG,N .T ., MONTENAY-GARESTIER,T . and HELENE,C. 1984. 
Nucleic acid-binding molecules with high affinity and base 
sequence specificity : intercalating agents covalently
linked to oligodeoxynucleotides. P.N.A.S. U.S.A. 81 :
3297-3301.
AYISI , N . K ., DE CLERCQ,E., WALL,R.A., HUGHES,H. and 
SACKS,S.L. 1984. Metabolic fate of (E )-5-(2-bromovinyl)- 
2'-deoxyuridine in herpes simplex virus and mock infected 
cells. ANTIM. AGENTS. CHEM. 26 : 762-765.
BABA,M ., KONNO,K ., SHIGETA,S. and DE CLERCQ,E. 1987.
In vitro activity of (S)-9-(hydroxy-2- phosphonyl- 
methoxypropyl) adenine against newly isolated clinical 
varicella-zoster virus strains. EUR. J. CLIN. MICROBIOL. 6 : 
158-165.
BABA,M., MORI,S., SHIGETA,S., and DE CLERCQ,E. 1987. 
Selective inhibitory effect of (S)-9-(3-hydroxy-2- 
phosphonylmethoxypropyl) adenine and 2 1-nor cyclic GMP on 
adenovirus replication in vitro. ANTIMICROB. AGENTS 
CHEMOTHER. 31 : 3 3 7-3 39.
BACH,M .C ., BAGWELL,S.P., KNAPP.N.P., DAVIS,K.M. and 
HEPSTROM,P.S. 1985. 9(1,3-dihydroxy-2-propoxymethy1)guanine 
for cytomegalovirus infections in patients with the Acquired 
Immunodeficiency Syndrome. ANN. INTERN. MED. 103 : 381-382.
BADER,J.P., BROWN,N.R., CHIANG,P.K. and CANTONI,G .L .
1978. 3-Deazaadenosine, an inhibitor of adenosylhomocysteine 
hydrolase, inhibits reproduction of Rous sarcoma virus and 
transformaton of chick embryo cells. VIROLOGY 89 : 495-505.
BAGLIONI,C. 1983. The molecular mediators of 
interferon action in : "INTERFERONS AND THEIR APPLICATIONS;
HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. VOL. 7 3."
BAGLIONI,C. 1979. Interferon induced enyme activities 
and their role in the antiviral state. CELL 17 : 255-264.
BALFOUR JR.,H .H., BEAN,B ., LASKIN,O.L., AMBINDER,R .F ., 
MEYERS,J.D., WADE,J .C ., ZAIA,J.A., AEPPLI,D., KIRK,L.E ., 
SEGRETI,A .C . and KEENEY,R.E. 1983. Acyclovir halts 
progression of herpes zoster in immunocompromised patients. 
N. ENG. J. MED. 308 : 1448-1453.
BALZARINI,J . and DE CLERCQ,E. 1984. Strategies for the 
measurement of the inhibitory effects of thymidine analogues 
on the activity of thymidylate synthase in intact murine 
leukaemia L1210 cells. BIOCHIM. BIOPHYS. ACTA. 785 : 36-45.
BALZARINI,J., DE CLERCQ,E., AYUSAWA,D . and SENO,T. 
1984a. Thymidylate synthetase deficient mouse FM3A mammary 
carcinoma cell line as a tool for studying the thymidine 
salvage pathway and the incorporation of thymidine analogues
B759U) induces reduced levels of BW B759U triphosphate. 
P.N.A.S., U.S.A. 83 : 8769-8773.
BODNER,A.J., CANTONI,G .L . and CHIANG,P.K. 1981. 
Antiviral activity of 3-deazaadenosine and 5'-deoxy- 
5'-isobutylthio-3-deazaadenosine (3-deaza-SIBA). BIOCHIM. 
BIOPHYS. RES. COMM. 98 : 476-481.
BORCHARDT,R.T ., EIDEN,L.E ., WU,B .S. and RUTLEDGE,C .0.
1979. Sinefungin, a potent inhibitor of S-adenosylmethionine 
protein O-methyltransferase. BIOCHIM. BIOPHYS. RES. COMMUN. 
89 : 919-924.
BORCHARDT,R.T., KELLER,B.T. and PATEL-THOMBRE,U . 1984. 
Neplanocin A : A potent inhibitor of S-adenosylhomocysteine 
hydrolase and of vaccinia virus multiplication in mouse L 
929 cells. J. BIOL. CHEM. 259 : 4353-4358.
BORCHARDT,R.T. ana PUGH,C.S.G. 1979. Analogues of 
S-adenosyl-L-homocysteine as inhibitors of viral mRNA 
methyltransferases in : "TRANSMETHYLATION" ppl97-206. Edited 
by E. Usdin, R.T. Borchardt and C.R. Creveling. Elsevier; 
North Holland, New York, Amsterdam, Oxford.
BORCHARDT,R.T., WU,Y .S., HUBER,J.A. and WYCPALEK,A .F .
1976. Potential inhibitors of S-adenosylmethionine dependent 
methyltransferases. 6. Structural modifications of 
S-adenosylmethionine. J. MED. CHEM. 19 : 1104-1110.
BORCHERDING,D .R . 1987. The synthesis and biological 
activity of acyclic and carboxylic analogues of neplanocin 
A., A Ph.D. Thesis., The University of Kansas.
BOSS,N .F ., MORRE,D .J ., MOLLENHAVER,H.H . 1984. 
Monensin-induced swelling of the Golgi apparatus cisternae 
mediated by a proton gradient. EUR. J. CELL. BIOL. 34 : 1-8.
BOTH,G .W ., BANERJEE,A.K. and SHATKIN,A.J. 1975. 
Methylation dependent translation of viral messenger RNAs in 
vi tro. P.N.A.S. U.S.A. 72 : 1189-1193.
BOTH,G .W ., FURUICHI,Y ., MUTHUKRISHNAN,S. and 
SHATKIN,A.J. 1975. Ribosome binding to reovirus mRNA in 
protein synthesis requires 5 '-terminal 7-methylguanosine. 
CELL. 6 : 185-195.
BOULANGER,P. and LONBERG-HOLM,K. 1981. Components of 
non-enveloped viruses which recognise receptors in : 
"RECEPTORS AND RECOGNITION", series B, Vol 8. pp21-46.
Edited by K .Lonberg-Holm and L.Philipson. Chapman and Hall, 
New York.
BUCHANAN,R.A . and HESS,F. 1980. Vidarabine (Vira-A) : 
pharmacology and clinical experience. PHARMACOL. THER. 8 : 
143-149.
BUETHNER,W. and WERCHAU,H. 1973. Incorporation of 
5-Iodo-2'-deoxyuridine (lUdR) into SV40 DNA. VIROL. 52 : 
553-561.
CAMPER,S.A., ALBERS,R.J., COWARD,J.K. and ROTTMAN,F .M 
1984. Effect of undermethylation of mRNA on cytoplasmic 
appearance and half life. MOL. CELL. BIOL. 4 : 538-543.
CANONICO,P.G . 1983. in : "ANTIBIOTICS VI, MODES AND
MECHANISMS OF MICROBIAL GROWTH INHIBITORS" ppl61-172.
Springer-Verlag.
CANONICO,P.G ., KENDE,M ., LUSCRI,B.J. and HUGGINS,J.W.
1984. In vivo activity of antivirals against exotic RNA 
viral infections. J. ANTIMICROB. CHEM. 14, Suppl. A : 27-41
CANTONI,G .L . and CHIANG,P.K. 1980. The role of 
S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase 
in the control of biological methylation , in : "NATURAL
SULPHUR COMPOUNDS: NOVEL BIOCHEMICAL AND STRUCTURAL 
ASPECTS". pp67-80. Edited by D.Cavallin, G.E. Gaull and 
V.Zappia. Plenum Publishing Corporation, New York and 
London.
CARP,R.I. 1964. Studies on the guanidine character of
poliovirus. VIROL. 22 : 270-279.
CASPAR,D. and KLUG,F. 1962. Physical principles in th 
construction of regular viruses. COLD SPRING HARBOUR SYMP. 
QUANT. BIOL. 2 7,1 : 1-24.
CAYLEY,P.J., SILVERMAN,R.H., WRESCHNER,D .H .,
KNIGHT,M., GILBERT,C.S., BROWN,R.E. and KERR,I.M. 1981. The
2-5A system in interferon treated and control cells in : 
"CELLULAR RESPONSES TO MOLECULAR MODULATIONS" pp347-360.
Edited by Mozes. Academic Press, New York.
CAZENAVE,R ., LOREAU,N ., THUONG,N .T ., TOULME,J.J. and 
HELENE,C. 1987. Enzymatic amplification of translation 
inhibition of rabbit B globin mRNA mediated by 
anti-messenger oligodeoxynucleotides covalently linked to 
intercalating agents. NUC. ACID. RES. 15 : 4717-4736.
CHANG,C.D. and COWARD,J.K. 1975. Effect of 
S-adenosylhomocysteine and S-tubercidinylhomocysteine on 
transfer riDonucleic acid methylation in
phytohaemagglutinin-stimulated lymphocytes. MOL. PHARMACOL.
11 : 701- 707 .
CHEN,T.R. 1977. In situ detecton of mycoplasma 
contamination in cell cultures by fluorescent Hoechst 33258 
stain. EXP. CELL. RES. 104 : 255-262.
CHENG,Y-C., DUTSCHMAN,G.E ., BASTON,K.F .,
SARNGADHARAN,M.G. and TING,R.Y.C. 1987. Human 
immunodeficiency virus reverse transcriptase : General 
properties and its interactions with nucleoside triphosphate 
analogues. J. BIOL. CHEM. 262 : 2187-2189.
CHENG,Y-C. and PRUSOFF,W.H. 1986. Antiviral 
chemotherapy in "CRC HANDBOOK OF CHEMOTHERAPUTIC AGENTS, VOL 
2". Edited by M. Verderame. CRC Press, Boca Raton, Florida.
CHIANG,P .K . and CANTONI,G .L . 1979. Perturbation of 
biochemial transmethylation by 3-deazaadenosine in vivo. 
BIOCHEM. PHARMACOL. 28 : 1897-1902.
CHIANG,P.K., CANTONI,G.L., BADER,J.P., SHANNON,N .M ., 
THOMAS,H.J. and MONTGOMERY,J .A . 1978. Adenosylhomocysteine 
hydrolase inhibitors : synthesis of 5'-deoxy 
5 1(isobutylthio)-3-deazaadenosine and its effect on Rous 
Sarcoma virus and Gross murine leukaemia virus. BIOCHIM. 
BIOPHYS. RES. COMMUN. 82 : 417-423.
CHOPPIN,P .W ., RICHARDSON,C.D. and SCHEID,A. 1983. 
Analogues of viral polypeptides which specifically inhibit 
viral replication in : "PROBLEMS OF ANTIVIRAL THERAPY"
ppl3-33. Edited by C. Stuart-Harris and John Oxford.
Academic Press, London and New York.
CHOPPIN,P .W ., RICHARDSON,C.D. and SCHEID,A. 1984. 
Oligopeptides as specific antiviral agents, in : "TARGETS
FOR THE DESIGN OF ANTIVIRAL AGENTS" pp 287-305. Edited by
E.De Clercq and R.T. Walker. Plenum Press, New York.
CHRISTOFINNS,G .J . and BEALE,A.J. 1968. Some biological 
characteristics of cell lines derived from normal rabbit 
kidney. J. PATH. BACT. 95 : 377-381.
CLEMENS,M.J. and WILLIAMS,B .R .G . 1978. Inhibition of 
cell free protein synthesis by pppA2'p5'A2'p5'a :a novel 
oligonucleotide synthesised by interferon treated L cell 
extracts. CELL 13 : 565-572.
COCHRAN,K.W., MAASAB,H.F ., TSUNODA,A . and BERLIN,B .S. 
1965. Studies on the antiviral activity of amantidine 
hydrochloride. ANNAL. N.Y. ACAD. SCI. 130 : 432-439.
COFFIN,J.M. 1986. Genetic variation in AIDS viruses.
CELL 46 : 1-4.
COLEMAN,V.R., TSU,E and JANETZ,E . 1968. Treatment 
resistance to idoxurdine in herpetic keratitis. PROC. SOC. 
EXP. BIOL. MED. 129 : 761-765.
COOK,S.D. 1988. In vitro and in vivo ocular studies 
using HSV 1 and HSV 2. Ph.D. thesis.
COONEY,D.A., DALAL,M ., MITSUYA,H ., McMAHON,J .B ., 
NADKARNI,M ., BALZARINI,J ., BRODER,S . and JOHNS,D.G. 1986. 
Initial studies on the cellular pharmacology of 
2',31-dideoxycytidine, an inhibitor of HTLV-111 infectivity. 
BIOCHEM PHARMACOL. 35 : 2065-2068.
COOPER,P.D. 1968. A genetic map of poliovirus 
temperature sensitive mutants. VIROL. 35 : 584-596.
COOPER,?., WENTWORTH,B. and McMAhon,D. 1970. Guanidine 
inhibition of poliovirus : a dependence of viral RNA 
synthesis on the configuration of the structural protein. 
VIROL. 40 : 486-493.
CROWELL,R.L. 1980. Receptors as determinants of 
cellular tropism in picornavirus infections, in : "RECEPTORS
AND HUMAN DISEASES". Edited by A.G. Bearn and P.W. Choppin. 
Josiah Macy,Jr. Foundation, New York.
CROWTHER,D . and MELNICK,J .L . 1961. Studies on the 
inhibitory action of guanidine on poliovirus multiplication 
in cell cultures. VIROL. 15 : 65-74.
CSONKA,G .W . and TYRRELL,D.A.J. 1984. Treatment of 
herpes genitalis with carbenoxolone and cicloxolone creams : 
a double-blind placebo-controlled clinical trial. BRIT. J. 
VEN. DIS. 60 : 178-181.
DALES,S. 1963. Association between the spindle 
apparatus and reovirus. P.N.A.S. U.S.A. 50 : 268-275.
DALES,S., GOMATOS,P. and HSU,K.C. 1965. The uptake and 
developement of reovirus in strain L cells followed with 
labelled viral ribonucleic acid and feritin-antibody 
conjugates. VIROL. 25 : 193-211.
DALGLEISH,A.G., BEVERLY,P .L .C ., CLAPHAM,P.R .,
CRAWFORD,D .H ., GREAVES,M.F. and WEISS,R.A. 1984. The CD4 
(T4) antigen is an essential component of the receptor for 
the AIDS retrovirus. NATURE 312 : 763-766.
DANIELS,R.S., DOWNIE,J.C., HAY,A .J ., KNOSSON,M.,
SKEHEL,J .J ., WANG,M.L. and WILEY,D.C. 1985. Fusion mutants 
of the influenza virus haemagglutunun glycoprotein. CELL 40
: 431-439 .
DARGAN,D.J. and SUBAK-SHARPE,J .H . 1985. The effect of 
triterpenoid compounds on uninfected and herpes simplex 
virus infected cells in culture. 1. Effect on cell growth, 
virus particles and virus replication. J. GEN. VIROL. 66 : 
1771-1784.
DARGAN,D.J. and SUBAK-SHARPE,J.H . 1986a. The effect of 
triterpenoid compounds on uninfected and herpes simplex 
virus infected cells in culture. 11. DNA and protein 
synthesis, polypeptide processing and transport. J. GEN. 
VIROL. 67 : 1831-1850.
DARGAN,D.J. and SUBAK-SHARPE,J .H . 1986b. The 
antiherpes activity of the triterpenoid compunds 
carbenoxolone sodium and cicloxolone sodium. J. ANTIM. CHEM. 
18,supplement W : 185-200.
DARGAN D.J. and SUBAK-SHARPE,J .H . 1988. The effect of 
triterpenoid compounds on uninfected and herpes simplex 
virus infected cells in culture. 111. U1trastructural study 
of virion maturation. J. GEN. VIROL. 69 : 439-444.
DARWELL,J.E .,Jr. 1979. Transcription units for mRNA 
production in eukaryotic cells and their DNA viruses. PROG. 
NUC.ACID. RES. MOL. BIOL. 22 : 327-353.
DAVIES, W . L . , GRUNERT , R . R . , HAFF , R . M . , McGAHEN, J . Vi. , 
NEUMAYER,E .M . and PAULSHOCK,M. 1964. Antiviral activity of 
1-adamantanamine (amantidine). SCIENCE 144 : 862-863.
DE,B .P . and BANERJEE,A.K. 1985. Requirements and 
functions of VSV L and NS proteins in the transcription 
process in vitro. BIOCHEM. BIOPHYS. RES. COMM. 126 : 40-49.
DE CLERCQ,E. 1982. Selective antiherpes agents. TRENDS 
PHARMACOL. SCIENCE. 3 : 492-499.
DE CLERCQ,E. 1985. Antiviral and antimetabolic 
activities of neplanocins. ANTIMICROB. AGENTS. CHEMOTHER. 28 
: 84-89.
DE CLERCQ,E. 1986. Chemotheraputic approaches to the 
treatment of the acquired immune deficiency syndrome (AIDS). 
J. MED. CHEM. 29 : 1561-1569.
DE CLERCQ,E. 1988a. Nucleoside analogues in the 
chemotherapy of viral infections : Recent developements, in 
: "APPLIED VIROLOGY RESEARCH VOL 1. NEW VACCINES AND
CHEMOTHERAPY" pp 219-232. Edited by E. Kurstak, R.G.
Marisyk. F.A . Murphy and M.H. Van Regen Mortel. Plenum
Medical Book Company, New York and London.
DE CLERCQ,E. 1988b. Molecular targets for selective 
antiviral chemotherapy in : "ANTIVIRAL DRUG DEVELOPEMENT : A
MULTIDISCIPLINARY APPROACH" pp 9 7-122. Edited by E. De 
Clercq and R.T. Walker. Plenun Press, New York and London.
DE CLERCQ,E. 1989. Approaches to chemotherapy of HIV 
infection in : "BIOCHEMICAL ASPECTS OF ANTIVIRAL DRUGS AND
VACCINES". SGM, ANNUAL MEETING, APRIL 1989, UNIVERSITY OF 
CAMBRIDGE.
DE CLERCQ,E., BALZARINI,J. BERNAERT,R ., HERDEWIJN,P . 
and VERBRUGGEN,A . 1985a. Selective anti-herpetic activity of 
carbocyclic analogues of (E )-5-(2-halogenoviny1)- 
2'-deoxyuridines : dependence on specific phosphorylation by 
viral thymidine kinase. BIOCHIM. BIOPHYS. RES. COMMUN. 126 : 
397-403.
DE CLERCQ,E., BALZARINI,J ., TORRENCE,P.F .,
MERTES,M.P., SCHMIDT,C.L., SHUGAR,D., BARR,P.J., JONES,A.S., 
VERHEST,G. and WALKER,R.T. 1981. Thymidylate synthetase as 
target enzyme for the inhibitory activity of 5-substitute 
2'-deoxyuridines on mouse leukaemia L 1210 cell growth. MOL. 
PHARMACOL. 19 : 3 21-3 30.
DE CLERCQ,E., BENOIT,Y., LAUREYS,G . and DELBEKE,M .J . 
1985b. In : "HERPES VIRUSES AND VIRUS CHEMOTHERAPY" pp
49-52. Edited by R. Kons. Esevier Science Publishers, 
Amsterdam.
DE CLERCQ,E., BERES,J . and BENTRUDE,N.G . 1987. Potent 
activity of S-fluoro-21-deoxyuridine and related compounds 
against thymidine kinase deficient (TK-) herpes simplex 
virus: targeted at thymidylate synthase. MOL. PHARMACOL. 32 
: 286-292.
DE CLERCQ,E. and BERNAERTS,R. 1987. Specific 
phosphorylation of 5-ethyl 2'-deoxyuridine by herpes simplex 
virus-infected cells and incorporation into viral DNA. J. 
BIOL. CHEM. 262, 31 : 14905-14911.
DE CLERCQ,E. and COOLS,M. 1985. Antiviral potency of 
adenosine analogues : correlation with inhibition of 
S-adenosylhomocysteine hydrolase. BIOCHIM. BIOPHYS. RES. 
COMMUN. 129 : 306-311.
DE CLERCQ,E., DESCAMPS,J., DE SOMER,P., BARR,P.J., 
JONES,A.S. and WALKER,R.T. 1979 . ( e )-5-( 2-bromovmyl)-
2 1-deoxyuridine : a potent and selective anti-herpes agent.
P.N.A.S. U.S.A. 76 : 2947-2951.
DE CLERCQ,E., DESCAMPS,J., DE SOMER,P. and HOLY,A. 
1978b. (s)-9-(2,3-dihydroxypropyl)adenine : an aliphatic
nucleoside analogue with broad spectrum antiviral activity. 
SCIENCE 200 : 563-565.
DE CLERCQ,E., DESCAMPS,J., HUANG,G-F. and 
TORRENCE,P.F . 1978a. 5-Nitro-2'-deoxyuridine and 
5-nitro-21-deoxyuridine 5 1-monophosphate: antiviral activity 
and inhibition of thymidylate synthetase in vivo. MOL. 
PHARMACOL. 14 : 422-43 0.
DE CLERCQ,E., DESGRANGES,C ., HERDENIJN,P , SIM,I.S., 
JONES,A.S., McLEAN,M.J. and WALKER,R.T. 1986a. Synthesis and 
antiviral activity of (E )-5-(2-bromovinyl)uraci1 and 
(E)-5-(2-bromovinyl)uridine. J. MED. CHEM. 29 : 213-219.
DE CLERCQ,E., DESGRANGES,C ., HERDENIJN,P ., SIM,I.S. 
and WALKER,R.T. 1985c. In : "PROCEEDINGS OF THE EIGHTH
INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY. VOL. 1" pp 
198-210. Edited by R. Dahlbom and J.L.G. Nillson. Swedish 
Pharmaceutical Press,Stockholm.
DE CLERCQ,E. and HOLY,A. 1979. Antiviral activity of 
aliphatic nucleoside analogues : structure-function 
relationship. J. MED. CHEM. 22 : 510-513.
DE CLERCQ,E. and HOLY,A. 1985. Alkyl esters of
3-adenin-9-yl-2-hydroxypropanoic acid : a new class of broad 
spectrum antiviral agents. J. MED. CHEM. : 282-287.
DE CLERCQ,E., HOLY,A., ROSENBERG,I., SAKUMA,T., 
BALZARINI,J. and MAUDGAL P.C. 1986b. A novel selective broad 
spectrum anti-DNA virus agent. NATURE 323 : 464-466.
DE CLERCQ,E. and ROSENWITH,B. 1985. Selective in vitro 
an in vivo activities of 5-(2-haloalky1) pyrimidine 
nucleoside analogues, particularly 5-(2-chloroethyl)- 
2'-deoxyuridine, against herpes simplex virus. ANTIMICROB. 
AGENTS. CHEMOTHER. 28 : 246-251.
DE CLERCQ,E. and SHUGAR. 1975. Antiviral activity of 
5-ethyl pyrimidine deoxynucleosides. BIOCHEM. PHARMACOL. 24 
: 1073-1078.
DE FERRA,F . and BAGLIONI,C. 1981. Viral messenger RNA 
unmethylated in the 5 '-terminal guanosine in interferon 
treated HeLa cells infected with vesicular stomatitis virus.
VIROL. 112 : 426-435.
DE FERRA,F. and BAGLIONI,C. 1983. Increase in
S-adenosylhomocysteine concentration in interferon treated 
HeLa cells and inhibition of vesicular stomatitis virus. 
VIROL. 112 : 426-435.
DE LA HABA,G. and CANTONI,G.L. 1959. The enzymatic 
synthesis of S-adenosyl-L-homocysteine from adenosine and 
homocysteine. J.BIOL. CHEM. 234 : 603-608.
DELONG,D.C. and REED,S.E. 1980. Inhibition of 
rhinovirus replication in organ culture by a potential 
antiviral drug. J. INFECT. DIS. 141 : 87-91.
DESGRANGES,C, DE CLERCQ,E., RAZAKA,G ., DROUILLET,F., 
BELLOC,I. and BRICAUD,H. 1986. Deoxyribosyl exchange 
reactions leading to the in vivo generation and regeneration 
of the antiviral agents (E )-5-(2-bromovinyl)- 
21-deoxyuridine, 5-ethyl-2'-deoxyuridine and 
5-(2-chloroetnyl)-21-deoxyuridine. BIOCHEM. PHARM. 35 : 
1647-1653.
DESGRANGES,C. , RAZAKA,G., RABAUD,M. , BRICAU D,H. , 
BALZARINI,J. and DE CLERCQ,E. 1983. Phosphorolysis of 
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 
5-substituted-2'-deoxyuridines by purified thymidine 
phosphorylase and intact blood platelets. BIOCHEM.
PHARMACOL. 32 : 3583-3590.
DIANA,G.D. and OTTO,M.J. 1985. Inhibitors of 
picornavirus uncoating as antiviral agents. PHARMAC. THER.
29 : 287-294.
DIANA,G.D., SALVADOR,U.J., ZALAY,E .S.,
CARABATEAS,P .M ., WILLIAMS,G .L ., COLLINS,J.C. and PANCIC,F. 
1977. Antiviral activity of some B-diketones. 2. Aryloxyl 
alkyl diketones. In vitro activity against both RNA and DNA 
viruses. J. MED. CHEM. 20 : 757-765.
DOLIN., REICHMAN,R.C ., MADORE,H.P ., MAYNARD,R.,
LINTON,P.N. and WEBBER-JONES,J. 1982. A controlled trial of 
amantidine and rimantidine in the prophylaxis of influenza A 
infection. NEW ENG. J. MED. 307 : 580-584.
DOURHOM,E., ROZENBAUM,W., MICHON,C., PERRONE,C., DE 
TRUCHIS,P., BOUVET,E. et al. 1988. Effects of zidovudine in 
365 consecutive patients with AIDS or AIDS related complex. 
THE LANCET,VOL 2 : 1297-1302.
DRACH,J .C . 1983. Purine nucleoside analogues as 
antiviral agents, in : " TARGETS FOR THE DESIGN OF ANTIVIRAL
AGENTS " pp 231-257. Edited by R.T. Walxer and E. De Clercq.
Plenum Press, London.
DULBECCO,R. and VOGT,M. 1954. Plaque formation and 
isolation of pure lines with poliomyelitis virus. J. EXP. 
MED. 99 : 167-182.
DUNPHY, W . G ., BRANDS,R. and ROTHMAN,J .E . 1985. 
Attachment of terminal N-acetylglucosamine to 
asparigine-1inked oligosaccharides occurs on the central 
cisternae of the Golgi stack. CELL 40 : 463-473.
EGGERS,H.J. 1985. Antiviral agents against 
picornaviruses. ANTI. RES. 1 : 57-65.
ELBEIN,A.D., MITCHELL,M., SANFORD,B .A ., FELLOWS,L.E. 
and EVANS,S.V. 1984. The pyrrolidine alkaloid 2,5 
rdihydroxymethyl-3,4di hydroxypyrrolidine inhibits 
glycoprotein processing. J. BIOL. CHEM. 259 : 12409-12413.
ELION,G.B., FURMAN,P.A., FYLE,J.A ., DE MIRANDA,P., 
BEAUCHAMP,L. and SCHAEFFER,H.J. 1977. Selectivity of action 
of an antiherpetic agent, 9-(2-hydroxymethyl) guanine. 
P.N.A.S. U.S.A. 74 : 5716-5720.
EMERSON,S.U. and YU,Y-H. 1975. Both NS and L proteins 
are required for in vitro RNA synthesis by vesicular 
stomatitis virus. J. VIROL. 15 : 1348-1356.
EMINI,E .A ., LEIBOWITZ,J ., DIAMOND,D .L ., BONIN,J. and 
WIMMER,E. 1984. Recombinants of Mahoney and Sabin strain 
poliovirus type 1 : analysis of in vitro phenotypic markers 
and evidence that resistance to guanidine maps in the 
non-structural proteins. VIROL. 137 : 71-85.
EPSTEIN,M.T., ESPINER,E.A ., DONALD,R.A. and HUGHES,H. 
1977. Effect of eating liquorice on the renin-angiotensin 
aldosterone axis in normal subjects. BRIT. MED. J. 1^ : 
488-490.
EVERITT,E . and PHILIPSON,L. 1974. Structural proteins 
of adenovirus XI. Purification of three low molecular weight 
virion proteins of adenovirus type 2 and their synthesis 
during productive infection. VIROL. 62 : 253-269.
FARREL,P.J ., SEN,G .C ., DUBOIS,M.F., RATNER,L ., 
SLATTERY,E. and LENGYEL,P. 1978. Interferon action : 2
distinct pathways for inhibition of protein synthesis by 
double-stranded RNA. P.N.A.S. 75 : 5893-5897.
FELLOWS,L.E. 1986. The biological activity of 
polyhydroxyalkaloids from plants. PEST. SCI. 17 : 602-606.
FELSENSTEIN,D. , D 1 AMICO,D .J . , HIRSCH,M.S.,
NEUMEYER,D . A ., CEDERBERG,D .M . , DE MIRANDA,P . and 
SCHOOLEY,R .T . 1985. Treatment of cytomegalovirus retinitis 
with 9- (2-hydroxy-l-(hydroxymethyl ethoxymethyl) 
ethoxymethyl]guanine. ANN. INTERN. MED. 103 : 377-380.
FIDDIAN,P. 1988. New analogues to acyclovir with 
increased potency to herpes viruses, in : "APPLIED VIROLOGY
RESEARCH, VOL 1. NEW VACCINES AND CHEMOTHERAPY" pp233-240. 
Edited by E. Kurstak, R.G. MarisyK, F.A. Murphy and M.H.V. 
Van Regenmortel. Plenum Medical Book Company, New Yorx and 
London.
FIELDS,B.N., RAINE,C.S. and SAUM,S.G. 1971. 
Temperature-sensitive mutants of reovirus type 3 : defects 
in viral maturation as studied by immunofluorescence and
electron microscopy. VIROL. 43 : 569-578.
FISCHER,P. H. , CHEN,M.S. and PRUSOFF,W.H. 1980 . The 
incorporaton of 5-iodo-51-amido-2',51-dideoxyuridine and 
5-iodo-2'-deoxyuridine into herpes simplex DNA. Relationship 
between antiviral activity and effects on DNA structure.
BIOCHIM. BIOPHYS. ACTA. 606 : 236-245.
FREEMAN,G.J., ROSE,J.K., CLINTON,G.M. and HUANG,A.S. 
1977. RNA synthesis of vesicular stomatitis virus. VII. 
Complete separation of the mRNAs of vesicular stomatitis 
virus. J. VIROL. 21 : 1094-1104.
FULLER,R.N. and NAGARAJAN,R . 1978. Inhibition of 
methyltransferases by some new analogues of
S-adenosylhomocysteine. BIOCHEM. PHARMACOL. 27 : 1981-1983.
FURMANN,U ., BAUSE,E. and PLOEGH,H. 1985. Inhibitors of 
oligosaccharide processing. BIOCHIM. BIOPHYS. ACTA. 825 : 
95-100.
FURMAN,P.A., FYFE,J.A . , ST. CLAIR,M.H., WEINHOLD,K . , 
RIDEOUT,J .L ., FREEMAN,G .A., et al. 1986. Phosphorylation of 
3 1-azido-31-deoxythymidine and selective interaction of the 
5'-triphosphate with human immunodeficiency virus with 
reverse transcriptase. P.N.A.S. U.S.A. 83 : 8333-8337.
FURUICHI,Y ., LA FINANDRA,A . and SHATKIN,A .J . 1977.
5'-terminal structure and mRNA stability. NATURE (LONDON)
266 : 235-239.
FYFE,J.A., KELLER,P.M., FURMAN,P.A., MILLER,R.L. and 
ELION,G.B. 1978. Thymidine kinase from herpes simplex virus 
phosphorylates the new antiviral compound 9-(2-hydroxy 
ethoxymethyl)guanine. J. BIOL. CHEM. 253 : 8721-8727.
GALBRAITH,A.W. 1985. Influenza- recent developments in 
prophylaxis and treatment. BRIT. MED. BULL. 41 : 381-385.
GALLO,R.C. and REITZ,M.S. JR. 1988. Human retroviruses 
and anti-viral therapies in : " ANTIVIRAL DRUG DEVELOPMENT.
A MULTIDISCIPLINARY APPROACH " pp7 3-8 0. Edited by E. De 
Clercq and R.T. Walker. Plenum Press, New York and London.
GETHING,M.J., WHITE,J.M. and WATERFIELD,M.D. 1978. 
Purification of the fusion protein of Sendai virus : 
analysis of the NH^-terminal sequence generated during 
precursor activation. P.N.A.S. U.S.A. 75 : 2737-2740.
GIL-FERNANDEZ,C . and DE CLERCQ,E. 1987. Comparitive 
efficacy of broad spectrum antiviral agents as inhibitors of 
African swine fever virus replication in vitro. ANTIVIRAL 
RESEARCH 7 : 151-154.
GLAZER,R.I. and KN0DE,M.C. 1984. Neplanocin A. A 
cyclopentenyl analogue of adenosine with specificity for 
inhibiting RNA methylation. J. BIOL. CHEM. : 12964-12969.
GOMATOS,P.J ., TAMM,I., DALES,S. and FRANKLIN,R .M .
1962. Reovirus type 3 : physical interactions with L cells. 
VIROL. 17 : 441-454.
GOSWAMI,B.B., BOREK,E., SHARMA,0.K ., FUJITAKI,J. and 
SMITH,R.A. 1979. The broad spectrum antiviral agent 
ribavirin inhibits capping of mRNA. BIOCHIM. BIOPHYS. RES. 
COMMUN. 89 : 830-836.
GOSWAMI,B.B., SHARMA,O.K., BOREK,E. and SMITH,R.A.
+* I-*
Current chemotherapy and immunotherapy. PROCEEDINGS 12 
INTERNATIONAL CONGRESS OF CHEMOTHERAPY., Florence, Italy, 
1981. Vol 2 : 1075-1086.
GRAHAM,F.L., SMILEY,S., RUSSELL,W.C. and NAIRN,R.
1977. Characteristics of a human cell line transformed by 
DNA fron adenovirus type 5. J. GEN. VIROL. 36 : 59-72.
GRESSER,I., DE MAEYER-GUIGNARD, TOVEY, M.G. and DE 
MAEYER,E. 1979. Electrophoretically pure mouse interferon 
exerts multiple biological effects. P.N.A.S U.S.A. 76 : 
5308-5312.
GRIENGL,H., BODENTEICH,M., HAYDEN,W., WANER,E., 
STREICHER,W ., STUTZ,P., BACHMAER,H., GHAZZOULI,I. and 
ROSENWITH,B . 1985. 5-(haloalky1)-2'-deoxyuridines : a novel 
type of potent antiviral nucleoside analogue. J. MED. CHEM. 
28 : 1679-1684.
GRIFFITHS,G., BRANDS,R., BURKE,B., LOWCARDI,D. and
WARREN,G. 1982. Viral memb rane proteins acquire galactose in 
trans Golgi cisternae during intracellular transport. J.
CELL BIOL. 95 : 781-792.
GRIFFITHS,G., QUINN,P. and WARREN,G. 1983. Dissection 
of the Golgi complex. 1. Monensin inhibits the transport of 
viral membrane proteins from medial to trans Golgi cisternae 
in baby hamster kidney cells infected with semliki forest 
virus. J. CELL. BIOL. 96 : 835-850.
GRUTERS,R.A., NEEFJES,J .J ., TERSMETTE,M ., DE GOEDE., 
TULP,A ., HUISMAN,H.G., MIEDEMA,F. and PLOEGH,H.L . 1987. 
Interference with HIV-induced synctium formation and viral 
infectivity by inhibition of trimming glucosidase. NATURE 
330 : 74-77.
HAHN,B.H ., SHAN,G.M ., TAYLOR,M.E., REDFELD,R .R ., 
MARKHAM,P.D., SALAHUDDIN,S.Z., WONG-STAAL,F., GALLO,R.C., 
PARKS,E.S. and PARKS,N.P. 1986. Genetic variation in HTLV 
III/LAV over time in patients with AIDS or at risk for AIDS. 
SCIENCE 232 : 1548-1553.
HAMRE,D., BERNSTEIN,J. and D0N0VICK,R. 1950. Activity 
of p-aminobenzoaldehyde 3-thiosemicarbazone on vaccinia 
virus in the chick embryo and in the mouse. PROC. SOC. EXP. 
BIOL. MED. 7 3 : 2 7 5-278.
HASOBE,M., MCKEE,J.G., BORCHERDING,D.R . and 
BORCHARDT,R .T . 1987. 9-(trans-2', trans-3'- 
dihydroxycyclopent-41-enyl-)-adenine and -3-deazaadenine : 
analogues of neplanocin A which retain potent antiviral 
activity but exhibit reduced cytotoxicity. ANTIMICROB. 
AGENTS. CHEMOTHER. 31,2 : 1849-1851.
HASOBE,M., MCKEE,J.G., BORCHERDING,D .R ., KELLER,B.T. 
and BORCHARDT,R.T. 1988. Effects of 9-(trans-2', 
trans-3'-dihydroxycyclopent-4'-enyl)-adenine and 
-3-deazaadenine on the metabolism of S-adenosylhomocysteine 
hydrolase in mouse L929 cells. MOL. PHARMACOL. 33 : 713-720.
HAY,A.J., WOLSTENHOLME,A.J., SKEHEL,J .J . and 
SMITH,M.H. 1985. The molecular basis of the specific 
anti-influenza action of amantidine. EMBO J. 4 : 3621-3624.
HAY,A .J . and ZAMBON,M.C. 1984. Multiple action of 
amantidine against influenza viruses, in : " ANTIVIRAL DRUGS
AND INTERFERON. THE MOLECULAR BASIS OF THEIR ACTIVITY " 
pp301-315. Edited by Y. Becker. Martinus Nijhoff, Boston.
HAY,A .J ., ZAMBON,M.C ., WOLSTENHOLME,A .J ., SKEHEL,J.J.
and SMITH,M.H. 1986. Molecular basis of resistance of 
influenza A viruses to amantidine. J. ANTIM. CHEM. 18,
Suppl. B. : 19-2 9.
HAYDEN,F.G. and GWALTNEY,J .M . 1982. Prophylactic 
activity of intranasal enviroxime against experimentally 
induced rhinovirus type 39 infection. ANTI. AGENTS. 
CHEMOTHER. 21 : 8 92-8 97.
HELENE,C. 1989. Modified oligonucleotides as antiviral 
agents in abstracts from : "BIOCHEMICAL ASPECTS OF ANTIVIRAL 
DRUGS AND VACCINES". SGM, ANNUAL MEETING, APRIL 1989, 
UNIVERSITY OF CAMBRIDGE.
HELENIUS,A ., MARSH.M. and WHITE,J. 1982. Inhibition of 
semliki forest virus penetration by lysomotrophic weak 
bases. J. GEN. VIROL. 58 : 47-61.
HELENIUS,A., KARTENBECK,J ., SIMONS,K. and FRIES,E.
1980. On the entry of semliki forest virus into BHK-21 
cells. J. CELL. BIOL. 84 : 404-420.
HELENIUS,A. KIELIAN,M., WELLSTEED,J ., MELLMAN,I. and 
RUDNICK,G. 1985. Effects of monovalent cations on semliki 
forest virus entry into BHK-21 cells. J. BIOL. CHEM. 260 : 
5691-5697.
HELGSTRAND,E., ERIKSSON,B., JOHANSSON,N.G .,
LANNERO,B., LARSSON,A., MISIORNY,A., NOREN,J.Q ., SJOBERG,B., 
STENBERG,K., STENING,G., STRIDH,S. and OBERG,B. 1978. 
Trisodium phosphonoformate, a new antiviral compound.
SCIENCE 201 : 819-821.
HELGSTRAND,E., FLODH,H., LERNESTEDT,J .0., LUNDSTROM,J. 
and OBERG,B. 1980. Trisodium phosphonoformate : antiviral 
activities, safety evaluation and preliminary clinical 
results, in : "DEVELOPMENTS IN ANTIVIRAL THERAPY" pp6 3-8 3.
Edited by Collier and Oxford . Academic Press, London.
HERDEWIJN,P ., DE CLERCQ,E., BALZARINI,J . and 
VANDERHAEGHE,H. 1985. Synthesis and antiviral activity of 
the carbocyclic analogues of (E )-5-(-2-halovinyl)- 
2 1-deoxyuridines and (E)-5-(2-halovinyl)-21-deoxyuridines.
J. MED. CHEM. 28 : 550-555.
HERRMANN JR.,E.C. 1961. Plaque inhibition test for 
detection of specific inhibitors of DNA containing viruses. 
PROC. SOC. EXP. BIOL. MED. 107 : 142-145.
HODDS,H .E ., BERNSTEIN,B., NISALAK,A ., TJIO,J.H. and 
SMADEL,J .E . 1963. Biological characteristies of a continuous
kidney cell line derived from the African Green Monkey . J. 
IMMUN. 91 : 416-422.
HOLBROOK,J.J., LILJAS,A., STEINDEL,S.T . and 
ROSSMAN,M.G. 1975. in : "THE ENZYMES VOL 11" ppl91-204. 
Edited by P.D. Boyer. Academic Press, New York.
HOMMA,M. and OHUCHI,M. 1973. Trypsin action on the 
growth of sendai virus in tissue culture cells. III. 
Structural difference of sendai viruses grown in eggs and in 
tissue culture cells. J. VIROL. 12 : 1457-1465.
HORWITZ,J.P., CHUA,J. and NOEL,M. 1964. Nucleosides V. 
The monomesylates of 1-(21-deoxy-B-D-lyxofuranosyl)thymine. 
J. ORG. CHEM. 29 : 2076-2078.
HSU,C .H ., MORGAN,E.M. and KINGSBURY,D .W . 1982.
Site-specific phosphorylation regulates the transcripitive 
activity of vesicular stomatitis NS protein. J. VIROL. 43 : 
104-112.
HSU,M .C ., SCHEID,A . and CHOPPIN, P.W. 1982.
Enhancement of membrane fusing activity of Sendai virus by 
exposure of the virus to basic pH is correlated with a 
conformational change in the fusion protein. P.N.A.S. U.S.A. 
79 : 5862-5866.
HUDSON,L.D., CONDRA,C . and LAZZARINI,R.A. 1986.
Cloning and expression of a viral phosphoprotein : structure 
suggests vesicular stomatitis virus NS may function by 
mimicking and RNA template. J. GEN. VIROL. 67 : 1571-1579.
IMBLUM, R.L. and WAGNER,R.R. 1974. Protein kinase and 
phosphoproteins of vesicular stomatitis virus. J. VIROL. 13 
: 113-124.
INABA,M ., NAGASHIMA,K., TUKAGOSHI,S. and SAKURA,Y.
1986. Biochemical mode of cytotoxic action of neplanocin A 
in L 1210 leukaemic cells. CANCER RES. : 1063-1067.
ISAACS,C.L. and KEENE,J.D. 1982. RNA 
polymerase-associated interactions near template promoter 
sequences of defective interfering particles of vesicular 
stomatitis virus. J. VIROL. 43 : 241-249.
ISAACS,A. and LINDEMANN,J. 1957. Virus interference I. 
The interferon. PROC. R. SOC. B147 : 258-267.
ISHITSUKA,H., NINOMIYA,Y . and SUHARA,Y . 1986.
Molecular basis of drug resistance to new antirhinovirus 
agents. J. ANTIM. CHEMOTHER. 18, Suppl. B. : 11-18.
ISHITSUKA,H., OHSAWA,C., OHIWA,T., UMEDA.,I. and
SUHARA,Y . 1982. Antipicornavirus flavone Ro 09-0179. ANTIM. 
AGENTS. CHEMOTHER. 22 : 611-666.
ITO,M ., NAKASHIMA,H., BABA, M . , PAUWELS,R., DE 
CLERCQ,E., SHIGETA,S. and YAMAMOTI,N. 1987. Inhibitory 
effect of glcyrrhizin on the in vitro infectivity and 
cytopathic activity of the human immunodeficiency virus 
(HIV/HTLV-III/LAV). ANT. RES. 7 : 127-137.
JACOBS,J.P., JONES,C.M. and BAILLE,J.P. 1970.
Characteristies of a human diploid cell designated MRC-5. 
NATURE 227 : 168-170.
JACQUEMONT,B and HUPPERT,J. 1977. Inhibition of viral 
methylation in herpes simplex virus type 1-infected cells by 
5' S-isobutyl-adenosine. J. VIROL. 22 : 160-167.
JENKINS,F.J. and CHEN,Y.C. 1981. Effect of ribavirin 
on Rous Sarcoma virus transformation. ANTIM. AGENTS. 
CHEMOTHER. 19 : 364-368.
JENSEN,E.M. and LUI,O.C. 1963. Inhibitory effect of 
simple aliphatic amines on influenza virus in tissue 
culture. PROC. SOC. EXPER. BIOL. MED. 112 : 456-459.
JOHNSON,P.C. and SCHLESINGER,M.J. 1980. Vesicular 
stomatitis virus and Sindbis virus glycoprotein transport to 
the cell surface is inhibited by ionophores. VIROL. 103 : 
407-424.
JONES,A.S., VERHELST,G. and WALKER,R.T. 1979. The 
synthesis of the potent anti-herpes virus agent,
E-5(2-bromovinyl)-2'-deoxyuridine and related compounds.
TET. LETT. 6 : 4415-4418.
JOUBERT,P .H., BAM.N.J. and MANYANE,N . 1986. Effect of 
an alpha glucosidase inhibitor (BAY m 1099) on prostprandial 
blood glucose and insulin in type II diabetes. EUR.J. CLIN. 
PHARM. 3 0 : 25 3-2 55.
KAEHLER,M ., COWARD,J. and ROTTMAN,F. 1979. Cytoplasmic 
location of undermethylated messenger RNA in Novikoff cells. 
NUC. ACID. RES. 6 : 1161-1175.
KAUFMAN,H.E. 1962. Clinical cure of herpes simplex 
keratitis by 5-iodo-21-deoxyuridine (27169). PROC. SOC. EXP. 
BIOL. 109 : 251-261.
KELLER,B.T. and BORCHARDT,R .T . 1986. Metabolism and 
mechanism of action of neplanocin A- a potent inhibitor of 
S-adenosylhomocysteine hydrolase, in : "BIOLOGICAL 
METHYLATION AND DRUG DESIGN" pp385-396 Edited by R.T.
Borchardt, C.R. Creveling and R.M. Uleand. The Human Press, 
Clifton, New York.
KELLER,B.T., CLARK,R.S., PEGG,A.E. and BORCHARDT,R .T .
1985. Purification and characterisatin of some metabolic 
effects of S-neplanocylmethionine. MOL. PHARMACOL. 28 : 
364-370.
KERANEN,S. and RUOHONEN,L. 1983. Non-structural 
proteins of semliki forest virus : synthesis processing and 
stability in infected cells. J. VIROL. 47 : 505-551.
KERR,I.M. and BROWN,R.E. 1978. pppA2'p51A2'p5'A : an 
inhibitor of protein synthesis synthesised with an enzyme 
fraction from interferon treated cells. P.N.A.S. U.S.A. 75 
256-260.
KERR,I.M., BROWN,R.E. and BALL,L.A. 1974. Increased 
sensitivity of cell free protein synthesis to double 
stranded RNA after interferon treatment. NATURE 250 : 57-59
KING,D.H. and FIDDIAN,A .D . 1986. In : "CLINICAL
ADVANCES IN ANTIVIRAL THERAPY" pp65-71. Edited by P. 
Lietman, S. Ohtani and A.P. Fiddian. University of Tokyo 
Press, Tokyo, Japan.
KINGSFORD,L. and EMERSON,S.U. 1980. Transcriptional 
activities of different phosphorylated species of NS protei 
from vesicular stomatitis virions and cytoplasm of infected 
cells. J. VIROL. 33 : 1097-1105.
KITS,S., ICHIMURA,I. and DE CLERCQ,E. 1987. 
Phosphorylation of nucleoside analogues by equine 
herpesvirus type 1 pyrimidine deoxyribonucleoside kinase. 
ANTIVIRAL RES. 7 : 5 3-5 7.
KLENK,H-D., ROTT,R., ORLICH,M. and BLODORN,J. 1975. 
Activation of influenza A viruses by trypsin treatment. 
VIROL. 68 : 425-439.
KORANT,B .D . 1977. Poliovirus coat protein as the site 
of guanidine action. VIROL. 81 : 17-28.
KORANT,B.D., LONBERG-HOLM,K ., NOBLE,J. and 
STANSKY,J .T . 1972. Naturally occurring and artificially 
produced components of 3 rhinoviruses. VIROL. 48 : 71-85.
KORANT,B.D., LONBERG-HOLM,K ., YIN,F-H. and NOBLE,J. 
1975. Fractionation of bilogically active and inactive 
populations of human rhinovirus type 2. VIROL. 63 : 384-394
KORNFELD,R . and KORNFELD,S. 1985. Assembly of 
asparigine linked oligosaccharides. ANNU. REV. BIOCHEM. 54
631-634 .
KRENITSKY,T .A ., HALL,W.W., DE MIRANDA,P.,
BEAUCHAMP,L.M., SCHAEFFER,H .J . and WHITEMAN,P .D . 1984.
-deoxyacyclovir : A xanthine oxidase-activated prodrug of 
acyclovir. P.N.A.S. U.S.A. 81 : 3209-3213.
KRUG,R .M ., BRONI,B .A . and BOULDY,M . 1979. Are tha 5' 
ends of influenza viral mRNAs synthesised in vivo or donated 
by host mRNAs. CELL 18 : 329-334.
LAEMMLI,U.K. 1970. Cleavage of structural proteins 
during the assembly of the head of bacteriophage T4. NATURE 
227 : 680-685.
LARDER,B., DARBY,G. and RICHMAN,D .D . 1989. HIV with 
reduced sensitivity to Zidovudine (AZT) isolated during 
prolonged therapy. SCIENCE 243 : 1731-1734.
LARDNER,B .A ., PURIFOY,D .J .M ., POWELL,K.L. and DARBY,G.
1987. Site-specific mutagenisis of AIDS virus reverse 
transcriptase. NATURE (London) 327 : 716-717.
LARSSON,A., STENBERG,K., ERICSON,A-C., HAGLUND,U.,
YISAK,W-A., JOHANSSON,N.G. , OBERG,B. and DATEMA,R . 1986.
Mode of actions, toxicity, pharmokinetics and efficacy of 
some new antiherpes guanosine analogues related to 
buciclovi r. ANTI. AGENTS. CHEM. 30 : 598-605.
LAZAROWITZ,S.G . and CHOPPIN,P.W. 1975. Enhancement of 
the infectivity of influenza A and B viruses by proteolytic 
cleavage of the haemagglutinin polypeptide. VIROL. 68 : 
440-454.
LAZAROWITZ,S.G., COMPANS,R.W. and CHOPPIN,P.W. 1971. 
Influenza virus structural and non-structural proteins in 
infected cells and their plasma membranes. VIROL. 46 : 
830-843.
LAZAROWITZ,S.G., GOLDBERG,A.R . and CHOPPIN,P.W. 1973. 
Proteolytic cleavage by plasmin of the HA polypeptide of 
influenza virus : host cell activation of serum plasminogen. 
VIROL. 5 6 : 17 2-18 0.
LEBLEU,B., SEN,G.C ., SHAILA,S., CABRER,B .and 
LENGYEL,P . 1976. Interferon, double-stranded RNA and protein 
phosphorylation. P.N.A.S. U.S.A. 73 : 3107-3111.
LEDGER,P.W. and TANZER,M.L. 1984. Monensin : a
perturbant of cellular physiology. TRENDS BIOCHEM. SCI. 9 :
313-314.
LE DOAN,T., PERROUAULT,L., PRASEUTH,D., HABHOUB,N.,
DECOUT, J . L ., THUONG,N . T . , LHOMME,J . and HELENE,C. 1987. 
Sequence specific recognition, photocrosslinking and 
cleavage of the DNA double helix by an 
oligo-[alpha]-thymidylate covalently linked to an 
azidoproflavine derivative. NUC. ACID. RES. 15 : 7749-7760.
LEIBOVITZ,A. 1963. The growth and maintenance of 
tissue cell cultures in free gas exchange with the 
atmosphere. AM. J. HYG. 78 : 173-180.
LENGYEL,P. 1981. Mechanism of interferon action : the 
(21-5')(A )n synthetase-RNase L pathway, in : " INTERFERON 3
pp78-99. Edited by I. Gresser. New York, Academic Press.
LENGYEL,P. 1982. Biochemistry of interferons and their 
actions. ANN. REV. BIOCHEM. 51 : 251-281.
LEVANDOWSKI,R.A., PACHUCKI,C .T ., RUBENIS,M. and 
JACKSON,G.G. 1982. Topical enviroxime against rhinovirus 
infection. ANTI. AGENTS. CHEM. 22 : 1004-1007.
LIFSON,J.D ., FEINBERG,M.B., REYES,G.R., RABIN,L., 
BANAPOUR,B . and CHAKRABARTI,S. 1986. Induction of CD4 
dependent cell fusion by the HTLV 111/LAV envelope 
glycoprotein. NATURE 323 : 725-728.
LIN,J.C ., SMITH,M.C. and PAGANO,J.S. 1984. Prolonged 
inhibitory effect of
9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication 
of Epstein-Barr virus. J. VIROL. 50 : 50-55.
LINNE,T. and PHILIPSON,L. 1980. The nature of the 
phosphate moiety of the adenovirus type 2 DNA-binding 
protein. EUR. J. BIOCHEM. 103 : 259-264.
LITTLER,E., ZEUTHEN,J., MCBRIDE,A .A .,
TROST-SORENSON,E., POWELL,K.L., WALSH-ARRAND,J .E . and 
ARRAND,J.R. 1986. Identification of an Epstein-Barr virus 
encoded thymidine kinase. EMBO. J. 5 : 1959-1966.
LODDO,B ., FERRARI,W., SPANEDDA,A . and BROTZU,G. 1962. 
In vitro guanidine resistance and guanidine dependence of 
poliovi ruses. EXPEREMENTIA 18 : 518-519.
LONBERG-HOLM,K. and KORANT,B.D. 1972. Early 
interaction of rhinoviruses with host cells. J. VIROL. 9 :
29-40.
LONBERG-HOLM,K. and YIN,F.H. 1973. Antigenic 
determinants of infective and inactivated human rhinovirus 
type 2. J. VIROL. 12 : 114-123.
LUNDGREN,B., ERICSON,A.C ., BERG,M. and DAREMA,R. 1986.
*  ; H-‘S t cfcc*»e>,e , r. < ■ > ^ ^ - s h A R P s y j.n . ir.Jt
(i-v\t>'OV c| prJti'-'VV ^^,atV)(T^)r‘j VV'U Vl^rp^av k.KlA-5 t i/V-y>i ^  K  <A
C tU -3  C vaA  inri r'S cj~ JVie i v v c U ^ d  b < j
v\l-W V V y |jO C  CWUt-V 'J v X h ? 'e > /> t  £ /V ) p e V lA 'C W C  '  *Svi-'/V^itrt'\'v'e
cp rrSv ->xvci,w'v i J  •
T- ^BN • V/COv. 5i. 3 12.
Efficacy of the acyclic guanosine analogue buciclovir 
[(R)-9-(3,4)-dihydroxybutyl)guanine] in experimental genital 
herpes. ANTI. AGENTS. CHEM. 29 : 294-297.
MACHIDA,H., KUNINAKA,A . and YOSHINO,H. 1982.
Inhibitory effects of antiherpesviral thymidine analogues 
against varicella zoster virus. ANTI. AGENTS. CHEM. 21 : 
358-361.
MACPHERSON,I.A. and STOKER,M.G.P . 1962. Polyoma 
transformation of hamster cell clones : an investigation of 
genetic factors affecting cell competence. VIROL. : 147-151.
MARCUS,P.I., ENGELHARDT,D .L ., HUNT,J.M. and 
SEKELLICK,M.J. 1971. Interferon action : inhibition of
vesicular stomatitis virus RNA synthesis induced by 
virion-bound polymerase. SCIENCE 174 : 593-598.
MARSH,M., WELLSTEED,J., KERN,H., HARMS,E . and 
HELENIUS,A. 1982. Monensin inhibits semliki forest virus 
penetration into baby hamster kidney (BHK-21) cells.
P.N.A.S. U.S.A. : 5297-5301.
MARX,J .L . 1989. Wider use of AIDS drugs advocated. 
SCIENCE 245 : 811.
MASUR,H ., LANE,C. and PALESTINE,A. 1986. Effect of 
9-(1,3-dihydroxy-2-propoxymethyl)guanine on serious 
cytomegalovirus disease in eight immunosuppressed homosexual 
mefi Ann. Intern. Med. 104 : 41-44.
MATUSZEWSKA,B . and BORCHARDT,R.T. 1987. The role of 
nicotinamide adenine dinucleotide in the inhibition of 
bovine liver S-adenosylhomocysteine hydrolase by neplanocin 
A. J. BIOL. CHEM. 262 : 265-268.
MAUDGAL,P .C ., DE CLERCQ,E. and HUYGHE,P. 1987.
Efficacy of (S)-HPMA against thymidine kinase-deficient 
herpes simplex keratitis. INVEST. OPTHALMOL. VIS. SCI. 28 : 
243-247.
MAUDGAL,P.C., DIELTENS,M., DE CLERCQ,E. and 
MISSOTEN,L . 1985. In : "HERPETIC EYE DISEASES" pp247-256.
Edited by P.C. Maudgal and L. Missofen. W. Jink Publishers, 
Dordrecht.
McCORMICK,J.B., KING,I.J., WEGG,P.A., SCRIBNER,C .L ., 
CRAVEN,R.B., JOHNSON,K.M ., ELLIOT,L.H. and
BELMONT-WILLIAMS,R . 1986. Effective therapy with ribavirin. 
NEW. ENG. J. MED. 314 : 20-26.
McCORMICK,J.B., MITCHELL,S.W ., GETCHELL,J .P . and
HICKSfD.R. 1984. Ribavirin suppresses replication of 
lymphadenopathy-associated virus in cultures of human adult 
T lymphocytes. LANCET 2 : 1367-1369.
McDOWELL,W., ROMERO,P.A., DATEMA,R . and SCHAWRZ,R.T. 
1987. Glucose trimming and mannose trimming affect different 
phases of the maturation of sindbis virus in infected BHK 
cells. VIROL. 161 : 37-44.
McGUIRT,P.V ., SHAW,J .E ., ELION,G.B. and FURMAN,P.A .
1984. Identification of small DNA fragments synthesised in 
herpes simplex virus-infected cells in the presence of 
acyclovir. ANTI. AGENTS. CHEM. 25 : 507-509.
McKENDRICK,M.W., CLARE,C., BURKE,C., HICKMOTT,E . and 
McKENDRICK,G.D .W. 1984. Oral acyclovir in herpes zoster.J. 
ANTI. CHEM. 14 : 661-665.
McKENDRICK,M.W. 1985. Oral acyclovir in herpes zoster. 
SCAND. J. INFECT. DIS. 17 (SUPPLEMENT 47) : 76-79.
McKINLAY,M.A., MIRALLES,J .V ., BRISSON,C.J. and 
PANCIC,F. 1982. Prevention of human poliovirus induced 
paralysis and death in mice by the novel antiviral agent 
arildone. ANTI. AGENTS. CHEM. 22 : 1022-1025.
MeSHARRY,J .J ., CALIGUIRI,L .A . and EGGERS,H.J. 1979. 
Inhibition of uncoating of polioviruses by arildone, a new 
antiviral drug. VIROL. 97 : 307-315.
MELLON,M.G. and EMERSON,S.U. 1978. Rebinding of 
transcriptase components (L and NS proteins) to the 
nucleocapsid template of vesicular stomatitis virus. J. 
VIROL. 2 7 : 5 6 0-56 7.
MELNICK,J.L., CROWTHER,D. and BARRERA-ORO,J. 1961. 
Rapid development of drug resistant mutants of poliovirus. 
SCIENCE 134 : 551-555.
MEYERS,J.D. 1985. Treatment of herpesvirus infections 
in the immunocompromised host. SCAND. J. INFECT. DIS. 17 
(SUPPLEMENT 47) : 128-136.
MITSUYA,H. and BRODER,S. 1986. Inhibition of the in 
vitro infectivity and cytopathic effect of human T 
lymphotropic virus type 111/lymphadenopathy-associated virus 
(HTLV 111/LAV) by 2',3'-dideoxynucleosides. P.N.A.S. U.S.A. 
83 : 1911-1915.
MITSUYA,H., WEINHOLD,K .J ., FURMAN.P.A., ST.CLAIR,M .H ., 
LEHRMAN,S.N ., GALLO,R.C., BOLOGNESI,D ., BARRY,D.W. and 
BRODER,S. 1985. 3'-azido-3'-deoxythymidine (BW A509U) : an
antiviral agent that inhibits the infectivity and cytopathic 
effect of human T-lymphotropic virus type 
111/lymphadenopathy-associated virus in vitro. P.N.A.S. 
U.S.A. 82 : 7096-7100.
MONTGOMERY,J.A., CLAYTON,S.J ., THOMAS,H.J.,
SHANNON,W.M., ARNETT,G., BODNER,A.J., KIM,I-K., CANTONI,G.L . 
and CHIANG,P.K. 1982. Carbocyclic analogue of 
3-deazaadenosine : a novel antiviral agent using 
S-adenosylhomocysteine hydrolase as a pharmacological 
target. J. MED. CHEM. 25 : 626-629.
MOYER,S.A. and BANERJEE,A.K . 1975. Messenger RNA 
species synthesised in vitro by the virion-associated RNA 
polymerase of vesicular stomatitis virus. CELL 4 : 37-43.
MOYER,S.A., GRUBMAN,M.J., EHRENFELD,E . and 
BANERJREE,A.K. 1975. Studies on the in vivo and in vitro 
messenger RNA species of vesicular stomatitis virus. VIROL. 
67 : 463-473.
MUESING,M.A., SMITH,D .H ., CABRADILLA,C .D .,
BENTON,C.V., LASKY,L .A . and CAPON,D.J. 1985. Nucleic acid 
structure and expression of the human AIDS/lymphadenopathy 
retrovirus. NATURE 313 : 450-458.
MUKHERJEE,P.K . and SIMPSON,R.W. 1987.
Transcriptionally defective nucleocapsids of vesicular 
stomatitis virus from cells treated with indomethacin.
VIROL. 156 : 25-31.
MULLER,W.E.G. 1979. Mechanisms of action and 
pharmacology : chemical agents in : "ANTIVIRAL AGENTS AND
VIRAL DISEASES OF MAN" pp77-149. Edited by Galasso, Merigan, 
Buchanan. Raven Press, New York.
MULLER,W.E.G., ZAHN,R .K ., BITTLINGMAIER,K . and 
FALKE,D . 1977. Inhibition of herpesvirus DNA synthesis by 
9-B-D-arabinofuranosyladenine in cellular and cell free 
systems. ANN. N.Y. ACAD. SCI. 284 : 34-48.
MULLER-DECKER,K ., AMTMANN,E . and SAUER,G. 1987. 
Inhibition of the phosphorylation of the regulatory 
non-structural protein of vesicular stomatitis virus by an 
antiviral xanthate compound. J. GEN. VIROL. 68 : 3045-3056.
MUNRO,S. and PELHAM,H.R .B . 1986. An hsp-70 like 
ptotein in the ER : identity with the 78kd glucose-regulated 
protein and immunoglobulin heavy chain binding protein. CELL 
46 : 2 91-3 0 0.
NEWMAN,J.F.E., ROWLANDS,D .J . and BROWN,F. 1973. A 
physiochemical subgrouping of the mammalian picornaviruses. 
J. GEN. VIROL. 18 : 171-180.
NICHOLSON,K.G . 1984. Antiviral agents in clinical 
practice. Antiviral therapy : respiratory infections, 
genital herpes and herpetic keratitis. LANCET 2 : 617-621.
NINOMIYA,Y ., AOYAMA,M., UMEDA,I., SUHARA,Y . and 
ISHITSUKA,H. 1985. Comparative studies on the modes of 
action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, 
RMI-15,731, 41,6-dichloroflavan and enviroxime. ANTI. 
AGENTS. CHEM. 27 : 595-599.
NINOMIYA., OHSAWA,C ., AOYAMA,M ., UMEDA,I ., SUHARA,Y. 
and ISHITSUKA,H. 1984. Antivirus agent Ro 09-0410 binds to 
rhinovirus specifically and stabilises the virus 
conformation. VIROL. 134 : 269-276.
NORTH,T.W. and COHEN,S.S. 1979. Aranucleosides and 
aranucleotides in viral chemotherapy. PHARMACOL. THER. 4 : 
81-86.
NOTARIANNI,E .L . and PRESTON,C.M. 1982. Activation of 
cellular stress protein genes by herpes simplex virus 
temperature sensitive mutants which over-produce immediate 
early polypeptides. VIROL 123 : 113-122.
NOWAKOWSKI,M., BLOOM,B.R., EHRENFELD,E . and SUMMERS,D 
1973. Restricted replication of vesicular stomatitis virus 
in human lymphoblastoid cells. J. VIROL. 12 : 1272-1278.
OBIJESKI,J.F. and SIMPSON,R.W. 1974. Conditional 
lethal mutants of vesicular stomatitis virus 11 : synthesis 
of virus-specific polypeptides in nonpermissive cells 
infected with RNA host-restricted mutants. VIROL. 57 : 
369-377.
OSTERHANS,A.D.M.E., GROEN,J. and DE CLERCQ,E. 1987. 
Selective inhibitory effects of (S)-9-(3_hydroxy-2- 
phosphonyl-methoxyproponyl)adenine and 1-(2-deoxy-2- 
fluoro-B-D-arabinofuranosyl)-5-iodouracil on seal 
herpesvirus (phocid herpesvirus 1) infection in vitro. 
ANTIVIRAL RES. 7 : 221-231.
OSTERTAG,W ., ROESLER,G., KREIG,C.J., COLE,T.,
CROZIER,T ., GAEDICKE,G., STEINHEIDER,G., KLUGE,N. and 
DUBE,S.K. 1974. Induction of endogenous virus and of 
thymidine kinase by bromodeoxyuridine in cell cultures 
transformed by Freind virus. P.N.A.S. U.S.A. 71 : 4980-4985
OSTRANDER,M. and CHENG, Y-C. 1980. Properties of 
herpes simlplex virus type 1 and type 2 DNA polymerase. 
BIOCHIM. BIOPHYS. ACTA. 609 : 232-245.
OTTO,M .J ., GOZ,B . and PRUSOFF,W.H. 1984. Antiviral 
activity of iodinated pyrimidine deoxyribonucleosides. In :
" ANTIVIRAL DRUGS AND INTERFERON : THE MOLECULAR BASIS OF 
THEIR ACTIVITY ". Edited by Y.C. Becker.
OTTO,M.J., LEE,J .J . and PRUSOFF,W.H. 1982. Effects of 
nucleoside analogues on the expression of herpes simplex 
virus type 1 induced protein. ANTI. RES. 2 : 267-274.
OXFORD,J.S., LOGAN,I.S. and POTTER,C.W. 1970. Passage 
of influenza strains in the presence of aminoadamantane. 
NATURE 226 : 82-83.
OXFORD,J.S. and GALBRAITH,A. 1980. Antiviral activity 
of amantidine : a review of laboratory and clinical data. 
PHARM. THERAP. 11 : 181-262.
PAGANO,J .S., SIXBEY,J .W . and LIN,J.C. 1983. Acyclovir 
and Epstein-Barr virus infection. J. ANTI. CHEM. 12 (B), 
113-121.
PALMER,J.L. and ABELES,R.H. 1976. Mechanism for 
enymatic thioether formation. Mechanism of action of 
S-adenosylhomocysteinase. J. BIOL. CHEM. 251 : 5817-5819.
PALMER,J.L. and ABELES,R.H. 1979. The mechanism of 
action of S-adenosylhomocysteinase. J. BIOL. CHEM. 254 : 
1217-1226.
PARTRIDGE,M. and POSWILLO,D .E . 1984. Topical 
carbenoxolone sodium in the management of herpes simplex 
infection. BRIT. J. ORAL. MAXI. SURG. 22 : 138-145.
PERRY,R.P. and KELLY,D.E. 1974. Existence of 
methylated messenger RNA in mouse L cells. CELL 1 : 37-42.
PERSSON,H., OBERG,B. and PHILIPSON,L. 1978. 
Purification and characterisation of an early protein (E14K) 
from Adenovirus type 2 infected cells. J. VIROL. 28 : 
119-139.
PESONEN,M. and KAARIAINEN,L. 1982. Incomplete complex 
oligosaccharides in semliki forest virus envelope proteins 
arrested within the cell in the presence of monensin. J.
MOL. BIOL. 158 : 213-230.
PETERSON,W.D., STULBERG,C.S . and SIMPSON,W.F. 1971. A 
permanent heteroploid human cell line with type B 
glucose-6-phosphate dehydrogenase (35455). PROC. SOC. EXP.
BIOL. MED. 136 : 1187-1191.
PETERSLUND,N .A ., SEYER-HANSEN,K., IPSEN,J., ESMANN,V ., 
SCHONHEYDER,H and JUHL,H. 1981. Acyclovir in herpes zoster. 
LANCET 2 : 827-830.
PETRI,T., PATTERSON,S. and DIMMOCK,N.J . 1982. 
Polymorphism of the NS1 proteins of type A influenza virus. 
J. GEN. VIROL. 61 : 217-231.
PHILLPOTTS,R.J., JONES,R.N., DELONG,D.C., REED,S.E., 
WALLACE,J. and TYRRELL,D .A .J . 1981. The activity of 
enviroxime against rhinovirus infection in man. LANCET 1 : 
1342-1344.
PHILLPOTTS,R.J . and TYRRELL,D .A.J. 1985. Rhinovirus 
colds. BRIT. MED. BULL. 41 : 386-390.
PHILLPOTTS,R.J., WALLACE,J.W ., TYRRELL,D .A .J ., 
FREESTONE,D. and SHEPHERD,W .W . 1983. Failure of oral 4,6 
dichloroflavan to protect against rhinovirus infection in 
man. ARCH. VIROL. 75 : 115-121.
PINCUS,S .E ., DIAMOND,D.C., EMINI,E .A . and NIMMER,E . 
1986. Guanidine-selected mutants of poliovirus : mapping of 
point mutations to polypeptide 2c. J. VIROL. 57 : 638-646.
PINCUS,S.E. and WIMMER,E . 1986. Production of 
guanidine resistant and dependent poliovirus mutants from 
cloned cDNA : mutations in polypeptide 2c are directly 
responsible for altered guanidine sensitivity. J. VIROL. 60 
: 506-514.
POMPEl,R ., FLORE,0., MARCILIUS,M.A., PANI,A. and 
LODDO,B . 1979. Glycyrrhizic acid inhibits virus growth and 
inactivates virus particles. NATURE, LONDON 281 : 689-690.
POMPEl,R ., PAGHI,L ., INGIANNI,A . and UCCHEDDU,P. 1983. 
Glycyrrhizic acid inhibits influenza virus growth in 
embryonated eggs. MICRO. 6 : 247-250.
POSWILLO,D .E . and ROBERTS,G.J. 1981. Topical 
carbenoxolone for orofacial herpes simplex infection. LANCET 
11 : 143-144.
POUYSSEGUR,J and YAMADA,K .M . 1978. Isolation and 
immunological characterisation of a glucose regulated 
fibroblast cell surface glycoprotein and its1 
non-glycosylated precursor. CELL 13 : 139-150.
PRA5EUTH,D ., PERROUAULT,L ., LE DOAN,T., CHASSIGNOL,M ., 
THUONG and HELENE,C. 1988. Sequence specific binding and 
photocrosslinking of alpha and beta oligodeoxynucleotides to
the major groove of DNA via triple helix formation. P.N.A.S. 
U.S.A. 85 : 1349-1353.
PRESSMAN,B.C. 1976. Biological applications of 
ionophores. ANN. REV. BIOCHEM. 45 : 501-530.
PRUSINER,P. and SUNDARALINGAM,M . 1973. A new class of 
synthetic nucleoside analogues with broad spectrum antiviral 
properties. NATURE, NEW BIOL. 244 : 116-118.
PRUSOFF,W.H. 1959 Synthesis and biological activities 
of iododeoxyuridine, an analogue of thymidine. BIOCHIM. 
BIOPHYS. ACTA. 32 : 295-293.
PRUSOFF,W.H. and LIN,T-S. 1988. Experimental aspects 
of antiviral pharmacology, in : " ANTIVIRAL DRUG 
DEVELOPEMENT " ppl7 3-202. Edited by E.De Clercq and R.T. 
Walker.
PRUSOFF,W .H. and OTTO,M.J. 1983. Problems in the 
pharmacology and pharmacokinetics of antivirals, in : 
PROBLEMS OF ANTIVIRAL THERAPY", pp 125-128. Edited by C.M. 
Stuart-Harris and J. Oxford. Academic Press, New York.
PUDNEY,M., VARMA,M.G.R . and LEAKE,C.J. 1973. 
Establishment of a cell line (XTC-2) from the South African 
clawed toad, XENOPUS LAEVIS. EXPER. 29 : 466-467.
PUGH,C .S.G ., BORCHARDT,R.T. and STONE,H.O. 1977. 
Inhibition of newcastle disease virion messenger RNA 
(guanine-7-)-methyltransferase by analogues of 
S-adenosylhomocysteine. BIOCHEM 16 : 3928-3932.
PUGH,C .S.G ., BORCHARDT,R.T. and STONE,H.O. 1978. 
Sinefungin, a potent inhibitor of virion mRNA (guanine-7-) 
methyltransferase, mRNA (nucleoside-2'-) methyltransferase, 
and viral multiplication. J. BIOL. CHEM. 253 : 4075-4077.
RAIES,A., LAWRENCE,F. ROBERT-GERO,M ., LOCHE,M . and 
CRAMER,R. 1976. Effect of 5 1-deoxy-5'-S-isobutyl adenosine 
on polyoma virus replication. FEBS. LETTS. 72 : 48-52.
RATNER,L ., HASELTINE,N.A., PATARCA,R .,LIVAK,K .J ., 
STARCICH,B . and JOSEPHS,S.F. 1985. Complete nucleotide 
sequence of AIDS virus, HTLV 111. NATURE 313 : 277-283.
REDDY,R., RO-CHOI,T .S ., HENNING,D. and BUSCH,H. 1974. 
Primary sequence of U-l nuclear ribonucleic acid of Novikoff 
hepatoma ascites cells. J. BIOL. CHEM. 249 : 6486-6494.
REINKE,C.M., DRACH,J .C ., SHIPMAN,C.J. JR. and 
WEISSBACH,A . 1978. in : "ONCOGENISIS AND HERPESVIRUSES III,
PART 2". Edited by G. De The, W. Henle and F. Rapp. IRAC,
Lyon, France.
REPP,R., TAMURA,T., BOSCHEK,C.B. , WEGE,H.,
SCHWARZ,R.T. and NIEMANN,H. 1985. The effects of processing 
inhibition of N-linked oligosaccharide on the intracellular 
migration og gpE2 of mouse hepatitis virus and the 
maturation of coronavirus particles. J. BIOL. CHEM. 260 : 
15873-15879.
REVEL,M. 1979. Molecular mechanisms involved in the 
antiviral effect of interferon, in :"INTERFERON 1" 
pplOl-163. Edited by I. Gresser. New York, Academic Press.
RHODES,D.P., ABRAHAM,S.A., COLONNO,R.J., JELNICK,W. 
and BANERJEE,A.K . 1977. Characterisation of vesicular 
stomatitis virus mRNA species synthesised in vitro. J.
VIROL. 21 : 1205-1112.
RICHARDSON,C.D . and CHOPPIN,P.W. 1983. Oligopeptides 
that specifically inhibit membrane fusion by paramyxovirus : 
studies on the site of action. VIROL. 131 : 518-532.
RICHARDSON,C.D., SCHEID,A. and CHOPPIN,P.W. 1980. 
Specific inhibition of parmyxovirus and myxovirus 
replication by oligopeptides with amino acid sequences 
similar to those at the N-termini of the F^ or HA^ 
polypeptides. VIROL. 105 : 205-222.
RICHARDSON,C.D., SCHEID,A. and CHOPPIN,P.W. 1987. 
Specific inhibition of paramyxovirus and myxovirus 
replication by hydrophobic oligopeptides, in : "THE
REPLICATION OF NEGATIVE STRAND VIRUSES". Edited by D.H.L. 
Bishop and R.W.Compans. Elsevier-North Holland, New York.
RICHARDSON,C.D., SCHEID,A. and CHOPPIN,P.W. 1981. 
Specific inhibition of paramyxovirus and myxovirus 
replication by hydrophobic oligopeptides, in : "THE
REPLICATION OF NEGATIVE STRAND VIRUSES". Edited by D.H.L. 
Bishop and R.W. Compans. Elsevier-North Holland, New York.
RINDLER,M.J., CHUMAN,L.M., SHAFFER,L. and SAIER 
JR.,M.H. 1979. Retention of differentiated properties in an 
established dog kidney epithelial cell line (MDCK). J. CELL. 
BIOL. 81 : 635-648.
ROBERT-GERO,M., LAWRENCE,F., FARRUGIA,G., BERNEMAN,A., 
BLANCHARD,D., VIGIER,P. and LEDERER,E . 1975. Inhibition of 
virus-induced cell transformation by synthetic analogues of 
S-adenosylhomocysteine. BIOCHIM. RES. COMMUN. 65 :1242-1249.
ROBERTS,R.B., HESELTINE,P .N ., MANSELL,P .W .A .,
DICKINSON,G.M., LEEDOM,J.M . and JOHNSON,K.M. 1987. Ribavirin 
delays progression of the lymphadenopathy syndrome to the 
acquired immune deficiency syndrome. CLIN. RES. 35 : 616A.
ROBERTS,W.K., HOVANESSIAN,A ., BROWN,R.E., CLEMENS,M.J. 
and KERR,I.M. 1976. Interferon-mediated protein kinase and 
low m.wt. inhibitor of protein synthesis. NATURE, LONDON.
264 : 477-480.
ROBERTS,R.B., LAURENCE,J., SCAVUZZO,D., KIM,Y . and 
MURRAY,H.W. 19 . Ribavirin in high risk patients for AIDS.
CLIN. RES. 34,2 : 678A.
ROBERTS,N.B. and TAYLOR,W.H. 1980. The actions of 
carbenoxolone on enzymes and their relation to its' 
theraputic effect, in : "SCANDINAVIAN JOURNAL OF
GASTROENTEROLOGY; XI INTERNATIONAL CONGRESS OF 
GASTROENTEROLOGY" 15, supplement 6 5 : 11-16. Edited by Sir 
F.A. Jones, T.C. Hunt and P.I. Reed.
ROBEY,W.G., SAFIA,B ., OROSZLAN,S., ARTHUR,L.O.,
GONDA,M.A., GALLO,R.C. and FISCHINGER,P.J . 1985. 
Characterisation of envelope and core structural gene 
products of HTLV 111 with sera from AIDS patients. SCIENCE 
228 : 593-595.
ROBINS,R.K. and REVANKER,G.R . 1988. Design of 
nucleoside analogues as potential antiviral agents in : 
"ANTIVIRAL DRUG DEVELOPEMENT, A MULTIDISCIPLINARY APPROACH" 
pp 11-36. Edited by E.De Clercq and R.T. Walker. Plenum 
Press, New York and London.
ROSSMAN,M.G. 1985. Structure of a human common cold 
virus and functional relationship to other picornaviruses. 
NATURE,LONDON 317 : 14 5-15 3.
ROTHMAN,J.E., MILLER,R.L. and URBANI,L .J . 1984. 
Intercompartmental transport in the Golgi complex is a 
dissociative process : facile transfer of membrane protein
between two Golgi populations. J. CELL. BIOL. 99 : 260-271.
ROTT,R. and KLENK,H-D. 1986. Pathogenicity of 
influenza virus in model systems, in : "OPTIONS FOR THE
CONTROL OF INFLUENZA" pp53-62. Edited by A.P. Kendal and 
P.A. Patriarca. New York, Alan R. Liss.
RUSSEL,W.C. and BLAIR,G.E. 1977. Polypeptide 
phosphorylation in adenovirus infected cells. J.GEN. VIROL. 
34 : 19-35.
SANCHEZ,A., DE,B .P . and BANERJEE,A .K . 1985. In vitro
phosphorylation of NS protein by the L protein of vesicular 
stomatitis virus. J. GEN. VIROL. 66 : 1025-1036.
SANSTORM,E.G., KAPLAN,J.C., BYINGTON,R.E. and 
HORSCH,M.S. 1985. Inhibition of human T cell lymphotropic 
virus type 111 in vitro by phosphonoformate. LANCET 1 : 
1480-1482.
SARIN,P.S., TAGUCHI,Y ., SUN,D., THORNTON,A.,
GALLO,R.C. and OBERG,B. 1985. Inhibition of HTLV 111/LAV 
replication by foscarnet. BIOCHEM. PHARMACOL. 34 :
4075-4079.
SAUER,G., AMTMANN,E., MELBER,K., KNAPP,A., MULLER,K., 
HUMMEL,K. and SCHERM,A . 1984. DNA and RNA virus species are 
inhibited by xanthates, a class of antiviral compounds with 
unique properties. P.N.A.S. U.S.A. 81 : 3263-3267.
SAUL,R ., GHIDONI,J.J., MOLYNEUX,R .J . and ELBEIN,A.D.
1985. Castanospermine inhibits -glucosidase activities and 
alters glycogen distribution in animals. P.N.A.S. U.S.A. 82 
: 93-97.
SAUNDERS,K. and KING,A.M.Q. 1982. Guanidine resistant 
mutants of apthovirus induce the synthesis of altered 
non-structural polypeptide, p34. J. VIROL. 42 : 389-394.
SAUNDERS,K., KING, A.M., McCAHON,D., NEWMAN,J.W., 
SLADE,W.R. and FORRS,S. 1985. Recombination and 
oligonucleotide analysis of guanidine resistant foot and 
mouth disease virus mutants. J.VIROL. 56 : 921-929.
SAUNDERS,P.P., TAN,M-T. and ROBINS,R.K. 1985. 
Metabolism and action of neplanocin A in Chinese hamster 
ovary cells. BIOCHEM. PHARMACOL. 34 : 2749-2754.
SAUNIER,B., KILKER,R.D., TZACK,J.S., QUAROM,A. and 
HERSCOVICS,A. 1982. Inhibition of N-linked complex 
oligosaccharide formation by 1-deoxynojirimycin, an 
inhibitor of processing glucosidases. J. BIOL. CHEM. 257 : 
14155-14161.
SCHANK,C ., ROGGLA,G., LUGER,A . and SCHERNTHANER,G .
1986. Effects of the alpha glucosidase inhibitor 1 
desoxynojirimycin (BAY m 1099) on postprandial blood 
glucose, serum insulin and L-peptide levels in type 11 
diabetes patients. EUR. J. CLIN. PHARM. 30 : 417-419.
SCHEID,A ., GRAVES,M.C., SILVER,S.M. and CHOPPIN,P.W. 
1978. Studies on the structure and function of paramyxovirus 
glycoproteins in : "NEGATIVE STRAND VIRUSES AND THE HOST
CELL". Edited by B.W.J. Mahy and R.D.Barry. Academic Press, 
London.
SCHEID,A ., GRAVES,M.C., SILVER,S.M. amd CHOPPIN,P.W. 
1978. Studies on the structure and function of paramyxovirus 
glycoproteins, in : "NEGATIVE STRAND VIRUSES AND THE HOST
CELL". Edited by Mahy and R.D. Barry. Academic Press London.
SCHEID,A. and CHOPPIN,P.W. 1973. Isolation and 
purification of the envelope proteins of Newcastle disease 
virus. J. VIROL. 11 : 263-271.
SCHEID,A. and CHOPPIN,P.W. 1974. Identification of 
biological activities of paramyxovirus glycoproteins. 
Activation of cell fusion, haemolysis and infectivity by 
proteolytic cleavage of an inactive precursor protein of 
Sendai virus. VIROL. 57 : 475-490.
SCHEID,A. and CHOPPIN,P.W. 1976. Protease activation 
mutants of Sendai virus : activation of biological
properties by specific proteases. VIROL. 69 : 265-277.
SCHEID and CHOPPIN,P.W. 1977. Two disulphide-1inked 
polypeptide chains constitute the active F protein of 
paramyxoviruses. VIROL. 80 : 54-66.
SCHEID,A., CALIGUIRI,L .A., COMPANS,R.W. and 
CHOPPIN,P.W. 1972. Isolation of paramyxovirus glycoproteins. 
Association of both haemagglutinating and neuraminidase 
activities with the larger SV5 glycoprotein. VIROL. 50 : 
640-652.
SCHERER,N.F., SYVERTON,J.T . and GEY,G .0. 1953. Studies 
on the propagation in vitro of poliomyelitis viruses IV. 
Viral multiplication in a stable strain of human malignant 
epithelial cells (strain HeLa) derived from an epidermoid of 
the cervix. J. EXP. MED. 97 : 695-711.
SCHINAZA,R.F., SCOTT,R.T., PETERS, J., RICE,V. and 
NAHMIAS,A.J. 1985. Antiviral activity of 5-ethyl- 
2'-deoxyuridine against herpes simplex viruses in cell 
culture, mice and guinea pigs. ANTI. AGENTS. CHEM. 28 : 
552-560.
SCHLEGEL,R., DICKSON,R.B ., WILLINGHAM,M.C. and 
PASTAN,I.H . 1982. Amantidine and dansylcadaverine inhibit 
vesicular stomatitis virus uptake and receptor-mediated 
endocytosis of alpha 2 macroglobulin. P.N.A.S. U.S.A. 79 : 
2291-2295.
SCHLENK,F. and DAINKO,J.L. 1974. The S-n-propyl
analogue of S-adenosylmethionine. BIOCHIM. BIOPHYS. ACTA.
385 : 312-323.
SCHLENK,F., HANNUM,C.H . and FERRO,A.J. 1978. 
Biosynthesis of adenosyl-D-methionine and adenosyl 
-2-methylmethionine by condida utilis. ARCH. BIOCHEM. 
BIOPHYS. 187 : 191-196.
SCHLESINGER,M.J., ASHBURNER,M. and TISSIERES,A. 1982. 
Heat shock from bacteria to man. COLD SPRING HARBOR 
LABORATORY, COLD SPRING HARBOR, NEW YORK.
SCHLESINGER,S., MALFER,C . and SCHLESINGER,M .J . 1984. 
The formation of VSV (San Juan strain) becomes t s when 
glucose residues are retained on the oligosaccharide of the 
glycoprotein. J. BIOL. CHEM. 259 : 7597-7601.
SELBY,P., POWLES,R.L ., BLAKE,S., STOLLE,K.,
MBIDDE,E.K ., McELWAIN,T .J ., HICKMOTT,E ., WHITEMAN,P .D . and 
FIDDIAN,A.P. 1984. Amino(hydroxyethoxymethyl)purine : a new 
well absorbed prodrug of acyclovir.
SEN,G.C ., SHAILA,S., LEBLEU,B ., BROWN,G.E.,
DESROSIERS,R.C. and LENGYEL,P. 1977. Impairment of reovirus 
mRNA methylation in extracts of interferon-treated Ehrlich 
ascites tumour cells : further characteristics of the 
phenomenon. J. VIROL. 21 : 69-83.
SHANNON,W.M. 1977. Selective inhibition of RNA tumour 
virus replication in vitro and evaluation of candidate 
antiviral agents in vivo. ANN. N.Y. ACAD. SCI. 284 :
472-507.
SHANNON,W.M. 1984. Mechanisms of action and 
pharmacology : "CHEMICAL AGENTS IN ANTIVIRAL AGENTS AND 
VIRAL DISEASES OF MAN". Edited by G.J. Galasso, T.C. Merigan 
and R.A. Buchanan. Raven Press, New York.
SHARPE,A.H., CHEN,L.B . and FIELDS,B.N. 1982. The 
interaction of mammalian reoviruses with the cytoskeleton of 
monkey kidney CV-1 cells. VIROL. 120 : 399-411.
SHARPE,A.H. and FEILDS,B.N. 1983. Pathogenisi of 
reovirus infection, in : " THE REOVIRIDAE " . pp229-285
Edited by W.K. Joklik. Plenum, New York.
SHEPP,D .H., DANDLIKER,P.S ., DE MIRANDA,P.,
BURNETTE,T.C., CEDERBERG,D.M., KIRK,L.E. and MEYERS,J.D.
1985. Activity of
9 -[ 2 -hydroxy-l-(hydroxymethyl)ethoxymethyljguanine in the 
treatment of cytomegalovirus pneumonia. ANN. INTERN. MED.
103 : 368-373.
SHIPMAN,C.J. 1969. Evaluation of 4-(2-hydroxyethyl) 
1-piperazineethane sulfonic acid (HEPES) as a tissue culture 
buffer. PROC. SOC. EXP. BIOL. MED. 130 : 305-310.
SHIPMAN,JR., SMITH,S.H., DRACH,J.C. and KLAYMAN,D .L .
1981. Antiviral activity of 2-acetylpyrimidine 
thiosemicarbazone against herpes simplex virus. ANTI.
AGENTS. CHEM. 19 : 682-685.
SHIU,R .P .C ., POUYSSEGUR,J. and PASTAN,I. 1977. Glucose 
depletion accounts for the induction of 2 transformation 
sensitive membrane proteins in Rous sarcoma virus 
transformed chick embryo fibroblasts. P.N.A.S. U.S.A. 74 : 
3840-3844.
SIDWELL,R .W ., ALLEN,L.B., HUFFMAN,J.H ., WITKOWSKI,J .T . 
and SIMON,L.N. 1975. Effect of 1-B-D-ribofuranosyl-1,
2.4-triazole-3-carboxamide (ribavirin) on friend leukaemia 
virus infections in mice (38647). PROC. SOC. EXP. BIOL. 148 
: 854-858.
SIDWELL,R.W., ARNETT,G., DIXON,G.J. and SCHABEL JR. 
F.M. 1969. Purine analogues as potential anticytomegalovirus 
agents. PROC. SOC. EXP. BIOL. MED. 131 : 1223-1230.
SIDWELL,R.W., HUFFMNAN,J.H., KHARKE,G.P ., ALLEN,L.B., 
WITOWSKI,J.T. and ROBINS,R.K. 1972. Broad spectrum antiviral 
activity of virazole : 1-B-D-ribofuranosyl-1,
2.4-triazole-3-carboxamide. SCIENCE 177 : 705-706. 
SILVERSTEIN,S.C . and SCHUP,P.H. 1970.
Immunofluorescent localization of double stranded RNA in 
reovirus infected cells. VIROL. 41 : 564-568.
SIMONS,K. and GARROF,H . 1980. The budding mechanisms 
of enveloped animal viruses. J. GEN. VIROL. 50 : 1-21.
SKEHEL,J.J., HAY,A .J . and ARMSTRONG,J.A. 1978. On the 
mechanism of inhibition of influenza virus replication by 
amantidine hydrochloride. J. GEN. VIROL. 38 : 97-110.
SMEE,D.F ., MARTIN,J.C., VERHEYDEN,J.P . and 
MATTHEWS,T.R. 1983. Anti-herpes virus activity of the 
acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. 
ANTI. AGENTS. CHEM. 23 : 676-682.
SMITH,M.S., BRIAN,E.L. and PAGANO,J.S. 1987.
Resumption of virus production after human immunodeficiency 
virus infection of T lymphocytes in the preence of 
azidothymidine. J. VIROL. 61 : 3769-3733.
SMITH,T.J., KREMER,M .J ., LOO,M., VRIEND,G., ARNOLD,E ., 
KAMER, G . , ROSSMAN,M.G., McKINLAY,M.A., DIANA,G.D. and 
OTTO,M.J. 1986. The site of attachment in human rhinovirus 
14 for antiviral agents that inhibit uncoating. SCIENCE 233 
: 1286-1293.
SODROSKI,J ., GOH,W .C ., ROSEN,C., CAMPBELL,K. and 
HASELTINE,W.A. 1986. Role of HTLV 111/LAV envelope in 
synctium formation and cytopathicity. NATURE 322 : 470-474.
SORGER,P .K . and PELHAM,H.R .B . 1987. The 
glucose-regulated protein grp94 is related to heat shock 
protein hsp90. J. MOL. BIOL. 194 : 341-344.
SPECTOR,T ., AVERETT,D .R ., NELSON,D.J., LAMBE,C .U ., 
MORRISON JR. R.W., ST. CLAIR,M.H. and FURMAN,P.A. 1985. 
Potentiation of antiherpetic activity of acyclovir by 
ribonucleotide reductase inhibition. P.N.A.S. U.S.A. 82 : 
4254-4257.
SPENDLOVE,R .S., LENNETTE,E.H ., KNIGHT,C.O. and 
CHIN,J.H. 1963. Developement of viral antigen and infectious 
virus on HeLa cells infected with reovirus. J. IMMUN. 90 : 
548-553.
SPRUANCE,S.L., FREEMAN,D.J. and SHETH N.V. 1985. 
Comparison of topically applied 5-ethyl-21-deoxyuridine and 
acyclovir in the treatment of cutaneous herpes simplex virus 
infection in guinea pigs. ANTI. AGENTS CHEM. 28 : 103-106.
STENBERG,K., LARSSON,A. and DATEMA,R . 1986. Metabolism 
and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in 
herpes simplex virus infected vero cells. J. BIOL. CHEM. 261 
: 2134-2138.
STEWART,W.E. 1979. Varied biologic effects of 
interferon, in : "INTERFERON 1" pp 29-38. Academic Press,
London.
STEWART,P.M., WALLACE,A .M., VALENTION,R., BURT,D ., 
SHACKLETON,C.H.L. and EDWARDS,C.R. 1987. Mineralcorticoid 
activity of liquorice II. Beta-hydroxysteroid dehydrogenase 
deficiency comes of age. LANCET 2 : 821-824.
STOTT,E.J. and KILLINGTON,R.A. 1972. Rhinoviruses.
ANN. REV. MICROB. 25 : 503-524.
STREETER,D.G., WITOWSKI,J .T ., KHARE,G.D .,
SIDWELL,R.W., BAUER,R.J., ROBINS,R.K. and SIMON,L.N. 1973. 
Mechanism of action of 1-B-D-ribofuranosyl-1,
2,4-triazole-3-carboxamide (virazole), a new broad spectrum
antiviral agent. P.N.A.S. U.S.A. 70 : 1174-1178.
STUART-HARRIS,C.H., SCHILD,G.C. and OXFORD,J.S. 1985. 
Influenza : The viruses and the disease., 2nd Edition, 
London. Edward Arnold.
SWALLOW,D.L., BUCKNALL,R .A ., STANIER,W .E .,
HUTCHISON,A. and GASKIN,H. 1977. A new antirhinovirus 
compound ICI 73602 : structure-properties and spectrum 
activity. ANN. N.Y. ACAD. SCI. 284 : 305-309.
SWALLOW,D.L. and KAMPFNER,G .L . 1985. The laboratory 
selection of antiviral agents. BRIT. MED. BULL. 41 :
322-332.
SYMONS,A.M. and PARKE, D.V. 1980. The effects of 
carbenoxolone on the stability of cellular membranes. SCAND. 
J. GASTRO. 15, supplement 65 : 3-10.
SZILAGYI,J.F. and PRINGLE,C.R. 1975. Virion 
transcriptase activity differences in host range mutants of 
vesicular stomatitis virus. J. VIROL. 16 : 927-936.
TASHIRO,M ., CIBROWSKI,P., KLENK,H-D., PULVERER,G. and 
ROTT,R. 1987a. Role of staphylococcus aureus in the 
developement of influenza pneumonia. NATURE, LONDON 325 : 
536-537.
TASHIRO,M., CIBROWSKI,P., REINACHER,M., PULVERER,G., 
KLENK,H-D. and ROTT,R. 1987b. Synergistic role of 
staphylococcal proteases in the induction of influenza virus 
pathogenicity. VIROL. 157 : 421-430.
TASHIRO,M., KLENK,H-D. and ROTT,R . 1987. Inhibitory 
effect of a protease inhibitor, leupeptin, on the 
developement of influenza pneumonia, mediated by concomitant 
bacteria. J .GEN. VIROL. 68 : 2039-2041.
THELANDER,L . and GRASLUND,T . 1983. Mechanism of 
inhibition of mammalian ribonucleotide reductase by the iron 
chelate of 1-formylisoquinoline thiosemicarbazone. J. BIOL. 
CHEM. 258 : 4063-4066.
TIDWELL,R.R., GERATZ,J .D ., DANN,0., VOLZ,G., ZEH,G. 
and LOEWE,H. 1978. Diarylamidine derivatives with one or 
both of the aryl moieties consisting of an indole or 
indole-like ring. Inhibitors of arginine-specific 
esteroproteases. J. MED. CHEM. 21 : 613-619.
TKACZ,J .S. and LAMPEN,J.O. 1975. Tunicamycin 
inhibition of polyisoprenyl N-acetyl glucosaminyl 
pyrophosphate formation in calf liver microsomes. BIOCHEM.
BIOPHYS. RES. COMMUN. 65 : 248-257.
TOLTZIS,P. and HUANG,A.S. 1986. Effect of ribavirin 
and macromolecular synthesis in vesicular stomatitis virus 
infected cells. ANTI. AGENTS. CHEMO. 29 : 1010-1016.
TOOLAN,H .W . 1954. Transplantable human neoplasms 
maintained in cortisone-treated laboratory animals : HS=I;
H.Ep.=1; H .Ep.=2; H.Ep.=3 and H.Emb.Rh.=I. CANCER RES. 14 : 
660-666.
TRICOT,G., DE CLERCQ,E., BOOGAERTS,M.A. and 
VERWILGHEN,R.L . 1986. Oral bromovinyldeoxyuridine therapy 
for herpes simplex and varicella-zoster virus infections in 
severely immunosuppressed patients : a preliminary clinical 
trial. J. MED. VIROL. 18 : 11-20.
TSUJINO,M., YAGINUMA,S., FUJII,T., HAYANO,K .,
MATSUDA,T ., WATANABE,T . and ABE,J. 1980. Neplanocins, new 
antitumour agents : Biological activities in : "CURRENT
CHEMOTHERAPY AND INFECTIOUS DISEASE" VOL 2, ppl559-1561. 
Edited by J.D. Nelson and C. Grassi. The American Society 
for Micribiology, Washington,D.C.
TURENNE-TESSIER,M., OOKA,G., DE THE,G. and DAILLIE,J.
1986. Characterisation of an Epstein-Barr virus induced 
thymidine kinase. J. VIROL. 57 : 1105-1112.
TYMS,A .S., BERRLE,E.M., RYDER,T.A., WASH,R.J.,
HEGARTY,M.P. and TAYLOR,D.L. 1987. Castanospermine and other 
plant alkaloid inhibitors of glucosidase activity block the 
growth of HIV. LANCET 11 : 1025-1026.
TYMS,A.S. and TAYLOR,D.L. 1988. Activity of 
glucosidase inhibitores against HIV infection. J. ANTIM. 
CHEM. 22 : 271-274.
VEDEL,M., LAWRENCE,F., ROBERT-GERO,M and LEDERER,E. 
1978. The antifungal antibiotic sinefungin as a very active 
inhibitor of methyltransferases and of the transformation of 
chick embryo fibroblasts by Rous sarcoma virus. BIOCHEM. 
BIOPHYS. RES. COMMUN. 85 : 371-376.
VERONESE,F.D., DEVICO,A.L., COPELAND,T.D .,
OROSSZLAN,S., GAALO,R .C . and SARNGADHARAN,M.G. 1985. 
Characterisation of gp41 as the transmembrane protein coded 
by the HTLV 111/LAV envelope gene. SCIENCE 229 : 1402-1404.
VILLAREAL,L.P., BREINDL,M. and HOLLAND,J.J. 1976. 
Determination of molar ratios of vesicular stomatitis virus 
induced RNA species in BHK-21 cells. BIOCHEM. 15 :
1 6 6 3 - 1 6 6 7 .
VORTUBA, I. , BERNAERTS,R., SAKUMA, T . , DE CLERCQ,E., 
MERTA,A., ROSENBERG,I. and HOLY,A. 1987. Intracellular 
phosphorylation of broad spectrum anti-DNA virus agent 
(S)-9-(3-nydroxy-2-phosphonylmethoxypropyl)adenine and 
inhibition of viral DNA synthesis. MOL. PHARMACOL. 32 : 
524-529.
VORTUBA,I. and HOLY,A. 1980. Inhibition of
S-adenosyl-homocysteine hydrolase by the aliphatic
nucleoside analogue-9-(S )-(2,3)-dihydroxypropyl)adenine.
COLL. CZECH. CHEM. COMMUN. 45 : 3039-3044.
VRANG,L., BAZIN,H., REMAUD,G. CHATTOPDHYAYA and
OBERG,B. 1987. Inhibition of the reverse transcriptase from
HIV by 3 1-azido-3'-deoxythymidine triphosphate and its threo
analogue. ANTIVIRAL. RES. 7 : 139-144.
VRANG,L. and OBERG,B. 1986. PPi analogs as inhibitors
of human T lymphotropic virus type 111 reverse
transcriptase. ANTI. AGENTS. CHEM. 29 : 867-872.
WALKER,B.D., KOWALSKI,M., GOTT,W.C., KOZARSKY,K.,
KRIEGER,M. and ROSEN,C. 1987. Inhibition of HIV synctium
formation and virus replication by castanospermine. P.N.A.S.
U.S.A. 84 : 8120-8124.
WALLBANK,A.M., MATTER,R.E. and KLINIKOWSKI,N.G. 1966.
1-adamantanamine hydrochloride inhibition of Rous and Esk
sarcoma viruses in cell culture. SCIENCE 152 : 1760-1761.
WELCH,W.J., GARRELS,J.I., THOMAS,G.P., LIN,J.J.C. and
FERAMISSO,J.R. 1983. Biochemical characterisation of the
mammalian stress proteins and identification of 2 stress
2 +proteins as glucose and Ca ionophore regulated proteins.
J. BIOL. CHEM. 258 : 7102-7111.
WHAUN,J .M ., MIURA,G.A., BROWN,N.D., GORDON,R.K. and 
CHIANG,P .K . 1986. Antimalarial activity of neplanocin A with 
perturbations in the metabolism of purines, polyamines and 
S-adenosyl methionine. J. PHARM. EXP. THERAP. 236 : 277-293.
WHITLEY,R.L. and ALFORD,C.A. 1978. Developemental 
aspects of selected antiviral chemotheraputic agents. A.
REV. MICROB. 32 : 285-300.
WHITLEY,R.J. and ALFORD,C.A. 1981. Parenteral 
antiviral chemotherapy of human herpesviruses, in : "THE
HUMAN HERPESVIRUSES" pp478-489. Edited by Nahmias. Elsevier, 
New York.
WHITLEY,R.J., ALFORD,C.A., HIRSCH,M.S., SCHOOLEY,R.T ., 
LUBY,J .P., AOKI,F.Y ., HANLEY,D., NAHMIAS,A.J. and SOONG,S-J.
1986. Vidarabine versus acyclovir therapy in herpes simplex 
encephalitis. NEW. ENG. J. MED. 314 : 144-149.
WILDY,P., RUSSELL,W.C. and HORNE,R.W. 1960. The 
morphology of herpes virus. VIROL. 12 : 204-222.
WONG-STAAL,F., SHAN,G.M ., HAHN,B.H ., SALAHUDDIN,S.Z., 
POPOVIC,M., MARKHAM,P., REDFIELD,R . and GALLO,R.C. 1985. 
Genomic diversity of human T lymphotropic virus type 111 
(HTLV 111). SCIENCE 229 : 759-762.
YARCHOAN,R ., MITSUYA,H ., THOMAS,R.V, PLUDA,J.M., 
HARTMAN,N.R., PERNO,C.-F., MARCZYK,K .S., ALLAIN,J.P. et al. 
1989. In vivo activity against HIV and favourable toxicity 
profile of 2',31-dideoxyinosine. SCIENCE 245 : 412-415.
YOSHIMURA,A., KURODA,K ., KAWASAKI,S., MAEDA,T . and 
OHNISHI,S. 1982. Infectious cell entry mechanism of 
influenza virus. J. VIROL. 43 : 284-292.
ZAPPIA,V ., ZYDEK-CWICK,C-R. and SCHLENK,F . 1969. The 
specificity of S-adenosyl methionine derivatives in methyl 
transfer reactions. J. BIOL. CHEM. 224 : 4499-4509.
ZERIAL,A., THUONG,N.T . and HELENE,C. 1987. Selective 
inhibiton of the cytopathic effect of type A influenza 
viruses by oligodeoxynucleotides covalently linked to an 
intercalating agent. NUC. ACID. RES. 15 : 9909-9919.
ZHIRNOV,O.D., OVCHARENKO,A .V . and BUKRINSKAYA,A.G.
1982. Proteolytic activation of influenza WSN virus in 
culture cells is performed by homologous plasma enzymes. J. 
GEN. VIROL. 63 : 469-474.
ZHIRNOV,0.P., OVCHARENKO,A.V. and BUKRINSKAYA,A.G. 
1984. Suppression of influenza virus replication in infected 
mice by protease inhibitors. J. GEN. VIROL. 65 : 191-196.

